<!DOCTYPE html><html lang="en"> <head><link rel="prefetch" href="/logo.webp"><link rel="preconnect" href="https://www.googletagmanager.com"><link rel="preconnect" href="https://pub.doubleverify.com"><link rel="preconnect" href="https://www.googletagservices.com"><link rel="icon" href="/favicon.svg" type="image/svg+xml"><link rel="icon" href="/favicon.ico" sizes="any"><link rel="apple-touch-icon" href="/apple-touch-icon.png"><meta charset="UTF-8"><meta name="viewport" content="width=device-width, initial-scale=1.0"><title>Gerson Regimen | CancerNetwork</title><link rel="canonical" href="https://www.cancernetwork.com/view/gerson-regimen/rss.xml"><meta name="description" content="Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy."><meta name="robots" content="index, follow"><meta property="og:title" content="Gerson Regimen | CancerNetwork"><meta property="og:type" content="website"><meta property="og:image" content="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png"><meta property="og:url" content="https://www.cancernetwork.com/view/gerson-regimen/rss.xml"><meta property="og:image:url" content="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png"><meta property="og:image:width" content="1200"><meta property="og:image:height" content="630"><meta property="og:image:alt" content="Gerson Regimen | CancerNetwork"><meta property="article:published_time" content="2026-10-10T13:52:28.923Z"><meta property="article:modified_time" content="2026-10-10T13:52:28.923Z"><meta property="article:author" content="Barrie R. Cassileth, MS, PhD"><meta property="article:tag" content="Integrative Oncology"><meta property="article:tag" content="Oncology Journal"><meta name="twitter:site" content="@onclive"><meta name="twitter:title" content="Gerson Regimen | CancerNetwork"><meta name="twitter:image" content="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png"><meta name="twitter:image:alt" content="Gerson Regimen | CancerNetwork"><meta name="twitter:description" content="Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy."><link rel="icon" href="/favicon.ico"><meta name="twitter:image" content="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png"><meta name="twitter:title" content="Gerson Regimen | CancerNetwork"><meta name="twitter:description" content="Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy."><script type="application/ld+json">{"@context":"https://schema.org","@type":"NewsArticle","headline":"Gerson Regimen","datePublished":"2010-02-09T05:00:00.000Z","dateModified":"2020-11-11T15:58:47.000Z","inLanguage":"en-US","image":{"@type":"ImageObject","url":"https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png","caption":"Gerson Regimen","alternateName":"Gerson Regimen"},"thumbnail":{"@type":"ImageObject","url":"https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png","caption":"Gerson Regimen","alternateName":"Gerson Regimen"},"publisher":{"@type":"Organization","name":"CancerNetwork","logo":{"@type":"ImageObject","url":"https://www.cancernetwork.com/logo.webp"}},"keywords":"Integrative Oncology, Oncology Journal","articleBody":"Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.\nThe strict dietary recommendations can cause severe nutritional deficiencies, and excessive use of coffee enemas can cause sepsis, dangerous electrolyte deficiencies, and death.\nA recent trial of the closely related Gonzalez therapy found that pancreatic cancer patients on standard chemotherapy survived three times longer and had better quality of life than those who chose the Gonzalez regimen (pancreatic enzymes, nutritional supplements, detoxification, and organic diet).\n-Barrie Cassileth, PhD\nALSO KNOWN AS: Gerson diet, Gerson therapy, Gerson method, Gerson program, Gerson treatment\nSUMMARY: The Gerson regimen, developed by Max Gerson in the 1930s, is promoted as an alternative cancer treatment. It involves consuming fresh, raw fruit and vegetable juices, eliminating salt from the diet, taking supplements such as potassium, vitamin B12, thyroid hormone, pancreatic enzymes, and detoxifying liver with coffee enemas to stimulate metabolism.\nGerson therapy is based on the theory that cancer is caused by alteration of cell metabolism by toxic environmental substances and processed food, which changes its sodium and potassium content. It emphasizes increasing potassium intake and minimizing sodium consumption in an effort to correct the electrolyte imbalance, repair tissue, and detoxify the liver. The coffee enemas are believed to cause dilation of bile ducts and excretion of toxic breakdown products by the liver and through the colon wall. None of these theories has been substantiated by scientific research.[1,2]\nDespite proponents’ claims of recovery rates as high as 70% to 90%, case reviews by the National Cancer Institute (NCI) and the New York County Medical Society found no evidence of usefulness for the Gerson diet.[3]\nAn NCI-sponsored study of Gonzalez therapy, which is similar to the Gerson diet, showed that patients with inoperable pancreatic adenocarcinoma who underwent standard chemotherapy with gemcitabine (Gemzar) survived three times longer and had better quality of life than those who chose enzyme treatment, which included pancreatic enzymes, nutritional supplements, detoxification, and an organic diet.[4]\nADVERSE REACTIONS: Adverse reactions to the Gerson regimen include flu-like symptoms, loss of appetite, perspiration with foul odor, weakness, dizziness, cold sores, fever blisters, high fever, tumor pain, intestinal cramping, diarrhea, and vomiting. (The Gerson Therapy Handbook claims that these adverse reactions are indicative of response.)[5] Campylobacter fetus sepsis caused by the liver injections was reported in 13 patients on Gerson therapy between1980 and 1986. Coma from low serum sodium occurred in 5 of these patients.[6]\nCoffee enemas cause electrolyte imbalance, which has resulted in serious infections, dehydration, colitis, constipation, and death.[7]\n \nReferences:\nREFERENCES\n\t\t\t\t\n1. Cope FW: A medical application of the Ling association-induction hypothesis: The high potassium, low sodium diet of the Gerson cancer therapy. Physiol Chem Phys 10:465-468, 1978. \n\t\t\t\t\n2. Jansson B: Geographic cancer risk and intracellular potassium/sodium ratios. Cancer Detect Prevent 9:171-194, 1986. \n\t\t\t\t\n3. American Cancer Society: Making treatment decisions: Gerson therapy. Available at http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Gerson_Therapy.asp?sitearea=ETO. Accessed Dec 30, 2009.\n\t\t\t\t\n4. Chabot JA, Tsai WY, Fine RL, et al: Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol Aug 17, 2009 (epub ahead of print).\n\t\t\t\t\n5. Gerson M: Gerson Therapy Handbook, 5th ed. San Diego, Calif; Gerson Institute; 1999.\n\t\t\t\t\n6. American Cancer Society: Questionable methods of cancer management: ‘Nutritional’ therapies. CA Cancer J Clin 43:309-319, 1993. \n\t\t\t\t\n7. Eisele JW, Reay DT: Deaths related to coffee enemas. JAMA 244:1608-1609, 1980.","description":"Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.","author":[{"@type":"Person","name":"Barrie R. Cassileth, MS, PhD","url":"https://www.cancernetwork.com/authors/barrie-r-cassileth-ms-phd"}]}</script><script type="application/ld+json">{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.cancernetwork.com/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https://www.cancernetwork.com/journals"},{"@type":"ListItem","position":3,"name":"Oncology Journal","item":"https://www.cancernetwork.com/journals/journals/oncology"},{"@type":"ListItem","position":4,"name":"Gerson Regimen"}]}</script><script type="application/ld+json">{"@context":"https://schema.org","@type":"Organization","contactPoint":{"@type":"ContactPoint","availableLanguage":["English"]},"name":"CancerNetwork - Oncology News and Clinical Expertise","alternateName":"Cancer Network","description":"CancerNetwork is home to the journal Oncology &amp; provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.","email":"MJHINFO@mjhlifesciences.com","telephone":"609-716-7777","sameAs":["https://www.facebook.com/Cancer-Network-124530046330/","https://www.linkedin.com/company/cancer-network/","https://twitter.com/CancerNetwrk","https://www.youtube.com/@CancerNetwork"],"address":{"@type":"PostalAddress","streetAddress":"259 Prospect Plains Rd, Bldg H","addressLocality":"Monroe","addressRegion":"New Jersey","postalCode":"08831","addressCountry":"United States of America"},"foundingDate":"1998-12-06","founder":{"@type":"Person","name":"MJH Life Sciences"},"employees":[{"@type":"Person","name":"Silas Inman"},{"@type":"Person","name":"Kristie Kahl"},{"@type":"Person","name":"Gina Mauro"}]}</script><meta data-mjh-consent-required="onetrust"><link rel="preconnect" href="https://cdn.cookielaw.org"><link rel="dns-prefetch" href="https://cdn.jsdelivr.net"><link rel="preconnect" href="https://cdn.segment.com"><link rel="preconnect" href="https://res.lassomarketing.io"><script src="https://cdn.jsdelivr.net/npm/@segment/analytics-consent-wrapper-onetrust@1.1.3/dist/umd/analytics-onetrust.umd.js" integrity="sha384-ZfcsAx1x7muBdnigLXYDf60HLhesYq26ml8RlUC8nybmvoJ3z9AujMUd8yos84Fv" crossorigin="anonymous"></script><script>
  window.dataLayer = window.dataLayer || [];
  function gtag() { dataLayer.push(arguments); }
  gtag('set', 'developer_id.dYWJhMj', true);
  gtag('consent', 'default', {
    ad_storage: 'denied',
    analytics_storage: 'denied',
    functionality_storage: 'denied',
    personalization_storage: 'denied',
    security_storage: 'granted',
    ad_user_data: 'denied',
    ad_personalization: 'denied',
    region: ["AT","BE","BG","HR","CY","CZ","DK","EE","FI","FR","DE","GR","HU","IE","IT","LV","LT","LU","MT","NL","PL","PT","RO","SK","SI","ES","SE","IS","LI","NO","GB","GG","JE","IM","CH","US-CA"],
    wait_for_update: 500,
  });
  gtag('consent', 'default', {
    ad_storage: 'granted',
    analytics_storage: 'granted',
    functionality_storage: 'granted',
    personalization_storage: 'granted',
    security_storage: 'granted',
    ad_user_data: 'granted',
    ad_personalization: 'granted',
  });
</script><script>
  (function () {
    if (window.__mjhFormsConsentParentCapture) return;
    var capture = window.__mjhFormsConsentParentCapture = { seen: false, groups: [] };
    window.addEventListener('OneTrustGroupsUpdated', function (event) {
      var detail = event && event.detail;
      var groups = Array.isArray(detail)
        ? detail
        : (typeof window.OnetrustActiveGroups === 'string' ? window.OnetrustActiveGroups.split(',').map(function (g) { return g.trim(); }) : []);
      capture.seen = true;
      capture.groups = groups.filter(function (group) { return typeof group === 'string'; });
    });
  })();
</script><script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="0196a059-28cb-71f3-a7fc-4659bcc6ca6d" data-document-language="true"></script><script type="text/javascript">
  function mjhUpdateGoogleConsent() {
    var groups = typeof window.OnetrustActiveGroups === 'string'
      ? window.OnetrustActiveGroups.split(',').map(function (g) { return g.trim(); })
      : [];
    var hasGroup = function (group) { return groups.indexOf(group) !== -1; };
    gtag('consent', 'update', {
      analytics_storage: hasGroup('C0002') ? 'granted' : 'denied',
      functionality_storage: hasGroup('C0003') ? 'granted' : 'denied',
      personalization_storage: hasGroup('C0004') ? 'granted' : 'denied',
      ad_storage: hasGroup('C0004') ? 'granted' : 'denied',
      ad_user_data: hasGroup('C0004') ? 'granted' : 'denied',
      ad_personalization: hasGroup('C0004') ? 'granted' : 'denied',
      security_storage: 'granted',
    });
  }
  function OptanonWrapper() { mjhUpdateGoogleConsent(); }
  window.addEventListener('OneTrustGroupsUpdated', mjhUpdateGoogleConsent);
</script><script async type="text/plain" class="optanon-category-C0004" src="https://res.lassomarketing.io/scripts/lasso-imp-id-min.js"></script><script>
    !function(){var analytics=window.analytics=window.analytics||[];if(!analytics.initialize)if(analytics.invoked)window.console&&console.error&&console.error("Segment snippet included twice.");else{analytics.invoked=!0;analytics.methods=["trackSubmit","trackClick","trackLink","trackForm","pageview","identify","reset","group","track","ready","alias","debug","page","once","off","on","addSourceMiddleware","addIntegrationMiddleware","setAnonymousId","addDestinationMiddleware"];analytics.factory=function(e){return function(){var t=Array.prototype.slice.call(arguments);t.unshift(e);analytics.push(t);return analytics}};for(var e=0;e<analytics.methods.length;e++){var key=analytics.methods[e];analytics[key]=analytics.factory(key)}analytics.load=function(key,e){var t=document.createElement("script");t.type="text/javascript";t.async=!0;t.src="https://cdn.segment.com/analytics.js/v1/"+key+"/analytics.min.js";var n=document.getElementsByTagName("script")[0];n.parentNode.insertBefore(t,n);analytics._loadOptions=e};analytics.SNIPPET_VERSION="4.13.1";

  var loaded = false;
  function loadSegment(lassoImpressionId) {
    if (loaded) return;
    loaded = true;
    window.LassoImpressionID = lassoImpressionId || '';
    withOneTrust(analytics).load("BBbKMoOjmhsxPnbd2nO6osz3zq67DzuN");
    analytics.page({ LassoImpressionID: window.LassoImpressionID });
  }

  if (!true) {
    loadSegment('');
    return;
  }

  var lassoAttempts = 0;
  function checkLasso() {
    if (typeof lassoImpID !== 'undefined') {
      loadSegment(lassoImpID());
    } else if (lassoAttempts >= 8) {
      loadSegment('');
    } else {
      lassoAttempts++;
      setTimeout(checkLasso, 250);
    }
  }
  checkLasso();
  }}();
</script><template data-mjh-forms-origin="https://forms.mjhlifesciences.com"></template><script type="module">const R="mjh:forms-consent-request",y="mjh:forms-consent-state",h="C0002",N="C0003",F="C0004",i=Object.freeze({performance:!1,functional:!1,targeting:!1}),w=["type","version"];function A(t){return typeof t=="object"&&t!==null&&!Array.isArray(t)}function U(t,e){return Object.keys(t).length===e.length&&e.every(r=>Object.prototype.hasOwnProperty.call(t,r))}function j(t){return!A(t)||!U(t,w)?!1:t.type===R&&t.version===1}function P(t,e=i){const n=t?{performance:e.performance===!0,functional:e.functional===!0,targeting:e.targeting===!0}:{...i};return{type:y,version:1,resolved:t,categories:n}}function m(t){const e=Array.isArray(t)?t.filter(r=>typeof r=="string"):typeof t=="string"?t.split(","):[],n=new Set(e.map(r=>r.trim()).filter(Boolean));return{performance:n.has(h),functional:n.has(N),targeting:n.has(F)}}const T="OneTrustGroupsUpdated";function b(t,e){const n=t.getAttribute("src");if(!n)return null;try{return new URL(n,e.baseURI).origin}catch{return null}}function p(t,e){return Array.from(t.querySelectorAll("iframe")).filter(n=>b(n,t)===e)}function G(t){const e=t.__mjhFormsConsentParentCapture;return e?.seen===!0?{resolved:!0,categories:m(e.groups)}:{resolved:!1,categories:{...i}}}function I(t){const e=t.win??window,n=t.doc??e.document,{formsOrigin:r,hasCmp:c}=t,l=()=>typeof c=="function"?c():c;let a=!1,u={...i};if(l()){const o=G(e);a=o.resolved,u=o.categories}const d=()=>P(a,u),O=o=>{if(o)try{o.postMessage(d(),r)}catch{}},f=()=>{for(const o of p(n,r))O(o.contentWindow)},_=o=>{if(!l())return;const s=o.detail,E=Array.isArray(s)?m(s):m(typeof e.OnetrustActiveGroups=="string"?e.OnetrustActiveGroups:[]);a=!0,u=E,f()},g=o=>{if(o.origin!==r||!j(o.data))return;const s=o.source;!s||!p(n,r).some(C=>C.contentWindow===s)||O(s)};return e.addEventListener(T,_),e.addEventListener("message",g),f(),{getState:d,broadcast:f,destroy(){e.removeEventListener(T,_),e.removeEventListener("message",g)}}}function L(t){const e=t.win??window;if(e.__mjhFormsConsentBridge)return e.__mjhFormsConsentBridge;const n=I(t),r={getState:n.getState,broadcast:n.broadcast,destroy(){n.destroy(),e.__mjhFormsConsentBridge===r&&delete e.__mjhFormsConsentBridge}};return e.__mjhFormsConsentBridge=r,r}function B(t=document){return t.querySelector("script[data-domain-script]")!==null}const S=document.querySelector("template[data-mjh-forms-origin]")?.getAttribute("data-mjh-forms-origin"),M=t=>{if(!t)return!1;try{const e=new URL(t);return e.origin!==t?!1:e.protocol==="https:"||e.protocol==="http:"&&["localhost","127.0.0.1"].includes(e.hostname)}catch{return!1}};M(S)&&L({formsOrigin:S,hasCmp:()=>B()});</script><!-- Safe globals for ad components. With no OneTrust ID they remain inert. --><script>
      window.googletag = window.googletag || { cmd: [] };
      window.onDvtagReady = function (callback, timeout = 750) {
        window.dvtag = window.dvtag || {};
        window.dvtag.cmd = window.dvtag.cmd || [];
        const opt = { callback, timeout, timestamp: new Date().getTime() };
        window.dvtag.cmd.push(function () {
          window.dvtag.queueAdRequest(opt);
        });
        setTimeout(function () {
          const cb = opt.callback;
          opt.callback = null;
          if (cb) cb();
        }, timeout);
      };
    </script><!-- GPT is not consent-gated: InitLoadSignals switches it to limited ads
         (no cookies, no personalization) without C0004. That switch only works
         from Google's limited-ads URL, so load from pagead2, not securepubads. --><script async src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async type="text/plain" class="optanon-category-C0004" src="https://pub.doubleverify.com/dvtag/20083417/DV1815449/pub.js"></script><script type="text/plain" class="optanon-category-C0002">
    (function (w, d, s, l, i) {
      w[l] = w[l] || [];
      w[l].push({ 'gtm.start': new Date().getTime(), event: 'gtm.js' });
      var f = d.getElementsByTagName(s)[0],
        j = d.createElement(s),
        dl = l != 'dataLayer' ? '&l=' + l : '';
      j.async = true;
      j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
      f.parentNode.insertBefore(j, f);
    })(window, document, 'script', 'dataLayer', "GTM-5KJPVFH");
  </script><!-- <ClientRouter  /> --><link rel="stylesheet" href="/_astro/_slug_.Ca0mYasc.css">
<style>:root{--primary-color: 192 100% 30%;--primary-color-dark: 192 100% 20%;--secondary-color: 205 75% 84%;--header-primary-color: 0 0% 100%;--header-primary-foreground: 0 0% 0%;--header-secondary-color: 192 100% 30%;--header-secondary-foreground: 0 0% 100%;--header-specialty-color: 0 0% 100%;--header-specialty-foreground: 0 0% 30%;--header-link-color: 0 0% 100%;--header-link-foreground: 0 0% 0%;--footer-primary-color: 192 100% 30%;--footer-primary-foreground: 205 75% 84%;--footer-secondary-color: 205 73% 84%;--footer-secondary-foreground: 192 100% 30%;--accent-color: 45 100% 50%;--warning-color: 348 98% 31%;--success-color: 126 43% 50%;--border-color: 0 0% 93.3%;--background-color: 0 0% 100%;--text-default-color: 0 0% 40%;--text-light-color: 0 0% 55%;--text-dark-color: 0 0% 7%;--link-color: 192 100% 30%;--link-hover-color: 348 98% 31%}
@keyframes form-builder-rich-content-reveal{0%{grid-template-rows:0fr;opacity:0;transform:translateY(-.5rem)}to{grid-template-rows:1fr;opacity:1;transform:translateY(0)}}.form-builder-rich-content-reveal{display:grid;animation:form-builder-rich-content-reveal .45s ease-out forwards}.form-builder-rich-content-reveal>.form-builder-rich-content-reveal-inner{min-height:0;overflow:hidden}@media (prefers-reduced-motion: reduce){.form-builder-rich-content-reveal{animation:none}}._blockContent_tqjon_1 p{margin-bottom:.75rem;line-height:1.7;font-size:.875rem;overflow-wrap:break-word}._blockContent_tqjon_1 li{font-size:.875rem;line-height:1.7}._blockContent_tqjon_1 a{color:#00f;text-decoration:underline}._blockContent_tqjon_1 .brightcove-fluid{position:relative;padding-bottom:56.25%;height:0;width:100%;margin-bottom:1rem}._blockContent_tqjon_1 .youtube-fluid iframe{height:500px}._blockContent_tqjon_1 .brightcove-fluid .video-js{height:100%;width:100%;position:absolute;inset:0}._blockContent_tqjon_1 blockquote{margin:0 10% 1rem;font-style:italic;text-align:center;font-size:x-large;padding:3rem 0;position:relative;background-image:url("data:image/svg+xml;utf8,<svg xmlns='http://www.w3.org/2000/svg' xmlns:xlink='http://www.w3.org/1999/xlink' viewBox='0 0 400 300'><polygon opacity='0.15' fill='currentColor' points='184,40 108,150 166,150 166,300 0,300 16,139 103,40'/><polygon opacity='0.15' fill='currentColor' points='216,260 292,150 234,150 234,0 400,0 384,161 297,260'/></svg>");background-repeat:no-repeat;background-position:top left;background-size:50px 50px}@media (max-width: 766px){._blockContent_tqjon_1 h6{overflow-wrap:break-word}._blockContent_tqjon_1 .multi-media-container div{flex-wrap:wrap}._blockContent_tqjon_1 .multi-media-container div .mobile-styling{width:100%}._blockContent_tqjon_1 .youtube-fluid iframe{height:360px}}@media (min-width: 768px){._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="4"]{height:100px}._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="3"]{height:130px}._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="2"]{height:200px}}@media (min-width: 992px){._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="4"]{height:150px}._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="3"]{height:200px}._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="2"]{height:300px}}.creative-slider-range{background:linear-gradient(to right,var(--creative-slider-fill-color) 0%,var(--creative-slider-fill-color) var(--creative-slider-percent),var(--creative-slider-track-color) var(--creative-slider-percent),var(--creative-slider-track-color) 100%)}.creative-slider-range::-webkit-slider-thumb{-webkit-appearance:none;appearance:none;width:34px;height:34px;border:4px solid var(--creative-slider-fill-color);border-radius:9999px;background:var(--creative-slider-thumb-color);box-shadow:0 6px 18px #0f172a2e;cursor:pointer}.creative-slider-range::-moz-range-thumb{width:28px;height:28px;border:4px solid var(--creative-slider-fill-color);border-radius:9999px;background:var(--creative-slider-thumb-color);box-shadow:0 6px 18px #0f172a2e;cursor:pointer}
</style>
<link rel="stylesheet" href="/_astro/index.BDf1c5ta.css">
<style>.embla{overflow:hidden;height:100%;width:100%}.embla__container{display:flex;flex-direction:column;height:85%;padding:0 0 2%}.vjs-text-track-cue{font-size:1.5rem!important}.embla__slide{flex:0 0 100%;min-width:0;height:100%;display:flex;align-items:center;justify-content:center;margin:0 0 calc(15% / 9);opacity:.3;transform:scale(.95);transition:opacity .3s ease,transform .3s ease}.embla__slide.is-snapped{opacity:1;transform:scale(1);z-index:2}.embla__slide.is-in-view:not(.is-snapped){opacity:.6;transform:scale(.97)}.embla__slide:not(.is-snapped) .shorts-video-container:after{content:"";position:absolute;inset:0;background:linear-gradient(to bottom,#0000001a,#0000004d,#0000001a);pointer-events:none;z-index:1}.embla.is-wheel-scrolling{cursor:grabbing}.embla.is-wheel-scrolling .embla__slide{pointer-events:none}.shorts-item{height:100%;position:relative;display:flex;flex-direction:column;align-items:center;justify-content:center;padding:0}.shorts-video-container{position:relative;width:100%;height:100%;max-height:min(90vh,calc(100vw * 16 / 9));margin:0 auto;border-radius:12px}@supports (aspect-ratio: 9 / 16){.shorts-video-container{aspect-ratio:9 / 16;width:auto;height:100%}}@supports not (aspect-ratio: 9 / 16){.shorts-video-container{width:56.25vh;height:100%}}.shorts-video-wrapper{position:relative;width:100%;height:100%}.bg-shorts-container .video-js{width:100%!important;height:100%!important;-o-object-fit:cover;object-fit:cover;position:absolute;top:0;left:0}.bg-shorts-container .video-js video{width:100%!important;height:100%!important;-o-object-fit:cover;object-fit:cover;position:absolute;top:0;left:0}.bg-shorts-container{width:100%;height:100%;position:relative}@media (max-width: 768px){.shorts-video-container{max-width:90vw}@supports (aspect-ratio: 9 / 16){.shorts-video-container{height:100%;max-height:75vh}}}.shorts-navigation-btn{transition:all .2s ease-in-out}.shorts-navigation-btn:hover{transform:scale(1.1);background-color:#ffffff4d}.shorts-navigation-btn:active{transform:scale(.95)}@keyframes pulse{0%,to{opacity:1}50%{opacity:.5}}.loading-pulse{animation:pulse 2s cubic-bezier(.4,0,.6,1) infinite}.shorts-overlay{background:linear-gradient(to top,rgba(0,0,0,.8) 0%,rgba(0,0,0,.4) 50%,transparent 100%)}.shorts-navigation,.shorts-navigation button{z-index:9999!important;pointer-events:auto}@media (max-width: 768px){.shorts-navigation{right:8px}.shorts-navigation button{width:32px;height:32px}}
</style>
<link rel="stylesheet" href="/_astro/chat-ui.Bja54IWp.css">
<style>@keyframes form-builder-rich-content-reveal{0%{grid-template-rows:0fr;opacity:0;transform:translateY(-.5rem)}to{grid-template-rows:1fr;opacity:1;transform:translateY(0)}}.form-builder-rich-content-reveal{display:grid;animation:form-builder-rich-content-reveal .45s ease-out forwards}.form-builder-rich-content-reveal>.form-builder-rich-content-reveal-inner{min-height:0;overflow:hidden}@media (prefers-reduced-motion: reduce){.form-builder-rich-content-reveal{animation:none}}._blockContent_tqjon_1 p{margin-bottom:.75rem;line-height:1.7;font-size:.875rem;overflow-wrap:break-word}._blockContent_tqjon_1 li{font-size:.875rem;line-height:1.7}._blockContent_tqjon_1 a{color:#00f;text-decoration:underline}._blockContent_tqjon_1 .brightcove-fluid{position:relative;padding-bottom:56.25%;height:0;width:100%;margin-bottom:1rem}._blockContent_tqjon_1 .youtube-fluid iframe{height:500px}._blockContent_tqjon_1 .brightcove-fluid .video-js{height:100%;width:100%;position:absolute;inset:0}._blockContent_tqjon_1 blockquote{margin:0 10% 1rem;font-style:italic;text-align:center;font-size:x-large;padding:3rem 0;position:relative;background-image:url("data:image/svg+xml;utf8,<svg xmlns='http://www.w3.org/2000/svg' xmlns:xlink='http://www.w3.org/1999/xlink' viewBox='0 0 400 300'><polygon opacity='0.15' fill='currentColor' points='184,40 108,150 166,150 166,300 0,300 16,139 103,40'/><polygon opacity='0.15' fill='currentColor' points='216,260 292,150 234,150 234,0 400,0 384,161 297,260'/></svg>");background-repeat:no-repeat;background-position:top left;background-size:50px 50px}@media (max-width: 766px){._blockContent_tqjon_1 h6{overflow-wrap:break-word}._blockContent_tqjon_1 .multi-media-container div{flex-wrap:wrap}._blockContent_tqjon_1 .multi-media-container div .mobile-styling{width:100%}._blockContent_tqjon_1 .youtube-fluid iframe{height:360px}}@media (min-width: 768px){._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="4"]{height:100px}._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="3"]{height:130px}._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="2"]{height:200px}}@media (min-width: 992px){._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="4"]{height:150px}._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="3"]{height:200px}._blockContent_tqjon_1 .multi-media-image-container .multi-media-image[images-count="2"]{height:300px}}.creative-slider-range{background:linear-gradient(to right,var(--creative-slider-fill-color) 0%,var(--creative-slider-fill-color) var(--creative-slider-percent),var(--creative-slider-track-color) var(--creative-slider-percent),var(--creative-slider-track-color) 100%)}.creative-slider-range::-webkit-slider-thumb{-webkit-appearance:none;appearance:none;width:34px;height:34px;border:4px solid var(--creative-slider-fill-color);border-radius:9999px;background:var(--creative-slider-thumb-color);box-shadow:0 6px 18px #0f172a2e;cursor:pointer}.creative-slider-range::-moz-range-thumb{width:28px;height:28px;border:4px solid var(--creative-slider-fill-color);border-radius:9999px;background:var(--creative-slider-thumb-color);box-shadow:0 6px 18px #0f172a2e;cursor:pointer}
</style>
<link rel="stylesheet" href="/_astro/index.BBKiLYLg.css"><script type="module" src="/_astro/page.D1uwR3nK.js"></script></head> <body> <style>astro-island,astro-slot,astro-static-slot{display:contents}</style><script>(()=>{var e=async t=>{await(await t())()};(self.Astro||(self.Astro={})).load=e;window.dispatchEvent(new Event("astro:load"));})();</script><script>(()=>{var A=Object.defineProperty;var g=(i,o,a)=>o in i?A(i,o,{enumerable:!0,configurable:!0,writable:!0,value:a}):i[o]=a;var d=(i,o,a)=>g(i,typeof o!="symbol"?o+"":o,a);{let i={0:t=>m(t),1:t=>a(t),2:t=>new RegExp(t),3:t=>new Date(t),4:t=>new Map(a(t)),5:t=>new Set(a(t)),6:t=>BigInt(t),7:t=>new URL(t),8:t=>new Uint8Array(t),9:t=>new Uint16Array(t),10:t=>new Uint32Array(t),11:t=>1/0*t},o=t=>{let[l,e]=t;return l in i?i[l](e):void 0},a=t=>t.map(o),m=t=>typeof t!="object"||t===null?t:Object.fromEntries(Object.entries(t).map(([l,e])=>[l,o(e)]));class y extends HTMLElement{constructor(){super(...arguments);d(this,"Component");d(this,"hydrator");d(this,"hydrate",async()=>{var b;if(!this.hydrator||!this.isConnected)return;let e=(b=this.parentElement)==null?void 0:b.closest("astro-island[ssr]");if(e){e.addEventListener("astro:hydrate",this.hydrate,{once:!0});return}let c=this.querySelectorAll("astro-slot"),n={},h=this.querySelectorAll("template[data-astro-template]");for(let r of h){let s=r.closest(this.tagName);s!=null&&s.isSameNode(this)&&(n[r.getAttribute("data-astro-template")||"default"]=r.innerHTML,r.remove())}for(let r of c){let s=r.closest(this.tagName);s!=null&&s.isSameNode(this)&&(n[r.getAttribute("name")||"default"]=r.innerHTML)}let p;try{p=this.hasAttribute("props")?m(JSON.parse(this.getAttribute("props"))):{}}catch(r){let s=this.getAttribute("component-url")||"<unknown>",v=this.getAttribute("component-export");throw v&&(s+=` (export ${v})`),console.error(`[hydrate] Error parsing props for component ${s}`,this.getAttribute("props"),r),r}let u;await this.hydrator(this)(this.Component,p,n,{client:this.getAttribute("client")}),this.removeAttribute("ssr"),this.dispatchEvent(new CustomEvent("astro:hydrate"))});d(this,"unmount",()=>{this.isConnected||this.dispatchEvent(new CustomEvent("astro:unmount"))})}disconnectedCallback(){document.removeEventListener("astro:after-swap",this.unmount),document.addEventListener("astro:after-swap",this.unmount,{once:!0})}connectedCallback(){if(!this.hasAttribute("await-children")||document.readyState==="interactive"||document.readyState==="complete")this.childrenConnectedCallback();else{let e=()=>{document.removeEventListener("DOMContentLoaded",e),c.disconnect(),this.childrenConnectedCallback()},c=new MutationObserver(()=>{var n;((n=this.lastChild)==null?void 0:n.nodeType)===Node.COMMENT_NODE&&this.lastChild.nodeValue==="astro:end"&&(this.lastChild.remove(),e())});c.observe(this,{childList:!0}),document.addEventListener("DOMContentLoaded",e)}}async childrenConnectedCallback(){let e=this.getAttribute("before-hydration-url");e&&await import(e),this.start()}async start(){let e=JSON.parse(this.getAttribute("opts")),c=this.getAttribute("client");if(Astro[c]===void 0){window.addEventListener(`astro:${c}`,()=>this.start(),{once:!0});return}try{await Astro[c](async()=>{let n=this.getAttribute("renderer-url"),[h,{default:p}]=await Promise.all([import(this.getAttribute("component-url")),n?import(n):()=>()=>{}]),u=this.getAttribute("component-export")||"default";if(!u.includes("."))this.Component=h[u];else{this.Component=h;for(let f of u.split("."))this.Component=this.Component[f]}return this.hydrator=p,this.hydrate},e,this)}catch(n){console.error(`[astro-island] Error hydrating ${this.getAttribute("component-url")}`,n)}}attributeChangedCallback(){this.hydrate()}}d(y,"observedAttributes",["props"]),customElements.get("astro-island")||customElements.define("astro-island",y)}})();</script><astro-island uid="1XbiL7" prefix="r16" component-url="/_astro/atoms.WR9ilctc.js" component-export="SanityClient" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;config&quot;:[0,{&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;useCdn&quot;:[0,true]}]}" ssr client="load" opts="{&quot;name&quot;:&quot;SanityClient&quot;,&quot;value&quot;:true}"></astro-island>  <astro-island uid="nyNrA" prefix="r17" component-url="/_astro/react.C2-qfAg2.js" component-export="AuthInit" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;config&quot;:[0,{&quot;region&quot;:[0,&quot;us-east-1&quot;],&quot;userPoolId&quot;:[0,&quot;us-east-1_qvUR8zszr&quot;],&quot;userPoolClientId&quot;:[0,&quot;72sqb1hdl874l7itgfjdcgd93r&quot;],&quot;oauthDomain&quot;:[0,&quot;id.mjhlifesciences.com&quot;],&quot;brandHost&quot;:[0],&quot;redirectSignIn&quot;:[1,[[0,&quot;https://www.cancernetwork.com/auth/callback&quot;]]],&quot;redirectSignOut&quot;:[1,[[0,&quot;https://www.cancernetwork.com&quot;]]]}]}" ssr client="load" opts="{&quot;name&quot;:&quot;AuthInit&quot;,&quot;value&quot;:true}"></astro-island> <!-- <VisualEditing enabled={visualEditingEnabled} zIndex={1000} /> -->    <script>(()=>{var e=async t=>{await(await t())()};(self.Astro||(self.Astro={})).only=e;window.dispatchEvent(new Event("astro:only"));})();</script><astro-island uid="1RQrsU" component-url="/_astro/index.CbMAomMR.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;settings&quot;:[0,{&quot;siteConfig&quot;:[0,{&quot;sanityClientConfig&quot;:[0,{&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;useCdn&quot;:[0,true]}],&quot;gtmID&quot;:[0,&quot;5KJPVFH&quot;],&quot;title&quot;:[0,&quot;CancerNetwork&quot;],&quot;attentiveLanguageBrandName&quot;:[0,&quot;Cancer Network&quot;],&quot;liveDomain&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;logo&quot;:[0,&quot;/logo.webp&quot;],&quot;white_logo&quot;:[0,&quot;/logo.webp&quot;],&quot;megaMenuTaxName&quot;:[0,&quot;clinical&quot;],&quot;twitter&quot;:[0,&quot;@onclive&quot;],&quot;sharingImageUrl&quot;:[0,&quot;https://cancernetwork.s3.amazonaws.com/cancernetwork-primary-10-15.png&quot;],&quot;fixSecondaryNavigationLinksIdentifier&quot;:[0,true],&quot;oneTrustId&quot;:[0,&quot;0196a059-28cb-71f3-a7fc-4659bcc6ca6d&quot;],&quot;subFooterLinks&quot;:[1,[[0,{&quot;url&quot;:[0,&quot;/&quot;],&quot;title&quot;:[0,&quot;Home&quot;]}],[0,{&quot;url&quot;:[0,&quot;/about&quot;],&quot;title&quot;:[0,&quot;About Us&quot;]}],[0,{&quot;url&quot;:[0,&quot;/news&quot;],&quot;title&quot;:[0,&quot;News&quot;]}],[0,{&quot;url&quot;:[0,&quot;/contact-us&quot;],&quot;title&quot;:[0,&quot;Contact Us&quot;]}]]],&quot;subscribe&quot;:[0,{&quot;href&quot;:[0,&quot;/subscribe&quot;],&quot;text&quot;:[0,&quot;Stay up to date on recent advances in the multidisciplinary approach to cancer.&quot;]}],&quot;customSpecialtyText&quot;:[0,&quot;Cancer Focus&quot;]}],&quot;styleConfig&quot;:[0,{&quot;logoSize&quot;:[0,&quot;medium&quot;],&quot;navigation&quot;:[0,5],&quot;footer&quot;:[0,1],&quot;featureDeck&quot;:[0,5],&quot;featureSlider&quot;:[0,1]}],&quot;adConfig&quot;:[0,{&quot;networkID&quot;:[0,&quot;4688&quot;],&quot;adUnit&quot;:[0,&quot;cmpm.cancernetwork&quot;]}],&quot;pageConfig&quot;:[0,{&quot;publicationName&quot;:[0,&quot;CancerNetwork&quot;],&quot;publicationUrl&quot;:[0,&quot;journals&quot;],&quot;authorUrl&quot;:[0,&quot;authors&quot;]}],&quot;sanityConfig&quot;:[0,{&quot;taxonomy&quot;:[0,{&quot;news&quot;:[0,&quot;cn_taxonomy_5565_news&quot;],&quot;conference&quot;:[0,&quot;f37ff7cb-bf12-45d7-aa1d-508e79d3b99f&quot;],&quot;clinical&quot;:[0,&quot;d4c0d7f9-f28d-423f-8bdc-0b7e0d1333d9&quot;]}],&quot;docGroup&quot;:[0,{&quot;conference&quot;:[0,&quot;cn_documentGroup_53204_conference&quot;]}],&quot;contentCategory&quot;:[0,{&quot;articles&quot;:[0,&quot;8bdaa7fc-960a-4b57-b076-75fdce3741bb&quot;],&quot;sponsored&quot;:[0,&quot;f62337b2-e8ae-4a6a-beb6-c93553984c92&quot;],&quot;videos&quot;:[0,&quot;42000fd0-0d05-4832-9f2c-62c21079b76c&quot;],&quot;podcasts&quot;:[0,&quot;93d57b69-2d72-45fe-8b8a-d18e7e7e5f20&quot;],&quot;poll&quot;:[0,&quot;9e4880fc-85b8-4ffb-a066-79af8dfaa4e1&quot;],&quot;hero&quot;:[0,&quot;2504da4c-b21a-465e-88ba-3841a00c0395&quot;],&quot;slideshows&quot;:[0,&quot;61085300-0cae-4cd1-b0e8-26323ac5c2e6&quot;]}]}],&quot;customPageTypes&quot;:[1,[]],&quot;gateEnabled&quot;:[0,&quot;modal&quot;],&quot;sMaxAge&quot;:[0,300],&quot;staleWhileRevalidate&quot;:[0,329],&quot;allowedDomains&quot;:[1,[[0,&quot;ce.dvm360.com&quot;],[0,&quot;www.pharmacytimes.org&quot;],[0,&quot;www.gotoper.com&quot;]]]}],&quot;targeting&quot;:[0,{&quot;content_placement&quot;:[1,[[0,&quot;news&quot;],[0,&quot;journals/oncology&quot;]]],&quot;document_url&quot;:[1,[[0,&quot;gerson-regimen&quot;]]],&quot;document_group&quot;:[1,[]],&quot;content_group&quot;:[1,[]],&quot;rootDocumentGroup&quot;:[1,[]],&quot;issue_url&quot;:[1,[[0,&quot;oncology-vol-24-no-2&quot;]]],&quot;publication_url&quot;:[1,[[0,&quot;oncology&quot;]]],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;barrie-r-cassileth-ms-phd&quot;]]],&quot;hostname&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;adLayer&quot;:[0,{&quot;adSlotSelection&quot;:[1,[]]}]}],&quot;gateData&quot;:[0,{}]}" ssr client="only" opts="{&quot;name&quot;:&quot;ADWelcome&quot;,&quot;value&quot;:true}"></astro-island> <!--
  top-banner slot — rendered immediately after the welcome ad so the
  marketing-layer top banner sits below ADWelcome in the DOM instead of
  above it. Marketing-layer wiring stays in DynamicRoute; this slot only
  controls vertical position. Brands that don't pass slot content (e.g.
  retinaresource's per-site DynamicRoute) get an empty slot and no change.
-->  <astro-island uid="Zu7phk" prefix="r68" component-url="/_astro/ADFloatingFooter.B82scVrj.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;networkID&quot;:[0,&quot;4688&quot;],&quot;adUnit&quot;:[0,&quot;cmpm.cancernetwork&quot;],&quot;targeting&quot;:[0,{&quot;content_placement&quot;:[1,[[0,&quot;news&quot;],[0,&quot;journals/oncology&quot;]]],&quot;document_url&quot;:[1,[[0,&quot;gerson-regimen&quot;]]],&quot;document_group&quot;:[1,[]],&quot;content_group&quot;:[1,[]],&quot;rootDocumentGroup&quot;:[1,[]],&quot;issue_url&quot;:[1,[[0,&quot;oncology-vol-24-no-2&quot;]]],&quot;publication_url&quot;:[1,[[0,&quot;oncology&quot;]]],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;barrie-r-cassileth-ms-phd&quot;]]],&quot;hostname&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;adLayer&quot;:[0,{&quot;adSlotSelection&quot;:[1,[]]}]}]}" ssr client="load" opts="{&quot;name&quot;:&quot;ADFloatingFooter&quot;,&quot;value&quot;:true}"></astro-island>     <astro-island uid="ZKARGH" prefix="r69" component-url="/_astro/ui.3g1jLusn.js" component-export="N5" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[0,{&quot;logoImage&quot;:[0,&quot;/logo.webp&quot;],&quot;mainLinks&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-04T09:53:43Z&quot;],&quot;_id&quot;:[0,&quot;73d769ef-2a17-46a6-bca8-0d20b68df649&quot;],&quot;_rev&quot;:[0,&quot;nb51mS4i9uU7ms5EQhHDKL&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-04-27T17:35:52Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;News&quot;],&quot;navParent&quot;:[0,null],&quot;sortOrder&quot;:[0,1],&quot;subQuery&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2022-01-20T15:04:48Z&quot;],&quot;_id&quot;:[0,&quot;d1f2a13e-1c25-4545-b106-0da70537e7ee&quot;],&quot;_rev&quot;:[0,&quot;OU32WOWh4YetHW0RkaOogi&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2022-01-20T15:10:10Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Global Bulletin&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;73d769ef-2a17-46a6-bca8-0d20b68df649&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;sortOrder&quot;:[0,3],&quot;url&quot;:[0,&quot;/global-bulletin&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-12T18:51:02Z&quot;],&quot;_id&quot;:[0,&quot;f9fa6861-cc03-4f97-9246-26ca43500332&quot;],&quot;_rev&quot;:[0,&quot;S0vXfcLWHTxXts4KsVzUPY&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2022-01-20T15:10:00Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;All News&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;73d769ef-2a17-46a6-bca8-0d20b68df649&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;sortOrder&quot;:[0,4],&quot;url&quot;:[0,&quot;/news&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2022-01-27T20:28:04Z&quot;],&quot;_id&quot;:[0,&quot;62f8ee51-aaad-464c-a5c2-43cb4a3b89fb&quot;],&quot;_rev&quot;:[0,&quot;o0IWerqcgsmXfA4Y1GQz2E&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-05-02T19:03:42Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;FDA Approval Alert&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;73d769ef-2a17-46a6-bca8-0d20b68df649&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/approval-alert&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2024-04-08T13:01:22Z&quot;],&quot;_id&quot;:[0,&quot;41eeee0e-d48c-4551-8e6e-2edd7c2064f4&quot;],&quot;_rev&quot;:[0,&quot;Mybxr4UNDjZgGKB8bCbAz5&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-05-02T19:04:27Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Women in Oncology&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;73d769ef-2a17-46a6-bca8-0d20b68df649&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/breaking-barriers&quot;]}]]],&quot;url&quot;:[0,&quot;/news&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-04T09:54:08Z&quot;],&quot;_id&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_rev&quot;:[0,&quot;nb51mS4i9uU7ms5EQhHDKL&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-04-27T17:35:48Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Media&quot;],&quot;navParent&quot;:[0,null],&quot;sortOrder&quot;:[0,2],&quot;subQuery&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2020-12-15T15:09:48Z&quot;],&quot;_id&quot;:[0,&quot;89c761ea-99c7-4918-b089-1bca2438af72&quot;],&quot;_rev&quot;:[0,&quot;n61pqJnY1CfDlUJFhf9EqD&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-12-22T15:38:44Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Around the Practice&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/around-the-practice&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2021-07-28T15:09:24Z&quot;],&quot;_id&quot;:[0,&quot;a9b98727-6afd-414d-acf7-75d2cd8d0d4f&quot;],&quot;_rev&quot;:[0,&quot;Cg9Iz2Ikq02EDLUz9Ojd5w&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2021-08-31T18:10:27Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Between the Lines&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/between-the-lines&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2022-03-25T15:06:04Z&quot;],&quot;_id&quot;:[0,&quot;3b11ef7d-df88-4df1-acc2-ad6b0e394952&quot;],&quot;_rev&quot;:[0,&quot;o1YOBeHimNufrIGjtZJEPM&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2022-03-25T15:06:04Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Face Off&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/face-off&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2024-10-22T20:32:35Z&quot;],&quot;_id&quot;:[0,&quot;7d1b304d-8193-4890-afa9-e626062161c7&quot;],&quot;_rev&quot;:[0,&quot;q15rgr9KO9mLI3ePQIuSVN&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2024-10-22T20:33:04Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;From All Angles&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/from-all-angles&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2024-11-25T20:32:29Z&quot;],&quot;_id&quot;:[0,&quot;1ced620a-3c07-4180-a781-040fd80a7bca&quot;],&quot;_rev&quot;:[0,&quot;HG9itg5Um8jvM5zF8LCxVw&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2024-11-25T20:32:51Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Meeting of the Minds&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/meeting-of-the-minds&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2021-01-07T18:04:01Z&quot;],&quot;_id&quot;:[0,&quot;03ca685f-2440-4f5d-9c55-c4fe10f5c786&quot;],&quot;_rev&quot;:[0,&quot;g4B6uv27sZb3vM8Dw7z6fh&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2021-04-20T20:38:25Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;OncView&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/oncview&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-25T10:02:17Z&quot;],&quot;_id&quot;:[0,&quot;5286b7e4-d31e-40b6-8bae-7d4967d7d3a1&quot;],&quot;_rev&quot;:[0,&quot;KpeQ5C4E447AzlNZ6AGRMt&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2024-11-04T16:50:13Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Podcasts&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/podcasts&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2026-02-24T18:47:49Z&quot;],&quot;_id&quot;:[0,&quot;80da8cb6-c21d-4017-8c61-305dc52f97e1&quot;],&quot;_rev&quot;:[0,&quot;6XsPwpOTKVBr6XShQEDtBw&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-02-24T18:48:55Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Shorts&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/shorts&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2023-03-14T13:54:29Z&quot;],&quot;_id&quot;:[0,&quot;136e1c6e-d48f-41d8-bf9b-51a968a201ef&quot;],&quot;_rev&quot;:[0,&quot;TctAtfg0qER1kILh39jbDu&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2023-03-14T13:54:59Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Training Academy&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/training-academy&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2024-01-18T16:10:29Z&quot;],&quot;_id&quot;:[0,&quot;90bd3f5c-afab-4e51-a13c-17ef8acfc330&quot;],&quot;_rev&quot;:[0,&quot;ZP7627ZkmfDRGke9IVhjwl&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2024-01-18T16:10:52Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Treatment Algorithms with the Oncology Brothers&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/treatment-algorithms-with-the-oncology-brothers?page=1&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2025-06-20T18:59:16Z&quot;],&quot;_id&quot;:[0,&quot;00b032fe-4ddf-4afb-adeb-74c90c71f602&quot;],&quot;_rev&quot;:[0,&quot;LbJ29QIVUPr32oT7mJUvzU&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-06-20T18:59:25Z&quot;],&quot;children&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2026-03-20T20:43:56Z&quot;],&quot;_id&quot;:[0,&quot;11b011a5-54e2-49c1-b8c6-3bf8c84f0329&quot;],&quot;_rev&quot;:[0,&quot;RRBJU8ZKMBnAFwZ5AD9KSB&quot;],&quot;_system&quot;:[0,{&quot;base&quot;:[0,{&quot;id&quot;:[0,&quot;11b011a5-54e2-49c1-b8c6-3bf8c84f0329&quot;],&quot;rev&quot;:[0,&quot;RRBJU8ZKMBnAFwZ5AD9JqF&quot;]}]}],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-03-20T20:45:02Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;TCT Takeaways With Yan Leyfman, MD&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;00b032fe-4ddf-4afb-adeb-74c90c71f602&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/leyfman&quot;]}]]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Videos&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;ace79040-35ee-4def-a64e-3816f4c5917b&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/videos&quot;]}]]]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-04T09:55:43Z&quot;],&quot;_id&quot;:[0,&quot;878118ee-82b5-40ee-8a2c-c75620c0681b&quot;],&quot;_rev&quot;:[0,&quot;nb51mS4i9uU7ms5EQhHDKL&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-04-27T17:35:43Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Conferences&quot;],&quot;navParent&quot;:[0,null],&quot;sortOrder&quot;:[0,3],&quot;subQuery&quot;:[1,[]],&quot;url&quot;:[0,&quot;/conference&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-04T13:38:12Z&quot;],&quot;_id&quot;:[0,&quot;60871695-8ad3-4415-b75f-58b7f6d36700&quot;],&quot;_rev&quot;:[0,&quot;tCyBcWK3K6yQ8bZ6dqW4mB&quot;],&quot;_system&quot;:[0,{&quot;base&quot;:[0,{&quot;id&quot;:[0,&quot;60871695-8ad3-4415-b75f-58b7f6d36700&quot;],&quot;rev&quot;:[0,&quot;nb51mS4i9uU7ms5EQhHDKL&quot;]}]}],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-09-19T17:43:29Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Publications&quot;],&quot;navParent&quot;:[0,null],&quot;sortOrder&quot;:[0,4],&quot;subQuery&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-04T13:39:31Z&quot;],&quot;_id&quot;:[0,&quot;4af570d1-18e7-492b-b6c6-54665e0a6c69&quot;],&quot;_rev&quot;:[0,&quot;Tc9ST9mIPUT5XLQ0xBp7Fk&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2021-10-15T18:57:48Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;All Journals&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;60871695-8ad3-4415-b75f-58b7f6d36700&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/journals&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2021-10-15T18:55:55Z&quot;],&quot;_id&quot;:[0,&quot;d25e2297-5868-45e4-91a8-4ffcd99102c1&quot;],&quot;_rev&quot;:[0,&quot;KTLLlpzz189b3POEW8L7tW&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2023-10-12T13:57:27Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Editorial Board&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;60871695-8ad3-4415-b75f-58b7f6d36700&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/oncology-journal/editors&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2021-10-15T18:56:31Z&quot;],&quot;_id&quot;:[0,&quot;aa327337-7647-4ccc-bbaa-769521ffdbd4&quot;],&quot;_rev&quot;:[0,&quot;lE8wIZ9OsNdmoPpth87tIB&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2023-02-17T21:58:01Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;For Authors&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;60871695-8ad3-4415-b75f-58b7f6d36700&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/oncology-journal&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2024-12-19T16:13:29Z&quot;],&quot;_id&quot;:[0,&quot;ade863ff-b1cc-4e65-88c2-7fd01f00eea1&quot;],&quot;_rev&quot;:[0,&quot;FbziG4hixVI5tq0aWIoP6A&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2024-12-19T16:13:45Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Year in Review&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;60871695-8ad3-4415-b75f-58b7f6d36700&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/year-in-review&quot;]}]]],&quot;url&quot;:[0,&quot;/journals&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-12-15T15:09:32Z&quot;],&quot;_id&quot;:[0,&quot;08936756-f409-4fc5-9427-b0a1b73410f0&quot;],&quot;_rev&quot;:[0,&quot;tCyBcWK3K6yQ8bZ6dqQg47&quot;],&quot;_system&quot;:[0,{&quot;base&quot;:[0,{&quot;id&quot;:[0,&quot;08936756-f409-4fc5-9427-b0a1b73410f0&quot;],&quot;rev&quot;:[0,&quot;ZQ1pHa0FSoYyNdjZM3Tq1s&quot;]}]}],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-09-19T16:21:31Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Events&quot;],&quot;navParent&quot;:[0,null],&quot;sortOrder&quot;:[0,5],&quot;subQuery&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2022-08-08T16:15:11Z&quot;],&quot;_id&quot;:[0,&quot;84987d48-a1ac-42aa-bfd1-3eb2fcc0fd40&quot;],&quot;_rev&quot;:[0,&quot;Au5FQX1Tn0XiNGHJlsxMXL&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2022-08-08T18:09:06Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Frontline Forum&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;08936756-f409-4fc5-9427-b0a1b73410f0&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/frontline-forum&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2023-03-14T17:17:31Z&quot;],&quot;_id&quot;:[0,&quot;d6f0cf1c-8174-42ca-94b6-342be0c6da11&quot;],&quot;_rev&quot;:[0,&quot;Z87fCgccOv6fV9u7SCvske&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2024-01-25T16:29:21Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Satellite Sessions&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;08936756-f409-4fc5-9427-b0a1b73410f0&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/satellite-sessions&quot;]}]]]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-04-27T17:32:03Z&quot;],&quot;_id&quot;:[0,&quot;da731728-85b9-4e3d-be4a-90603e271abf&quot;],&quot;_rev&quot;:[0,&quot;3ZLFv6zkTKtlSEmNi65Ar6&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2021-01-28T22:23:45Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;CME/CE&quot;],&quot;navParent&quot;:[0,null],&quot;sortOrder&quot;:[0,6],&quot;subQuery&quot;:[1,[]],&quot;url&quot;:[0,&quot;/continuing-education&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-21T16:11:59Z&quot;],&quot;_id&quot;:[0,&quot;0e4e107d-fd6f-46bf-b456-991cb1352ec9&quot;],&quot;_rev&quot;:[0,&quot;YhOde3kZoemWRwPqRdUxEv&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2021-01-28T22:23:30Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Resources&quot;],&quot;navParent&quot;:[0,null],&quot;sortOrder&quot;:[0,7],&quot;subQuery&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2022-08-31T13:44:03Z&quot;],&quot;_id&quot;:[0,&quot;bca9818f-47f0-4dfc-bb60-2ccce94edf4d&quot;],&quot;_rev&quot;:[0,&quot;lMvZbMHTM1M8gRaYkLaHZ0&quot;],&quot;_system&quot;:[0,{&quot;base&quot;:[0,{&quot;id&quot;:[0,&quot;bca9818f-47f0-4dfc-bb60-2ccce94edf4d&quot;],&quot;rev&quot;:[0,&quot;CDXqxqJ4c7akEZTOa6tm2A&quot;]}]}],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-02-18T18:10:32Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Awareness Month&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;0e4e107d-fd6f-46bf-b456-991cb1352ec9&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;sortOrder&quot;:[0,1],&quot;url&quot;:[0,&quot;/awareness-month&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2026-02-18T18:06:36Z&quot;],&quot;_id&quot;:[0,&quot;07b43790-4cf8-4643-a711-a9b0b15d34f3&quot;],&quot;_rev&quot;:[0,&quot;bMzLx7lQUFfrTcFFArDgHk&quot;],&quot;_system&quot;:[0,{&quot;base&quot;:[0,{&quot;id&quot;:[0,&quot;07b43790-4cf8-4643-a711-a9b0b15d34f3&quot;],&quot;rev&quot;:[0,&quot;S4s3yaI81wNC0q4jXoJ16v&quot;]}]}],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-07-15T16:15:33Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;The Bispecifics Network&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;0e4e107d-fd6f-46bf-b456-991cb1352ec9&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;sortOrder&quot;:[0,2],&quot;url&quot;:[0,&quot;/the-bispecifics-network&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-11T14:02:30Z&quot;],&quot;_id&quot;:[0,&quot;6ab73041-1716-492a-94d3-6e864bd51ecf&quot;],&quot;_rev&quot;:[0,&quot;K6I48n2NS1AEwwBAtT1BK8&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2021-10-08T16:30:26Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Nurse Practitioners/Physician&#39;s Assistants&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;0e4e107d-fd6f-46bf-b456-991cb1352ec9&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/roles/nurse&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2021-07-01T20:06:46Z&quot;],&quot;_id&quot;:[0,&quot;5cbc1ecd-2539-48b5-b10e-139fbcf9e36b&quot;],&quot;_rev&quot;:[0,&quot;Nvlj4sUoIeSL1TfxUL2LYj&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2021-07-01T20:06:46Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Partners&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;0e4e107d-fd6f-46bf-b456-991cb1352ec9&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/partners&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2021-02-02T16:34:27Z&quot;],&quot;_id&quot;:[0,&quot;64639699-7299-4373-bfe8-4f070dab7e7f&quot;],&quot;_rev&quot;:[0,&quot;2oYS3tMBWrBZ5fcjWKOT3X&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2021-02-02T16:34:38Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Sponsored&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;0e4e107d-fd6f-46bf-b456-991cb1352ec9&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/resources/sponsored-resources&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2023-03-02T17:04:50Z&quot;],&quot;_id&quot;:[0,&quot;4e3bfb96-b56e-4822-8783-3b2f7c27b1bf&quot;],&quot;_rev&quot;:[0,&quot;o0IWerqcgsmXfA4Y1GUFfe&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-05-02T19:09:58Z&quot;],&quot;children&quot;:[1,[]],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Sponsored Media&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;0e4e107d-fd6f-46bf-b456-991cb1352ec9&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/sponsored-media?page=1&quot;]}]]],&quot;url&quot;:[0,&quot;/resources&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2024-05-02T17:57:43Z&quot;],&quot;_id&quot;:[0,&quot;84dd2e45-1109-4e99-a6a0-88ea6d3b7e08&quot;],&quot;_rev&quot;:[0,&quot;7LI3ZgNaIzU1ATj4YCRP9g&quot;],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-06-05T16:47:25Z&quot;],&quot;blank&quot;:[0,true],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Career Center&quot;],&quot;navParent&quot;:[0,null],&quot;sortOrder&quot;:[0,9],&quot;subQuery&quot;:[1,[]],&quot;url&quot;:[0,&quot;/career-center&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-04-27T17:32:29Z&quot;],&quot;_id&quot;:[0,&quot;2f68fc0f-6830-46cd-988e-9a522a57a35e&quot;],&quot;_rev&quot;:[0,&quot;J3VliBhXp11bg6Txxg2TdZ&quot;],&quot;_system&quot;:[0,{&quot;base&quot;:[0,{&quot;id&quot;:[0,&quot;2f68fc0f-6830-46cd-988e-9a522a57a35e&quot;],&quot;rev&quot;:[0,&quot;KdSi0sfYJE6bgxBjNj5JHU&quot;]}]}],&quot;_type&quot;:[0,&quot;mainNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-03-26T16:36:51Z&quot;],&quot;blank&quot;:[0,true],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Subscribe&quot;],&quot;navParent&quot;:[0,null],&quot;sortOrder&quot;:[0,10],&quot;subQuery&quot;:[1,[]],&quot;url&quot;:[0,&quot;/subscribe&quot;]}]]],&quot;secondaryLinks&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_9_anemia&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;adverse-effects&quot;],&quot;name&quot;:[0,&quot;Adverse Effects&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;f299be6d-b660-4f3e-98ea-677229e8ae3e&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;artifical-intelligence&quot;],&quot;name&quot;:[0,&quot;Artificial Intelligence&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_71_braincancer&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;brain-cancer&quot;],&quot;name&quot;:[0,&quot;Brain Cancer&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_72_breastcancer&quot;],&quot;children&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_196_herpositivebreastcancer&quot;],&quot;identifier&quot;:[0,&quot;her2-positive-breast-cancer&quot;],&quot;name&quot;:[0,&quot;HER2-Positive Breast Cancer&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_419_triplenegativebreastcancer&quot;],&quot;identifier&quot;:[0,&quot;triple-negative-breast-cancer&quot;],&quot;name&quot;:[0,&quot;Triple-Negative Breast Cancer&quot;],&quot;sortOrder&quot;:[0,null]}]]],&quot;identifier&quot;:[0,&quot;breast-cancer&quot;],&quot;name&quot;:[0,&quot;Breast Cancer&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,1]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_176_gastrointestinalcancer&quot;],&quot;children&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_118_colorectalcancer&quot;],&quot;identifier&quot;:[0,&quot;colorectal-cancer&quot;],&quot;name&quot;:[0,&quot;Colorectal Cancer&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_161_esophagealcancer&quot;],&quot;identifier&quot;:[0,&quot;esophageal-cancer&quot;],&quot;name&quot;:[0,&quot;Esophageal Cancer&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_295_pancreaticcancer&quot;],&quot;identifier&quot;:[0,&quot;pancreatic-cancer&quot;],&quot;name&quot;:[0,&quot;Pancreatic Cancer&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_4183_gastriccancer&quot;],&quot;identifier&quot;:[0,&quot;gastric-cancer&quot;],&quot;name&quot;:[0,&quot;Gastric Cancer&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;d1e58a5e-7ace-4695-b24f-e8ad7c464065&quot;],&quot;identifier&quot;:[0,&quot;liver-cancer&quot;],&quot;name&quot;:[0,&quot;Liver Cancer&quot;],&quot;sortOrder&quot;:[0,null]}]]],&quot;identifier&quot;:[0,&quot;gastrointestinal-cancer&quot;],&quot;name&quot;:[0,&quot;Gastrointestinal Cancer&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_183_genitourinarycancers&quot;],&quot;children&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_224_kidneycancer&quot;],&quot;identifier&quot;:[0,&quot;kidney-cancer&quot;],&quot;name&quot;:[0,&quot;Kidney Cancer&quot;],&quot;sortOrder&quot;:[0,2]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_53_bladdercancer&quot;],&quot;identifier&quot;:[0,&quot;bladder-cancer&quot;],&quot;name&quot;:[0,&quot;Bladder Cancer&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_688_prostatecancer&quot;],&quot;identifier&quot;:[0,&quot;prostate-cancer&quot;],&quot;name&quot;:[0,&quot;Prostate Cancer&quot;],&quot;sortOrder&quot;:[0,null]}]]],&quot;identifier&quot;:[0,&quot;genitourinary-cancers&quot;],&quot;name&quot;:[0,&quot;Genitourinary Cancers&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;oncotherapy_taxonomy_186_gynecologiccancers&quot;],&quot;children&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_155_endometrialcancer&quot;],&quot;identifier&quot;:[0,&quot;endometrial-cancer&quot;],&quot;name&quot;:[0,&quot;Endometrial Cancer&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_52236_ovariancancer&quot;],&quot;identifier&quot;:[0,&quot;ovarian-cancer&quot;],&quot;name&quot;:[0,&quot;Ovarian Cancer&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_87_cervicalcancer&quot;],&quot;identifier&quot;:[0,&quot;cervical-cancer&quot;],&quot;name&quot;:[0,&quot;Cervical Cancer&quot;],&quot;sortOrder&quot;:[0,null]}]]],&quot;identifier&quot;:[0,&quot;gynecologic-cancer&quot;],&quot;name&quot;:[0,&quot;Gynecologic Cancers&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_52310_headneckcancer&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;head-neck-cancer&quot;],&quot;name&quot;:[0,&quot;Head &amp; Neck Cancer&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_194_hematology&quot;],&quot;children&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_259_multiplemyeloma&quot;],&quot;identifier&quot;:[0,&quot;multiple-myeloma&quot;],&quot;name&quot;:[0,&quot;Multiple Myeloma&quot;],&quot;sortOrder&quot;:[0,5]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_264_myelodysplasticsyndromes&quot;],&quot;identifier&quot;:[0,&quot;myelodysplastic-syndromes&quot;],&quot;name&quot;:[0,&quot;Myelodysplastic Syndromes&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_4118_myeloproliferativeneoplasms&quot;],&quot;identifier&quot;:[0,&quot;myeloproliferative-neoplasms&quot;],&quot;name&quot;:[0,&quot;Myeloproliferative Neoplasms&quot;],&quot;sortOrder&quot;:[0,null]}]]],&quot;identifier&quot;:[0,&quot;hematology&quot;],&quot;name&quot;:[0,&quot;Hematologic Oncology&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;oncotherapy_taxonomy_672_infection&quot;],&quot;children&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;oncotherapy_taxonomy_699_vaccines&quot;],&quot;identifier&quot;:[0,&quot;vaccines&quot;],&quot;name&quot;:[0,&quot;Vaccines&quot;],&quot;sortOrder&quot;:[0,null]}]]],&quot;identifier&quot;:[0,&quot;infection&quot;],&quot;name&quot;:[0,&quot;Infection&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_20603_leukemia&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;leukemia&quot;],&quot;name&quot;:[0,&quot;Leukemia&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,3]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_51926_lungcancer&quot;],&quot;children&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;0cd241e9-70bb-416a-ba73-287c3d006c22&quot;],&quot;identifier&quot;:[0,&quot;small-cell-lung-cancer&quot;],&quot;name&quot;:[0,&quot;Small Cell Lung Cancer (SCLC)&quot;],&quot;sortOrder&quot;:[0,7]}],[0,{&quot;_id&quot;:[0,&quot;cf2e3b51-125a-4795-9098-f826079e02e9&quot;],&quot;identifier&quot;:[0,&quot;nsclc&quot;],&quot;name&quot;:[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;],&quot;sortOrder&quot;:[0,6]}]]],&quot;identifier&quot;:[0,&quot;lung-cancer&quot;],&quot;name&quot;:[0,&quot;Lung Cancer&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_229_lymphoma&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;lymphoma&quot;],&quot;name&quot;:[0,&quot;Lymphoma&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,4]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_270_neuroendocrinetumors&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;neuroendocrine-tumors&quot;],&quot;name&quot;:[0,&quot;Neuroendocrine Tumors&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_4152_oncology&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;oncology&quot;],&quot;name&quot;:[0,&quot;Oncology&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_3540_pediatriccancers&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;pediatric-cancers&quot;],&quot;name&quot;:[0,&quot;Pediatric Cancers&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;c8955047-0237-4d28-8a47-314a90413e82&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;psycho-oncology&quot;],&quot;name&quot;:[0,&quot;Psycho-Oncology&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;oncotherapy_taxonomy_342_radiationoncology&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;radiation-oncology&quot;],&quot;name&quot;:[0,&quot;Radiation Oncology&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_359_sarcoma&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;sarcoma&quot;],&quot;name&quot;:[0,&quot;Sarcoma&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;oncotherapy_taxonomy_367_screening&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;screening&quot;],&quot;name&quot;:[0,&quot;Screening&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;6241355d-1e60-45b2-86ce-5b6e6bd16ca9&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;skin-cancer-n-melanoma&quot;],&quot;name&quot;:[0,&quot;Skin Cancer &amp; Melanoma&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_4806_surgery&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;surgery&quot;],&quot;name&quot;:[0,&quot;Surgery&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;cn_taxonomy_410_thyroidcancer&quot;],&quot;children&quot;:[1,[]],&quot;identifier&quot;:[0,&quot;thyroid-cancer&quot;],&quot;name&quot;:[0,&quot;Thyroid Cancer&quot;],&quot;parentIdentifier&quot;:[0,&quot;clinical&quot;],&quot;sortOrder&quot;:[0,null]}]]],&quot;socialLinks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;cf1a4e4539f3&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;Facebook&quot;],&quot;url&quot;:[0,&quot;https://www.facebook.com/Cancer-Network-124530046330/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;322cbf854512&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;LinkedIn&quot;],&quot;url&quot;:[0,&quot;https://www.linkedin.com/company/cancer-network/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;95a8c955ea12&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;X&quot;],&quot;url&quot;:[0,&quot;https://twitter.com/CancerNetwrk&quot;]}],[0,{&quot;_key&quot;:[0,&quot;3616df2f3815&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;RSS&quot;],&quot;url&quot;:[0,&quot;/rss.xml&quot;]}],[0,{&quot;_key&quot;:[0,&quot;1c8fcd4705db&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;Youtube&quot;],&quot;url&quot;:[0,&quot;https://www.youtube.com/@CancerNetwork&quot;]}]]],&quot;spotlight&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2026-03-24T19:43:34Z&quot;],&quot;_id&quot;:[0,&quot;16f658a9-fe2e-4455-b65b-499333ef7fbf&quot;],&quot;_rev&quot;:[0,&quot;mtL45ybwAE3Mdps5QkrH1c&quot;],&quot;_type&quot;:[0,&quot;subNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-03-24T19:43:59Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Psycho-Oncology&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;75989b19-cd8d-409b-a1ab-0fa08d53776c&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;sortOrder&quot;:[0,1],&quot;url&quot;:[0,&quot;/clinical/psycho-oncology&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2026-03-27T13:14:53Z&quot;],&quot;_id&quot;:[0,&quot;dd1646e8-05a2-4a17-885d-3ccf13162a0a&quot;],&quot;_rev&quot;:[0,&quot;1ZRaM7s7WfHZVVjkO3Qsv7&quot;],&quot;_type&quot;:[0,&quot;subNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-03-27T13:16:11Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Artificial Intelligence&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;75989b19-cd8d-409b-a1ab-0fa08d53776c&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/clinical/artifical-intelligence&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2026-06-10T01:37:43Z&quot;],&quot;_id&quot;:[0,&quot;3bbdea9d-3a22-4c32-8d86-8b558957a307&quot;],&quot;_rev&quot;:[0,&quot;cxG6WGqtby4sD0hmXHZPOO&quot;],&quot;_type&quot;:[0,&quot;subNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-06-10T01:38:04Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Career Center&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;75989b19-cd8d-409b-a1ab-0fa08d53776c&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/career-center&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2025-05-09T14:05:46Z&quot;],&quot;_id&quot;:[0,&quot;c1ccce5c-6956-4322-8e85-812b477a62c2&quot;],&quot;_rev&quot;:[0,&quot;F7SamYu4K1mT7Wx2bJ7lY1&quot;],&quot;_type&quot;:[0,&quot;subNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-05-09T14:06:19Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Radiation Oncology&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;75989b19-cd8d-409b-a1ab-0fa08d53776c&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/clinical/radiation-oncology&quot;]}],[0,{&quot;_createdAt&quot;:[0,&quot;2025-05-09T14:06:30Z&quot;],&quot;_id&quot;:[0,&quot;f66f5a10-6388-4a4e-87f7-3685d60f86d7&quot;],&quot;_rev&quot;:[0,&quot;YoCMcWtyE05XxlGKAiPinW&quot;],&quot;_type&quot;:[0,&quot;subNavigation&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-05-09T14:06:42Z&quot;],&quot;is_active&quot;:[0,true],&quot;name&quot;:[0,&quot;Surgery&quot;],&quot;navParent&quot;:[0,{&quot;_ref&quot;:[0,&quot;75989b19-cd8d-409b-a1ab-0fa08d53776c&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;/clinical/surgery&quot;]}]]],&quot;footer&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-21T05:32:50Z&quot;],&quot;_id&quot;:[0,&quot;siteSettings&quot;],&quot;_rev&quot;:[0,&quot;4hScsMJksV8DfWCIi5xR9D&quot;],&quot;_system&quot;:[0,{&quot;base&quot;:[0,{&quot;id&quot;:[0,&quot;siteSettings&quot;],&quot;rev&quot;:[0,&quot;MwLKLXcGME1e2SHZC28FAQ&quot;]}]}],&quot;_type&quot;:[0,&quot;siteSettings&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-09-01T16:39:56Z&quot;],&quot;address&quot;:[0,{&quot;addressCountry&quot;:[0,&quot;United States of America&quot;],&quot;addressLocality&quot;:[0,&quot;Monroe&quot;],&quot;addressRegion&quot;:[0,&quot;New Jersey&quot;],&quot;postalCode&quot;:[0,&quot;08831&quot;],&quot;streetAddress&quot;:[0,&quot;259 Prospect Plains Rd, Bldg H&quot;]}],&quot;alternateName&quot;:[0,&quot;Cancer Network&quot;],&quot;contactPoint&quot;:[0,{&quot;email&quot;:[0,&quot;MJHINFO@mjhlifesciences.com&quot;],&quot;telephone&quot;:[0,&quot;609-716-7777&quot;]}],&quot;creativeLayout&quot;:[0,null],&quot;creativeLayoutLatestNews&quot;:[0,null],&quot;description&quot;:[0,&quot;CancerNetwork is home to the journal Oncology &amp; provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.&quot;],&quot;employees&quot;:[1,[[0,&quot;Silas Inman&quot;],[0,&quot;Kristie Kahl&quot;],[0,&quot;Gina Mauro&quot;]]],&quot;footerLinks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;8bd16c9bde67&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;About&quot;],&quot;url&quot;:[0,&quot;/about&quot;]}],[0,{&quot;_key&quot;:[0,&quot;ea0dfb860a3f&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Advertise&quot;],&quot;url&quot;:[0,&quot;/advertise&quot;]}],[0,{&quot;_key&quot;:[0,&quot;469bf68ad414&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;CureToday.com&quot;],&quot;url&quot;:[0,&quot;https://www.curetoday.com&quot;]}],[0,{&quot;_key&quot;:[0,&quot;84af95169a2e&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;OncLive.com&quot;],&quot;url&quot;:[0,&quot;https://www.onclive.com&quot;]}],[0,{&quot;_key&quot;:[0,&quot;6020c55d604e&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;OncNursingNews.com&quot;],&quot;url&quot;:[0,&quot;https://www.oncnursingnews.com/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;875b21c82b0f&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;TargetedOnc.com&quot;],&quot;url&quot;:[0,&quot;https://www.targetedonc.com/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;f96b785e0728&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Editorial&quot;],&quot;url&quot;:[0,&quot;/oncology-journal/about-editors/editorial-board&quot;]}],[0,{&quot;_key&quot;:[0,&quot;3231ba8a0915&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Contact&quot;],&quot;url&quot;:[0,&quot;https://www.cancernetwork.com/contact-us&quot;]}],[0,{&quot;_key&quot;:[0,&quot;ea912af38c6b&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Terms and Conditions&quot;],&quot;url&quot;:[0,&quot;/terms&quot;]}],[0,{&quot;_key&quot;:[0,&quot;fb5ad6bdf90e&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Privacy&quot;],&quot;url&quot;:[0,&quot;/privacy&quot;]}],[0,{&quot;_key&quot;:[0,&quot;b18a84a0197e&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Do Not Sell My Personal Information&quot;],&quot;url&quot;:[0,&quot;https://www.mjhlifesciences.com/ccpa?domain=www.cancernetwork.com&quot;]}]]],&quot;founder&quot;:[0,&quot;MJH Life Sciences&quot;],&quot;foundingDate&quot;:[0,&quot;1998-12-06&quot;],&quot;gaID&quot;:[0,&quot;UA-630614-16,UA-155582410-3&quot;],&quot;iconUrl&quot;:[0,&quot;https://www.cancernetwork.com/pubmedOncologyText.png&quot;],&quot;idLayerSchema&quot;:[0,{&quot;active&quot;:[0,true],&quot;fields&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;p1&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;32a5b498-2d9d-414c-96f0-fbfaca8620f8&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p2&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;18a93476-c49b-42f9-9b04-0f1ff76521c8&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p3&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;2c2aeff6-2e51-402c-8669-592c1ced14f7&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p4&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;0e0f9cfc-d576-481c-bf80-edf53e8adf79&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p5&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;d70cd5df-6b30-4509-a16a-b7401bd5d6e6&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p6&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;40853432-71f1-4558-82ca-2d8753add7b7&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p7&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;e9467504-2b98-42ad-9872-a4674f4014da&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p8&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;91d6accd-dad2-4b70-bf40-548278d9eca0&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p9&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;de1eb7be-22f0-417e-8b0b-5c5b40de0d6d&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}]]]}],&quot;name&quot;:[0,&quot;CancerNetwork - Oncology News and Clinical Expertise&quot;],&quot;orangizationName&quot;:[0,&quot;CancerNetwork&quot;],&quot;printMagazineConfig&quot;:[0,{&quot;enabled&quot;:[0,true],&quot;publications&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;86c7e68f767d&quot;],&quot;name&quot;:[0,&quot;Oncology® Magazine&quot;],&quot;publicationId&quot;:[0,&quot;55&quot;]}]]]}],&quot;profilePageConfig&quot;:[0,{&quot;active&quot;:[0,true],&quot;profileTab&quot;:[0,{&quot;content&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;f1&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;32a5b498-2d9d-414c-96f0-fbfaca8620f8&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f2&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;18a93476-c49b-42f9-9b04-0f1ff76521c8&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f3&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;2c2aeff6-2e51-402c-8669-592c1ced14f7&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f4&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;0e0f9cfc-d576-481c-bf80-edf53e8adf79&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f5&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;d70cd5df-6b30-4509-a16a-b7401bd5d6e6&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f6&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;40853432-71f1-4558-82ca-2d8753add7b7&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f7&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;e9467504-2b98-42ad-9872-a4674f4014da&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f8&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;91d6accd-dad2-4b70-bf40-548278d9eca0&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f9&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;de1eb7be-22f0-417e-8b0b-5c5b40de0d6d&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}]]]}]}],&quot;salesforceDMPId&quot;:[0,&quot;upniwmm0d&quot;],&quot;siteURL&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;socialLinks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;cf1a4e4539f3&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;Facebook&quot;],&quot;url&quot;:[0,&quot;https://www.facebook.com/Cancer-Network-124530046330/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;322cbf854512&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;LinkedIn&quot;],&quot;url&quot;:[0,&quot;https://www.linkedin.com/company/cancer-network/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;95a8c955ea12&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;X&quot;],&quot;url&quot;:[0,&quot;https://twitter.com/CancerNetwrk&quot;]}],[0,{&quot;_key&quot;:[0,&quot;3616df2f3815&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;RSS&quot;],&quot;url&quot;:[0,&quot;/rss.xml&quot;]}],[0,{&quot;_key&quot;:[0,&quot;1c8fcd4705db&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;Youtube&quot;],&quot;url&quot;:[0,&quot;https://www.youtube.com/@CancerNetwork&quot;]}]]]}]]],&quot;logoWidth&quot;:[0,null],&quot;logoHeight&quot;:[0,null],&quot;showSocialIcons&quot;:[0,null]}],&quot;customSpecialtyText&quot;:[0,&quot;Cancer Focus&quot;],&quot;logoSize&quot;:[0,&quot;medium&quot;],&quot;specialtyColumns&quot;:[0],&quot;mainNavigationItems&quot;:[0],&quot;isSpecialtyDisabled&quot;:[0],&quot;authEnabled&quot;:[0,true],&quot;scoutEnabled&quot;:[0,true],&quot;paymentsTabEnabled&quot;:[0,false],&quot;idlayerUrl&quot;:[0,&quot;https://id.mjhlifesciences.com&quot;]}" ssr client="load" opts="{&quot;name&quot;:&quot;N5&quot;,&quot;value&quot;:true}" await-children><header id="navigation" data-site-nav="true" class="sticky top-0 z-[9948029] w-full border-b bg-header-primary text-header-primary-foreground"><div class="mx-auto flex h-16 w-full max-w-[1480px] items-center px-4 md:px-6"><div class="flex items-center gap-2"><div class="mr-2 md:hidden"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="cursor-pointer" height="26" width="26" xmlns="http://www.w3.org/2000/svg"><path d="M4 6l16 0"></path><path d="M4 12l16 0"></path><path d="M4 18l16 0"></path></svg></div><a href="/" class="min-w-0 lg:mr-6"><img src="/logo.webp" alt="Logo Image" class="max-h-8 sm:max-h-10 h-auto w-auto max-w-full object-contain" loading="lazy" decoding="async"/></a></div><div class="hidden flex-1 items-center justify-between gap-4 px-4 xs:flex"><div class="relative z-[9999] flex h-8 max-w-lg flex-1 items-center justify-between rounded-full bg-white ring-1 ring-header-primary-foreground transition-shadow duration-200 "><input type="text" placeholder="Search..." class="w-full bg-transparent px-2 py-1 text-sm text-black focus:outline-none" aria-label="Search"/><div class="cursor-pointer rounded-full border-none bg-primary px-5 py-2 text-header-primary-foreground transition hover:opacity-90"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" color="white" style="color:white" height="16" width="16" xmlns="http://www.w3.org/2000/svg"><circle cx="11" cy="11" r="8"></circle><line x1="21" y1="21" x2="16.65" y2="16.65"></line></svg></div></div><nav class="hidden flex-1 items-center justify-center gap-4 text-sm font-medium text-header-primary-foreground md:flex"><div class="group relative"><a href="/news" class="flex cursor-pointer items-center">News<svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="ml-1 h-4 w-4 transition duration-200 group-hover:rotate-180" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></a><div class="absolute left-0 z-[9999] hidden w-max max-w-80 rounded-md border bg-white p-1 text-black shadow-lg group-hover:block"><a href="/global-bulletin" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Global Bulletin</a><a href="/news" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">All News</a><a href="/approval-alert" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">FDA Approval Alert</a><a href="/breaking-barriers" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Women in Oncology</a></div></div><div class="group relative"><div class="flex cursor-pointer items-center">Media<svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="ml-1 h-4 w-4 transition duration-200 group-hover:rotate-180" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></div><div class="absolute left-0 z-[9999] hidden w-max max-w-80 rounded-md border bg-white p-1 text-black shadow-lg group-hover:block"><a href="/around-the-practice" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Around the Practice</a><a href="/between-the-lines" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Between the Lines</a><a href="/face-off" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Face Off</a><a href="/from-all-angles" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">From All Angles</a><a href="/meeting-of-the-minds" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Meeting of the Minds</a><a href="/oncview" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">OncView</a><a href="/podcasts" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Podcasts</a><a href="/shorts" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Shorts</a><a href="/training-academy" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Training Academy</a><a href="/treatment-algorithms-with-the-oncology-brothers?page=1" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Treatment Algorithms with the Oncology Brothers</a><a href="/videos" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Videos</a></div></div><div class="group relative"><a href="/conference">Conferences</a></div><div class="group relative"><a href="/journals" class="flex cursor-pointer items-center">Publications<svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="ml-1 h-4 w-4 transition duration-200 group-hover:rotate-180" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></a><div class="absolute left-0 z-[9999] hidden w-max max-w-80 rounded-md border bg-white p-1 text-black shadow-lg group-hover:block"><a href="/journals" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">All Journals</a><a href="/oncology-journal/editors" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Editorial Board</a><a href="/oncology-journal" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">For Authors</a><a href="/year-in-review" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Year in Review</a></div></div><div class="group relative"><div class="flex cursor-pointer items-center">More<svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="ml-1 h-4 w-4 transition duration-200 group-hover:rotate-180" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></div><div class="absolute left-0 z-[9999] hidden w-max max-w-80 rounded-md border bg-white p-1 text-black shadow-lg group-hover:block"><div class="group/item relative"><div class="group/second flex cursor-pointer items-center justify-between rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Events<svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="ml-1 h-4 w-4 transition duration-200 group-hover/second:rotate-[90deg]" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></div><div class="absolute right-full top-0 z-[9999] hidden w-max max-w-80 rounded-md border bg-white p-1 text-black shadow-lg group-hover/item:block"><a href="/frontline-forum" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Frontline Forum</a><a href="/satellite-sessions" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Satellite Sessions</a></div></div><div class="group/item relative"><a href="/continuing-education" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">CME/CE</a></div><div class="group/item relative"><a href="/resources" class="group/second flex cursor-pointer items-center justify-between rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Resources<svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="ml-1 h-4 w-4 transition duration-200 group-hover/second:rotate-[90deg]" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></a><div class="absolute right-full top-0 z-[9999] hidden w-max max-w-80 rounded-md border bg-white p-1 text-black shadow-lg group-hover/item:block"><a href="/awareness-month" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Awareness Month</a><a href="/the-bispecifics-network" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">The Bispecifics Network</a><a href="/roles/nurse" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Nurse Practitioners/Physician&#x27;s Assistants</a><a href="/partners" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Partners</a><a href="/resources/sponsored-resources" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Sponsored</a><a href="/sponsored-media?page=1" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Sponsored Media</a></div></div><div class="group/item relative"><a href="/career-center" class="block rounded-md px-2 py-1.5 text-sm hover:bg-primary hover:text-white">Career Center</a></div></div></div></nav></div><div class="ml-auto flex items-center xs:ml-0"><a href="/subscribe" class="border-header-primary-color ml-2 flex h-8 items-center gap-1 rounded-full border px-4 py-1 text-sm font-medium text-header-primary-foreground hover:shadow-md"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" height="16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="M4 4h16c1.1 0 2 .9 2 2v12c0 1.1-.9 2-2 2H4c-1.1 0-2-.9-2-2V6c0-1.1.9-2 2-2z"></path><polyline points="22,6 12,13 2,6"></polyline></svg><p class="hidden md:block">Subscribe</p></a><button type="button" class="group relative ml-2 flex h-8 items-center gap-1.5 rounded-full px-3 py-1 text-sm font-medium text-header-primary-foreground transition-all hover:bg-header-primary-foreground/10 active:scale-95" aria-label="Open Scout assistant"><span aria-hidden="true" class="pointer-events-none absolute inset-0 overflow-hidden rounded-full p-[1.5px]"><span class="absolute inset-[-110%] animate-spin [animation-duration:4s] bg-[conic-gradient(from_0deg,#60a5fa,#22d3ee,#2563eb,#60a5fa)] opacity-60 transition-opacity group-hover:opacity-100"></span><span class="absolute inset-[1.5px] rounded-full bg-header-primary"></span></span><img src="/scout.svg" alt="Scout AI" width="20" height="20" class="relative h-5 w-5 shrink-0 rounded-full" style="object-fit:contain"/><span class="relative hidden lg:inline">Scout</span></button><button type="button" id="radix-:r69R3p:" aria-haspopup="menu" aria-expanded="false" data-state="closed" class="ml-2 flex h-8 items-center gap-1 rounded-full border border-header-primary-foreground/30 px-3 py-1 text-sm font-medium text-header-primary-foreground hover:bg-header-primary-foreground/10"><div class="relative"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" height="16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="M20 21v-2a4 4 0 0 0-4-4H8a4 4 0 0 0-4 4v2"></path><circle cx="12" cy="7" r="4"></circle></svg></div><span class="hidden lg:block">My Account</span><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-4 w-4" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></button></div></div><div class="fixed left-0 top-0 z-[100000] h-full w-80 transform bg-primary shadow-lg transition-transform duration-300 ease-in-out md:hidden -translate-x-full"><div class="flex h-full flex-col"><div class="flex justify-end p-4"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 512 512" class="cursor-pointer text-white" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M405 136.798L375.202 107 256 226.202 136.798 107 107 136.798 226.202 256 107 375.202 136.798 405 256 285.798 375.202 405 405 375.202 285.798 256z"></path></svg></div><div class="flex-1 overflow-y-auto px-5 pb-6 text-sm font-semibold text-white"><form role="search" class="mb-4 flex w-full items-center gap-2.5 rounded-xl border border-white/30 px-4 py-3 text-base font-normal text-white transition-all focus-within:bg-white/10 xs:hidden"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="shrink-0 text-white/70" aria-hidden="true" height="20" width="20" xmlns="http://www.w3.org/2000/svg"><circle cx="11" cy="11" r="8"></circle><line x1="21" y1="21" x2="16.65" y2="16.65"></line></svg><input type="text" placeholder="Search..." aria-label="Search" class="w-full bg-transparent text-white placeholder:text-white/60 focus:outline-none" value=""/></form><button type="button" class="mb-4 flex w-full items-center gap-2.5 rounded-xl border border-white/30 px-4 py-3 text-base font-semibold text-white transition-all hover:bg-white/10 active:scale-[0.98]"><img src="/scout.svg" alt="Scout AI" width="24" height="24" class="h-6 w-6 rounded-full" style="object-fit:contain"/>Scout</button><ul><li class="rounded-md py-2"><div class="flex flex-col"><div class="flex w-full items-center justify-between pl-2"><a href="/news" class="block text-lg">News</a><button type="button" aria-label="Toggle News submenu" aria-expanded="false"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="mr-2 cursor-pointer transition-transform duration-200 " color="white" style="color:white" height="20" width="20" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></button></div></div></li><li class="rounded-md py-2"><div class="flex flex-col"><div class="flex w-full items-center justify-between pl-2"><span class="block text-lg">Media</span><button type="button" aria-label="Toggle Media submenu" aria-expanded="false"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="mr-2 cursor-pointer transition-transform duration-200 " color="white" style="color:white" height="20" width="20" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></button></div></div></li><li class="rounded-md py-2"><a class="block pl-2 text-lg" href="/conference">Conferences</a></li><li class="rounded-md py-2"><div class="flex flex-col"><div class="flex w-full items-center justify-between pl-2"><a href="/journals" class="block text-lg">Publications</a><button type="button" aria-label="Toggle Publications submenu" aria-expanded="false"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="mr-2 cursor-pointer transition-transform duration-200 " color="white" style="color:white" height="20" width="20" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></button></div></div></li><li class="rounded-md py-2"><div class="flex flex-col"><div class="flex w-full items-center justify-between pl-2"><span class="block text-lg">Events</span><button type="button" aria-label="Toggle Events submenu" aria-expanded="false"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="mr-2 cursor-pointer transition-transform duration-200 " color="white" style="color:white" height="20" width="20" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></button></div></div></li><li class="rounded-md py-2"><a class="block pl-2 text-lg" href="/continuing-education">CME/CE</a></li><li class="rounded-md py-2"><div class="flex flex-col"><div class="flex w-full items-center justify-between pl-2"><a href="/resources" class="block text-lg">Resources</a><button type="button" aria-label="Toggle Resources submenu" aria-expanded="false"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="mr-2 cursor-pointer transition-transform duration-200 " color="white" style="color:white" height="20" width="20" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></button></div></div></li><li class="rounded-md py-2"><a class="block pl-2 text-lg" href="/career-center">Career Center</a></li><li class="rounded-md py-2"><a class="block pl-2 text-lg" href="/subscribe">Subscribe</a></li></ul></div></div></div><div id="" class="sticky left-0 top-0 z-[1000] h-12 w-full bg-header-secondary text-header-secondary-foreground shadow-lg transition-all"><div class=" mx-auto w-full max-w-[1480px] px-4 md:px-6"><div id="specialty-links-dropdown" class="absolute left-0 top-full hidden w-full bg-white shadow-lg"><div class=" mx-auto w-full max-w-[1480px] px-4 md:px-6"><ul class="max-h-[80vh] overflow-y-auto py-6 xl:columns-5 md:columns-4 "><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/adverse-effects">Adverse Effects</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/artifical-intelligence">Artificial Intelligence</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/brain-cancer">Brain Cancer</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/breast-cancer">Breast Cancer</a><ul><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/her2-positive-breast-cancer">HER2-Positive Breast Cancer</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/triple-negative-breast-cancer">Triple-Negative Breast Cancer</a></li></ul></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/gastrointestinal-cancer">Gastrointestinal Cancer</a><ul><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/colorectal-cancer">Colorectal Cancer</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/esophageal-cancer">Esophageal Cancer</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/pancreatic-cancer">Pancreatic Cancer</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/gastric-cancer">Gastric Cancer</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/liver-cancer">Liver Cancer</a></li></ul></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/genitourinary-cancers">Genitourinary Cancers</a><ul><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/kidney-cancer">Kidney Cancer</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/bladder-cancer">Bladder Cancer</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/prostate-cancer">Prostate Cancer</a></li></ul></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/gynecologic-cancer">Gynecologic Cancers</a><ul><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/endometrial-cancer">Endometrial Cancer</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/ovarian-cancer">Ovarian Cancer</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/cervical-cancer">Cervical Cancer</a></li></ul></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/head-neck-cancer">Head &amp; Neck Cancer</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/hematology">Hematologic Oncology</a><ul><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/multiple-myeloma">Multiple Myeloma</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/myelodysplastic-syndromes">Myelodysplastic Syndromes</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/myeloproliferative-neoplasms">Myeloproliferative Neoplasms</a></li></ul></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/infection">Infection</a><ul><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/vaccines">Vaccines</a></li></ul></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/leukemia">Leukemia</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/lung-cancer">Lung Cancer</a><ul><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/small-cell-lung-cancer">Small Cell Lung Cancer (SCLC)</a></li><li class="py-0 pl-2"><a class="pr-6 text-sm italic leading-4 text-gray-600 hover:underline" href="/clinical/nsclc">Non-Small Cell Lung Cancer (NSCLC)</a></li></ul></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/lymphoma">Lymphoma</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/neuroendocrine-tumors">Neuroendocrine Tumors</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/oncology">Oncology</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/pediatric-cancers">Pediatric Cancers</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/psycho-oncology">Psycho-Oncology</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/radiation-oncology">Radiation Oncology</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/sarcoma">Sarcoma</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/screening">Screening</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/skin-cancer-n-melanoma">Skin Cancer &amp; Melanoma</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/surgery">Surgery</a></li><li class="break-inside-avoid py-1"><a class="break-inside-avoid break-words text-sm font-semibold leading-6 text-black hover:underline" href="/clinical/thyroid-cancer">Thyroid Cancer</a></li></ul></div></div><div class="relative flex h-full justify-center pt-1.5 xl:justify-start"><button class="inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 px-4 py-2 mr-4 h-9 bg-header-specialty text-sm font-medium text-header-specialty-foreground hover:bg-header-specialty" id="specialty-button" aria-expanded="false" aria-controls="specialty-links-dropdown" aria-haspopup="menu">Cancer Focus<svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="relative top-[1px] ml-1 h-4 w-4 transition-all duration-200 false" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M6 9l6 6l6 -6"></path></svg></button><div class="no-scrollbar hidden overflow-auto md:flex"><div class="flex shrink-0 items-center"><span class="mr-1 whitespace-pre text-sm font-bold">Spotlight - </span><div><a class="cursor-pointer whitespace-pre text-xs" href="/clinical/psycho-oncology">Psycho-Oncology</a><span class="mx-1 text-gray-400">|</span></div><div><a class="cursor-pointer whitespace-pre text-xs" href="/clinical/artifical-intelligence">Artificial Intelligence</a><span class="mx-1 text-gray-400">|</span></div><div><a class="cursor-pointer whitespace-pre text-xs" href="/career-center">Career Center</a><span class="mx-1 text-gray-400">|</span></div><div><a class="cursor-pointer whitespace-pre text-xs" href="/clinical/radiation-oncology">Radiation Oncology</a><span class="mx-1 text-gray-400">|</span></div><div><a class="cursor-pointer whitespace-pre text-xs" href="/clinical/surgery">Surgery</a></div></div></div></div></div></div></header><!--astro:end--></astro-island> <astro-island uid="Z2dt94q" component-url="/_astro/chat-ui.wCF6gzR5.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{}" ssr client="only" opts="{&quot;name&quot;:&quot;ChatUI&quot;,&quot;value&quot;:&quot;react&quot;}"></astro-island> <div class="relative flex min-h-screen flex-col"> <div class="flex flex-col"> <div>  <main class="flex-1 pb-12"> <div slot="template" class="2xl:px-12 mx-auto w-full max-w-[1480px] px-4 md:px-6 "> <div class="relative grid w-full flex-1 grid-cols-12 place-content-start gap-8"> <div class="flex flex-col items-center justify-center col-span-12  mb-6 min-h-[50px]"> <astro-island uid="1MvCV6" prefix="r78" component-url="/_astro/AD728x90.CoAy7aPs.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[0,null],&quot;networkID&quot;:[0,&quot;4688&quot;],&quot;adUnit&quot;:[0,&quot;cmpm.cancernetwork&quot;],&quot;targeting&quot;:[0,{&quot;content_placement&quot;:[1,[[0,&quot;news&quot;],[0,&quot;journals/oncology&quot;]]],&quot;document_url&quot;:[1,[[0,&quot;gerson-regimen&quot;]]],&quot;document_group&quot;:[1,[]],&quot;content_group&quot;:[1,[]],&quot;rootDocumentGroup&quot;:[1,[]],&quot;issue_url&quot;:[1,[[0,&quot;oncology-vol-24-no-2&quot;]]],&quot;publication_url&quot;:[1,[[0,&quot;oncology&quot;]]],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;barrie-r-cassileth-ms-phd&quot;]]],&quot;hostname&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;adLayer&quot;:[0,{&quot;adSlotSelection&quot;:[1,[]]}]}],&quot;hidden&quot;:[0,false]}" ssr client="load" opts="{&quot;name&quot;:&quot;AD728x90&quot;,&quot;value&quot;:true}" await-children><div id="leaderboardWrapper" class="leaderboardAdWrapper mx-auto mt-1 relative z-[51] flex min-h-[90px] flex-col items-center justify-center md:min-h-[102px]"><div class="bg-transparent"><div class="relative hidden text-center text-[8px] text-gray-600">Advertisement</div><div id="div-gpt-ad-top" class="AD728x90 mx-auto text-center"></div></div></div><!--astro:end--></astro-island>  </div> </div> </div><div slot="grid" class="2xl:px-12 mx-auto w-full max-w-[1380px] px-4 md:px-6 xl:px-24"> <div class="flex w-full flex-row gap-4"> <div class="relative grid flex-1 grid-cols-12 place-content-start gap-8"><div class="flex flex-col items-center justify-center col-span-12  "> <astro-island uid="Z21zYr3" prefix="r79" component-url="/_astro/next-article-button.Bei96qZo.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;articles&quot;:[1,[[0,&quot;/view/weighing-the-promise-and-trade-offs-of-car-nk-cell-therapy-for-cancer&quot;],[0,&quot;/view/building-a-low-dose-radiation-therapy-program-for-benign-disease&quot;],[0,&quot;/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization&quot;],[0,&quot;/view/ramantamig-achieves-impressive-rates-of-mrd-negativity-in-rrmm&quot;],[0,&quot;/view/selcodebart-yields-hematologic-responses-in-anemia-from-myelofibrosis&quot;],[0,&quot;/view/how-do-long-term-maia-and-cepheus-data-reinforce-daratumumab-use-in-ndmm-&quot;],[0,&quot;/view/adjuvant-radiotherapy-reduced-recurrence-in-resected-atypical-meningioma&quot;],[0,&quot;/view/vir-5500-receives-fda-fast-track-designation-for-late-line-metastatic-crpc&quot;],[0,&quot;/view/can-an-all-oral-hma-regimen-change-frontline-care-in-unfit-aml-&quot;],[0,&quot;/view/building-out-a-radiopharmaceuticals-program-in-oncology-care&quot;],[0,&quot;/view/how-to-navigate-ramantamig-s-low-grade-toxicities-in-multiple-myeloma&quot;],[0,&quot;/view/fda-approves-atezolizumab-chemo-for-stage-iii-dmmr-msi-h-colon-cancer&quot;],[0,&quot;/view/how-can-cooperative-groups-close-outcome-gaps-in-hiv-associated-lymphoma-&quot;],[0,&quot;/view/carotuximab-apalutamide-further-extends-pfs-in-metastatic-crpc&quot;],[0,&quot;/view/how-would-a-talapro-3-approval-affect-hrr-altered-metastatic-hspc-care-&quot;],[0,&quot;/view/iberdomide-combination-doubles-pfs-vs-soc-therapy-in-r-r-multiple-myeloma&quot;],[0,&quot;/view/random-start-protocols-allow-fertility-preservation-without-delaying-treatment&quot;],[0,&quot;/view/novel-cancer-vaccine-plus-temozolomide-miss-primary-end-point-in-glioblastoma&quot;],[0,&quot;/view/weighing-safety-vs-persistence-with-car-nk-cell-therapy&quot;],[0,&quot;/view/what-does-nrg-gu002-mean-for-docetaxel-after-prostatectomy-&quot;]]],&quot;currentArticle&quot;:[0,&quot;gerson-regimen&quot;]}" ssr client="load" opts="{&quot;name&quot;:&quot;NextArticleButton&quot;,&quot;value&quot;:true}"></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  -mb-8"> <astro-island uid="Z1zJs1J" prefix="r80" component-url="/_astro/index.OxaSNWfq.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;items&quot;:[1,[[0,null],[0,&quot;Articles&quot;],[0,&quot;February 9, 2010&quot;]]],&quot;className&quot;:[0,&quot;w-full text-base  md:text-lg&quot;]}" ssr client="load" opts="{&quot;name&quot;:&quot;ArticleTypeBreadCrumbComponent&quot;,&quot;value&quot;:true}" await-children><div class="w-full text-base  md:text-lg flex flex-row items-center gap-1"><span style="color:#003366;font-weight:700"></span><span class="font-light" style="color:#6b7280">|</span><span style="color:#003366;font-weight:700">Articles</span><span class="font-light" style="color:#6b7280">|</span><span style="color:#6b7280;font-weight:400">February 9, 2010</span></div><!--astro:end--></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12   -mt-1"> <div class="-mb-6 w-full text-sm text-gray-600 md:text-base"> <section aria-label="Publication information" class="flex flex-col gap-y-1"> <p class="-mb-1"> <a href="/journals/oncology" class="text-gray-700 hover:text-gray-900"> Oncology </a> </p> <ul class="flex flex-col gap-y-1 md:flex-row md:flex-wrap md:items-center md:[&>li+li]:before:ml-1 md:[&>li+li]:before:text-gray-400 md:[&>li+li]:before:content-['|']"> <li>ONCOLOGY Vol 24 No 2</li> <li>
Volume <span class="font-bold">24</span> </li> <li>
Issue <span class="font-bold">2</span> </li>  </ul> </section> </div> </div><div class="flex flex-col items-center justify-center col-span-12  "> <h1 class="text-2xl md:text-2xl xl:text-3xl font-bold text-left text-pretty w-full " children="Gerson Regimen">Gerson Regimen</h1> </div><div class="flex flex-col items-center justify-center col-span-12  !block -mt-6"> <astro-island uid="Z206huE" prefix="r81" component-url="/_astro/author-list.Cftuf6QD.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;authors&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-12T09:11:08Z&quot;],&quot;_id&quot;:[0,&quot;cn_author_317672&quot;],&quot;_rev&quot;:[0,&quot;89xezVoxyX62cPX9Rki8La&quot;],&quot;_type&quot;:[0,&quot;author&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-06-26T19:38:10Z&quot;],&quot;authorType&quot;:[0,&quot;author&quot;],&quot;displayName&quot;:[0,&quot;Barrie R. Cassileth, MS, PhD&quot;],&quot;url&quot;:[0,{&quot;_type&quot;:[0,&quot;slug&quot;],&quot;current&quot;:[0,&quot;barrie-r-cassileth-ms-phd&quot;]}]}]]],&quot;fieldType&quot;:[0,&quot;authors&quot;]}" ssr client="load" opts="{&quot;name&quot;:&quot;AuthorsList&quot;,&quot;value&quot;:true}" await-children><div class=""><span class="text-md"><span class="mr-1 italic">Author(s)</span><a href="/authors/barrie-r-cassileth-ms-phd" class="mr-1 text-link hover:text-link-hover"><i>Barrie R. Cassileth, MS, PhD</i></a></span></div><!--astro:end--></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  "> <astro-island uid="Z1is0pL" component-url="/_astro/ArticleChatCTA.BMEgRFgf.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{}" ssr client="only" opts="{&quot;name&quot;:&quot;ArticleChatCTA&quot;,&quot;value&quot;:&quot;react&quot;}"></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  "> <p class="w-full text-gray-700 italic text-base" children="Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.">Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.</p> </div><div class="flex flex-col items-center justify-center col-span-12  flex justify-center items-center sm:hidden"> <astro-island uid="1AcXmb" prefix="r82" component-url="/_astro/AD300x250.DpBj1VD8.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[0,null],&quot;networkID&quot;:[0,&quot;4688&quot;],&quot;adUnit&quot;:[0,&quot;cmpm.cancernetwork&quot;],&quot;pos&quot;:[0,&quot;rec1-mobile&quot;],&quot;targeting&quot;:[0,{&quot;content_placement&quot;:[1,[[0,&quot;news&quot;],[0,&quot;journals/oncology&quot;]]],&quot;document_url&quot;:[1,[[0,&quot;gerson-regimen&quot;]]],&quot;document_group&quot;:[1,[]],&quot;content_group&quot;:[1,[]],&quot;rootDocumentGroup&quot;:[1,[]],&quot;issue_url&quot;:[1,[[0,&quot;oncology-vol-24-no-2&quot;]]],&quot;publication_url&quot;:[1,[[0,&quot;oncology&quot;]]],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;barrie-r-cassileth-ms-phd&quot;]]],&quot;hostname&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;adLayer&quot;:[0,{&quot;adSlotSelection&quot;:[1,[]]}]}],&quot;hidden&quot;:[0,false]}" ssr client="load" opts="{&quot;name&quot;:&quot;AD300x250&quot;,&quot;value&quot;:true}" await-children><div class="z-50"><div class="hidden text-center text-[8px] text-gray-500">Advertisement</div><div id="div-gpt-ad-rec1-mobile" class="" style="width:300px;min-height:250px"></div></div><!--astro:end--></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  " data-scroll-depth-region="article-body"> <div id="block-content" class="w-full _blockContent_s7hzj_1 "> <p class="">Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.</p><p class="">The strict dietary recommendations can cause severe nutritional deficiencies, and excessive use of coffee enemas can cause sepsis, dangerous electrolyte deficiencies, and death.</p><p class="">A recent trial of the closely related Gonzalez therapy found that pancreatic cancer patients on standard chemotherapy survived three times longer and had better quality of life than those who chose the Gonzalez regimen (pancreatic enzymes, nutritional supplements, detoxification, and organic diet).</p><p class="">-<em>Barrie Cassileth, PhD</em></p><p class=""><strong>ALSO KNOWN AS:</strong> Gerson diet, Gerson therapy, Gerson method, Gerson program, Gerson treatment</p><astro-island uid="2cWTnV" prefix="r83" component-url="/_astro/figure.DVOFG3ht.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;value&quot;:[0,{&quot;_key&quot;:[0,&quot;kbtzOTSW&quot;],&quot;_type&quot;:[0,&quot;figure&quot;],&quot;asset&quot;:[0,{&quot;_createdAt&quot;:[0,&quot;2020-06-09T06:36:21Z&quot;],&quot;_id&quot;:[0,&quot;image-2e03f572093fb586d628535cb0d8ba25992bb2a2-200x192-png&quot;],&quot;_ref&quot;:[0,&quot;image-2e03f572093fb586d628535cb0d8ba25992bb2a2-200x192-png&quot;],&quot;_rev&quot;:[0,&quot;2cZRobJdCnKNZSLmCQSCuL&quot;],&quot;_type&quot;:[0,&quot;sanity.imageAsset&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-06-09T06:36:21Z&quot;],&quot;assetId&quot;:[0,&quot;2e03f572093fb586d628535cb0d8ba25992bb2a2&quot;],&quot;extension&quot;:[0,&quot;png&quot;],&quot;metadata&quot;:[0,{&quot;dimensions&quot;:[0,{&quot;_type&quot;:[0,&quot;sanity.imageDimensions&quot;],&quot;aspectRatio&quot;:[0,1.0416666666666667],&quot;height&quot;:[0,192],&quot;width&quot;:[0,200]}]}],&quot;mimeType&quot;:[0,&quot;image/png&quot;],&quot;originalFilename&quot;:[0,&quot;1843226.png&quot;],&quot;path&quot;:[0,&quot;images/0vv8moc6/cancernetwork/2e03f572093fb586d628535cb0d8ba25992bb2a2-200x192.png&quot;],&quot;sha1hash&quot;:[0,&quot;2e03f572093fb586d628535cb0d8ba25992bb2a2&quot;],&quot;size&quot;:[0,61382],&quot;uploadId&quot;:[0,&quot;uJTMNQDUX1SnHkgUrPjNIQgcozrfjfO0&quot;],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2e03f572093fb586d628535cb0d8ba25992bb2a2-200x192.png&quot;]}],&quot;blank&quot;:[0,false],&quot;caption&quot;:[0,&quot;&quot;],&quot;link&quot;:[0,&quot;1522193.png&quot;],&quot;medias&quot;:[0,null],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}]}" ssr client="load" opts="{&quot;name&quot;:&quot;FigurePlugin&quot;,&quot;value&quot;:true}"></astro-island><p class=""><strong>SUMMARY:</strong> The Gerson regimen, developed by Max Gerson in the 1930s, is promoted as an alternative cancer treatment. It involves consuming fresh, raw fruit and vegetable juices, eliminating salt from the diet, taking supplements such as potassium, vitamin B12, thyroid hormone, pancreatic enzymes, and detoxifying liver with coffee enemas to stimulate metabolism.</p><p class="">Gerson therapy is based on the theory that cancer is caused by alteration of cell metabolism by toxic environmental substances and processed food, which changes its sodium and potassium content. It emphasizes increasing potassium intake and minimizing sodium consumption in an effort to correct the electrolyte imbalance, repair tissue, and detoxify the liver. The coffee enemas are believed to cause dilation of bile ducts and excretion of toxic breakdown products by the liver and through the colon wall. None of these theories has been substantiated by scientific research.[1,2]</p><p class="">Despite proponents’ claims of recovery rates as high as 70% to 90%, case reviews by the National Cancer Institute (NCI) and the New York County Medical Society found no evidence of usefulness for the Gerson diet.[3]</p><p class="">An NCI-sponsored study of Gonzalez therapy, which is similar to the Gerson diet, showed that patients with inoperable pancreatic adenocarcinoma who underwent standard chemotherapy with gemcitabine (Gemzar) survived three times longer and had better quality of life than those who chose enzyme treatment, which included pancreatic enzymes, nutritional supplements, detoxification, and an organic diet.[4]</p> </div> </div><div class="flex flex-col items-center justify-center col-span-12  has-[>astro-island:empty]:hidden [&#38;:has(>astro-island:empty)+*]:-mt-8"> <script>(()=>{var l=(n,t)=>{let i=async()=>{await(await n())()},e=typeof t.value=="object"?t.value:void 0,s={timeout:e==null?void 0:e.timeout};"requestIdleCallback"in window?window.requestIdleCallback(i,s):setTimeout(i,s.timeout||200)};(self.Astro||(self.Astro={})).idle=l;window.dispatchEvent(new Event("astro:idle"));})();</script><astro-island uid="1PmP9N" prefix="r71" component-url="/_astro/RecommendedForYou.CGa5dyV8.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;articles&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;de825fd8-becf-47b2-b75e-f36c32be2975&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T22:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Conference&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/lymphoma&quot;],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;aspectRatio&quot;:[0,0.8626887131560029],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-03e77b4f328a10c74086cdfdbf704078d6050f18-1200x1391-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/03e77b4f328a10c74086cdfdbf704078d6050f18-1200x1391.jpg&quot;]}],&quot;title&quot;:[0,&quot;Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer&quot;],&quot;url&quot;:[0,&quot;/view/weighing-the-promise-and-trade-offs-of-car-nk-cell-therapy-for-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;69d6a710-7599-4939-88dc-d745376d37cf&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.&quot;],&quot;aspectRatio&quot;:[0,0.8],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-363270bf0783d219c3528f46e9e77d5dc1f186e9-200x250-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Tyler J. WIlhite, MD\nUPMC HIllman Cancer Center&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/363270bf0783d219c3528f46e9e77d5dc1f186e9-200x250.png&quot;]}],&quot;title&quot;:[0,&quot;Building a Low-Dose Radiation Therapy Program for Benign Disease&quot;],&quot;url&quot;:[0,&quot;/view/building-a-low-dose-radiation-therapy-program-for-benign-disease&quot;]}],[0,{&quot;_id&quot;:[0,&quot;dcf42da5-6ed8-46d7-93ce-7dea016f9603&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-09T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5af592353ad710d026c1636a0a523c535b1213f7-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5af592353ad710d026c1636a0a523c535b1213f7-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization &quot;],&quot;url&quot;:[0,&quot;/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization&quot;]}],[0,{&quot;_id&quot;:[0,&quot;da5bf0e0-2138-4b4a-a044-ffb88bda705b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-09T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM&quot;],&quot;url&quot;:[0,&quot;/view/ramantamig-achieves-impressive-rates-of-mrd-negativity-in-rrmm&quot;]}],[0,{&quot;_id&quot;:[0,&quot;1abdedd9-ac41-4260-84de-d6d50f58626a&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Myeloproliferative Neoplasms&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/myeloproliferative-neoplasms&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;aspectRatio&quot;:[0,1.1111111111111112],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300.jpg&quot;]}],&quot;title&quot;:[0,&quot;Selcodebart Yields Hematologic Responses in Anemia From Myelofibrosis&quot;],&quot;url&quot;:[0,&quot;/view/selcodebart-yields-hematologic-responses-in-anemia-from-myelofibrosis&quot;]}],[0,{&quot;_id&quot;:[0,&quot;732a9b36-4ae9-433f-a71e-af1a03502d39&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T16:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Multiple Myeloma&quot;],[0,&quot;News&quot;],[0,&quot;Between the Lines&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;news&quot;],[0,&quot;between-the-lines&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.2939197930142303],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-d23a730915dd101042071359cc623e55511245dc-5001x3865-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d23a730915dd101042071359cc623e55511245dc-5001x3865.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?&quot;],&quot;url&quot;:[0,&quot;/view/how-do-long-term-maia-and-cepheus-data-reinforce-daratumumab-use-in-ndmm-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;4e4318a7-7243-43a4-bdac-6c144f7aeb04&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Journal Articles&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma: © 程 加星 - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c12520957948ebfc324e247b1151b3dd28a0420d-5120x2880-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c12520957948ebfc324e247b1151b3dd28a0420d-5120x2880.jpg&quot;]}],&quot;title&quot;:[0,&quot;Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma&quot;],&quot;url&quot;:[0,&quot;/view/adjuvant-radiotherapy-reduced-recurrence-in-resected-atypical-meningioma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;10e9fead-dd59-4720-bf6d-81561b8910c1&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.326],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;VIR-5500 Receives FDA Fast Track Designation for Late-Line Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/vir-5500-receives-fda-fast-track-designation-for-late-line-metastatic-crpc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;bdcb9830-1f2f-448c-a13a-8983f523a17c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Leukemia&quot;],[0,&quot;Frontline Forum&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/leukemia&quot;],[0,&quot;frontline-forum&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Acute lymphoblastic leukemia, bone marrow smear, 3D illustration | Image Credit: © Dr_Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-0888f4313a1f4443719b9c25dc719a35a434624c-6000x4000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0888f4313a1f4443719b9c25dc719a35a434624c-6000x4000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Can an All-Oral HMA Regimen Change Frontline Care in Unfit AML?&quot;],&quot;url&quot;:[0,&quot;/view/can-an-all-oral-hma-regimen-change-frontline-care-in-unfit-aml-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2ce5e471-a073-41a3-89b5-0798f9a3a843&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.&quot;],&quot;aspectRatio&quot;:[0,1.1333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3d031c79ae7db09f00e6bc06661074fdcd9363fa-680x600-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3d031c79ae7db09f00e6bc06661074fdcd9363fa-680x600.png&quot;]}],&quot;title&quot;:[0,&quot;Building out a Radiopharmaceuticals Program in Oncology Care&quot;],&quot;url&quot;:[0,&quot;/view/building-out-a-radiopharmaceuticals-program-in-oncology-care&quot;]}],[0,{&quot;_id&quot;:[0,&quot;0a750f3a-2571-4ddf-a0da-72d9d4e66a35&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-08T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Multiple Myeloma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/multiple-myeloma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-73e516a152d585762295aa34ac2f7799a65bc365-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/73e516a152d585762295aa34ac2f7799a65bc365-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;How to Navigate Ramantamig’s Low-Grade Toxicities in Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/how-to-navigate-ramantamig-s-low-grade-toxicities-in-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;f0c9c6d3-d81b-4957-bfc8-d90654feb6b5&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T18:06:23.010Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Colorectal Cancer&quot;],[0,&quot;Breaking News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/colorectal-cancer&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.&quot;],&quot;aspectRatio&quot;:[0,1.7561779242174629],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214.png&quot;]}],&quot;title&quot;:[0,&quot;FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer&quot;],&quot;url&quot;:[0,&quot;/view/fda-approves-atezolizumab-chemo-for-stage-iii-dmmr-msi-h-colon-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a7ce683b-60fc-4d25-ad98-6ef2dc85f88a&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/lymphoma&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.&quot;],&quot;aspectRatio&quot;:[0,0.75],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6ea1db064178195d78b3a00bceabd3bee8221f6a-1200x1600-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6ea1db064178195d78b3a00bceabd3bee8221f6a-1200x1600.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Can Cooperative Groups Close Outcome Gaps in HIV-Associated Lymphoma?&quot;],&quot;url&quot;:[0,&quot;/view/how-can-cooperative-groups-close-outcome-gaps-in-hiv-associated-lymphoma-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;71ecb5f3-7faf-4fcd-8421-1b81256d63f8&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com &quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200.jpg&quot;]}],&quot;title&quot;:[0,&quot;Carotuximab/Apalutamide Further Extends PFS in Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/carotuximab-apalutamide-further-extends-pfs-in-metastatic-crpc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6840ba0f-2c19-4843-847d-3a4f24c451e4&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Features&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com &quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Would a TALAPRO-3 Approval Affect HRR-Altered Metastatic HSPC Care?&quot;],&quot;url&quot;:[0,&quot;/view/how-would-a-talapro-3-approval-affect-hrr-altered-metastatic-hspc-care-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6d4ecba1-a983-4b9c-9fc9-cde198cdd527&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;News Reports&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/multiple-myeloma&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-aa6c8671e89654e467dee9953de212fd795b6cdd-3600x2400-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/aa6c8671e89654e467dee9953de212fd795b6cdd-3600x2400.jpg&quot;]}],&quot;title&quot;:[0,&quot;Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/iberdomide-combination-doubles-pfs-vs-soc-therapy-in-r-r-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;1ba1d048-0d0e-4345-9472-e8ba4622eaf4&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-08T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c766e547f7a3f757b43e5b55450d9fb80d6bb9c9-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c766e547f7a3f757b43e5b55450d9fb80d6bb9c9-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Random-Start Protocols Allow Fertility Preservation Without Delaying Treatment&quot;],&quot;url&quot;:[0,&quot;/view/random-start-protocols-allow-fertility-preservation-without-delaying-treatment&quot;]}],[0,{&quot;_id&quot;:[0,&quot;0761906e-4c99-4b2f-b202-41fea1351861&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Brain Cancer&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;clinical/brain-cancer&quot;],[0,null],[0,&quot;news&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma: © Lila Patel - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,2],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3c798420b1690f45ac174a47810b2706c6da4419-6250x3125-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3c798420b1690f45ac174a47810b2706c6da4419-6250x3125.jpg&quot;]}],&quot;title&quot;:[0,&quot;Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma&quot;],&quot;url&quot;:[0,&quot;/view/novel-cancer-vaccine-plus-temozolomide-miss-primary-end-point-in-glioblastoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a1fe3ff8-af24-4828-8c35-9498315ce769&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-07T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Hematologic Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/hematology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-7f38f421040582f3589ececbc92f5af59a790798-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7f38f421040582f3589ececbc92f5af59a790798-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Weighing Safety vs Persistence With CAR NK Cell Therapy&quot;],&quot;url&quot;:[0,&quot;/view/weighing-safety-vs-persistence-with-car-nk-cell-therapy&quot;]}],[0,{&quot;_id&quot;:[0,&quot;439cf6ed-2c24-4680-9112-4713db911bf7&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-b3e1284863602927a2f01680a4fbc1a9457c702a-1000x1000-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b3e1284863602927a2f01680a4fbc1a9457c702a-1000x1000.png&quot;]}],&quot;title&quot;:[0,&quot;What Does NRG GU002 Mean for Docetaxel After Prostatectomy?&quot;],&quot;url&quot;:[0,&quot;/view/what-does-nrg-gu002-mean-for-docetaxel-after-prostatectomy-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;09f7be41-e1c2-4a7a-a3ca-f1042e01de56&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Features&quot;],[0,&quot;Multiple Myeloma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/multiple-myeloma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.1135781383432963],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-98b0a5776b30f62a4b369314573127ce4172195e-1304x1171-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/98b0a5776b30f62a4b369314573127ce4172195e-1304x1171.png&quot;]}],&quot;title&quot;:[0,&quot;Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/considering-talquetamab-and-emerging-bispecifics-in-r-r-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;f4052e5c-f969-4db7-96cf-c445882d926e&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T17:31:49.936Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Breaking News&quot;],[0,&quot;Breast Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/breast-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.&quot;],&quot;aspectRatio&quot;:[0,1.910828025477707],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628.png&quot;]}],&quot;title&quot;:[0,&quot;FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer&quot;],&quot;url&quot;:[0,&quot;/view/fda-approves-tucatinib-combo-as-maintenance-in-her2-breast-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a8cfa260-82f4-40cb-b053-2305362083eb&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Head &amp; Neck Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/head-neck-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Medical illustration of laryngeal cancer, covering laryngeal tumor pathology, ENT diagnosis, clinical staging and professional treatment solutions for head and neck oncology research | Image Credit: © 程 加星 - stock.adobe.com &quot;],&quot;aspectRatio&quot;:[0,1.7843137254901962],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5d898f4bbe7c163006d09715bc4230d21fbb4ad8-5824x3264-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5d898f4bbe7c163006d09715bc4230d21fbb4ad8-5824x3264.jpg&quot;]}],&quot;title&quot;:[0,&quot;Transmucosal Patch Yields Pathologic Responses in Non-Invasive Oral Cancer&quot;],&quot;url&quot;:[0,&quot;/view/transmucosal-patch-yields-pathologic-responses-in-non-invasive-oral-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;f3d3417b-5c23-4cd0-857d-436983d12509&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Lung Cancer&quot;],[0,&quot;Sarcoma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/lung-cancer&quot;],[0,&quot;clinical/sarcoma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.&quot;],&quot;aspectRatio&quot;:[0,1.3333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-139a18b2c4d4432bcf06d40954215538bbbd35c8-8000x6000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/139a18b2c4d4432bcf06d40954215538bbbd35c8-8000x6000.jpg&quot;]}],&quot;title&quot;:[0,&quot;OST-HER2 Shows Significant Final 3-Year OS Benefit in Osteosarcoma Trial&quot;],&quot;url&quot;:[0,&quot;/view/ost-her2-shows-significant-final-3-year-os-benefit-in-osteosarcoma-trial&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cfb5e1df-b9e8-402a-aeef-6f42d2019a0d&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-07T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-ab09d2d8d89f66dc114b5a33c5dbed16c60eb21a-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ab09d2d8d89f66dc114b5a33c5dbed16c60eb21a-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Personalized Vaccines May Have Utility Across All Lung Cancer Stages&quot;],&quot;url&quot;:[0,&quot;/view/personalized-vaccines-may-have-utility-across-all-lung-cancer-stages&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a29aad96-4910-4d47-83f6-fed8a266171b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-07T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, discussed the system breakdowns that delay fertility referrals and how EHR triggers can automate the process.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-0cd3f7d9f7516a528202e5ba752225dc9211794d-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0cd3f7d9f7516a528202e5ba752225dc9211794d-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Clear Ownership and EHR Triggers Can Close Gaps in Oncofertility Referrals&quot;],&quot;url&quot;:[0,&quot;/view/clear-ownership-and-ehr-triggers-can-close-gaps-in-oncofertility-referrals&quot;]}],[0,{&quot;_id&quot;:[0,&quot;d1fcadfa-4d79-4a5e-9a0a-9912a243996e&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Zachary L. Bercu, MD, RPVI, FSIR, discusses the Liberty robotic system’s applications in liver and kidney cancer as well as the feasibility of remote procedures.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Q&amp;As&quot;],[0,&quot;News&quot;],[0,&quot;Liver Cancer&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;clinical/liver-cancer&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Interventional radiology operation room in modern clinic: © Vadim - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.4998585572843],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-9ab1017fcb2dfd91fb1d188e8fc39928c5ec0432-5302x3535-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Interventional radiology operation room in modern clinic: © Vadim - stock.adobe.com&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9ab1017fcb2dfd91fb1d188e8fc39928c5ec0432-5302x3535.jpg&quot;]}],&quot;title&quot;:[0,&quot;Clinical Applications and the Future of Remote Endovascular Procedures&quot;],&quot;url&quot;:[0,&quot;/view/clinical-applications-and-the-future-of-remote-endovascular-procedures&quot;]}],[0,{&quot;_id&quot;:[0,&quot;526b01db-8278-4f6a-9e70-045bcc189740&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e8e7f8835f5c4d82fae608ea8f494d1a8179ac51-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e8e7f8835f5c4d82fae608ea8f494d1a8179ac51-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Taking The First Steps for a Personalized Lung Cancer Vaccine Trial&quot;],&quot;url&quot;:[0,&quot;/view/taking-the-first-steps-for-a-personalized-lung-cancer-vaccine-trial&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2888becd-40d7-478c-9b8f-ce82fc0ee636&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-438ad9b3dee2f9dc61fe279881aff2e76e7142a5-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/438ad9b3dee2f9dc61fe279881aff2e76e7142a5-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;How the Big Ten CRC Moves Bench Discoveries Toward Multicenter Trials&quot;],&quot;url&quot;:[0,&quot;/view/how-the-big-ten-crc-moves-bench-discoveries-toward-multicenter-trials&quot;]}],[0,{&quot;_id&quot;:[0,&quot;907e9fa1-295f-4176-b85a-bb6c908a8c46&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T16:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Ovarian Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/ovarian-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC: © Lars Neumann - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.1666666666666667],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-d90c589883bf085523d6948612da705f50ed131e-7000x6000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d90c589883bf085523d6948612da705f50ed131e-7000x6000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC&quot;],&quot;url&quot;:[0,&quot;/view/avutometinib-defactinib-shows-activity-in-kras-wild-type-recurrent-lgsoc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6a269e02-fab9-4f35-908a-1966bac5b053&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-98283df37f0b9355008d14aa3c157b16f0d3622b-300x300-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/98283df37f0b9355008d14aa3c157b16f0d3622b-300x300.png&quot;]}],&quot;title&quot;:[0,&quot;Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC&quot;],&quot;url&quot;:[0,&quot;/view/firmonertinib-misses-pfs-end-point-in-first-line-egfr-exon-20-nsclc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;77175ce9-2047-4067-aa05-0f287358217e&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Adding fixed-duration epcoritamab to R-CHOP reduced the risk of progression or death by 51% in patients with newly diagnosed DLBCL.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Lymphoma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/lymphoma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Cancer cell or cancerous tumor amidst flowing red blood cells in a blood vessel, artery or vein 3D rendering illustration. Medicine, pathology, oncology, disesase, science concepts. | Image Credit: © Matthieu - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3b0bfef9b4f2eb76acb7dd4c2bf687a15bce5ed4-3840x2160-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Adding fixed-duration epcoritamab to R-CHOP reduced the risk of progression or death by 51% in patients with newly diagnosed DLBCL.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3b0bfef9b4f2eb76acb7dd4c2bf687a15bce5ed4-3840x2160.jpg&quot;]}],&quot;title&quot;:[0,&quot;Epcoritamab/R-CHOP Shows PFS Benefit in Newly Diagnosed DLBCL&quot;],&quot;url&quot;:[0,&quot;/view/epcoritamab-r-chop-shows-pfs-benefit-in-newly-diagnosed-dlbcl&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a7e12428-e64b-4b7c-aa31-89b3ebf8d84f&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chirag Jain, MBBS, discussed onco-anxiology, a proposed framework for identifying and managing anxiety at each stage of the cancer journey.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Psycho-Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/psycho-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-f458c1b985bf224a5348c9a348b5107298b8bed1-3000x2000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f458c1b985bf224a5348c9a348b5107298b8bed1-3000x2000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Onco-Anxiology Framework Targets Anxiety Across the Cancer Care Continuum&quot;],&quot;url&quot;:[0,&quot;/view/onco-anxiology-framework-targets-anxiety-across-the-cancer-care-continuum&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a5907f9e-097e-42f7-a69f-69ac7a3d0912&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T13:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Multiple Myeloma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/multiple-myeloma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6e3e75081cc80dc4919ecd564f4c3c34e533e8f1-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6e3e75081cc80dc4919ecd564f4c3c34e533e8f1-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy&quot;],&quot;url&quot;:[0,&quot;/view/selinexor-based-quadruplet-targets-myeloma-after-t-cell-redirecting-therapy&quot;]}],[0,{&quot;_id&quot;:[0,&quot;e96667ae-8be9-4457-b1dc-67381cb7828d&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, explained why male fertility preservation information trails female content online and how cancer centers can fix it.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-60a12baec05223e0c724d18e59f4d84b33d58608-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/60a12baec05223e0c724d18e59f4d84b33d58608-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Male Oncofertility Content Still Lags on NCI Cancer Center Websites&quot;],&quot;url&quot;:[0,&quot;/view/male-oncofertility-content-still-lags-on-nci-cancer-center-websites&quot;]}],[0,{&quot;_id&quot;:[0,&quot;69f411de-88fc-41e7-b98b-955fad526371&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Liver Cancer&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/liver-cancer&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Modern interventional radiology system with hepatic anatomy illustration: © MDJOYNAL - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7916666666666667],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-414d4b3f59782b8802b059d41e8ec0ff2e39ac42-11008x6144-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/414d4b3f59782b8802b059d41e8ec0ff2e39ac42-11008x6144.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Emory Became the First Adopter of the Liberty Endovascular Robotic System&quot;],&quot;url&quot;:[0,&quot;/view/how-emory-became-the-first-adopter-of-the-liberty-endovascular-robotic-system&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2fe5b2e0-d23f-47c0-b464-84ed996f11b4&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-05T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-2ccd046c9f58fef04ec5acd94a98ff48ea68b5ef-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2ccd046c9f58fef04ec5acd94a98ff48ea68b5ef-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Why High-Risk Stage I NSCLC Needs a Postsurgical Vaccine Option&quot;],&quot;url&quot;:[0,&quot;/view/why-high-risk-stage-i-nsclc-needs-a-post-surgical-vaccine-option&quot;]}],[0,{&quot;_id&quot;:[0,&quot;557d86ef-79c5-4a21-829d-c92ffdc7ead3&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-05T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Lymphoma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/lymphoma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-81284df7ef93c1a3e50bf46408946dab8935685c-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/81284df7ef93c1a3e50bf46408946dab8935685c-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma&quot;],&quot;url&quot;:[0,&quot;/view/expanding-car-t-and-bispecific-antibody-research-in-hiv-associated-lymphoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;c910233e-796c-4927-a5b2-8f66aa48b736&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T18:31:04.081Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Ovarian Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/ovarian-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Rina-S Elicits Responses in PROC Regardless of FRα Expression: © magicmine - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-f5d139d6b30af88101f0c7ddcec7f60b55491e85-3840x2160-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f5d139d6b30af88101f0c7ddcec7f60b55491e85-3840x2160.jpg&quot;]}],&quot;title&quot;:[0,&quot;Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression&quot;],&quot;url&quot;:[0,&quot;/view/rinatabart-sesutecan-elicits-responses-in-proc-regardless-of-fr-expression&quot;]}],[0,{&quot;_id&quot;:[0,&quot;008808ab-4083-44a0-8c5b-c4f986f9b1c5&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, discusses oncofertility gaps at NCI-designated cancer centers and ways to speed fertility referrals for patients.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,0.75],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-644c414c2596a469d7e9b910e0f3e100975897ae-360x480-webp&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/644c414c2596a469d7e9b910e0f3e100975897ae-360x480.webp&quot;]}],&quot;title&quot;:[0,&quot;How Can Oncologists Make Fertility Preservation a Routine Part of Cancer Care?&quot;],&quot;url&quot;:[0,&quot;/view/how-can-oncologists-make-fertility-preservation-a-routine-part-of-cancer-care-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;028d7fb3-c1f0-4d60-a900-ff173616144d&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e23e475b94cd7b5475a8179067d9c25efb4e9524-4500x3000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e23e475b94cd7b5475a8179067d9c25efb4e9524-4500x3000.jpg&quot;]}],&quot;title&quot;:[0,&quot;NDA Submission Begins for Zipalertinib Combo in First-Line EGFR+ NSCLC&quot;],&quot;url&quot;:[0,&quot;/view/nda-submission-begins-for-zipalertinib-combo-in-first-line-egfr-nsclc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;7068f1f9-ec52-4640-a51e-308cb6580342&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5f4653807e8f7745a965fa94caafdd22cb5a477b-5000x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5f4653807e8f7745a965fa94caafdd22cb5a477b-5000x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Berzosertib Combo Shows No Response Benefit in Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/berzosertib-combo-shows-no-response-benefit-in-metastatic-crpc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;57ebb931-148e-4bc4-9711-d8cc76bf8e25&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T14:15:52.124Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Ovarian Cancer&quot;],[0,&quot;News Reports&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/ovarian-cancer&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer: © magicmine - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-73f50db252d86472148b009ebd1797e4e3c07449-3840x2160-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/73f50db252d86472148b009ebd1797e4e3c07449-3840x2160.jpg&quot;]}],&quot;title&quot;:[0,&quot;Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer&quot;],&quot;url&quot;:[0,&quot;/view/ubamatamab-yields-responses-in-recurrent-low-grade-serous-ovarian-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;071acca8-a2df-490c-b764-f70dad7f331c&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-05T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Lung Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/lung-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-421e3c00e2218f7c0ac702d801e8829085c49481-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/421e3c00e2218f7c0ac702d801e8829085c49481-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Balancing Cure and Toxicity in Complex Lung Cancer Radiotherapy Regimens&quot;],&quot;url&quot;:[0,&quot;/view/balancing-cure-and-toxicity-in-complex-lung-cancer-radiotherapy-regimens&quot;]}],[0,{&quot;_id&quot;:[0,&quot;97f44d5b-4496-499f-849e-a65fa19d7607&quot;],&quot;contentCategory&quot;:[0,&quot;Podcasts&quot;],&quot;published&quot;:[0,&quot;2026-10-05T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Podcasts&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;],[0,&quot;Recent Episodes&quot;],[0,&quot;FDA Approval Alert: The Need-to-Know&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;podcasts&quot;],[0,&quot;clinical/nsclc&quot;],[0,&quot;recent-episodes&quot;],[0,&quot;fda-approval-alert&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.&quot;],&quot;aspectRatio&quot;:[0,1.013143483023001],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5e7b4abec0c9247ee5bbe4c47ebe34bff52a7155-6475x6391-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5e7b4abec0c9247ee5bbe4c47ebe34bff52a7155-6475x6391.jpg&quot;]}],&quot;title&quot;:[0,&quot;What Does Sevabertinib’s Expanded Approval Mean for HER2+ NSCLC? &quot;],&quot;url&quot;:[0,&quot;/view/what-does-sevabertinib-s-expanded-approval-mean-for-her2-nsclc-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;e0f410e1-b664-4de7-a447-12ab409d998d&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-04T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said J. Thaddeus Beck, MD, FACP.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.&quot;],&quot;aspectRatio&quot;:[0,0.6666666666666666],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said J. Thaddeus Beck, MD, FACP.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Is Subcutaneous Administration Changing Oncology Care Delivery?&quot;],&quot;url&quot;:[0,&quot;/view/how-is-subcutaneous-administration-changing-oncology-care-delivery-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6b6ee501-e8f3-4206-b7be-728e52657184&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-04T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Lung Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/lung-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c837dfa48a7bae21d18228f476b4b0a830badd95-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c837dfa48a7bae21d18228f476b4b0a830badd95-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?&quot;],&quot;url&quot;:[0,&quot;/view/how-well-does-radiotherapy-pair-with-dual-pd-1-lag-3-blockade-in-nsclc-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6edb4c55-6b18-4a67-a03b-d8d5e7724d4c&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-04T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-eb81880dbc2fefdb57bd6463630d57277b2319da-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/eb81880dbc2fefdb57bd6463630d57277b2319da-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/prioritizing-proton-therapy-for-pelvic-nodal-irradiation-in-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;58c2bd34-0540-4c61-9e9f-06677ba16445&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-03T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.162217659137577],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1e6dc9be604f77b92beb831886975d08318b17bc-566x487-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1e6dc9be604f77b92beb831886975d08318b17bc-566x487.jpg&quot;]}],&quot;title&quot;:[0,&quot;Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery&quot;],&quot;url&quot;:[0,&quot;/view/alliance-a071801-supports-fractionated-srs-after-brain-metastasis-surgery&quot;]}],[0,{&quot;_id&quot;:[0,&quot;5af6847f-8281-4085-875e-63013654969a&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-03T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-7ebc64944997fe4c839ade0c5969782898d4f598-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7ebc64944997fe4c839ade0c5969782898d4f598-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Rectal Spacers May Reduce Toxicity of Proton Therapy in Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/rectal-spacers-may-reduce-toxicity-of-proton-therapy-in-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;c77761a2-97f4-4b76-9227-0a7a8a2a1ab6&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Dynamic Video&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3d3e2eccd85358bb564c97a5a9f5a966eea0ecbd-1280x720-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3d3e2eccd85358bb564c97a5a9f5a966eea0ecbd-1280x720.png&quot;]}],&quot;title&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on Radiation Oncology&#39;s Next Frontier and Mentorship&quot;],&quot;url&quot;:[0,&quot;/view/bruce-haffty-md-and-mutlay-sayan-md-on-radiation-oncology-s-next-frontier-and-mentorship&quot;]}],[0,{&quot;_id&quot;:[0,&quot;b2f8f85d-79d6-4610-850e-e65a3c8b28f2&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-479ad7fa962c4064930c11973aac309e064087e5-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/479ad7fa962c4064930c11973aac309e064087e5-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups&quot;],&quot;url&quot;:[0,&quot;/view/assessing-impt-outcomes-across-localized-prostate-cancer-risk-groups&quot;]}],[0,{&quot;_id&quot;:[0,&quot;76b023e0-6c69-47f9-94d3-b54da7545595&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-02T19:45:05.106Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Breaking News&quot;],[0,&quot;News&quot;],[0,&quot;Leukemia&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;clinical/leukemia&quot;],[0,&quot;clinical/lymphoma&quot;],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.&quot;],&quot;aspectRatio&quot;:[0,1.7561779242174629],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214.png&quot;]}],&quot;title&quot;:[0,&quot;FDA OKs Pirtobrutinib in Frontline CLL/SLL&quot;],&quot;url&quot;:[0,&quot;/view/fda-oks-pirtobrutinib-in-frontline-cll-sll&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2eeb7443-1cb1-4c2c-bc8a-39db1604becf&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c59144717b9371bc671c11a71ea6bd964a247767-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c59144717b9371bc671c11a71ea6bd964a247767-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Making Outpatient Cellular Therapy Dosing the Default in Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/making-outpatient-cellular-therapy-dosing-the-default-in-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;32a9d524-c07e-4cfa-83e3-1e7077357b3b&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-02T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7753120665742026],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-4f123c1e22b36e7db3d61e261146ef486e1dd340-1280x721-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4f123c1e22b36e7db3d61e261146ef486e1dd340-1280x721.png&quot;]}],&quot;title&quot;:[0,&quot;Fractionated SRS Improves Surgical Bed Control After Brain Metastasis Resection&quot;],&quot;url&quot;:[0,&quot;/view/fractionated-srs-improves-surgical-bed-control-after-brain-metastasis-resection&quot;]}],[0,{&quot;_id&quot;:[0,&quot;565185c2-3aeb-4662-9eac-ee92ed9b85fd&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-02T14:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Breast Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/breast-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.&quot;],&quot;aspectRatio&quot;:[0,1.5429025423728813],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-19aeb1ca058f8b9c18fc24096b95943b2c6cf9f8-5826x3776-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/19aeb1ca058f8b9c18fc24096b95943b2c6cf9f8-5826x3776.jpg&quot;]}],&quot;title&quot;:[0,&quot;Giredestrant Combo Boosts PFS in Pretreated ER+ Advanced Breast Cancer&quot;],&quot;url&quot;:[0,&quot;/view/giredestrant-combo-boosts-pfs-in-pretreated-er-advanced-breast-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;12c5eb6c-671d-4fc6-884d-98440f5a9f93&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Pancreatic Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/pancreatic-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,null],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,null]}],&quot;title&quot;:[0,&quot;Preoperative SBRT Shows High Resection Rates in Pancreatic Adenocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/preoperative-sbrt-shows-high-resection-rates-in-pancreatic-adenocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2f4e24d2-41f0-4065-b1c4-11f35b1ecaff&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;Gastrointestinal Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-88cf2921a6e8d5ecf991281aa033975fe9bec231-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/88cf2921a6e8d5ecf991281aa033975fe9bec231-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Understanding the KRAS Mutation Landscape in Biliary Tract Cancer&quot;],&quot;url&quot;:[0,&quot;/view/understanding-the-kras-mutation-landscape-in-biliary-tract-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;fee70db8-4956-4a6d-97b7-e1c89c1bb667&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-01T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Pancreatic Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/pancreatic-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-02ac8915e1374c39e25224c9c6a74c20d48c9c18-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/02ac8915e1374c39e25224c9c6a74c20d48c9c18-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;What Drove the SBRT Quality-of-Life Advantage in Pancreatic Cancer?&quot;],&quot;url&quot;:[0,&quot;/view/what-drove-the-sbrt-quality-of-life-advantage-in-pancreatic-cancer-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;3a3d3f2b-8830-47eb-ba22-c058cd6fd51c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.&quot;],&quot;aspectRatio&quot;:[0,0.667779632721202],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-a1adeba6d98b02e8d431e9fe662448f33d2d9a6f-1200x1797-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a1adeba6d98b02e8d431e9fe662448f33d2d9a6f-1200x1797.jpg&quot;]}],&quot;title&quot;:[0,&quot;Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?&quot;],&quot;url&quot;:[0,&quot;/view/where-does-intensity-modulated-proton-therapy-fit-in-prostate-cancer-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;614d83bc-3cba-43c5-bfc5-c6f1f855528c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Conference&quot;],[0,&quot;Slideshows&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;conference&quot;],[0,&quot;resources/slideshows&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.&quot;],&quot;aspectRatio&quot;:[0,1.5463917525773196],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-9f56eba4eb61989ef5c263c5f21a030fc69b3e09-1200x776-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9f56eba4eb61989ef5c263c5f21a030fc69b3e09-1200x776.jpg&quot;]}],&quot;title&quot;:[0,&quot;IMS 2026: Key Updates Across The Multiple Myeloma Paradigm&quot;],&quot;url&quot;:[0,&quot;/view/ims-2026-key-updates-across-the-multiple-myeloma-paradigm&quot;]}],[0,{&quot;_id&quot;:[0,&quot;7deac2da-3616-45d6-a6f2-0d838d2a659c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News Reports&quot;],[0,&quot;News&quot;],[0,&quot;Small Cell Lung Cancer (SCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;clinical/small-cell-lung-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.&quot;],&quot;aspectRatio&quot;:[0,1.4002333722287048],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-555f5be80532573a6654f0b562c43e11aedf99df-1200x857-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/555f5be80532573a6654f0b562c43e11aedf99df-1200x857.jpg&quot;]}],&quot;title&quot;:[0,&quot;FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC&quot;],&quot;url&quot;:[0,&quot;/view/fda-discussion-prompts-voluntary-withdrawal-of-bla-for-i-dxd-in-es-sclc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;918f9260-959d-4257-b42f-10b5b7158fbe&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T15:02:42.344Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.&quot;],&quot;aspectRatio&quot;:[0,1.1111111111111112],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300.jpg&quot;]}],&quot;title&quot;:[0,&quot;Tabelecleucel BLA Resubmitted to FDA for EBV-Positive PTLD&quot;],&quot;url&quot;:[0,&quot;/view/tabelecleucel-bla-resubmitted-to-fda-for-ebv-positive-ptld&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2931406c-52b2-41ee-9e2f-482ed00f2fce&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-01T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Pancreatic Cancer&quot;],[0,&quot;Surgery&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/pancreatic-cancer&quot;],[0,&quot;clinical/surgery&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e14ddc5983a7b4b2c9e75769d3215c9b33f88957-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e14ddc5983a7b4b2c9e75769d3215c9b33f88957-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;SBRT Preserves Quality of Life Before Pancreatic Cancer Surgery&quot;],&quot;url&quot;:[0,&quot;/view/sbrt-preserves-quality-of-life-before-pancreatic-cancer-surgery&quot;]}],[0,{&quot;_id&quot;:[0,&quot;58f7274a-2816-4cad-a5f2-a3f13c43aa51&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T13:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News Reports&quot;],[0,&quot;News&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,0.9902439024390244],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5bb0fb502597b441b504933051804df03d668f46-406x410-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5bb0fb502597b441b504933051804df03d668f46-406x410.png&quot;]}],&quot;title&quot;:[0,&quot;SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer &quot;],&quot;url&quot;:[0,&quot;/view/sbrt-matches-disease-control-of-prostatectomy-in-localized-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;da1dd275-78ce-4c1f-8f3a-6818aa01f9b0&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-01T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;News&quot;],[0,&quot;Gastrointestinal Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;news&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-ae63c7e65ca956fb4d26cc120cc8521b840b02a5-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ae63c7e65ca956fb4d26cc120cc8521b840b02a5-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Early Clinical Data Show KRAS Inhibitors Can Work in Cholangiocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/early-clinical-data-show-kras-inhibitors-can-work-in-cholangiocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;34763092-92a1-4ca8-964c-d6354761f76c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?&quot;],&quot;aspectRatio&quot;:[0,0.8],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c46052a450f03752d4e3278cebceb69e9c658b2c-4000x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c46052a450f03752d4e3278cebceb69e9c658b2c-4000x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?&quot;],&quot;url&quot;:[0,&quot;/view/what-does-talapro-3-mean-for-frontline-treatment-of-hrr-altered-mhspc-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;be9d87b5-c7e4-46bd-b847-ce1a181a333f&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.326],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/aglatimagene-combo-shows-sustained-immune-remodeling-in-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;43ce25c8-912d-482b-b3fb-80d2b6543575&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The ROADS investigators reported no differences between cesium-131 tile-based radiation therapy and SRT in quality of life, functional status, or neurocognitive function.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases: © Sebastian Kaulitzki - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.3333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-02c2654f19c2e270c10911db15c14c07e74d3722-5000x3750-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The ROADS investigators reported no differences between cesium-131 tile-based radiation therapy and SRT in quality of life, functional status, or neurocognitive function.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/02c2654f19c2e270c10911db15c14c07e74d3722-5000x3750.jpg&quot;]}],&quot;title&quot;:[0,&quot;Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases&quot;],&quot;url&quot;:[0,&quot;/view/tile-based-radiation-improves-surgical-bed-recurrence-in-brain-metastases&quot;]}],[0,{&quot;_id&quot;:[0,&quot;acebb5c3-510d-4a20-a061-316888ac4c32&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Conference&quot;],[0,&quot;Pancreatic Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Q&amp;As&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/pancreatic-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.1166666666666667],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-f8dbad1e1efc44c0fb739d75f02a25b9fe0e8f38-6700x6000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f8dbad1e1efc44c0fb739d75f02a25b9fe0e8f38-6700x6000.jpg&quot;]}],&quot;title&quot;:[0,&quot;SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery&quot;],&quot;url&quot;:[0,&quot;/view/sbrt-matches-chemoradiation-preserves-qol-before-pancreatic-surgery&quot;]}],[0,{&quot;_id&quot;:[0,&quot;9c1de5e5-7dbc-4b42-bc89-af1ff281102b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-30T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Conference&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;News&quot;],[0,&quot;Gastrointestinal Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;conference&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;news&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c9a5184869b1549f49e584933622a660ffdba996-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c9a5184869b1549f49e584933622a660ffdba996-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Sequencing FGFR2 Inhibitors in Previously Treated Cholangiocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/sequencing-fgfr2-inhibitors-in-previously-treated-cholangiocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;3514886b-2219-4599-b70e-7b95ab8a2ba0&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T22:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.&quot;],&quot;aspectRatio&quot;:[0,0.7272727272727273],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-283af1206310c49850e4e13c57aa0e2ec6e47043-1200x1650-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/283af1206310c49850e4e13c57aa0e2ec6e47043-1200x1650.jpg&quot;]}],&quot;title&quot;:[0,&quot;Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care&quot;],&quot;url&quot;:[0,&quot;/view/integrating-talazoparib-plus-enzalutamide-into-hrr-mutated-mhspc-care&quot;]}],[0,{&quot;_id&quot;:[0,&quot;d1286dfa-d844-41a1-b1a2-f84a1b417110&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-29T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;Gastrointestinal Cancer&quot;],[0,&quot;News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;],[0,&quot;news&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3f7c04b33626ec6e6a1ace83c981e5c811592693-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3f7c04b33626ec6e6a1ace83c981e5c811592693-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/lirafugratinib-approval-adds-a-third-fgfr2-inhibitor-in-cholangiocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;b3782e19-5e92-4092-b100-a66ab2d602d2&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;],[0,&quot;Small Cell Lung Cancer (SCLC)&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/small-cell-lung-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.&quot;],&quot;aspectRatio&quot;:[0,1.3498312710911136],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-604dbc90ff1ae66780777fdd394c550f4c835df8-1200x889-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/604dbc90ff1ae66780777fdd394c550f4c835df8-1200x889.jpg&quot;]}],&quot;title&quot;:[0,&quot;SRS Improves Survival Vs Hippocampal Avoidant-WBRT in SCLC Brain Metastases&quot;],&quot;url&quot;:[0,&quot;/view/srs-improves-survival-vs-hippocampal-avoidant-wbrt-in-sclc-brain-metastases&quot;]}],[0,{&quot;_id&quot;:[0,&quot;503b257c-42ec-4488-98dc-121c288a6b58&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-821879789eef5f47bbc210b9c96ef210efd90022-1200x800-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/821879789eef5f47bbc210b9c96ef210efd90022-1200x800.jpg&quot;]}],&quot;title&quot;:[0,&quot;BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/bcma-gprc5d-car-t-cell-therapy-shows-early-efficacy-in-r-r-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;57f1794d-d767-40f5-a95b-dac99e3ebeef&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-29T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Brain Cancer&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/brain-cancer&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6ef85fa1e255f6a8e2b33c9ac2f54aff120abb04-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6ef85fa1e255f6a8e2b33c9ac2f54aff120abb04-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;When Single-Fraction SRS Still Makes Sense for Resected Brain Metastases&quot;],&quot;url&quot;:[0,&quot;/view/when-single-fraction-srs-still-makes-sense-for-resected-brain-metastases&quot;]}],[0,{&quot;_id&quot;:[0,&quot;ea16e1f5-76ca-4ac0-a438-4d50df7fecaa&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-a6130eed7d7f2e33168953c10354d4e6d720da1e-1200x675-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a6130eed7d7f2e33168953c10354d4e6d720da1e-1200x675.jpg&quot;]}],&quot;title&quot;:[0,&quot;Extended Belantamab Mafodotin Dosing Eases Ocular Function in DREAMM-9&quot;],&quot;url&quot;:[0,&quot;/view/extended-belantamab-mafodotin-dosing-eases-ocular-function-in-dreamm-9&quot;]}],[0,{&quot;_id&quot;:[0,&quot;e8c75242-5d86-47a3-8f79-d8e98a48a9fb&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T16:00:07.919Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma: © Sebastian Kaulitzki - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,2],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1844269e0cec8c0da218113457254f361f8ed7b0-8000x4000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1844269e0cec8c0da218113457254f361f8ed7b0-8000x4000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma&quot;],&quot;url&quot;:[0,&quot;/view/proton-therapy-does-not-improve-survival-in-hepatocellular-carcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;8c915645-078a-4c53-bead-b8d3b65439c4&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Journal Articles&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.3333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-9e83c0e9492f23d2ea77b28b0776b1f4da6a6af8-5000x3750-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9e83c0e9492f23d2ea77b28b0776b1f4da6a6af8-5000x3750.jpg&quot;]}],&quot;title&quot;:[0,&quot;Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/multimodal-biopsy-combo-shows-low-morbidity-in-suspected-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;04a6f888-5e7f-4f94-8fbe-6cb4253d5acf&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-29T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;news&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6d5b5776983f3642970057d4e322e81a12874e5a-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6d5b5776983f3642970057d4e322e81a12874e5a-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape&quot;],&quot;url&quot;:[0,&quot;/view/where-mrd-testing-fits-into-myeloma-s-treatment-and-regulatory-landscape&quot;]}]]],&quot;currentArticleId&quot;:[0,&quot;cn_article_374309&quot;],&quot;clientConfig&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;],&quot;storageNamespace&quot;:[0,&quot;cancernetwork&quot;],&quot;cookies&quot;:[0,{&quot;prefs&quot;:[0,&quot;cancernetwork_prefs&quot;],&quot;cognitoId&quot;:[0,&quot;cancernetwork_cognito_id&quot;]}],&quot;prefsEventName&quot;:[0,&quot;cancernetwork:personalization-prefs&quot;],&quot;endpoint&quot;:[0],&quot;idlayer&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;]}],&quot;engagement&quot;:[0,{&quot;segmentDualWrite&quot;:[0,true]}],&quot;taxonomyQuery&quot;:[0,{&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;parentGroup&quot;:[0,&quot;clinical&quot;]}],&quot;experiment&quot;:[0,{&quot;enabled&quot;:[0,true],&quot;salt&quot;:[0,&quot;dv6834-cancernetwork-homepage-v1&quot;]}]}],&quot;excludeIds&quot;:[1,[[0,&quot;de825fd8-becf-47b2-b75e-f36c32be2975&quot;],[0,&quot;69d6a710-7599-4939-88dc-d745376d37cf&quot;],[0,&quot;dcf42da5-6ed8-46d7-93ce-7dea016f9603&quot;],[0,&quot;da5bf0e0-2138-4b4a-a044-ffb88bda705b&quot;],[0,&quot;1abdedd9-ac41-4260-84de-d6d50f58626a&quot;],[0,&quot;732a9b36-4ae9-433f-a71e-af1a03502d39&quot;],[0,&quot;4e4318a7-7243-43a4-bdac-6c144f7aeb04&quot;],[0,&quot;10e9fead-dd59-4720-bf6d-81561b8910c1&quot;]]],&quot;title&quot;:[0,&quot;For You&quot;],&quot;rail&quot;:[0,&quot;for_you_inline&quot;],&quot;placement&quot;:[0,&quot;inline&quot;],&quot;placementOverride&quot;:[0,null],&quot;size&quot;:[0,8],&quot;layout&quot;:[0,&quot;strip&quot;]}" ssr client="idle" opts="{&quot;name&quot;:&quot;RecommendedForYou&quot;,&quot;value&quot;:true}"></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  " data-scroll-depth-region="article-body"> <div id="block-content" class="w-full _blockContent_s7hzj_1 "> <astro-island uid="Z3E48q" prefix="r84" component-url="/_astro/figure.DVOFG3ht.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;value&quot;:[0,{&quot;_key&quot;:[0,&quot;u3tvQRrg&quot;],&quot;_type&quot;:[0,&quot;figure&quot;],&quot;asset&quot;:[0,{&quot;_createdAt&quot;:[0,&quot;2020-06-09T06:36:21Z&quot;],&quot;_id&quot;:[0,&quot;image-6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846-380x486-jpg&quot;],&quot;_ref&quot;:[0,&quot;image-6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846-380x486-jpg&quot;],&quot;_rev&quot;:[0,&quot;gHtozpBUvKAPYE37IWAR54&quot;],&quot;_type&quot;:[0,&quot;sanity.imageAsset&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-06-09T06:36:21Z&quot;],&quot;assetId&quot;:[0,&quot;6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846&quot;],&quot;extension&quot;:[0,&quot;jpg&quot;],&quot;metadata&quot;:[0,{&quot;dimensions&quot;:[0,{&quot;_type&quot;:[0,&quot;sanity.imageDimensions&quot;],&quot;aspectRatio&quot;:[0,0.7818930041152263],&quot;height&quot;:[0,486],&quot;width&quot;:[0,380]}]}],&quot;mimeType&quot;:[0,&quot;image/jpeg&quot;],&quot;originalFilename&quot;:[0,&quot;1522197.png&quot;],&quot;path&quot;:[0,&quot;images/0vv8moc6/cancernetwork/6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846-380x486.jpg&quot;],&quot;sha1hash&quot;:[0,&quot;6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846&quot;],&quot;size&quot;:[0,54371],&quot;uploadId&quot;:[0,&quot;UzARJ1AKTb4LtAysVOFSgcvzUsqcUaCX&quot;],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846-380x486.jpg&quot;]}],&quot;blank&quot;:[0,false],&quot;caption&quot;:[0,&quot;&quot;],&quot;link&quot;:[0,&quot;1522197.png&quot;],&quot;medias&quot;:[0,null],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}]}" ssr client="load" opts="{&quot;name&quot;:&quot;FigurePlugin&quot;,&quot;value&quot;:true}"></astro-island><p class=""><strong>ADVERSE REACTIONS:</strong> Adverse reactions to the Gerson regimen include flu-like symptoms, loss of appetite, perspiration with foul odor, weakness, dizziness, cold sores, fever blisters, high fever, tumor pain, intestinal cramping, diarrhea, and vomiting. (<em>The Gerson Therapy Handbook</em> claims that these adverse reactions are indicative of response.)[5] <em>Campylobacter fetus</em> sepsis caused by the liver injections was reported in 13 patients on Gerson therapy between1980 and 1986. Coma from low serum sodium occurred in 5 of these patients.[6]</p><p class="">Coffee enemas cause electrolyte imbalance, which has resulted in serious infections, dehydration, colitis, constipation, and death.[7]</p><p class=""> </p><h3 class="pb-4 pt-2 text-xl">References:</h3><p class=""><strong>REFERENCES</strong></p><p class="">				</p><p class="">1. Cope FW: A medical application of the Ling association-induction hypothesis: The high potassium, low sodium diet of the Gerson cancer therapy. <em>Physiol Chem Phys</em> 10:465-468, 1978. </p><p class="">				</p><p class="">2. Jansson B: Geographic cancer risk and intracellular potassium/sodium ratios. C<em>ancer Detect Prevent</em> 9:171-194, 1986. </p><p class="">				</p><p class="">3. American Cancer Society: Making treatment decisions: Gerson therapy. Available at http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Gerson_Therapy.asp?sitearea=ETO. Accessed Dec 30, 2009.</p><p class="">				</p><p class="">4. Chabot JA, Tsai WY, Fine RL, et al: Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. <em>J Clin Oncol</em> Aug 17, 2009 (epub ahead of print).</p><p class="">				</p><p class="">5. Gerson M: <em>Gerson Therapy Handbook</em>, 5th ed. San Diego, Calif; Gerson Institute; 1999.</p><p class="">				</p><p class="">6. American Cancer Society: Questionable methods of cancer management: ‘Nutritional’ therapies. <em>CA Cancer J Clin</em> 43:309-319, 1993. </p><p class="">				</p><p class="">7. Eisele JW, Reay DT: Deaths related to coffee enemas. <em>JAMA</em> 244:1608-1609, 1980.</p> </div> </div><div class="flex flex-col items-center justify-center col-span-12  " data-scroll-depth-region="article-body"> <div id="block-content" class="w-full _blockContent_s7hzj_1 ">  </div> </div><div class="flex flex-col items-center justify-center col-span-12  "> <astro-island uid="Xi361" prefix="r85" component-url="/_astro/index.b88-7STk.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;cn_article_399509&quot;],&quot;articleType&quot;:[0,&quot;Publication&quot;],&quot;authors&quot;:[0,null],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,4],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-17T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;This activity is based on review articles in the journal ONCOLOGY. It is developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;ONCOLOGY Continuing Medical Education February 2010&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/oncology-continuing-medical-education-february-2010&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cn_article_400344&quot;],&quot;articleType&quot;:[0,null],&quot;authors&quot;:[1,[[0,{&quot;displayName&quot;:[0,&quot;Philip J. Tofilon, PhD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/philip-j-tofilon-phd&quot;]}],[0,{&quot;displayName&quot;:[0,&quot;Kevin A. Camphausen, MD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/kevin-camphausen-md&quot;]}]]],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,30],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-16T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The epigenetic control of gene expression has been shown to play an important role in cancer initiation, progression, and resistance. Thus, agents that modify the epigenetic environment of tumors will likely be an important addition to the anticancer arsenal. Specifically, there is much interest in modulating histone acetylation using a new class of drugs, histone deacetylase (HDAC) inhibitors. Preclinical data have demonstrated the efficacy of various HDAC inhibitors as anticancer agents, with the greatest effects shown when HDAC inhibitors are used in combination with other therapies. As a result of encouraging preclinical data, numerous HDAC inhibitors are being investigated in clinical trials either as monotherapies or in conjunction with other treatments such as chemotherapy, biologic therapy, or radiation therapy. In fact, vorinostat and depsipeptide, two actively studied HDAC inhibitors, were recently approved for the treatment of refractory cutaneous T-cell lymphoma. Although the use of HDAC inhibitors has generated great enthusiasm, a significant amount of work still needs to be done in order to understand their mechanisms of action, as well as to determine the appropriate patient characteristics and subsets of cancer for which HDAC inhibitors hold the most potential for effective treatment.&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;HDAC Inhibitors  in Cancer Care&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/hdac-inhibitors-cancer-care&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cn_article_400338&quot;],&quot;articleType&quot;:[0,null],&quot;authors&quot;:[1,[[0,{&quot;displayName&quot;:[0,&quot;Roger M. Macklis, MD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/roger-m-macklis-md&quot;]}]]],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,14],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-15T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;No branch of oncology has been more attuned to the vision of new genetically engineered targeted therapies than the field of hematopoietic malignancies. Ujjani and Cheson have produced a masterful summary of one extremely important component of the targeted therapy revolution-the realm of monoclonal antibodies directed against malignant lymphoma surface antigens.[1] The review presents a wonderful update and a glimpse of future potentially curative macromolecular cocktails. It is an attractive vision.&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;‘Vitamin R’ and Its Younger Siblings&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/vitamin-r-and-its-younger-siblings&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cn_article_400339&quot;],&quot;articleType&quot;:[0,null],&quot;authors&quot;:[1,[[0,{&quot;displayName&quot;:[0,&quot;Amelia B. Zelnak, MD, MSc&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/amelia-b-zelnak-md-msc&quot;]}]]],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,5],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-15T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Large clinical trials have demonstrated that preoperative therapy for primary operable breast cancer improves breast-conservation rates, with equivalent disease-free (DFS) and overall survival (OS) compared to adjuvant therapy.[1] Connolly and Stearns provide an excellent review of additional benefits of neoadjuvant therapy and emphasize the importance of a multidisciplinary approach to treating patients in this setting.&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;Clarifying the Role of Neoadjuvant Therapy in Breast Cancer&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/clarifying-role-neoadjuvant-therapy-breast-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cn_article_400340&quot;],&quot;articleType&quot;:[0,null],&quot;authors&quot;:[1,[[0,{&quot;displayName&quot;:[0,&quot;Roisin M. Connolly, MB&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/roisin-m-connolly-mb&quot;]}],[0,{&quot;displayName&quot;:[0,&quot;Vered Stearns, MD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/vered-stearns-md&quot;]}]]],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,46],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-15T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;While the administration of neoadjuvant chemotherapy is recommended for women with locally advanced breast cancer, its use in the primary operable setting has been debated and is the focus of this review.&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;A Multidisciplinary Approach to Neoadjuvant Therapy for Primary Operable Breast Cancer&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/multidisciplinary-approach-neoadjuvant-therapy-primary-operable-breast-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cn_article_400341&quot;],&quot;articleType&quot;:[0,null],&quot;authors&quot;:[1,[[0,{&quot;displayName&quot;:[0,&quot;Paul A. Marks, MD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/paul-marks-md&quot;]}]]],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,6],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-15T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Shabason and colleagues’ review of the development of histone deacetylase (HDAC) inhibitors as treatment for cancers is timely, with an emphasis on therapeutic strategies combining HDAC inhibitors and radiation therapy. As the authors indicate, vorinostat (Zolinza)-originally known as suberoylanilide hydroxamic acid, or SAHA-was the first of the HDAC inhibitors approved by the US Food and Drug Administration (FDA) for clinical use in the treatment of cutaneous T-cell lymphoma (CTCL).[1] In November 2009, a second HDAC inhibitor-romidepsin (Istodax)-received FDA approval for the treatment of CTCL. Currently there is a great deal of competition in the HDAC inhibitor field, as several new and, hopefully, more effective compounds are being developed and entering clinical trials.[2]&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;HDAC Inhibitors: Much to Learn About Effective Therapy&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/hdac-inhibitors-much-learn-about-effective-therapy&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cn_article_400342&quot;],&quot;articleType&quot;:[0,null],&quot;authors&quot;:[1,[[0,{&quot;displayName&quot;:[0,&quot;Serena T. Wong, MD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/serena-t-wong-md&quot;]}],[0,{&quot;displayName&quot;:[0,&quot;Mark N. Stein, MD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/mark-n-stein-md&quot;]}]]],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,19],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-15T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Shabason et al have written a thoughtful review of an exciting new class of agents, histone deacetylase (HDAC) inhibitors. While the authors focus primarily on the role of HDAC inhibitors in combination with radiation therapy, we would like to highlight some potential strategies combining these agents with systemic therapies for the treatment of cancer.&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;HDAC Inhibitor Research: Still in Its Infancy&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/hdac-inhibitor-research-still-its-infancy&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cn_article_400343&quot;],&quot;articleType&quot;:[0,null],&quot;authors&quot;:[1,[[0,{&quot;displayName&quot;:[0,&quot;Chaitra Ujjani, MD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/chaitra-ujjani-md&quot;]}],[0,{&quot;displayName&quot;:[0,&quot;Bruce D. Cheson, MD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/bruce-d-cheson-md&quot;]}]]],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,63],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-15T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;he treatment of B-cell malignancies has been revolutionized by the availability of safe and effective monoclonal antibodies. The addition of rituximab to standard chemotherapy regimens prolongs the survival of patients with diffuse large B-cell lymphoma (DLBCL) and follicular non-Hodgkin lymphoma. Nevertheless, indolent and mantle cell lymphomas remain incurable, and 30% to 40% of patients with DLBCL still die from their disease. Much ongoing research has focused on optimizing monoclonal antibody use, integrating them into multiagent regimens, and developing newer antibodies. Attempts to improve on the efficacy of monoclonal antibody–based therapy have included altering the dosing schedule, optimizing patient selection, maintenance therapy, improving upon the rituximab molecule, radioimmunotherapy, as well as combinations with cytotoxic molecules and other novel agents. Preliminary data with a number of treatment regimens are promising in indolent and aggressive lymphomas. The eventual goal of targeted therapies is to individualize treatment to increase response and survival, while reducing treatment-related toxicity.&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;Monoclonal Antibodies  in Advanced B-cell Lymphomas&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/monoclonal-antibodies-advanced-b-cell-lymphomas&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cn_article_364477&quot;],&quot;articleType&quot;:[0,null],&quot;authors&quot;:[1,[[0,{&quot;displayName&quot;:[0,&quot;John L. Marshall, MD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/john-l-marshall-md&quot;]}]]],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,11],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-11T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In my practice as an oncologist specializing in gastrointestinal tract cancers, a recent week was fairly typical. I saw 50 patients, ranging in age from 32 to 87, equally divided between men and women. Though a couple of them have inherited a gene that may have caused their GI cancers, I have no explanation for why most developed their disease. It is as if they were simply struck by lightning.&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;Fighting a Smarter  War on Cancer&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/fighting-smarter-war-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cn_article_364478&quot;],&quot;articleType&quot;:[0,null],&quot;authors&quot;:[0,null],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,2],&quot;isGated&quot;:[0,null],&quot;pageNumber&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-11T05:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the largest survey to date of US oncologists’ attitudes about the cost of cancer treatments, researchers at Tufts Medical Center and the University of Michigan found that 84% of oncologists consider their patients’ out-of-pocket costs when recommending cancer treatment. However, fewer than half of the respondents surveyed frequently discuss cost issues with patients.&quot;],&quot;thumbnail&quot;:[0,null],&quot;title&quot;:[0,&quot;Costs Play Role in Oncologists’ Treatment Recommendations, But Most Physicians Do Not Discuss Cost Issues With Patients&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/costs-play-role-oncologists-treatment-recommendations-most-physicians-do-not-discuss-cost-issues&quot;]}]]],&quot;title&quot;:[0,&quot;Articles in this issue&quot;],&quot;hidden&quot;:[0,false]}" ssr client="load" opts="{&quot;name&quot;:&quot;Slider&quot;,&quot;value&quot;:true}" await-children><div class="relative mt-3 flex w-full md:mt-0"><div class="relative h-full w-full border-b border-b-gray-200 pb-2" role="region" aria-roledescription="carousel"><div class="flex flex-row gap-2"><div class="mr-2 w-fit pb-3"><h2 class="rounded bg-primary px-2 py-1 text-xs font-light uppercase text-white">Articles in this issue</h2></div><button class="inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 border border-input bg-background hover:bg-accent hover:text-accent-foreground w-8 h-6 rounded-md" disabled=""><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-4 w-4" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M5 12l6 6"></path><path d="M5 12l6 -6"></path></svg><span class="sr-only">Previous slide</span></button><button class="inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 border border-input bg-background hover:bg-accent hover:text-accent-foreground w-8 h-6 rounded-md" disabled=""><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-4 w-4" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg><span class="sr-only">Next slide</span></button></div><div class="overflow-hidden"><div class="flex -ml-4"><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/oncology-continuing-medical-education-february-2010" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">ONCOLOGY Continuing Medical Education February 2010</a></div></div><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/hdac-inhibitors-cancer-care" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">HDAC Inhibitors  in Cancer Care</a></div></div><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/vitamin-r-and-its-younger-siblings" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">‘Vitamin R’ and Its Younger Siblings</a></div></div><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/clarifying-role-neoadjuvant-therapy-breast-cancer" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">Clarifying the Role of Neoadjuvant Therapy in Breast Cancer</a></div></div><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/multidisciplinary-approach-neoadjuvant-therapy-primary-operable-breast-cancer" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">A Multidisciplinary Approach to Neoadjuvant Therapy for Primary Operable Breast Cancer</a></div></div><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/hdac-inhibitors-much-learn-about-effective-therapy" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">HDAC Inhibitors: Much to Learn About Effective Therapy</a></div></div><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/hdac-inhibitor-research-still-its-infancy" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">HDAC Inhibitor Research: Still in Its Infancy</a></div></div><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/monoclonal-antibodies-advanced-b-cell-lymphomas" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">Monoclonal Antibodies  in Advanced B-cell Lymphomas</a></div></div><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/fighting-smarter-war-cancer" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">Fighting a Smarter  War on Cancer</a></div></div><div role="group" aria-roledescription="slide" class="min-w-0 shrink-0 grow-0 pl-4 mr-2 flex basis-64 flex-col sm:basis-1/2 md:basis-1/3 xl:basis-1/4"><div class="relative flex min-h-20 flex-col gap-2 border-r border-r-gray-200"><p class="text-xs font-light text-typo-light">over 16 years<!-- --> ago</p><p class="absolute right-6 top-0 hidden rounded border bg-gray-100 px-1 text-[10px] font-light uppercase text-black md:block">Article</p><a href="/view/costs-play-role-oncologists-treatment-recommendations-most-physicians-do-not-discuss-cost-issues" class="line-clamp-2 overflow-hidden text-ellipsis pr-4 text-sm font-bold text-typo-dark">Costs Play Role in Oncologists’ Treatment Recommendations, But Most Physicians Do Not Discuss Cost Issues With Patients</a></div></div></div></div></div></div><!--astro:end--></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  "> <astro-island uid="yEVV4" component-url="/_astro/index.B6QSCOMi.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[0,{&quot;sanityClientConfig&quot;:[0,{&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;useCdn&quot;:[0,true]}],&quot;gtmID&quot;:[0,&quot;5KJPVFH&quot;],&quot;title&quot;:[0,&quot;CancerNetwork&quot;],&quot;attentiveLanguageBrandName&quot;:[0,&quot;Cancer Network&quot;],&quot;liveDomain&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;logo&quot;:[0,&quot;/logo.webp&quot;],&quot;white_logo&quot;:[0,&quot;/logo.webp&quot;],&quot;megaMenuTaxName&quot;:[0,&quot;clinical&quot;],&quot;twitter&quot;:[0,&quot;@onclive&quot;],&quot;sharingImageUrl&quot;:[0,&quot;https://cancernetwork.s3.amazonaws.com/cancernetwork-primary-10-15.png&quot;],&quot;fixSecondaryNavigationLinksIdentifier&quot;:[0,true],&quot;oneTrustId&quot;:[0,&quot;0196a059-28cb-71f3-a7fc-4659bcc6ca6d&quot;],&quot;subFooterLinks&quot;:[1,[[0,{&quot;url&quot;:[0,&quot;/&quot;],&quot;title&quot;:[0,&quot;Home&quot;]}],[0,{&quot;url&quot;:[0,&quot;/about&quot;],&quot;title&quot;:[0,&quot;About Us&quot;]}],[0,{&quot;url&quot;:[0,&quot;/news&quot;],&quot;title&quot;:[0,&quot;News&quot;]}],[0,{&quot;url&quot;:[0,&quot;/contact-us&quot;],&quot;title&quot;:[0,&quot;Contact Us&quot;]}]]],&quot;subscribe&quot;:[0,{&quot;href&quot;:[0,&quot;/subscribe&quot;],&quot;text&quot;:[0,&quot;Stay up to date on recent advances in the multidisciplinary approach to cancer.&quot;]}],&quot;customSpecialtyText&quot;:[0,&quot;Cancer Focus&quot;]}],&quot;sourceContentId&quot;:[0,&quot;/view/gerson-regimen&quot;],&quot;subscriptionBrandName&quot;:[0],&quot;subscriptionBrandDisplayName&quot;:[0],&quot;subscriptionSubheading&quot;:[0],&quot;subscriptionEndpoint&quot;:[0],&quot;subscriptionBrands&quot;:[0]}" ssr client="only" opts="{&quot;name&quot;:&quot;NewsletterReact&quot;,&quot;value&quot;:&quot;react&quot;}"></astro-island><noscript><section class="w-full rounded-2xl border bg-background p-5 text-typo shadow-sm sm:p-6"> <h3 class="text-base font-semibold text-typo-dark">Newsletter</h3>  <p class="mt-1 text-sm leading-relaxed text-typo">Stay up to date on recent advances in the multidisciplinary approach to cancer.</p> <a href="/subscribe" class="mt-4 inline-flex w-full items-center justify-center rounded-xl bg-primary px-4 py-3 text-sm font-semibold text-white">
Subscribe
</a> </section></noscript> </div><div class="flex flex-col items-center justify-center col-span-12  flex justify-center items-center sm:hidden"> <astro-island uid="InT1s" prefix="r86" component-url="/_astro/AD300x250.DpBj1VD8.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[0,null],&quot;networkID&quot;:[0,&quot;4688&quot;],&quot;adUnit&quot;:[0,&quot;cmpm.cancernetwork&quot;],&quot;pos&quot;:[0,&quot;rec2-mobile&quot;],&quot;targeting&quot;:[0,{&quot;content_placement&quot;:[1,[[0,&quot;news&quot;],[0,&quot;journals/oncology&quot;]]],&quot;document_url&quot;:[1,[[0,&quot;gerson-regimen&quot;]]],&quot;document_group&quot;:[1,[]],&quot;content_group&quot;:[1,[]],&quot;rootDocumentGroup&quot;:[1,[]],&quot;issue_url&quot;:[1,[[0,&quot;oncology-vol-24-no-2&quot;]]],&quot;publication_url&quot;:[1,[[0,&quot;oncology&quot;]]],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;barrie-r-cassileth-ms-phd&quot;]]],&quot;hostname&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;adLayer&quot;:[0,{&quot;adSlotSelection&quot;:[1,[]]}]}],&quot;hidden&quot;:[0,false]}" ssr client="load" opts="{&quot;name&quot;:&quot;AD300x250&quot;,&quot;value&quot;:true}" await-children><div class="z-50"><div class="hidden text-center text-[8px] text-gray-500">Advertisement</div><div id="div-gpt-ad-rec2-mobile" class="" style="width:300px;min-height:250px"></div></div><!--astro:end--></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  "> <nav aria-label="Content placements" class="w-full"><div class="flex flex-wrap items-center"><div class="flex items-center flex-nowrap"><a href="/journals/oncology" class="p-2 text-sm text-primary">Oncology Journal</a></div></div></nav> </div><div class="flex flex-col items-center justify-center col-span-12  "> <hr class="w-full"/> </div><div class="flex flex-col items-center justify-center col-span-12  "> <astro-island uid="kQCrb" prefix="r72" component-url="/_astro/RecommendedForYou.CGa5dyV8.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;articles&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;de825fd8-becf-47b2-b75e-f36c32be2975&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T22:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Conference&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/lymphoma&quot;],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;aspectRatio&quot;:[0,0.8626887131560029],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-03e77b4f328a10c74086cdfdbf704078d6050f18-1200x1391-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/03e77b4f328a10c74086cdfdbf704078d6050f18-1200x1391.jpg&quot;]}],&quot;title&quot;:[0,&quot;Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer&quot;],&quot;url&quot;:[0,&quot;/view/weighing-the-promise-and-trade-offs-of-car-nk-cell-therapy-for-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;69d6a710-7599-4939-88dc-d745376d37cf&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.&quot;],&quot;aspectRatio&quot;:[0,0.8],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-363270bf0783d219c3528f46e9e77d5dc1f186e9-200x250-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Tyler J. WIlhite, MD\nUPMC HIllman Cancer Center&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/363270bf0783d219c3528f46e9e77d5dc1f186e9-200x250.png&quot;]}],&quot;title&quot;:[0,&quot;Building a Low-Dose Radiation Therapy Program for Benign Disease&quot;],&quot;url&quot;:[0,&quot;/view/building-a-low-dose-radiation-therapy-program-for-benign-disease&quot;]}],[0,{&quot;_id&quot;:[0,&quot;dcf42da5-6ed8-46d7-93ce-7dea016f9603&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-09T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5af592353ad710d026c1636a0a523c535b1213f7-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5af592353ad710d026c1636a0a523c535b1213f7-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization &quot;],&quot;url&quot;:[0,&quot;/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization&quot;]}],[0,{&quot;_id&quot;:[0,&quot;da5bf0e0-2138-4b4a-a044-ffb88bda705b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-09T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM&quot;],&quot;url&quot;:[0,&quot;/view/ramantamig-achieves-impressive-rates-of-mrd-negativity-in-rrmm&quot;]}],[0,{&quot;_id&quot;:[0,&quot;1abdedd9-ac41-4260-84de-d6d50f58626a&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Myeloproliferative Neoplasms&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/myeloproliferative-neoplasms&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;aspectRatio&quot;:[0,1.1111111111111112],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300.jpg&quot;]}],&quot;title&quot;:[0,&quot;Selcodebart Yields Hematologic Responses in Anemia From Myelofibrosis&quot;],&quot;url&quot;:[0,&quot;/view/selcodebart-yields-hematologic-responses-in-anemia-from-myelofibrosis&quot;]}],[0,{&quot;_id&quot;:[0,&quot;732a9b36-4ae9-433f-a71e-af1a03502d39&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T16:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Multiple Myeloma&quot;],[0,&quot;News&quot;],[0,&quot;Between the Lines&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;news&quot;],[0,&quot;between-the-lines&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.2939197930142303],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-d23a730915dd101042071359cc623e55511245dc-5001x3865-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d23a730915dd101042071359cc623e55511245dc-5001x3865.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?&quot;],&quot;url&quot;:[0,&quot;/view/how-do-long-term-maia-and-cepheus-data-reinforce-daratumumab-use-in-ndmm-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;4e4318a7-7243-43a4-bdac-6c144f7aeb04&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Journal Articles&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma: © 程 加星 - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c12520957948ebfc324e247b1151b3dd28a0420d-5120x2880-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c12520957948ebfc324e247b1151b3dd28a0420d-5120x2880.jpg&quot;]}],&quot;title&quot;:[0,&quot;Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma&quot;],&quot;url&quot;:[0,&quot;/view/adjuvant-radiotherapy-reduced-recurrence-in-resected-atypical-meningioma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;10e9fead-dd59-4720-bf6d-81561b8910c1&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.326],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;VIR-5500 Receives FDA Fast Track Designation for Late-Line Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/vir-5500-receives-fda-fast-track-designation-for-late-line-metastatic-crpc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;bdcb9830-1f2f-448c-a13a-8983f523a17c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Leukemia&quot;],[0,&quot;Frontline Forum&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/leukemia&quot;],[0,&quot;frontline-forum&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Acute lymphoblastic leukemia, bone marrow smear, 3D illustration | Image Credit: © Dr_Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-0888f4313a1f4443719b9c25dc719a35a434624c-6000x4000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0888f4313a1f4443719b9c25dc719a35a434624c-6000x4000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Can an All-Oral HMA Regimen Change Frontline Care in Unfit AML?&quot;],&quot;url&quot;:[0,&quot;/view/can-an-all-oral-hma-regimen-change-frontline-care-in-unfit-aml-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2ce5e471-a073-41a3-89b5-0798f9a3a843&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.&quot;],&quot;aspectRatio&quot;:[0,1.1333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3d031c79ae7db09f00e6bc06661074fdcd9363fa-680x600-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3d031c79ae7db09f00e6bc06661074fdcd9363fa-680x600.png&quot;]}],&quot;title&quot;:[0,&quot;Building out a Radiopharmaceuticals Program in Oncology Care&quot;],&quot;url&quot;:[0,&quot;/view/building-out-a-radiopharmaceuticals-program-in-oncology-care&quot;]}],[0,{&quot;_id&quot;:[0,&quot;0a750f3a-2571-4ddf-a0da-72d9d4e66a35&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-08T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Multiple Myeloma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/multiple-myeloma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-73e516a152d585762295aa34ac2f7799a65bc365-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/73e516a152d585762295aa34ac2f7799a65bc365-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;How to Navigate Ramantamig’s Low-Grade Toxicities in Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/how-to-navigate-ramantamig-s-low-grade-toxicities-in-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;f0c9c6d3-d81b-4957-bfc8-d90654feb6b5&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T18:06:23.010Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Colorectal Cancer&quot;],[0,&quot;Breaking News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/colorectal-cancer&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.&quot;],&quot;aspectRatio&quot;:[0,1.7561779242174629],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214.png&quot;]}],&quot;title&quot;:[0,&quot;FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer&quot;],&quot;url&quot;:[0,&quot;/view/fda-approves-atezolizumab-chemo-for-stage-iii-dmmr-msi-h-colon-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a7ce683b-60fc-4d25-ad98-6ef2dc85f88a&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/lymphoma&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.&quot;],&quot;aspectRatio&quot;:[0,0.75],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6ea1db064178195d78b3a00bceabd3bee8221f6a-1200x1600-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6ea1db064178195d78b3a00bceabd3bee8221f6a-1200x1600.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Can Cooperative Groups Close Outcome Gaps in HIV-Associated Lymphoma?&quot;],&quot;url&quot;:[0,&quot;/view/how-can-cooperative-groups-close-outcome-gaps-in-hiv-associated-lymphoma-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;71ecb5f3-7faf-4fcd-8421-1b81256d63f8&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com &quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200.jpg&quot;]}],&quot;title&quot;:[0,&quot;Carotuximab/Apalutamide Further Extends PFS in Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/carotuximab-apalutamide-further-extends-pfs-in-metastatic-crpc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6840ba0f-2c19-4843-847d-3a4f24c451e4&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Features&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com &quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Would a TALAPRO-3 Approval Affect HRR-Altered Metastatic HSPC Care?&quot;],&quot;url&quot;:[0,&quot;/view/how-would-a-talapro-3-approval-affect-hrr-altered-metastatic-hspc-care-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6d4ecba1-a983-4b9c-9fc9-cde198cdd527&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;News Reports&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/multiple-myeloma&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-aa6c8671e89654e467dee9953de212fd795b6cdd-3600x2400-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/aa6c8671e89654e467dee9953de212fd795b6cdd-3600x2400.jpg&quot;]}],&quot;title&quot;:[0,&quot;Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/iberdomide-combination-doubles-pfs-vs-soc-therapy-in-r-r-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;1ba1d048-0d0e-4345-9472-e8ba4622eaf4&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-08T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c766e547f7a3f757b43e5b55450d9fb80d6bb9c9-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c766e547f7a3f757b43e5b55450d9fb80d6bb9c9-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Random-Start Protocols Allow Fertility Preservation Without Delaying Treatment&quot;],&quot;url&quot;:[0,&quot;/view/random-start-protocols-allow-fertility-preservation-without-delaying-treatment&quot;]}],[0,{&quot;_id&quot;:[0,&quot;0761906e-4c99-4b2f-b202-41fea1351861&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Brain Cancer&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;clinical/brain-cancer&quot;],[0,null],[0,&quot;news&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma: © Lila Patel - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,2],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3c798420b1690f45ac174a47810b2706c6da4419-6250x3125-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3c798420b1690f45ac174a47810b2706c6da4419-6250x3125.jpg&quot;]}],&quot;title&quot;:[0,&quot;Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma&quot;],&quot;url&quot;:[0,&quot;/view/novel-cancer-vaccine-plus-temozolomide-miss-primary-end-point-in-glioblastoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a1fe3ff8-af24-4828-8c35-9498315ce769&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-07T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Hematologic Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/hematology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-7f38f421040582f3589ececbc92f5af59a790798-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7f38f421040582f3589ececbc92f5af59a790798-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Weighing Safety vs Persistence With CAR NK Cell Therapy&quot;],&quot;url&quot;:[0,&quot;/view/weighing-safety-vs-persistence-with-car-nk-cell-therapy&quot;]}],[0,{&quot;_id&quot;:[0,&quot;439cf6ed-2c24-4680-9112-4713db911bf7&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-b3e1284863602927a2f01680a4fbc1a9457c702a-1000x1000-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b3e1284863602927a2f01680a4fbc1a9457c702a-1000x1000.png&quot;]}],&quot;title&quot;:[0,&quot;What Does NRG GU002 Mean for Docetaxel After Prostatectomy?&quot;],&quot;url&quot;:[0,&quot;/view/what-does-nrg-gu002-mean-for-docetaxel-after-prostatectomy-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;09f7be41-e1c2-4a7a-a3ca-f1042e01de56&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Features&quot;],[0,&quot;Multiple Myeloma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/multiple-myeloma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.1135781383432963],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-98b0a5776b30f62a4b369314573127ce4172195e-1304x1171-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/98b0a5776b30f62a4b369314573127ce4172195e-1304x1171.png&quot;]}],&quot;title&quot;:[0,&quot;Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/considering-talquetamab-and-emerging-bispecifics-in-r-r-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;f4052e5c-f969-4db7-96cf-c445882d926e&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T17:31:49.936Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Breaking News&quot;],[0,&quot;Breast Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/breast-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.&quot;],&quot;aspectRatio&quot;:[0,1.910828025477707],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628.png&quot;]}],&quot;title&quot;:[0,&quot;FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer&quot;],&quot;url&quot;:[0,&quot;/view/fda-approves-tucatinib-combo-as-maintenance-in-her2-breast-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a8cfa260-82f4-40cb-b053-2305362083eb&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Head &amp; Neck Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/head-neck-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Medical illustration of laryngeal cancer, covering laryngeal tumor pathology, ENT diagnosis, clinical staging and professional treatment solutions for head and neck oncology research | Image Credit: © 程 加星 - stock.adobe.com &quot;],&quot;aspectRatio&quot;:[0,1.7843137254901962],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5d898f4bbe7c163006d09715bc4230d21fbb4ad8-5824x3264-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5d898f4bbe7c163006d09715bc4230d21fbb4ad8-5824x3264.jpg&quot;]}],&quot;title&quot;:[0,&quot;Transmucosal Patch Yields Pathologic Responses in Non-Invasive Oral Cancer&quot;],&quot;url&quot;:[0,&quot;/view/transmucosal-patch-yields-pathologic-responses-in-non-invasive-oral-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;f3d3417b-5c23-4cd0-857d-436983d12509&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Lung Cancer&quot;],[0,&quot;Sarcoma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/lung-cancer&quot;],[0,&quot;clinical/sarcoma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.&quot;],&quot;aspectRatio&quot;:[0,1.3333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-139a18b2c4d4432bcf06d40954215538bbbd35c8-8000x6000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/139a18b2c4d4432bcf06d40954215538bbbd35c8-8000x6000.jpg&quot;]}],&quot;title&quot;:[0,&quot;OST-HER2 Shows Significant Final 3-Year OS Benefit in Osteosarcoma Trial&quot;],&quot;url&quot;:[0,&quot;/view/ost-her2-shows-significant-final-3-year-os-benefit-in-osteosarcoma-trial&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cfb5e1df-b9e8-402a-aeef-6f42d2019a0d&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-07T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-ab09d2d8d89f66dc114b5a33c5dbed16c60eb21a-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ab09d2d8d89f66dc114b5a33c5dbed16c60eb21a-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Personalized Vaccines May Have Utility Across All Lung Cancer Stages&quot;],&quot;url&quot;:[0,&quot;/view/personalized-vaccines-may-have-utility-across-all-lung-cancer-stages&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a29aad96-4910-4d47-83f6-fed8a266171b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-07T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, discussed the system breakdowns that delay fertility referrals and how EHR triggers can automate the process.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-0cd3f7d9f7516a528202e5ba752225dc9211794d-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0cd3f7d9f7516a528202e5ba752225dc9211794d-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Clear Ownership and EHR Triggers Can Close Gaps in Oncofertility Referrals&quot;],&quot;url&quot;:[0,&quot;/view/clear-ownership-and-ehr-triggers-can-close-gaps-in-oncofertility-referrals&quot;]}],[0,{&quot;_id&quot;:[0,&quot;d1fcadfa-4d79-4a5e-9a0a-9912a243996e&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Zachary L. Bercu, MD, RPVI, FSIR, discusses the Liberty robotic system’s applications in liver and kidney cancer as well as the feasibility of remote procedures.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Q&amp;As&quot;],[0,&quot;News&quot;],[0,&quot;Liver Cancer&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;clinical/liver-cancer&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Interventional radiology operation room in modern clinic: © Vadim - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.4998585572843],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-9ab1017fcb2dfd91fb1d188e8fc39928c5ec0432-5302x3535-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Interventional radiology operation room in modern clinic: © Vadim - stock.adobe.com&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9ab1017fcb2dfd91fb1d188e8fc39928c5ec0432-5302x3535.jpg&quot;]}],&quot;title&quot;:[0,&quot;Clinical Applications and the Future of Remote Endovascular Procedures&quot;],&quot;url&quot;:[0,&quot;/view/clinical-applications-and-the-future-of-remote-endovascular-procedures&quot;]}],[0,{&quot;_id&quot;:[0,&quot;526b01db-8278-4f6a-9e70-045bcc189740&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e8e7f8835f5c4d82fae608ea8f494d1a8179ac51-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e8e7f8835f5c4d82fae608ea8f494d1a8179ac51-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Taking The First Steps for a Personalized Lung Cancer Vaccine Trial&quot;],&quot;url&quot;:[0,&quot;/view/taking-the-first-steps-for-a-personalized-lung-cancer-vaccine-trial&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2888becd-40d7-478c-9b8f-ce82fc0ee636&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-438ad9b3dee2f9dc61fe279881aff2e76e7142a5-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/438ad9b3dee2f9dc61fe279881aff2e76e7142a5-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;How the Big Ten CRC Moves Bench Discoveries Toward Multicenter Trials&quot;],&quot;url&quot;:[0,&quot;/view/how-the-big-ten-crc-moves-bench-discoveries-toward-multicenter-trials&quot;]}],[0,{&quot;_id&quot;:[0,&quot;907e9fa1-295f-4176-b85a-bb6c908a8c46&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T16:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Ovarian Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/ovarian-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC: © Lars Neumann - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.1666666666666667],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-d90c589883bf085523d6948612da705f50ed131e-7000x6000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d90c589883bf085523d6948612da705f50ed131e-7000x6000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC&quot;],&quot;url&quot;:[0,&quot;/view/avutometinib-defactinib-shows-activity-in-kras-wild-type-recurrent-lgsoc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6a269e02-fab9-4f35-908a-1966bac5b053&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-98283df37f0b9355008d14aa3c157b16f0d3622b-300x300-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/98283df37f0b9355008d14aa3c157b16f0d3622b-300x300.png&quot;]}],&quot;title&quot;:[0,&quot;Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC&quot;],&quot;url&quot;:[0,&quot;/view/firmonertinib-misses-pfs-end-point-in-first-line-egfr-exon-20-nsclc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;77175ce9-2047-4067-aa05-0f287358217e&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Adding fixed-duration epcoritamab to R-CHOP reduced the risk of progression or death by 51% in patients with newly diagnosed DLBCL.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Lymphoma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/lymphoma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Cancer cell or cancerous tumor amidst flowing red blood cells in a blood vessel, artery or vein 3D rendering illustration. Medicine, pathology, oncology, disesase, science concepts. | Image Credit: © Matthieu - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3b0bfef9b4f2eb76acb7dd4c2bf687a15bce5ed4-3840x2160-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Adding fixed-duration epcoritamab to R-CHOP reduced the risk of progression or death by 51% in patients with newly diagnosed DLBCL.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3b0bfef9b4f2eb76acb7dd4c2bf687a15bce5ed4-3840x2160.jpg&quot;]}],&quot;title&quot;:[0,&quot;Epcoritamab/R-CHOP Shows PFS Benefit in Newly Diagnosed DLBCL&quot;],&quot;url&quot;:[0,&quot;/view/epcoritamab-r-chop-shows-pfs-benefit-in-newly-diagnosed-dlbcl&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a7e12428-e64b-4b7c-aa31-89b3ebf8d84f&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chirag Jain, MBBS, discussed onco-anxiology, a proposed framework for identifying and managing anxiety at each stage of the cancer journey.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Psycho-Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/psycho-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-f458c1b985bf224a5348c9a348b5107298b8bed1-3000x2000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f458c1b985bf224a5348c9a348b5107298b8bed1-3000x2000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Onco-Anxiology Framework Targets Anxiety Across the Cancer Care Continuum&quot;],&quot;url&quot;:[0,&quot;/view/onco-anxiology-framework-targets-anxiety-across-the-cancer-care-continuum&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a5907f9e-097e-42f7-a69f-69ac7a3d0912&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T13:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Multiple Myeloma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/multiple-myeloma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6e3e75081cc80dc4919ecd564f4c3c34e533e8f1-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6e3e75081cc80dc4919ecd564f4c3c34e533e8f1-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy&quot;],&quot;url&quot;:[0,&quot;/view/selinexor-based-quadruplet-targets-myeloma-after-t-cell-redirecting-therapy&quot;]}],[0,{&quot;_id&quot;:[0,&quot;e96667ae-8be9-4457-b1dc-67381cb7828d&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, explained why male fertility preservation information trails female content online and how cancer centers can fix it.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-60a12baec05223e0c724d18e59f4d84b33d58608-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/60a12baec05223e0c724d18e59f4d84b33d58608-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Male Oncofertility Content Still Lags on NCI Cancer Center Websites&quot;],&quot;url&quot;:[0,&quot;/view/male-oncofertility-content-still-lags-on-nci-cancer-center-websites&quot;]}],[0,{&quot;_id&quot;:[0,&quot;69f411de-88fc-41e7-b98b-955fad526371&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Liver Cancer&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/liver-cancer&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Modern interventional radiology system with hepatic anatomy illustration: © MDJOYNAL - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7916666666666667],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-414d4b3f59782b8802b059d41e8ec0ff2e39ac42-11008x6144-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/414d4b3f59782b8802b059d41e8ec0ff2e39ac42-11008x6144.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Emory Became the First Adopter of the Liberty Endovascular Robotic System&quot;],&quot;url&quot;:[0,&quot;/view/how-emory-became-the-first-adopter-of-the-liberty-endovascular-robotic-system&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2fe5b2e0-d23f-47c0-b464-84ed996f11b4&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-05T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-2ccd046c9f58fef04ec5acd94a98ff48ea68b5ef-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2ccd046c9f58fef04ec5acd94a98ff48ea68b5ef-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Why High-Risk Stage I NSCLC Needs a Postsurgical Vaccine Option&quot;],&quot;url&quot;:[0,&quot;/view/why-high-risk-stage-i-nsclc-needs-a-post-surgical-vaccine-option&quot;]}],[0,{&quot;_id&quot;:[0,&quot;557d86ef-79c5-4a21-829d-c92ffdc7ead3&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-05T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Lymphoma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/lymphoma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-81284df7ef93c1a3e50bf46408946dab8935685c-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/81284df7ef93c1a3e50bf46408946dab8935685c-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma&quot;],&quot;url&quot;:[0,&quot;/view/expanding-car-t-and-bispecific-antibody-research-in-hiv-associated-lymphoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;c910233e-796c-4927-a5b2-8f66aa48b736&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T18:31:04.081Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Ovarian Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/ovarian-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Rina-S Elicits Responses in PROC Regardless of FRα Expression: © magicmine - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-f5d139d6b30af88101f0c7ddcec7f60b55491e85-3840x2160-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f5d139d6b30af88101f0c7ddcec7f60b55491e85-3840x2160.jpg&quot;]}],&quot;title&quot;:[0,&quot;Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression&quot;],&quot;url&quot;:[0,&quot;/view/rinatabart-sesutecan-elicits-responses-in-proc-regardless-of-fr-expression&quot;]}],[0,{&quot;_id&quot;:[0,&quot;008808ab-4083-44a0-8c5b-c4f986f9b1c5&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, discusses oncofertility gaps at NCI-designated cancer centers and ways to speed fertility referrals for patients.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,0.75],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-644c414c2596a469d7e9b910e0f3e100975897ae-360x480-webp&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/644c414c2596a469d7e9b910e0f3e100975897ae-360x480.webp&quot;]}],&quot;title&quot;:[0,&quot;How Can Oncologists Make Fertility Preservation a Routine Part of Cancer Care?&quot;],&quot;url&quot;:[0,&quot;/view/how-can-oncologists-make-fertility-preservation-a-routine-part-of-cancer-care-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;028d7fb3-c1f0-4d60-a900-ff173616144d&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e23e475b94cd7b5475a8179067d9c25efb4e9524-4500x3000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e23e475b94cd7b5475a8179067d9c25efb4e9524-4500x3000.jpg&quot;]}],&quot;title&quot;:[0,&quot;NDA Submission Begins for Zipalertinib Combo in First-Line EGFR+ NSCLC&quot;],&quot;url&quot;:[0,&quot;/view/nda-submission-begins-for-zipalertinib-combo-in-first-line-egfr-nsclc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;7068f1f9-ec52-4640-a51e-308cb6580342&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5f4653807e8f7745a965fa94caafdd22cb5a477b-5000x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5f4653807e8f7745a965fa94caafdd22cb5a477b-5000x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Berzosertib Combo Shows No Response Benefit in Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/berzosertib-combo-shows-no-response-benefit-in-metastatic-crpc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;57ebb931-148e-4bc4-9711-d8cc76bf8e25&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T14:15:52.124Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Ovarian Cancer&quot;],[0,&quot;News Reports&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/ovarian-cancer&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer: © magicmine - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-73f50db252d86472148b009ebd1797e4e3c07449-3840x2160-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/73f50db252d86472148b009ebd1797e4e3c07449-3840x2160.jpg&quot;]}],&quot;title&quot;:[0,&quot;Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer&quot;],&quot;url&quot;:[0,&quot;/view/ubamatamab-yields-responses-in-recurrent-low-grade-serous-ovarian-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;071acca8-a2df-490c-b764-f70dad7f331c&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-05T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Lung Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/lung-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-421e3c00e2218f7c0ac702d801e8829085c49481-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/421e3c00e2218f7c0ac702d801e8829085c49481-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Balancing Cure and Toxicity in Complex Lung Cancer Radiotherapy Regimens&quot;],&quot;url&quot;:[0,&quot;/view/balancing-cure-and-toxicity-in-complex-lung-cancer-radiotherapy-regimens&quot;]}],[0,{&quot;_id&quot;:[0,&quot;97f44d5b-4496-499f-849e-a65fa19d7607&quot;],&quot;contentCategory&quot;:[0,&quot;Podcasts&quot;],&quot;published&quot;:[0,&quot;2026-10-05T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Podcasts&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;],[0,&quot;Recent Episodes&quot;],[0,&quot;FDA Approval Alert: The Need-to-Know&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;podcasts&quot;],[0,&quot;clinical/nsclc&quot;],[0,&quot;recent-episodes&quot;],[0,&quot;fda-approval-alert&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.&quot;],&quot;aspectRatio&quot;:[0,1.013143483023001],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5e7b4abec0c9247ee5bbe4c47ebe34bff52a7155-6475x6391-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5e7b4abec0c9247ee5bbe4c47ebe34bff52a7155-6475x6391.jpg&quot;]}],&quot;title&quot;:[0,&quot;What Does Sevabertinib’s Expanded Approval Mean for HER2+ NSCLC? &quot;],&quot;url&quot;:[0,&quot;/view/what-does-sevabertinib-s-expanded-approval-mean-for-her2-nsclc-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;e0f410e1-b664-4de7-a447-12ab409d998d&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-04T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said J. Thaddeus Beck, MD, FACP.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.&quot;],&quot;aspectRatio&quot;:[0,0.6666666666666666],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said J. Thaddeus Beck, MD, FACP.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Is Subcutaneous Administration Changing Oncology Care Delivery?&quot;],&quot;url&quot;:[0,&quot;/view/how-is-subcutaneous-administration-changing-oncology-care-delivery-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6b6ee501-e8f3-4206-b7be-728e52657184&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-04T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Lung Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/lung-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c837dfa48a7bae21d18228f476b4b0a830badd95-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c837dfa48a7bae21d18228f476b4b0a830badd95-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?&quot;],&quot;url&quot;:[0,&quot;/view/how-well-does-radiotherapy-pair-with-dual-pd-1-lag-3-blockade-in-nsclc-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6edb4c55-6b18-4a67-a03b-d8d5e7724d4c&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-04T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-eb81880dbc2fefdb57bd6463630d57277b2319da-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/eb81880dbc2fefdb57bd6463630d57277b2319da-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/prioritizing-proton-therapy-for-pelvic-nodal-irradiation-in-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;58c2bd34-0540-4c61-9e9f-06677ba16445&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-03T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.162217659137577],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1e6dc9be604f77b92beb831886975d08318b17bc-566x487-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1e6dc9be604f77b92beb831886975d08318b17bc-566x487.jpg&quot;]}],&quot;title&quot;:[0,&quot;Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery&quot;],&quot;url&quot;:[0,&quot;/view/alliance-a071801-supports-fractionated-srs-after-brain-metastasis-surgery&quot;]}],[0,{&quot;_id&quot;:[0,&quot;5af6847f-8281-4085-875e-63013654969a&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-03T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-7ebc64944997fe4c839ade0c5969782898d4f598-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7ebc64944997fe4c839ade0c5969782898d4f598-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Rectal Spacers May Reduce Toxicity of Proton Therapy in Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/rectal-spacers-may-reduce-toxicity-of-proton-therapy-in-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;c77761a2-97f4-4b76-9227-0a7a8a2a1ab6&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Dynamic Video&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3d3e2eccd85358bb564c97a5a9f5a966eea0ecbd-1280x720-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3d3e2eccd85358bb564c97a5a9f5a966eea0ecbd-1280x720.png&quot;]}],&quot;title&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on Radiation Oncology&#39;s Next Frontier and Mentorship&quot;],&quot;url&quot;:[0,&quot;/view/bruce-haffty-md-and-mutlay-sayan-md-on-radiation-oncology-s-next-frontier-and-mentorship&quot;]}],[0,{&quot;_id&quot;:[0,&quot;b2f8f85d-79d6-4610-850e-e65a3c8b28f2&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-479ad7fa962c4064930c11973aac309e064087e5-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/479ad7fa962c4064930c11973aac309e064087e5-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups&quot;],&quot;url&quot;:[0,&quot;/view/assessing-impt-outcomes-across-localized-prostate-cancer-risk-groups&quot;]}],[0,{&quot;_id&quot;:[0,&quot;76b023e0-6c69-47f9-94d3-b54da7545595&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-02T19:45:05.106Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Breaking News&quot;],[0,&quot;News&quot;],[0,&quot;Leukemia&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;clinical/leukemia&quot;],[0,&quot;clinical/lymphoma&quot;],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.&quot;],&quot;aspectRatio&quot;:[0,1.7561779242174629],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214.png&quot;]}],&quot;title&quot;:[0,&quot;FDA OKs Pirtobrutinib in Frontline CLL/SLL&quot;],&quot;url&quot;:[0,&quot;/view/fda-oks-pirtobrutinib-in-frontline-cll-sll&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2eeb7443-1cb1-4c2c-bc8a-39db1604becf&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c59144717b9371bc671c11a71ea6bd964a247767-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c59144717b9371bc671c11a71ea6bd964a247767-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Making Outpatient Cellular Therapy Dosing the Default in Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/making-outpatient-cellular-therapy-dosing-the-default-in-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;32a9d524-c07e-4cfa-83e3-1e7077357b3b&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-02T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7753120665742026],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-4f123c1e22b36e7db3d61e261146ef486e1dd340-1280x721-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4f123c1e22b36e7db3d61e261146ef486e1dd340-1280x721.png&quot;]}],&quot;title&quot;:[0,&quot;Fractionated SRS Improves Surgical Bed Control After Brain Metastasis Resection&quot;],&quot;url&quot;:[0,&quot;/view/fractionated-srs-improves-surgical-bed-control-after-brain-metastasis-resection&quot;]}],[0,{&quot;_id&quot;:[0,&quot;565185c2-3aeb-4662-9eac-ee92ed9b85fd&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-02T14:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Breast Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/breast-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.&quot;],&quot;aspectRatio&quot;:[0,1.5429025423728813],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-19aeb1ca058f8b9c18fc24096b95943b2c6cf9f8-5826x3776-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/19aeb1ca058f8b9c18fc24096b95943b2c6cf9f8-5826x3776.jpg&quot;]}],&quot;title&quot;:[0,&quot;Giredestrant Combo Boosts PFS in Pretreated ER+ Advanced Breast Cancer&quot;],&quot;url&quot;:[0,&quot;/view/giredestrant-combo-boosts-pfs-in-pretreated-er-advanced-breast-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;12c5eb6c-671d-4fc6-884d-98440f5a9f93&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Pancreatic Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/pancreatic-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,null],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,null]}],&quot;title&quot;:[0,&quot;Preoperative SBRT Shows High Resection Rates in Pancreatic Adenocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/preoperative-sbrt-shows-high-resection-rates-in-pancreatic-adenocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2f4e24d2-41f0-4065-b1c4-11f35b1ecaff&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;Gastrointestinal Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-88cf2921a6e8d5ecf991281aa033975fe9bec231-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/88cf2921a6e8d5ecf991281aa033975fe9bec231-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Understanding the KRAS Mutation Landscape in Biliary Tract Cancer&quot;],&quot;url&quot;:[0,&quot;/view/understanding-the-kras-mutation-landscape-in-biliary-tract-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;fee70db8-4956-4a6d-97b7-e1c89c1bb667&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-01T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Pancreatic Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/pancreatic-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-02ac8915e1374c39e25224c9c6a74c20d48c9c18-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/02ac8915e1374c39e25224c9c6a74c20d48c9c18-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;What Drove the SBRT Quality-of-Life Advantage in Pancreatic Cancer?&quot;],&quot;url&quot;:[0,&quot;/view/what-drove-the-sbrt-quality-of-life-advantage-in-pancreatic-cancer-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;3a3d3f2b-8830-47eb-ba22-c058cd6fd51c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.&quot;],&quot;aspectRatio&quot;:[0,0.667779632721202],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-a1adeba6d98b02e8d431e9fe662448f33d2d9a6f-1200x1797-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a1adeba6d98b02e8d431e9fe662448f33d2d9a6f-1200x1797.jpg&quot;]}],&quot;title&quot;:[0,&quot;Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?&quot;],&quot;url&quot;:[0,&quot;/view/where-does-intensity-modulated-proton-therapy-fit-in-prostate-cancer-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;614d83bc-3cba-43c5-bfc5-c6f1f855528c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Conference&quot;],[0,&quot;Slideshows&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;conference&quot;],[0,&quot;resources/slideshows&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.&quot;],&quot;aspectRatio&quot;:[0,1.5463917525773196],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-9f56eba4eb61989ef5c263c5f21a030fc69b3e09-1200x776-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9f56eba4eb61989ef5c263c5f21a030fc69b3e09-1200x776.jpg&quot;]}],&quot;title&quot;:[0,&quot;IMS 2026: Key Updates Across The Multiple Myeloma Paradigm&quot;],&quot;url&quot;:[0,&quot;/view/ims-2026-key-updates-across-the-multiple-myeloma-paradigm&quot;]}],[0,{&quot;_id&quot;:[0,&quot;7deac2da-3616-45d6-a6f2-0d838d2a659c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News Reports&quot;],[0,&quot;News&quot;],[0,&quot;Small Cell Lung Cancer (SCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;clinical/small-cell-lung-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.&quot;],&quot;aspectRatio&quot;:[0,1.4002333722287048],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-555f5be80532573a6654f0b562c43e11aedf99df-1200x857-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/555f5be80532573a6654f0b562c43e11aedf99df-1200x857.jpg&quot;]}],&quot;title&quot;:[0,&quot;FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC&quot;],&quot;url&quot;:[0,&quot;/view/fda-discussion-prompts-voluntary-withdrawal-of-bla-for-i-dxd-in-es-sclc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;918f9260-959d-4257-b42f-10b5b7158fbe&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T15:02:42.344Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.&quot;],&quot;aspectRatio&quot;:[0,1.1111111111111112],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300.jpg&quot;]}],&quot;title&quot;:[0,&quot;Tabelecleucel BLA Resubmitted to FDA for EBV-Positive PTLD&quot;],&quot;url&quot;:[0,&quot;/view/tabelecleucel-bla-resubmitted-to-fda-for-ebv-positive-ptld&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2931406c-52b2-41ee-9e2f-482ed00f2fce&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-01T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Pancreatic Cancer&quot;],[0,&quot;Surgery&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/pancreatic-cancer&quot;],[0,&quot;clinical/surgery&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e14ddc5983a7b4b2c9e75769d3215c9b33f88957-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e14ddc5983a7b4b2c9e75769d3215c9b33f88957-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;SBRT Preserves Quality of Life Before Pancreatic Cancer Surgery&quot;],&quot;url&quot;:[0,&quot;/view/sbrt-preserves-quality-of-life-before-pancreatic-cancer-surgery&quot;]}],[0,{&quot;_id&quot;:[0,&quot;58f7274a-2816-4cad-a5f2-a3f13c43aa51&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T13:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News Reports&quot;],[0,&quot;News&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,0.9902439024390244],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5bb0fb502597b441b504933051804df03d668f46-406x410-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5bb0fb502597b441b504933051804df03d668f46-406x410.png&quot;]}],&quot;title&quot;:[0,&quot;SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer &quot;],&quot;url&quot;:[0,&quot;/view/sbrt-matches-disease-control-of-prostatectomy-in-localized-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;da1dd275-78ce-4c1f-8f3a-6818aa01f9b0&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-01T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;News&quot;],[0,&quot;Gastrointestinal Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;news&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-ae63c7e65ca956fb4d26cc120cc8521b840b02a5-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ae63c7e65ca956fb4d26cc120cc8521b840b02a5-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Early Clinical Data Show KRAS Inhibitors Can Work in Cholangiocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/early-clinical-data-show-kras-inhibitors-can-work-in-cholangiocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;34763092-92a1-4ca8-964c-d6354761f76c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?&quot;],&quot;aspectRatio&quot;:[0,0.8],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c46052a450f03752d4e3278cebceb69e9c658b2c-4000x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c46052a450f03752d4e3278cebceb69e9c658b2c-4000x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?&quot;],&quot;url&quot;:[0,&quot;/view/what-does-talapro-3-mean-for-frontline-treatment-of-hrr-altered-mhspc-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;be9d87b5-c7e4-46bd-b847-ce1a181a333f&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.326],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/aglatimagene-combo-shows-sustained-immune-remodeling-in-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;43ce25c8-912d-482b-b3fb-80d2b6543575&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The ROADS investigators reported no differences between cesium-131 tile-based radiation therapy and SRT in quality of life, functional status, or neurocognitive function.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases: © Sebastian Kaulitzki - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.3333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-02c2654f19c2e270c10911db15c14c07e74d3722-5000x3750-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The ROADS investigators reported no differences between cesium-131 tile-based radiation therapy and SRT in quality of life, functional status, or neurocognitive function.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/02c2654f19c2e270c10911db15c14c07e74d3722-5000x3750.jpg&quot;]}],&quot;title&quot;:[0,&quot;Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases&quot;],&quot;url&quot;:[0,&quot;/view/tile-based-radiation-improves-surgical-bed-recurrence-in-brain-metastases&quot;]}],[0,{&quot;_id&quot;:[0,&quot;acebb5c3-510d-4a20-a061-316888ac4c32&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Conference&quot;],[0,&quot;Pancreatic Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Q&amp;As&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/pancreatic-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.1166666666666667],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-f8dbad1e1efc44c0fb739d75f02a25b9fe0e8f38-6700x6000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f8dbad1e1efc44c0fb739d75f02a25b9fe0e8f38-6700x6000.jpg&quot;]}],&quot;title&quot;:[0,&quot;SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery&quot;],&quot;url&quot;:[0,&quot;/view/sbrt-matches-chemoradiation-preserves-qol-before-pancreatic-surgery&quot;]}],[0,{&quot;_id&quot;:[0,&quot;9c1de5e5-7dbc-4b42-bc89-af1ff281102b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-30T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Conference&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;News&quot;],[0,&quot;Gastrointestinal Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;conference&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;news&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c9a5184869b1549f49e584933622a660ffdba996-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c9a5184869b1549f49e584933622a660ffdba996-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Sequencing FGFR2 Inhibitors in Previously Treated Cholangiocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/sequencing-fgfr2-inhibitors-in-previously-treated-cholangiocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;3514886b-2219-4599-b70e-7b95ab8a2ba0&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T22:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.&quot;],&quot;aspectRatio&quot;:[0,0.7272727272727273],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-283af1206310c49850e4e13c57aa0e2ec6e47043-1200x1650-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/283af1206310c49850e4e13c57aa0e2ec6e47043-1200x1650.jpg&quot;]}],&quot;title&quot;:[0,&quot;Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care&quot;],&quot;url&quot;:[0,&quot;/view/integrating-talazoparib-plus-enzalutamide-into-hrr-mutated-mhspc-care&quot;]}],[0,{&quot;_id&quot;:[0,&quot;d1286dfa-d844-41a1-b1a2-f84a1b417110&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-29T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;Gastrointestinal Cancer&quot;],[0,&quot;News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;],[0,&quot;news&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3f7c04b33626ec6e6a1ace83c981e5c811592693-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3f7c04b33626ec6e6a1ace83c981e5c811592693-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/lirafugratinib-approval-adds-a-third-fgfr2-inhibitor-in-cholangiocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;b3782e19-5e92-4092-b100-a66ab2d602d2&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;],[0,&quot;Small Cell Lung Cancer (SCLC)&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/small-cell-lung-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.&quot;],&quot;aspectRatio&quot;:[0,1.3498312710911136],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-604dbc90ff1ae66780777fdd394c550f4c835df8-1200x889-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/604dbc90ff1ae66780777fdd394c550f4c835df8-1200x889.jpg&quot;]}],&quot;title&quot;:[0,&quot;SRS Improves Survival Vs Hippocampal Avoidant-WBRT in SCLC Brain Metastases&quot;],&quot;url&quot;:[0,&quot;/view/srs-improves-survival-vs-hippocampal-avoidant-wbrt-in-sclc-brain-metastases&quot;]}],[0,{&quot;_id&quot;:[0,&quot;503b257c-42ec-4488-98dc-121c288a6b58&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-821879789eef5f47bbc210b9c96ef210efd90022-1200x800-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/821879789eef5f47bbc210b9c96ef210efd90022-1200x800.jpg&quot;]}],&quot;title&quot;:[0,&quot;BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/bcma-gprc5d-car-t-cell-therapy-shows-early-efficacy-in-r-r-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;57f1794d-d767-40f5-a95b-dac99e3ebeef&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-29T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Brain Cancer&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/brain-cancer&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6ef85fa1e255f6a8e2b33c9ac2f54aff120abb04-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6ef85fa1e255f6a8e2b33c9ac2f54aff120abb04-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;When Single-Fraction SRS Still Makes Sense for Resected Brain Metastases&quot;],&quot;url&quot;:[0,&quot;/view/when-single-fraction-srs-still-makes-sense-for-resected-brain-metastases&quot;]}],[0,{&quot;_id&quot;:[0,&quot;ea16e1f5-76ca-4ac0-a438-4d50df7fecaa&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-a6130eed7d7f2e33168953c10354d4e6d720da1e-1200x675-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a6130eed7d7f2e33168953c10354d4e6d720da1e-1200x675.jpg&quot;]}],&quot;title&quot;:[0,&quot;Extended Belantamab Mafodotin Dosing Eases Ocular Function in DREAMM-9&quot;],&quot;url&quot;:[0,&quot;/view/extended-belantamab-mafodotin-dosing-eases-ocular-function-in-dreamm-9&quot;]}],[0,{&quot;_id&quot;:[0,&quot;e8c75242-5d86-47a3-8f79-d8e98a48a9fb&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T16:00:07.919Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma: © Sebastian Kaulitzki - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,2],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1844269e0cec8c0da218113457254f361f8ed7b0-8000x4000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1844269e0cec8c0da218113457254f361f8ed7b0-8000x4000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma&quot;],&quot;url&quot;:[0,&quot;/view/proton-therapy-does-not-improve-survival-in-hepatocellular-carcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;8c915645-078a-4c53-bead-b8d3b65439c4&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Journal Articles&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.3333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-9e83c0e9492f23d2ea77b28b0776b1f4da6a6af8-5000x3750-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9e83c0e9492f23d2ea77b28b0776b1f4da6a6af8-5000x3750.jpg&quot;]}],&quot;title&quot;:[0,&quot;Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/multimodal-biopsy-combo-shows-low-morbidity-in-suspected-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;04a6f888-5e7f-4f94-8fbe-6cb4253d5acf&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-29T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;news&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6d5b5776983f3642970057d4e322e81a12874e5a-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6d5b5776983f3642970057d4e322e81a12874e5a-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape&quot;],&quot;url&quot;:[0,&quot;/view/where-mrd-testing-fits-into-myeloma-s-treatment-and-regulatory-landscape&quot;]}]]],&quot;currentArticleId&quot;:[0,&quot;cn_article_374309&quot;],&quot;clientConfig&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;],&quot;storageNamespace&quot;:[0,&quot;cancernetwork&quot;],&quot;cookies&quot;:[0,{&quot;prefs&quot;:[0,&quot;cancernetwork_prefs&quot;],&quot;cognitoId&quot;:[0,&quot;cancernetwork_cognito_id&quot;]}],&quot;prefsEventName&quot;:[0,&quot;cancernetwork:personalization-prefs&quot;],&quot;endpoint&quot;:[0],&quot;idlayer&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;]}],&quot;engagement&quot;:[0,{&quot;segmentDualWrite&quot;:[0,true]}],&quot;taxonomyQuery&quot;:[0,{&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;parentGroup&quot;:[0,&quot;clinical&quot;]}],&quot;experiment&quot;:[0,{&quot;enabled&quot;:[0,true],&quot;salt&quot;:[0,&quot;dv6834-cancernetwork-homepage-v1&quot;]}]}],&quot;excludeIds&quot;:[1,[[0,&quot;de825fd8-becf-47b2-b75e-f36c32be2975&quot;],[0,&quot;69d6a710-7599-4939-88dc-d745376d37cf&quot;],[0,&quot;dcf42da5-6ed8-46d7-93ce-7dea016f9603&quot;],[0,&quot;da5bf0e0-2138-4b4a-a044-ffb88bda705b&quot;],[0,&quot;1abdedd9-ac41-4260-84de-d6d50f58626a&quot;],[0,&quot;732a9b36-4ae9-433f-a71e-af1a03502d39&quot;],[0,&quot;4e4318a7-7243-43a4-bdac-6c144f7aeb04&quot;],[0,&quot;10e9fead-dd59-4720-bf6d-81561b8910c1&quot;]]],&quot;title&quot;:[0,&quot;For You&quot;],&quot;rail&quot;:[0,&quot;for_you&quot;],&quot;placement&quot;:[0,&quot;end&quot;],&quot;placementOverride&quot;:[0,null],&quot;size&quot;:[0,8],&quot;layout&quot;:[0,&quot;inline&quot;]}" ssr client="idle" opts="{&quot;name&quot;:&quot;RecommendedForYou&quot;,&quot;value&quot;:true}"></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  "> <astro-island uid="Z1Vuxzg" prefix="r73" component-url="/_astro/ForYouNotify.DuIdfFTd.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;articles&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;de825fd8-becf-47b2-b75e-f36c32be2975&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T22:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Conference&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/lymphoma&quot;],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;aspectRatio&quot;:[0,0.8626887131560029],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-03e77b4f328a10c74086cdfdbf704078d6050f18-1200x1391-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/03e77b4f328a10c74086cdfdbf704078d6050f18-1200x1391.jpg&quot;]}],&quot;title&quot;:[0,&quot;Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer&quot;],&quot;url&quot;:[0,&quot;/view/weighing-the-promise-and-trade-offs-of-car-nk-cell-therapy-for-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;69d6a710-7599-4939-88dc-d745376d37cf&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.&quot;],&quot;aspectRatio&quot;:[0,0.8],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-363270bf0783d219c3528f46e9e77d5dc1f186e9-200x250-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Tyler J. WIlhite, MD\nUPMC HIllman Cancer Center&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/363270bf0783d219c3528f46e9e77d5dc1f186e9-200x250.png&quot;]}],&quot;title&quot;:[0,&quot;Building a Low-Dose Radiation Therapy Program for Benign Disease&quot;],&quot;url&quot;:[0,&quot;/view/building-a-low-dose-radiation-therapy-program-for-benign-disease&quot;]}],[0,{&quot;_id&quot;:[0,&quot;dcf42da5-6ed8-46d7-93ce-7dea016f9603&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-09T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5af592353ad710d026c1636a0a523c535b1213f7-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5af592353ad710d026c1636a0a523c535b1213f7-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization &quot;],&quot;url&quot;:[0,&quot;/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization&quot;]}],[0,{&quot;_id&quot;:[0,&quot;da5bf0e0-2138-4b4a-a044-ffb88bda705b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-09T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM&quot;],&quot;url&quot;:[0,&quot;/view/ramantamig-achieves-impressive-rates-of-mrd-negativity-in-rrmm&quot;]}],[0,{&quot;_id&quot;:[0,&quot;1abdedd9-ac41-4260-84de-d6d50f58626a&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Myeloproliferative Neoplasms&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/myeloproliferative-neoplasms&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;aspectRatio&quot;:[0,1.1111111111111112],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300.jpg&quot;]}],&quot;title&quot;:[0,&quot;Selcodebart Yields Hematologic Responses in Anemia From Myelofibrosis&quot;],&quot;url&quot;:[0,&quot;/view/selcodebart-yields-hematologic-responses-in-anemia-from-myelofibrosis&quot;]}],[0,{&quot;_id&quot;:[0,&quot;732a9b36-4ae9-433f-a71e-af1a03502d39&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T16:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Multiple Myeloma&quot;],[0,&quot;News&quot;],[0,&quot;Between the Lines&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;news&quot;],[0,&quot;between-the-lines&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.2939197930142303],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-d23a730915dd101042071359cc623e55511245dc-5001x3865-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d23a730915dd101042071359cc623e55511245dc-5001x3865.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?&quot;],&quot;url&quot;:[0,&quot;/view/how-do-long-term-maia-and-cepheus-data-reinforce-daratumumab-use-in-ndmm-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;4e4318a7-7243-43a4-bdac-6c144f7aeb04&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Journal Articles&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma: © 程 加星 - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c12520957948ebfc324e247b1151b3dd28a0420d-5120x2880-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c12520957948ebfc324e247b1151b3dd28a0420d-5120x2880.jpg&quot;]}],&quot;title&quot;:[0,&quot;Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma&quot;],&quot;url&quot;:[0,&quot;/view/adjuvant-radiotherapy-reduced-recurrence-in-resected-atypical-meningioma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;10e9fead-dd59-4720-bf6d-81561b8910c1&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.326],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;VIR-5500 Receives FDA Fast Track Designation for Late-Line Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/vir-5500-receives-fda-fast-track-designation-for-late-line-metastatic-crpc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;bdcb9830-1f2f-448c-a13a-8983f523a17c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Leukemia&quot;],[0,&quot;Frontline Forum&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/leukemia&quot;],[0,&quot;frontline-forum&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Acute lymphoblastic leukemia, bone marrow smear, 3D illustration | Image Credit: © Dr_Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-0888f4313a1f4443719b9c25dc719a35a434624c-6000x4000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0888f4313a1f4443719b9c25dc719a35a434624c-6000x4000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Can an All-Oral HMA Regimen Change Frontline Care in Unfit AML?&quot;],&quot;url&quot;:[0,&quot;/view/can-an-all-oral-hma-regimen-change-frontline-care-in-unfit-aml-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2ce5e471-a073-41a3-89b5-0798f9a3a843&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.&quot;],&quot;aspectRatio&quot;:[0,1.1333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3d031c79ae7db09f00e6bc06661074fdcd9363fa-680x600-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3d031c79ae7db09f00e6bc06661074fdcd9363fa-680x600.png&quot;]}],&quot;title&quot;:[0,&quot;Building out a Radiopharmaceuticals Program in Oncology Care&quot;],&quot;url&quot;:[0,&quot;/view/building-out-a-radiopharmaceuticals-program-in-oncology-care&quot;]}],[0,{&quot;_id&quot;:[0,&quot;0a750f3a-2571-4ddf-a0da-72d9d4e66a35&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-08T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Multiple Myeloma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/multiple-myeloma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-73e516a152d585762295aa34ac2f7799a65bc365-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/73e516a152d585762295aa34ac2f7799a65bc365-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;How to Navigate Ramantamig’s Low-Grade Toxicities in Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/how-to-navigate-ramantamig-s-low-grade-toxicities-in-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;f0c9c6d3-d81b-4957-bfc8-d90654feb6b5&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T18:06:23.010Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Colorectal Cancer&quot;],[0,&quot;Breaking News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/colorectal-cancer&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.&quot;],&quot;aspectRatio&quot;:[0,1.7561779242174629],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214.png&quot;]}],&quot;title&quot;:[0,&quot;FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer&quot;],&quot;url&quot;:[0,&quot;/view/fda-approves-atezolizumab-chemo-for-stage-iii-dmmr-msi-h-colon-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a7ce683b-60fc-4d25-ad98-6ef2dc85f88a&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/lymphoma&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.&quot;],&quot;aspectRatio&quot;:[0,0.75],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6ea1db064178195d78b3a00bceabd3bee8221f6a-1200x1600-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6ea1db064178195d78b3a00bceabd3bee8221f6a-1200x1600.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Can Cooperative Groups Close Outcome Gaps in HIV-Associated Lymphoma?&quot;],&quot;url&quot;:[0,&quot;/view/how-can-cooperative-groups-close-outcome-gaps-in-hiv-associated-lymphoma-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;71ecb5f3-7faf-4fcd-8421-1b81256d63f8&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com &quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200.jpg&quot;]}],&quot;title&quot;:[0,&quot;Carotuximab/Apalutamide Further Extends PFS in Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/carotuximab-apalutamide-further-extends-pfs-in-metastatic-crpc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6840ba0f-2c19-4843-847d-3a4f24c451e4&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Features&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com &quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1952a5b8242c4aa323ad6bb53ca6f50fece90909-1200x1200.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Would a TALAPRO-3 Approval Affect HRR-Altered Metastatic HSPC Care?&quot;],&quot;url&quot;:[0,&quot;/view/how-would-a-talapro-3-approval-affect-hrr-altered-metastatic-hspc-care-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6d4ecba1-a983-4b9c-9fc9-cde198cdd527&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-08T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;News Reports&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/multiple-myeloma&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-aa6c8671e89654e467dee9953de212fd795b6cdd-3600x2400-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/aa6c8671e89654e467dee9953de212fd795b6cdd-3600x2400.jpg&quot;]}],&quot;title&quot;:[0,&quot;Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/iberdomide-combination-doubles-pfs-vs-soc-therapy-in-r-r-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;1ba1d048-0d0e-4345-9472-e8ba4622eaf4&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-08T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c766e547f7a3f757b43e5b55450d9fb80d6bb9c9-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c766e547f7a3f757b43e5b55450d9fb80d6bb9c9-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Random-Start Protocols Allow Fertility Preservation Without Delaying Treatment&quot;],&quot;url&quot;:[0,&quot;/view/random-start-protocols-allow-fertility-preservation-without-delaying-treatment&quot;]}],[0,{&quot;_id&quot;:[0,&quot;0761906e-4c99-4b2f-b202-41fea1351861&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Brain Cancer&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;clinical/brain-cancer&quot;],[0,null],[0,&quot;news&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma: © Lila Patel - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,2],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3c798420b1690f45ac174a47810b2706c6da4419-6250x3125-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3c798420b1690f45ac174a47810b2706c6da4419-6250x3125.jpg&quot;]}],&quot;title&quot;:[0,&quot;Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma&quot;],&quot;url&quot;:[0,&quot;/view/novel-cancer-vaccine-plus-temozolomide-miss-primary-end-point-in-glioblastoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a1fe3ff8-af24-4828-8c35-9498315ce769&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-07T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Hematologic Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/hematology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-7f38f421040582f3589ececbc92f5af59a790798-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7f38f421040582f3589ececbc92f5af59a790798-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Weighing Safety vs Persistence With CAR NK Cell Therapy&quot;],&quot;url&quot;:[0,&quot;/view/weighing-safety-vs-persistence-with-car-nk-cell-therapy&quot;]}],[0,{&quot;_id&quot;:[0,&quot;439cf6ed-2c24-4680-9112-4713db911bf7&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-b3e1284863602927a2f01680a4fbc1a9457c702a-1000x1000-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b3e1284863602927a2f01680a4fbc1a9457c702a-1000x1000.png&quot;]}],&quot;title&quot;:[0,&quot;What Does NRG GU002 Mean for Docetaxel After Prostatectomy?&quot;],&quot;url&quot;:[0,&quot;/view/what-does-nrg-gu002-mean-for-docetaxel-after-prostatectomy-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;09f7be41-e1c2-4a7a-a3ca-f1042e01de56&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Features&quot;],[0,&quot;Multiple Myeloma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/multiple-myeloma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.1135781383432963],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-98b0a5776b30f62a4b369314573127ce4172195e-1304x1171-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/98b0a5776b30f62a4b369314573127ce4172195e-1304x1171.png&quot;]}],&quot;title&quot;:[0,&quot;Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/considering-talquetamab-and-emerging-bispecifics-in-r-r-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;f4052e5c-f969-4db7-96cf-c445882d926e&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T17:31:49.936Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Breaking News&quot;],[0,&quot;Breast Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/breast-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.&quot;],&quot;aspectRatio&quot;:[0,1.910828025477707],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628.png&quot;]}],&quot;title&quot;:[0,&quot;FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer&quot;],&quot;url&quot;:[0,&quot;/view/fda-approves-tucatinib-combo-as-maintenance-in-her2-breast-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a8cfa260-82f4-40cb-b053-2305362083eb&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Head &amp; Neck Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/head-neck-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Medical illustration of laryngeal cancer, covering laryngeal tumor pathology, ENT diagnosis, clinical staging and professional treatment solutions for head and neck oncology research | Image Credit: © 程 加星 - stock.adobe.com &quot;],&quot;aspectRatio&quot;:[0,1.7843137254901962],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5d898f4bbe7c163006d09715bc4230d21fbb4ad8-5824x3264-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5d898f4bbe7c163006d09715bc4230d21fbb4ad8-5824x3264.jpg&quot;]}],&quot;title&quot;:[0,&quot;Transmucosal Patch Yields Pathologic Responses in Non-Invasive Oral Cancer&quot;],&quot;url&quot;:[0,&quot;/view/transmucosal-patch-yields-pathologic-responses-in-non-invasive-oral-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;f3d3417b-5c23-4cd0-857d-436983d12509&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-07T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Lung Cancer&quot;],[0,&quot;Sarcoma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/lung-cancer&quot;],[0,&quot;clinical/sarcoma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.&quot;],&quot;aspectRatio&quot;:[0,1.3333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-139a18b2c4d4432bcf06d40954215538bbbd35c8-8000x6000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/139a18b2c4d4432bcf06d40954215538bbbd35c8-8000x6000.jpg&quot;]}],&quot;title&quot;:[0,&quot;OST-HER2 Shows Significant Final 3-Year OS Benefit in Osteosarcoma Trial&quot;],&quot;url&quot;:[0,&quot;/view/ost-her2-shows-significant-final-3-year-os-benefit-in-osteosarcoma-trial&quot;]}],[0,{&quot;_id&quot;:[0,&quot;cfb5e1df-b9e8-402a-aeef-6f42d2019a0d&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-07T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-ab09d2d8d89f66dc114b5a33c5dbed16c60eb21a-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ab09d2d8d89f66dc114b5a33c5dbed16c60eb21a-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Personalized Vaccines May Have Utility Across All Lung Cancer Stages&quot;],&quot;url&quot;:[0,&quot;/view/personalized-vaccines-may-have-utility-across-all-lung-cancer-stages&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a29aad96-4910-4d47-83f6-fed8a266171b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-07T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, discussed the system breakdowns that delay fertility referrals and how EHR triggers can automate the process.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-0cd3f7d9f7516a528202e5ba752225dc9211794d-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0cd3f7d9f7516a528202e5ba752225dc9211794d-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Clear Ownership and EHR Triggers Can Close Gaps in Oncofertility Referrals&quot;],&quot;url&quot;:[0,&quot;/view/clear-ownership-and-ehr-triggers-can-close-gaps-in-oncofertility-referrals&quot;]}],[0,{&quot;_id&quot;:[0,&quot;d1fcadfa-4d79-4a5e-9a0a-9912a243996e&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Zachary L. Bercu, MD, RPVI, FSIR, discusses the Liberty robotic system’s applications in liver and kidney cancer as well as the feasibility of remote procedures.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Q&amp;As&quot;],[0,&quot;News&quot;],[0,&quot;Liver Cancer&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;clinical/liver-cancer&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Interventional radiology operation room in modern clinic: © Vadim - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.4998585572843],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-9ab1017fcb2dfd91fb1d188e8fc39928c5ec0432-5302x3535-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Interventional radiology operation room in modern clinic: © Vadim - stock.adobe.com&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9ab1017fcb2dfd91fb1d188e8fc39928c5ec0432-5302x3535.jpg&quot;]}],&quot;title&quot;:[0,&quot;Clinical Applications and the Future of Remote Endovascular Procedures&quot;],&quot;url&quot;:[0,&quot;/view/clinical-applications-and-the-future-of-remote-endovascular-procedures&quot;]}],[0,{&quot;_id&quot;:[0,&quot;526b01db-8278-4f6a-9e70-045bcc189740&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e8e7f8835f5c4d82fae608ea8f494d1a8179ac51-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e8e7f8835f5c4d82fae608ea8f494d1a8179ac51-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Taking The First Steps for a Personalized Lung Cancer Vaccine Trial&quot;],&quot;url&quot;:[0,&quot;/view/taking-the-first-steps-for-a-personalized-lung-cancer-vaccine-trial&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2888becd-40d7-478c-9b8f-ce82fc0ee636&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-438ad9b3dee2f9dc61fe279881aff2e76e7142a5-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/438ad9b3dee2f9dc61fe279881aff2e76e7142a5-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;How the Big Ten CRC Moves Bench Discoveries Toward Multicenter Trials&quot;],&quot;url&quot;:[0,&quot;/view/how-the-big-ten-crc-moves-bench-discoveries-toward-multicenter-trials&quot;]}],[0,{&quot;_id&quot;:[0,&quot;907e9fa1-295f-4176-b85a-bb6c908a8c46&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T16:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Ovarian Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/ovarian-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC: © Lars Neumann - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.1666666666666667],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-d90c589883bf085523d6948612da705f50ed131e-7000x6000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d90c589883bf085523d6948612da705f50ed131e-7000x6000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC&quot;],&quot;url&quot;:[0,&quot;/view/avutometinib-defactinib-shows-activity-in-kras-wild-type-recurrent-lgsoc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6a269e02-fab9-4f35-908a-1966bac5b053&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-98283df37f0b9355008d14aa3c157b16f0d3622b-300x300-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/98283df37f0b9355008d14aa3c157b16f0d3622b-300x300.png&quot;]}],&quot;title&quot;:[0,&quot;Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC&quot;],&quot;url&quot;:[0,&quot;/view/firmonertinib-misses-pfs-end-point-in-first-line-egfr-exon-20-nsclc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;77175ce9-2047-4067-aa05-0f287358217e&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Adding fixed-duration epcoritamab to R-CHOP reduced the risk of progression or death by 51% in patients with newly diagnosed DLBCL.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Lymphoma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/lymphoma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Cancer cell or cancerous tumor amidst flowing red blood cells in a blood vessel, artery or vein 3D rendering illustration. Medicine, pathology, oncology, disesase, science concepts. | Image Credit: © Matthieu - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3b0bfef9b4f2eb76acb7dd4c2bf687a15bce5ed4-3840x2160-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Adding fixed-duration epcoritamab to R-CHOP reduced the risk of progression or death by 51% in patients with newly diagnosed DLBCL.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3b0bfef9b4f2eb76acb7dd4c2bf687a15bce5ed4-3840x2160.jpg&quot;]}],&quot;title&quot;:[0,&quot;Epcoritamab/R-CHOP Shows PFS Benefit in Newly Diagnosed DLBCL&quot;],&quot;url&quot;:[0,&quot;/view/epcoritamab-r-chop-shows-pfs-benefit-in-newly-diagnosed-dlbcl&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a7e12428-e64b-4b7c-aa31-89b3ebf8d84f&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-06T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chirag Jain, MBBS, discussed onco-anxiology, a proposed framework for identifying and managing anxiety at each stage of the cancer journey.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Psycho-Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/psycho-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-f458c1b985bf224a5348c9a348b5107298b8bed1-3000x2000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f458c1b985bf224a5348c9a348b5107298b8bed1-3000x2000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Onco-Anxiology Framework Targets Anxiety Across the Cancer Care Continuum&quot;],&quot;url&quot;:[0,&quot;/view/onco-anxiology-framework-targets-anxiety-across-the-cancer-care-continuum&quot;]}],[0,{&quot;_id&quot;:[0,&quot;a5907f9e-097e-42f7-a69f-69ac7a3d0912&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T13:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Multiple Myeloma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/multiple-myeloma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6e3e75081cc80dc4919ecd564f4c3c34e533e8f1-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6e3e75081cc80dc4919ecd564f4c3c34e533e8f1-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy&quot;],&quot;url&quot;:[0,&quot;/view/selinexor-based-quadruplet-targets-myeloma-after-t-cell-redirecting-therapy&quot;]}],[0,{&quot;_id&quot;:[0,&quot;e96667ae-8be9-4457-b1dc-67381cb7828d&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-06T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, explained why male fertility preservation information trails female content online and how cancer centers can fix it.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-60a12baec05223e0c724d18e59f4d84b33d58608-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/60a12baec05223e0c724d18e59f4d84b33d58608-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Male Oncofertility Content Still Lags on NCI Cancer Center Websites&quot;],&quot;url&quot;:[0,&quot;/view/male-oncofertility-content-still-lags-on-nci-cancer-center-websites&quot;]}],[0,{&quot;_id&quot;:[0,&quot;69f411de-88fc-41e7-b98b-955fad526371&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Liver Cancer&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/liver-cancer&quot;],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Modern interventional radiology system with hepatic anatomy illustration: © MDJOYNAL - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7916666666666667],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-414d4b3f59782b8802b059d41e8ec0ff2e39ac42-11008x6144-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/414d4b3f59782b8802b059d41e8ec0ff2e39ac42-11008x6144.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Emory Became the First Adopter of the Liberty Endovascular Robotic System&quot;],&quot;url&quot;:[0,&quot;/view/how-emory-became-the-first-adopter-of-the-liberty-endovascular-robotic-system&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2fe5b2e0-d23f-47c0-b464-84ed996f11b4&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-05T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-2ccd046c9f58fef04ec5acd94a98ff48ea68b5ef-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2ccd046c9f58fef04ec5acd94a98ff48ea68b5ef-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Why High-Risk Stage I NSCLC Needs a Postsurgical Vaccine Option&quot;],&quot;url&quot;:[0,&quot;/view/why-high-risk-stage-i-nsclc-needs-a-post-surgical-vaccine-option&quot;]}],[0,{&quot;_id&quot;:[0,&quot;557d86ef-79c5-4a21-829d-c92ffdc7ead3&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-05T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Lymphoma&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/lymphoma&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-81284df7ef93c1a3e50bf46408946dab8935685c-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/81284df7ef93c1a3e50bf46408946dab8935685c-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma&quot;],&quot;url&quot;:[0,&quot;/view/expanding-car-t-and-bispecific-antibody-research-in-hiv-associated-lymphoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;c910233e-796c-4927-a5b2-8f66aa48b736&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T18:31:04.081Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Ovarian Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/ovarian-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Rina-S Elicits Responses in PROC Regardless of FRα Expression: © magicmine - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-f5d139d6b30af88101f0c7ddcec7f60b55491e85-3840x2160-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f5d139d6b30af88101f0c7ddcec7f60b55491e85-3840x2160.jpg&quot;]}],&quot;title&quot;:[0,&quot;Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression&quot;],&quot;url&quot;:[0,&quot;/view/rinatabart-sesutecan-elicits-responses-in-proc-regardless-of-fr-expression&quot;]}],[0,{&quot;_id&quot;:[0,&quot;008808ab-4083-44a0-8c5b-c4f986f9b1c5&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Melody Rasouli, MD, MBA, FACOG, discusses oncofertility gaps at NCI-designated cancer centers and ways to speed fertility referrals for patients.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,0.75],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-644c414c2596a469d7e9b910e0f3e100975897ae-360x480-webp&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/644c414c2596a469d7e9b910e0f3e100975897ae-360x480.webp&quot;]}],&quot;title&quot;:[0,&quot;How Can Oncologists Make Fertility Preservation a Routine Part of Cancer Care?&quot;],&quot;url&quot;:[0,&quot;/view/how-can-oncologists-make-fertility-preservation-a-routine-part-of-cancer-care-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;028d7fb3-c1f0-4d60-a900-ff173616144d&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/nsclc&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e23e475b94cd7b5475a8179067d9c25efb4e9524-4500x3000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e23e475b94cd7b5475a8179067d9c25efb4e9524-4500x3000.jpg&quot;]}],&quot;title&quot;:[0,&quot;NDA Submission Begins for Zipalertinib Combo in First-Line EGFR+ NSCLC&quot;],&quot;url&quot;:[0,&quot;/view/nda-submission-begins-for-zipalertinib-combo-in-first-line-egfr-nsclc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;7068f1f9-ec52-4640-a51e-308cb6580342&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5f4653807e8f7745a965fa94caafdd22cb5a477b-5000x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5f4653807e8f7745a965fa94caafdd22cb5a477b-5000x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Berzosertib Combo Shows No Response Benefit in Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/berzosertib-combo-shows-no-response-benefit-in-metastatic-crpc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;57ebb931-148e-4bc4-9711-d8cc76bf8e25&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-05T14:15:52.124Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Ovarian Cancer&quot;],[0,&quot;News Reports&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/ovarian-cancer&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer: © magicmine - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-73f50db252d86472148b009ebd1797e4e3c07449-3840x2160-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/73f50db252d86472148b009ebd1797e4e3c07449-3840x2160.jpg&quot;]}],&quot;title&quot;:[0,&quot;Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer&quot;],&quot;url&quot;:[0,&quot;/view/ubamatamab-yields-responses-in-recurrent-low-grade-serous-ovarian-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;071acca8-a2df-490c-b764-f70dad7f331c&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-05T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Lung Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/lung-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-421e3c00e2218f7c0ac702d801e8829085c49481-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/421e3c00e2218f7c0ac702d801e8829085c49481-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Balancing Cure and Toxicity in Complex Lung Cancer Radiotherapy Regimens&quot;],&quot;url&quot;:[0,&quot;/view/balancing-cure-and-toxicity-in-complex-lung-cancer-radiotherapy-regimens&quot;]}],[0,{&quot;_id&quot;:[0,&quot;97f44d5b-4496-499f-849e-a65fa19d7607&quot;],&quot;contentCategory&quot;:[0,&quot;Podcasts&quot;],&quot;published&quot;:[0,&quot;2026-10-05T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Podcasts&quot;],[0,&quot;Non-Small Cell Lung Cancer (NSCLC)&quot;],[0,&quot;Recent Episodes&quot;],[0,&quot;FDA Approval Alert: The Need-to-Know&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;podcasts&quot;],[0,&quot;clinical/nsclc&quot;],[0,&quot;recent-episodes&quot;],[0,&quot;fda-approval-alert&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.&quot;],&quot;aspectRatio&quot;:[0,1.013143483023001],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5e7b4abec0c9247ee5bbe4c47ebe34bff52a7155-6475x6391-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5e7b4abec0c9247ee5bbe4c47ebe34bff52a7155-6475x6391.jpg&quot;]}],&quot;title&quot;:[0,&quot;What Does Sevabertinib’s Expanded Approval Mean for HER2+ NSCLC? &quot;],&quot;url&quot;:[0,&quot;/view/what-does-sevabertinib-s-expanded-approval-mean-for-her2-nsclc-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;e0f410e1-b664-4de7-a447-12ab409d998d&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-04T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said J. Thaddeus Beck, MD, FACP.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.&quot;],&quot;aspectRatio&quot;:[0,0.6666666666666666],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said J. Thaddeus Beck, MD, FACP.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Is Subcutaneous Administration Changing Oncology Care Delivery?&quot;],&quot;url&quot;:[0,&quot;/view/how-is-subcutaneous-administration-changing-oncology-care-delivery-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6b6ee501-e8f3-4206-b7be-728e52657184&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-04T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Lung Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/lung-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c837dfa48a7bae21d18228f476b4b0a830badd95-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c837dfa48a7bae21d18228f476b4b0a830badd95-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?&quot;],&quot;url&quot;:[0,&quot;/view/how-well-does-radiotherapy-pair-with-dual-pd-1-lag-3-blockade-in-nsclc-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;6edb4c55-6b18-4a67-a03b-d8d5e7724d4c&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-04T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-eb81880dbc2fefdb57bd6463630d57277b2319da-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/eb81880dbc2fefdb57bd6463630d57277b2319da-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/prioritizing-proton-therapy-for-pelvic-nodal-irradiation-in-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;58c2bd34-0540-4c61-9e9f-06677ba16445&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-03T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.162217659137577],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1e6dc9be604f77b92beb831886975d08318b17bc-566x487-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1e6dc9be604f77b92beb831886975d08318b17bc-566x487.jpg&quot;]}],&quot;title&quot;:[0,&quot;Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery&quot;],&quot;url&quot;:[0,&quot;/view/alliance-a071801-supports-fractionated-srs-after-brain-metastasis-surgery&quot;]}],[0,{&quot;_id&quot;:[0,&quot;5af6847f-8281-4085-875e-63013654969a&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-03T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-7ebc64944997fe4c839ade0c5969782898d4f598-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7ebc64944997fe4c839ade0c5969782898d4f598-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Rectal Spacers May Reduce Toxicity of Proton Therapy in Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/rectal-spacers-may-reduce-toxicity-of-proton-therapy-in-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;c77761a2-97f4-4b76-9227-0a7a8a2a1ab6&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Dynamic Video&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3d3e2eccd85358bb564c97a5a9f5a966eea0ecbd-1280x720-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3d3e2eccd85358bb564c97a5a9f5a966eea0ecbd-1280x720.png&quot;]}],&quot;title&quot;:[0,&quot;Bruce Haffty, MD, and Mutlay Sayan, MD, on Radiation Oncology&#39;s Next Frontier and Mentorship&quot;],&quot;url&quot;:[0,&quot;/view/bruce-haffty-md-and-mutlay-sayan-md-on-radiation-oncology-s-next-frontier-and-mentorship&quot;]}],[0,{&quot;_id&quot;:[0,&quot;b2f8f85d-79d6-4610-850e-e65a3c8b28f2&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-479ad7fa962c4064930c11973aac309e064087e5-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/479ad7fa962c4064930c11973aac309e064087e5-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups&quot;],&quot;url&quot;:[0,&quot;/view/assessing-impt-outcomes-across-localized-prostate-cancer-risk-groups&quot;]}],[0,{&quot;_id&quot;:[0,&quot;76b023e0-6c69-47f9-94d3-b54da7545595&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-02T19:45:05.106Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Breaking News&quot;],[0,&quot;News&quot;],[0,&quot;Leukemia&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;clinical/leukemia&quot;],[0,&quot;clinical/lymphoma&quot;],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.&quot;],&quot;aspectRatio&quot;:[0,1.7561779242174629],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/049a2d75a2445c82f3b5f3aaa49a7d47c6ca2e50-2132x1214.png&quot;]}],&quot;title&quot;:[0,&quot;FDA OKs Pirtobrutinib in Frontline CLL/SLL&quot;],&quot;url&quot;:[0,&quot;/view/fda-oks-pirtobrutinib-in-frontline-cll-sll&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2eeb7443-1cb1-4c2c-bc8a-39db1604becf&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c59144717b9371bc671c11a71ea6bd964a247767-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c59144717b9371bc671c11a71ea6bd964a247767-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Making Outpatient Cellular Therapy Dosing the Default in Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/making-outpatient-cellular-therapy-dosing-the-default-in-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;32a9d524-c07e-4cfa-83e3-1e7077357b3b&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-02T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7753120665742026],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-4f123c1e22b36e7db3d61e261146ef486e1dd340-1280x721-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4f123c1e22b36e7db3d61e261146ef486e1dd340-1280x721.png&quot;]}],&quot;title&quot;:[0,&quot;Fractionated SRS Improves Surgical Bed Control After Brain Metastasis Resection&quot;],&quot;url&quot;:[0,&quot;/view/fractionated-srs-improves-surgical-bed-control-after-brain-metastasis-resection&quot;]}],[0,{&quot;_id&quot;:[0,&quot;565185c2-3aeb-4662-9eac-ee92ed9b85fd&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-02T14:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Breast Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/breast-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.&quot;],&quot;aspectRatio&quot;:[0,1.5429025423728813],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-19aeb1ca058f8b9c18fc24096b95943b2c6cf9f8-5826x3776-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/19aeb1ca058f8b9c18fc24096b95943b2c6cf9f8-5826x3776.jpg&quot;]}],&quot;title&quot;:[0,&quot;Giredestrant Combo Boosts PFS in Pretreated ER+ Advanced Breast Cancer&quot;],&quot;url&quot;:[0,&quot;/view/giredestrant-combo-boosts-pfs-in-pretreated-er-advanced-breast-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;12c5eb6c-671d-4fc6-884d-98440f5a9f93&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Pancreatic Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/pancreatic-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,null],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,null]}],&quot;title&quot;:[0,&quot;Preoperative SBRT Shows High Resection Rates in Pancreatic Adenocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/preoperative-sbrt-shows-high-resection-rates-in-pancreatic-adenocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2f4e24d2-41f0-4065-b1c4-11f35b1ecaff&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-02T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;Gastrointestinal Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-88cf2921a6e8d5ecf991281aa033975fe9bec231-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/88cf2921a6e8d5ecf991281aa033975fe9bec231-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Understanding the KRAS Mutation Landscape in Biliary Tract Cancer&quot;],&quot;url&quot;:[0,&quot;/view/understanding-the-kras-mutation-landscape-in-biliary-tract-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;fee70db8-4956-4a6d-97b7-e1c89c1bb667&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-01T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Surgery&quot;],[0,&quot;Pancreatic Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/surgery&quot;],[0,&quot;clinical/pancreatic-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-02ac8915e1374c39e25224c9c6a74c20d48c9c18-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/02ac8915e1374c39e25224c9c6a74c20d48c9c18-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;What Drove the SBRT Quality-of-Life Advantage in Pancreatic Cancer?&quot;],&quot;url&quot;:[0,&quot;/view/what-drove-the-sbrt-quality-of-life-advantage-in-pancreatic-cancer-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;3a3d3f2b-8830-47eb-ba22-c058cd6fd51c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.&quot;],&quot;aspectRatio&quot;:[0,0.667779632721202],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-a1adeba6d98b02e8d431e9fe662448f33d2d9a6f-1200x1797-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a1adeba6d98b02e8d431e9fe662448f33d2d9a6f-1200x1797.jpg&quot;]}],&quot;title&quot;:[0,&quot;Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?&quot;],&quot;url&quot;:[0,&quot;/view/where-does-intensity-modulated-proton-therapy-fit-in-prostate-cancer-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;614d83bc-3cba-43c5-bfc5-c6f1f855528c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Conference&quot;],[0,&quot;Slideshows&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;conference&quot;],[0,&quot;resources/slideshows&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.&quot;],&quot;aspectRatio&quot;:[0,1.5463917525773196],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-9f56eba4eb61989ef5c263c5f21a030fc69b3e09-1200x776-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9f56eba4eb61989ef5c263c5f21a030fc69b3e09-1200x776.jpg&quot;]}],&quot;title&quot;:[0,&quot;IMS 2026: Key Updates Across The Multiple Myeloma Paradigm&quot;],&quot;url&quot;:[0,&quot;/view/ims-2026-key-updates-across-the-multiple-myeloma-paradigm&quot;]}],[0,{&quot;_id&quot;:[0,&quot;7deac2da-3616-45d6-a6f2-0d838d2a659c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News Reports&quot;],[0,&quot;News&quot;],[0,&quot;Small Cell Lung Cancer (SCLC)&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;clinical/small-cell-lung-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.&quot;],&quot;aspectRatio&quot;:[0,1.4002333722287048],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-555f5be80532573a6654f0b562c43e11aedf99df-1200x857-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/555f5be80532573a6654f0b562c43e11aedf99df-1200x857.jpg&quot;]}],&quot;title&quot;:[0,&quot;FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC&quot;],&quot;url&quot;:[0,&quot;/view/fda-discussion-prompts-voluntary-withdrawal-of-bla-for-i-dxd-in-es-sclc&quot;]}],[0,{&quot;_id&quot;:[0,&quot;918f9260-959d-4257-b42f-10b5b7158fbe&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T15:02:42.344Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.&quot;],&quot;aspectRatio&quot;:[0,1.1111111111111112],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300.jpg&quot;]}],&quot;title&quot;:[0,&quot;Tabelecleucel BLA Resubmitted to FDA for EBV-Positive PTLD&quot;],&quot;url&quot;:[0,&quot;/view/tabelecleucel-bla-resubmitted-to-fda-for-ebv-positive-ptld&quot;]}],[0,{&quot;_id&quot;:[0,&quot;2931406c-52b2-41ee-9e2f-482ed00f2fce&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-01T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Pancreatic Cancer&quot;],[0,&quot;Surgery&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/pancreatic-cancer&quot;],[0,&quot;clinical/surgery&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e14ddc5983a7b4b2c9e75769d3215c9b33f88957-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e14ddc5983a7b4b2c9e75769d3215c9b33f88957-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;SBRT Preserves Quality of Life Before Pancreatic Cancer Surgery&quot;],&quot;url&quot;:[0,&quot;/view/sbrt-preserves-quality-of-life-before-pancreatic-cancer-surgery&quot;]}],[0,{&quot;_id&quot;:[0,&quot;58f7274a-2816-4cad-a5f2-a3f13c43aa51&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-01T13:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News Reports&quot;],[0,&quot;News&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;news&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,0.9902439024390244],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5bb0fb502597b441b504933051804df03d668f46-406x410-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5bb0fb502597b441b504933051804df03d668f46-406x410.png&quot;]}],&quot;title&quot;:[0,&quot;SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer &quot;],&quot;url&quot;:[0,&quot;/view/sbrt-matches-disease-control-of-prostatectomy-in-localized-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;da1dd275-78ce-4c1f-8f3a-6818aa01f9b0&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-01T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;News&quot;],[0,&quot;Gastrointestinal Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;news&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-ae63c7e65ca956fb4d26cc120cc8521b840b02a5-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ae63c7e65ca956fb4d26cc120cc8521b840b02a5-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Early Clinical Data Show KRAS Inhibitors Can Work in Cholangiocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/early-clinical-data-show-kras-inhibitors-can-work-in-cholangiocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;34763092-92a1-4ca8-964c-d6354761f76c&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?&quot;],&quot;aspectRatio&quot;:[0,0.8],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c46052a450f03752d4e3278cebceb69e9c658b2c-4000x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c46052a450f03752d4e3278cebceb69e9c658b2c-4000x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?&quot;],&quot;url&quot;:[0,&quot;/view/what-does-talapro-3-mean-for-frontline-treatment-of-hrr-altered-mhspc-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;be9d87b5-c7e4-46bd-b847-ce1a181a333f&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.326],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/aglatimagene-combo-shows-sustained-immune-remodeling-in-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;43ce25c8-912d-482b-b3fb-80d2b6543575&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The ROADS investigators reported no differences between cesium-131 tile-based radiation therapy and SRT in quality of life, functional status, or neurocognitive function.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases: © Sebastian Kaulitzki - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.3333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-02c2654f19c2e270c10911db15c14c07e74d3722-5000x3750-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The ROADS investigators reported no differences between cesium-131 tile-based radiation therapy and SRT in quality of life, functional status, or neurocognitive function.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/02c2654f19c2e270c10911db15c14c07e74d3722-5000x3750.jpg&quot;]}],&quot;title&quot;:[0,&quot;Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases&quot;],&quot;url&quot;:[0,&quot;/view/tile-based-radiation-improves-surgical-bed-recurrence-in-brain-metastases&quot;]}],[0,{&quot;_id&quot;:[0,&quot;acebb5c3-510d-4a20-a061-316888ac4c32&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-30T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Conference&quot;],[0,&quot;Pancreatic Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Q&amp;As&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/pancreatic-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,null]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1.1166666666666667],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-f8dbad1e1efc44c0fb739d75f02a25b9fe0e8f38-6700x6000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f8dbad1e1efc44c0fb739d75f02a25b9fe0e8f38-6700x6000.jpg&quot;]}],&quot;title&quot;:[0,&quot;SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery&quot;],&quot;url&quot;:[0,&quot;/view/sbrt-matches-chemoradiation-preserves-qol-before-pancreatic-surgery&quot;]}],[0,{&quot;_id&quot;:[0,&quot;9c1de5e5-7dbc-4b42-bc89-af1ff281102b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-30T12:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Conference&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;News&quot;],[0,&quot;Gastrointestinal Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;conference&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;news&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c9a5184869b1549f49e584933622a660ffdba996-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c9a5184869b1549f49e584933622a660ffdba996-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Sequencing FGFR2 Inhibitors in Previously Treated Cholangiocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/sequencing-fgfr2-inhibitors-in-previously-treated-cholangiocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;3514886b-2219-4599-b70e-7b95ab8a2ba0&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T22:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.&quot;],&quot;aspectRatio&quot;:[0,0.7272727272727273],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-283af1206310c49850e4e13c57aa0e2ec6e47043-1200x1650-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/283af1206310c49850e4e13c57aa0e2ec6e47043-1200x1650.jpg&quot;]}],&quot;title&quot;:[0,&quot;Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care&quot;],&quot;url&quot;:[0,&quot;/view/integrating-talazoparib-plus-enzalutamide-into-hrr-mutated-mhspc-care&quot;]}],[0,{&quot;_id&quot;:[0,&quot;d1286dfa-d844-41a1-b1a2-f84a1b417110&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-29T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;Gastrointestinal Cancer&quot;],[0,&quot;News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/gastrointestinal-cancer&quot;],[0,&quot;news&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-3f7c04b33626ec6e6a1ace83c981e5c811592693-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3f7c04b33626ec6e6a1ace83c981e5c811592693-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma&quot;],&quot;url&quot;:[0,&quot;/view/lirafugratinib-approval-adds-a-third-fgfr2-inhibitor-in-cholangiocarcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;b3782e19-5e92-4092-b100-a66ab2d602d2&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;],[0,&quot;Small Cell Lung Cancer (SCLC)&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/small-cell-lung-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.&quot;],&quot;aspectRatio&quot;:[0,1.3498312710911136],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-604dbc90ff1ae66780777fdd394c550f4c835df8-1200x889-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/604dbc90ff1ae66780777fdd394c550f4c835df8-1200x889.jpg&quot;]}],&quot;title&quot;:[0,&quot;SRS Improves Survival Vs Hippocampal Avoidant-WBRT in SCLC Brain Metastases&quot;],&quot;url&quot;:[0,&quot;/view/srs-improves-survival-vs-hippocampal-avoidant-wbrt-in-sclc-brain-metastases&quot;]}],[0,{&quot;_id&quot;:[0,&quot;503b257c-42ec-4488-98dc-121c288a6b58&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T19:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.5],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-821879789eef5f47bbc210b9c96ef210efd90022-1200x800-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/821879789eef5f47bbc210b9c96ef210efd90022-1200x800.jpg&quot;]}],&quot;title&quot;:[0,&quot;BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma&quot;],&quot;url&quot;:[0,&quot;/view/bcma-gprc5d-car-t-cell-therapy-shows-early-efficacy-in-r-r-multiple-myeloma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;57f1794d-d767-40f5-a95b-dac99e3ebeef&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-29T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Brain Cancer&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/brain-cancer&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6ef85fa1e255f6a8e2b33c9ac2f54aff120abb04-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6ef85fa1e255f6a8e2b33c9ac2f54aff120abb04-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;When Single-Fraction SRS Still Makes Sense for Resected Brain Metastases&quot;],&quot;url&quot;:[0,&quot;/view/when-single-fraction-srs-still-makes-sense-for-resected-brain-metastases&quot;]}],[0,{&quot;_id&quot;:[0,&quot;ea16e1f5-76ca-4ac0-a438-4d50df7fecaa&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-a6130eed7d7f2e33168953c10354d4e6d720da1e-1200x675-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a6130eed7d7f2e33168953c10354d4e6d720da1e-1200x675.jpg&quot;]}],&quot;title&quot;:[0,&quot;Extended Belantamab Mafodotin Dosing Eases Ocular Function in DREAMM-9&quot;],&quot;url&quot;:[0,&quot;/view/extended-belantamab-mafodotin-dosing-eases-ocular-function-in-dreamm-9&quot;]}],[0,{&quot;_id&quot;:[0,&quot;e8c75242-5d86-47a3-8f79-d8e98a48a9fb&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T16:00:07.919Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Conference&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma: © Sebastian Kaulitzki - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,2],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-1844269e0cec8c0da218113457254f361f8ed7b0-8000x4000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1844269e0cec8c0da218113457254f361f8ed7b0-8000x4000.jpg&quot;]}],&quot;title&quot;:[0,&quot;Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma&quot;],&quot;url&quot;:[0,&quot;/view/proton-therapy-does-not-improve-survival-in-hepatocellular-carcinoma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;8c915645-078a-4c53-bead-b8d3b65439c4&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-09-29T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Journal Articles&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.3333333333333333],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-9e83c0e9492f23d2ea77b28b0776b1f4da6a6af8-5000x3750-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9e83c0e9492f23d2ea77b28b0776b1f4da6a6af8-5000x3750.jpg&quot;]}],&quot;title&quot;:[0,&quot;Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer&quot;],&quot;url&quot;:[0,&quot;/view/multimodal-biopsy-combo-shows-low-morbidity-in-suspected-prostate-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;04a6f888-5e7f-4f94-8fbe-6cb4253d5acf&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-09-29T14:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Conference&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;News&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,null],[0,&quot;videos&quot;],[0,&quot;conference&quot;],[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;news&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6d5b5776983f3642970057d4e322e81a12874e5a-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6d5b5776983f3642970057d4e322e81a12874e5a-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape&quot;],&quot;url&quot;:[0,&quot;/view/where-mrd-testing-fits-into-myeloma-s-treatment-and-regulatory-landscape&quot;]}]]],&quot;currentArticleId&quot;:[0,&quot;cn_article_374309&quot;],&quot;clientConfig&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;],&quot;storageNamespace&quot;:[0,&quot;cancernetwork&quot;],&quot;cookies&quot;:[0,{&quot;prefs&quot;:[0,&quot;cancernetwork_prefs&quot;],&quot;cognitoId&quot;:[0,&quot;cancernetwork_cognito_id&quot;]}],&quot;prefsEventName&quot;:[0,&quot;cancernetwork:personalization-prefs&quot;],&quot;endpoint&quot;:[0],&quot;idlayer&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;]}],&quot;engagement&quot;:[0,{&quot;segmentDualWrite&quot;:[0,true]}],&quot;taxonomyQuery&quot;:[0,{&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;parentGroup&quot;:[0,&quot;clinical&quot;]}],&quot;experiment&quot;:[0,{&quot;enabled&quot;:[0,true],&quot;salt&quot;:[0,&quot;dv6834-cancernetwork-homepage-v1&quot;]}]}],&quot;excludeIds&quot;:[1,[[0,&quot;de825fd8-becf-47b2-b75e-f36c32be2975&quot;],[0,&quot;69d6a710-7599-4939-88dc-d745376d37cf&quot;],[0,&quot;dcf42da5-6ed8-46d7-93ce-7dea016f9603&quot;],[0,&quot;da5bf0e0-2138-4b4a-a044-ffb88bda705b&quot;],[0,&quot;1abdedd9-ac41-4260-84de-d6d50f58626a&quot;],[0,&quot;732a9b36-4ae9-433f-a71e-af1a03502d39&quot;],[0,&quot;4e4318a7-7243-43a4-bdac-6c144f7aeb04&quot;],[0,&quot;10e9fead-dd59-4720-bf6d-81561b8910c1&quot;]]],&quot;title&quot;:[0,&quot;For You&quot;],&quot;rail&quot;:[0,&quot;for_you_notify&quot;],&quot;placement&quot;:[0,&quot;notify&quot;],&quot;placementOverride&quot;:[0,null],&quot;size&quot;:[0,3]}" ssr client="idle" opts="{&quot;name&quot;:&quot;ForYouNotify&quot;,&quot;value&quot;:true}"></astro-island> <astro-island uid="Z1biqeV" prefix="r74" component-url="/_astro/ArticleReadTracker.BZSFkpLX.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;contentId&quot;:[0,&quot;cn_article_374309&quot;],&quot;clientConfig&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;],&quot;storageNamespace&quot;:[0,&quot;cancernetwork&quot;],&quot;cookies&quot;:[0,{&quot;prefs&quot;:[0,&quot;cancernetwork_prefs&quot;],&quot;cognitoId&quot;:[0,&quot;cancernetwork_cognito_id&quot;]}],&quot;prefsEventName&quot;:[0,&quot;cancernetwork:personalization-prefs&quot;],&quot;endpoint&quot;:[0],&quot;idlayer&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;]}],&quot;engagement&quot;:[0,{&quot;segmentDualWrite&quot;:[0,true]}],&quot;taxonomyQuery&quot;:[0,{&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;parentGroup&quot;:[0,&quot;clinical&quot;]}],&quot;experiment&quot;:[0,{&quot;enabled&quot;:[0,true],&quot;salt&quot;:[0,&quot;dv6834-cancernetwork-homepage-v1&quot;]}]}]}" ssr client="idle" opts="{&quot;name&quot;:&quot;ArticleReadTracker&quot;,&quot;value&quot;:true}"></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  mb-10 mt-10"> <astro-island uid="Z2rgdGv" prefix="r75" component-url="/_astro/TrackedCardSlider.B3G13Z0v.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;de825fd8-becf-47b2-b75e-f36c32be2975&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T22:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Conference&quot;],[0,&quot;Lymphoma&quot;],[0,&quot;Hematologic Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;conference&quot;],[0,&quot;clinical/lymphoma&quot;],[0,&quot;clinical/hematology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;aspectRatio&quot;:[0,0.8626887131560029],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-03e77b4f328a10c74086cdfdbf704078d6050f18-1200x1391-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/03e77b4f328a10c74086cdfdbf704078d6050f18-1200x1391.jpg&quot;]}],&quot;title&quot;:[0,&quot;Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer&quot;],&quot;url&quot;:[0,&quot;/view/weighing-the-promise-and-trade-offs-of-car-nk-cell-therapy-for-cancer&quot;]}],[0,{&quot;_id&quot;:[0,&quot;69d6a710-7599-4939-88dc-d745376d37cf&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T21:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Q&amp;As&quot;],[0,&quot;Radiation Oncology&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/radiation-oncology&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.&quot;],&quot;aspectRatio&quot;:[0,0.8],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-363270bf0783d219c3528f46e9e77d5dc1f186e9-200x250-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Tyler J. WIlhite, MD\nUPMC HIllman Cancer Center&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/363270bf0783d219c3528f46e9e77d5dc1f186e9-200x250.png&quot;]}],&quot;title&quot;:[0,&quot;Building a Low-Dose Radiation Therapy Program for Benign Disease&quot;],&quot;url&quot;:[0,&quot;/view/building-a-low-dose-radiation-therapy-program-for-benign-disease&quot;]}],[0,{&quot;_id&quot;:[0,&quot;dcf42da5-6ed8-46d7-93ce-7dea016f9603&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-09T20:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Videos&quot;],[0,&quot;Prostate Cancer&quot;],[0,&quot;Radiation Oncology&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;videos&quot;],[0,&quot;clinical/prostate-cancer&quot;],[0,&quot;clinical/radiation-oncology&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-5af592353ad710d026c1636a0a523c535b1213f7-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5af592353ad710d026c1636a0a523c535b1213f7-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization &quot;],&quot;url&quot;:[0,&quot;/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization&quot;]}],[0,{&quot;_id&quot;:[0,&quot;da5bf0e0-2138-4b4a-a044-ffb88bda705b&quot;],&quot;contentCategory&quot;:[0,&quot;Videos&quot;],&quot;published&quot;:[0,&quot;2026-10-09T18:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Videos&quot;],[0,&quot;1:1 Video&quot;],[0,&quot;Multiple Myeloma&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;videos&quot;],[0,null],[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080.png&quot;]}],&quot;title&quot;:[0,&quot;Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM&quot;],&quot;url&quot;:[0,&quot;/view/ramantamig-achieves-impressive-rates-of-mrd-negativity-in-rrmm&quot;]}],[0,{&quot;_id&quot;:[0,&quot;1abdedd9-ac41-4260-84de-d6d50f58626a&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T17:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;News Reports&quot;],[0,&quot;Myeloproliferative Neoplasms&quot;],[0,&quot;Conference&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/myeloproliferative-neoplasms&quot;],[0,&quot;conference&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;aspectRatio&quot;:[0,1.1111111111111112],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. &quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300.jpg&quot;]}],&quot;title&quot;:[0,&quot;Selcodebart Yields Hematologic Responses in Anemia From Myelofibrosis&quot;],&quot;url&quot;:[0,&quot;/view/selcodebart-yields-hematologic-responses-in-anemia-from-myelofibrosis&quot;]}],[0,{&quot;_id&quot;:[0,&quot;732a9b36-4ae9-433f-a71e-af1a03502d39&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T16:30:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;Multiple Myeloma&quot;],[0,&quot;News&quot;],[0,&quot;Between the Lines&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;clinical/multiple-myeloma&quot;],[0,&quot;news&quot;],[0,&quot;between-the-lines&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.2939197930142303],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-d23a730915dd101042071359cc623e55511245dc-5001x3865-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d23a730915dd101042071359cc623e55511245dc-5001x3865.jpg&quot;]}],&quot;title&quot;:[0,&quot;How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?&quot;],&quot;url&quot;:[0,&quot;/view/how-do-long-term-maia-and-cepheus-data-reinforce-daratumumab-use-in-ndmm-&quot;]}],[0,{&quot;_id&quot;:[0,&quot;4e4318a7-7243-43a4-bdac-6c144f7aeb04&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T16:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Journal Articles&quot;],[0,&quot;Brain Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,null],[0,&quot;clinical/brain-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma: © 程 加星 - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.7777777777777777],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-c12520957948ebfc324e247b1151b3dd28a0420d-5120x2880-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c12520957948ebfc324e247b1151b3dd28a0420d-5120x2880.jpg&quot;]}],&quot;title&quot;:[0,&quot;Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma&quot;],&quot;url&quot;:[0,&quot;/view/adjuvant-radiotherapy-reduced-recurrence-in-resected-atypical-meningioma&quot;]}],[0,{&quot;_id&quot;:[0,&quot;10e9fead-dd59-4720-bf6d-81561b8910c1&quot;],&quot;contentCategory&quot;:[0,&quot;Articles&quot;],&quot;published&quot;:[0,&quot;2026-10-09T15:00:00Z&quot;],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.&quot;],&quot;taxonomyNames&quot;:[1,[[0,&quot;News&quot;],[0,&quot;Prostate Cancer&quot;]]],&quot;taxonomySlugs&quot;:[1,[[0,&quot;news&quot;],[0,&quot;clinical/prostate-cancer&quot;]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;alt&quot;:[0,&quot;Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr Microbe - stock.adobe.com&quot;],&quot;aspectRatio&quot;:[0,1.326],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;caption&quot;:[0,&quot;VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.&quot;],&quot;linkDisabled&quot;:[0,false],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000.jpg&quot;]}],&quot;title&quot;:[0,&quot;VIR-5500 Receives FDA Fast Track Designation for Late-Line Metastatic CRPC&quot;],&quot;url&quot;:[0,&quot;/view/vir-5500-receives-fda-fast-track-designation-for-late-line-metastatic-crpc&quot;]}]]],&quot;contentType&quot;:[0,&quot;article&quot;],&quot;title&quot;:[0,&quot;Related to this article&quot;],&quot;viewMoreUrl&quot;:[0,&quot;/news&quot;],&quot;viewMoreText&quot;:[0,&quot;View more&quot;],&quot;rail&quot;:[0,&quot;related_to_article&quot;],&quot;clientConfig&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;],&quot;storageNamespace&quot;:[0,&quot;cancernetwork&quot;],&quot;cookies&quot;:[0,{&quot;prefs&quot;:[0,&quot;cancernetwork_prefs&quot;],&quot;cognitoId&quot;:[0,&quot;cancernetwork_cognito_id&quot;]}],&quot;prefsEventName&quot;:[0,&quot;cancernetwork:personalization-prefs&quot;],&quot;endpoint&quot;:[0],&quot;idlayer&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;]}],&quot;engagement&quot;:[0,{&quot;segmentDualWrite&quot;:[0,true]}],&quot;taxonomyQuery&quot;:[0,{&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;parentGroup&quot;:[0,&quot;clinical&quot;]}],&quot;experiment&quot;:[0,{&quot;enabled&quot;:[0,true],&quot;salt&quot;:[0,&quot;dv6834-cancernetwork-homepage-v1&quot;]}]}]}" ssr client="idle" opts="{&quot;name&quot;:&quot;TrackedCardSlider&quot;,&quot;value&quot;:true}" await-children><section class="w-full" data-testid="tracked-card-slider"><div class="flex w-full"><div class="relative h-full w-full pb-5" role="region" aria-roledescription="carousel"><div class="mb-8 flex w-full justify-between"><div class="flex w-full"><h2 class="text-2xl font-bold text-typo-dark lg:shrink-0 lg:text-3xl">Related to this article</h2></div><div class="text-md mt-4 flex w-full items-center justify-end pr-2 font-semibold hover:text-link-hover"><a href="/news">View more</a></div></div><div class="overflow-hidden"><div class="flex -ml-4 px-0.5 pb-4"><div role="group" aria-roledescription="slide" class="min-w-0 pl-4 mr-2 flex flex-col first-of-type:pl-4 flex-[0_0_22rem]"><article class="group flex h-full w-full max-w-full flex-col justify-between rounded border-none bg-white/80 p-0 shadow backdrop-blur-sm transition-transform duration-300 md:max-w-sm"><a href="/view/weighing-the-promise-and-trade-offs-of-car-nk-cell-therapy-for-cancer"><div style="aspect-ratio:0.8626887131560029" class="relative h-48 w-full overflow-hidden object-cover"><img fetchpriority="auto" loading="eager" alt="“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD." class="h-full w-full rounded-t object-cover transition-transform duration-500 group-hover:scale-105 false" src="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/03e77b4f328a10c74086cdfdbf704078d6050f18-1200x1391.jpg?w=350&amp;fit=crop&amp;auto=format"/></div></a><div class="bg-white-100 h-full rounded-b p-5"><div class="flex w-full flex-col gap-1 px-0"><time class="text-typo-light text-sm" dateTime="2026-10-09T22:00:00Z">October 9th, 2026</time><div class="tracking-tight text-typo-dark pb-4 text-lg font-semibold"><a href="/view/weighing-the-promise-and-trade-offs-of-car-nk-cell-therapy-for-cancer" class="hover:underline">Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer</a></div><div class="text-typo mb-4 line-clamp-3 overflow-hidden text-ellipsis text-sm">“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.</div></div></div><div class="flex w-full items-center pb-4 pl-4"><a href="/view/weighing-the-promise-and-trade-offs-of-car-nk-cell-therapy-for-cancer" class="flex items-center gap-2"><span class="text-ellipsis text-balance font-semibold capitalize text-primary group-hover:text-primary">Read more</span><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-5 w-5 text-primary transition-transform group-hover:translate-x-1" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg></a></div></article></div><div role="group" aria-roledescription="slide" class="min-w-0 pl-4 mr-2 flex flex-col first-of-type:pl-4 flex-[0_0_22rem]"><article class="group flex h-full w-full max-w-full flex-col justify-between rounded border-none bg-white/80 p-0 shadow backdrop-blur-sm transition-transform duration-300 md:max-w-sm"><a href="/view/building-a-low-dose-radiation-therapy-program-for-benign-disease"><div style="aspect-ratio:0.8" class="relative h-48 w-full overflow-hidden object-cover"><img fetchpriority="auto" loading="eager" alt="Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases." class="h-full w-full rounded-t object-cover transition-transform duration-500 group-hover:scale-105 false" src="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/363270bf0783d219c3528f46e9e77d5dc1f186e9-200x250.png?w=350&amp;fit=crop&amp;auto=format"/></div></a><div class="bg-white-100 h-full rounded-b p-5"><div class="flex w-full flex-col gap-1 px-0"><time class="text-typo-light text-sm" dateTime="2026-10-09T21:00:00Z">October 9th, 2026</time><div class="tracking-tight text-typo-dark pb-4 text-lg font-semibold"><a href="/view/building-a-low-dose-radiation-therapy-program-for-benign-disease" class="hover:underline">Building a Low-Dose Radiation Therapy Program for Benign Disease</a></div><div class="text-typo mb-4 line-clamp-3 overflow-hidden text-ellipsis text-sm">Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.</div></div></div><div class="flex w-full items-center pb-4 pl-4"><a href="/view/building-a-low-dose-radiation-therapy-program-for-benign-disease" class="flex items-center gap-2"><span class="text-ellipsis text-balance font-semibold capitalize text-primary group-hover:text-primary">Read more</span><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-5 w-5 text-primary transition-transform group-hover:translate-x-1" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg></a></div></article></div><div role="group" aria-roledescription="slide" class="min-w-0 pl-4 mr-2 flex flex-col first-of-type:pl-4 flex-[0_0_22rem]"><article class="group flex h-full w-full max-w-full flex-col justify-between rounded border-none bg-white/80 p-0 shadow backdrop-blur-sm transition-transform duration-300 md:max-w-sm"><a href="/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization"><div style="aspect-ratio:1.7777777777777777" class="relative h-48 w-full overflow-hidden object-cover"><img fetchpriority="auto" loading="eager" alt="Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands." class="h-full w-full rounded-t object-cover transition-transform duration-500 group-hover:scale-105 false" src="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5af592353ad710d026c1636a0a523c535b1213f7-1920x1080.png?w=350&amp;fit=crop&amp;auto=format"/></div></a><div class="bg-white-100 h-full rounded-b p-5"><div class="flex w-full flex-col gap-1 px-0"><time class="text-typo-light text-sm" dateTime="2026-10-09T20:00:00Z">October 9th, 2026</time><div class="tracking-tight text-typo-dark pb-4 text-lg font-semibold"><a href="/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization" class="hover:underline">Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization </a></div><div class="text-typo mb-4 line-clamp-3 overflow-hidden text-ellipsis text-sm">Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.</div></div></div><div class="flex w-full items-center pb-4 pl-4"><a href="/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization" class="flex items-center gap-2"><span class="text-ellipsis text-balance font-semibold capitalize text-primary group-hover:text-primary">Read more</span><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-5 w-5 text-primary transition-transform group-hover:translate-x-1" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg></a></div></article></div><div role="group" aria-roledescription="slide" class="min-w-0 pl-4 mr-2 flex flex-col first-of-type:pl-4 flex-[0_0_22rem]"><article class="group flex h-full w-full max-w-full flex-col justify-between rounded border-none bg-white/80 p-0 shadow backdrop-blur-sm transition-transform duration-300 md:max-w-sm"><a href="/view/ramantamig-achieves-impressive-rates-of-mrd-negativity-in-rrmm"><div style="aspect-ratio:1.7777777777777777" class="relative h-48 w-full overflow-hidden object-cover"><img fetchpriority="auto" loading="eager" alt="Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma." class="h-full w-full rounded-t object-cover transition-transform duration-500 group-hover:scale-105 false" src="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080.png?w=350&amp;fit=crop&amp;auto=format"/></div></a><div class="bg-white-100 h-full rounded-b p-5"><div class="flex w-full flex-col gap-1 px-0"><time class="text-typo-light text-sm" dateTime="2026-10-09T18:00:00Z">October 9th, 2026</time><div class="tracking-tight text-typo-dark pb-4 text-lg font-semibold"><a href="/view/ramantamig-achieves-impressive-rates-of-mrd-negativity-in-rrmm" class="hover:underline">Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM</a></div><div class="text-typo mb-4 line-clamp-3 overflow-hidden text-ellipsis text-sm">Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.</div></div></div><div class="flex w-full items-center pb-4 pl-4"><a href="/view/ramantamig-achieves-impressive-rates-of-mrd-negativity-in-rrmm" class="flex items-center gap-2"><span class="text-ellipsis text-balance font-semibold capitalize text-primary group-hover:text-primary">Read more</span><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-5 w-5 text-primary transition-transform group-hover:translate-x-1" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg></a></div></article></div><div role="group" aria-roledescription="slide" class="min-w-0 pl-4 mr-2 flex flex-col first-of-type:pl-4 flex-[0_0_22rem]"><article class="group flex h-full w-full max-w-full flex-col justify-between rounded border-none bg-white/80 p-0 shadow backdrop-blur-sm transition-transform duration-300 md:max-w-sm"><a href="/view/selcodebart-yields-hematologic-responses-in-anemia-from-myelofibrosis"><div style="aspect-ratio:1.1111111111111112" class="relative h-48 w-full overflow-hidden object-cover"><img fetchpriority="auto" loading="eager" alt="In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. " class="h-full w-full rounded-t object-cover transition-transform duration-500 group-hover:scale-105 false" src="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e0fdb5e583b34d13cd4410746060efa4e0b6a96a-7000x6300.jpg?w=350&amp;fit=crop&amp;auto=format"/></div></a><div class="bg-white-100 h-full rounded-b p-5"><div class="flex w-full flex-col gap-1 px-0"><time class="text-typo-light text-sm" dateTime="2026-10-09T17:00:00Z">October 9th, 2026</time><div class="tracking-tight text-typo-dark pb-4 text-lg font-semibold"><a href="/view/selcodebart-yields-hematologic-responses-in-anemia-from-myelofibrosis" class="hover:underline">Selcodebart Yields Hematologic Responses in Anemia From Myelofibrosis</a></div><div class="text-typo mb-4 line-clamp-3 overflow-hidden text-ellipsis text-sm">In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis. </div></div></div><div class="flex w-full items-center pb-4 pl-4"><a href="/view/selcodebart-yields-hematologic-responses-in-anemia-from-myelofibrosis" class="flex items-center gap-2"><span class="text-ellipsis text-balance font-semibold capitalize text-primary group-hover:text-primary">Read more</span><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-5 w-5 text-primary transition-transform group-hover:translate-x-1" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg></a></div></article></div><div role="group" aria-roledescription="slide" class="min-w-0 pl-4 mr-2 flex flex-col first-of-type:pl-4 flex-[0_0_22rem]"><article class="group flex h-full w-full max-w-full flex-col justify-between rounded border-none bg-white/80 p-0 shadow backdrop-blur-sm transition-transform duration-300 md:max-w-sm"><a href="/view/how-do-long-term-maia-and-cepheus-data-reinforce-daratumumab-use-in-ndmm-"><div style="aspect-ratio:1.2939197930142303" class="relative h-48 w-full overflow-hidden object-cover"><img fetchpriority="auto" loading="eager" alt="How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com" class="h-full w-full rounded-t object-cover transition-transform duration-500 group-hover:scale-105 false" src="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d23a730915dd101042071359cc623e55511245dc-5001x3865.jpg?w=350&amp;fit=crop&amp;auto=format"/></div></a><div class="bg-white-100 h-full rounded-b p-5"><div class="flex w-full flex-col gap-1 px-0"><time class="text-typo-light text-sm" dateTime="2026-10-09T16:30:00Z">October 9th, 2026</time><div class="tracking-tight text-typo-dark pb-4 text-lg font-semibold"><a href="/view/how-do-long-term-maia-and-cepheus-data-reinforce-daratumumab-use-in-ndmm-" class="hover:underline">How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?</a></div><div class="text-typo mb-4 line-clamp-3 overflow-hidden text-ellipsis text-sm">Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.</div></div></div><div class="flex w-full items-center pb-4 pl-4"><a href="/view/how-do-long-term-maia-and-cepheus-data-reinforce-daratumumab-use-in-ndmm-" class="flex items-center gap-2"><span class="text-ellipsis text-balance font-semibold capitalize text-primary group-hover:text-primary">Read more</span><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-5 w-5 text-primary transition-transform group-hover:translate-x-1" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg></a></div></article></div><div role="group" aria-roledescription="slide" class="min-w-0 pl-4 mr-2 flex flex-col first-of-type:pl-4 flex-[0_0_22rem]"><article class="group flex h-full w-full max-w-full flex-col justify-between rounded border-none bg-white/80 p-0 shadow backdrop-blur-sm transition-transform duration-300 md:max-w-sm"><a href="/view/adjuvant-radiotherapy-reduced-recurrence-in-resected-atypical-meningioma"><div style="aspect-ratio:1.7777777777777777" class="relative h-48 w-full overflow-hidden object-cover"><img fetchpriority="auto" loading="eager" alt="Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma: © 程 加星 - stock.adobe.com" class="h-full w-full rounded-t object-cover transition-transform duration-500 group-hover:scale-105 false" src="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c12520957948ebfc324e247b1151b3dd28a0420d-5120x2880.jpg?w=350&amp;fit=crop&amp;auto=format"/></div></a><div class="bg-white-100 h-full rounded-b p-5"><div class="flex w-full flex-col gap-1 px-0"><time class="text-typo-light text-sm" dateTime="2026-10-09T16:00:00Z">October 9th, 2026</time><div class="tracking-tight text-typo-dark pb-4 text-lg font-semibold"><a href="/view/adjuvant-radiotherapy-reduced-recurrence-in-resected-atypical-meningioma" class="hover:underline">Adjuvant Radiotherapy Reduced Recurrence in Resected Atypical Meningioma</a></div><div class="text-typo mb-4 line-clamp-3 overflow-hidden text-ellipsis text-sm">Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.</div></div></div><div class="flex w-full items-center pb-4 pl-4"><a href="/view/adjuvant-radiotherapy-reduced-recurrence-in-resected-atypical-meningioma" class="flex items-center gap-2"><span class="text-ellipsis text-balance font-semibold capitalize text-primary group-hover:text-primary">Read more</span><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-5 w-5 text-primary transition-transform group-hover:translate-x-1" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg></a></div></article></div><div role="group" aria-roledescription="slide" class="min-w-0 pl-4 mr-2 flex flex-col first-of-type:pl-4 flex-[0_0_22rem]"><article class="group flex h-full w-full max-w-full flex-col justify-between rounded border-none bg-white/80 p-0 shadow backdrop-blur-sm transition-transform duration-300 md:max-w-sm"><a href="/view/vir-5500-receives-fda-fast-track-designation-for-late-line-metastatic-crpc"><div style="aspect-ratio:1.326" class="relative h-48 w-full overflow-hidden object-cover"><img fetchpriority="auto" loading="eager" alt="Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr Microbe - stock.adobe.com" class="h-full w-full rounded-t object-cover transition-transform duration-500 group-hover:scale-105 false" src="https://cdn.sanity.io/images/0vv8moc6/cancernetwork/330ffaf0cf1c409a14da3ba3004d2e095104d54d-6630x5000.jpg?w=350&amp;fit=crop&amp;auto=format"/></div></a><div class="bg-white-100 h-full rounded-b p-5"><div class="flex w-full flex-col gap-1 px-0"><time class="text-typo-light text-sm" dateTime="2026-10-09T15:00:00Z">October 9th, 2026</time><div class="tracking-tight text-typo-dark pb-4 text-lg font-semibold"><a href="/view/vir-5500-receives-fda-fast-track-designation-for-late-line-metastatic-crpc" class="hover:underline">VIR-5500 Receives FDA Fast Track Designation for Late-Line Metastatic CRPC</a></div><div class="text-typo mb-4 line-clamp-3 overflow-hidden text-ellipsis text-sm">VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.</div></div></div><div class="flex w-full items-center pb-4 pl-4"><a href="/view/vir-5500-receives-fda-fast-track-designation-for-late-line-metastatic-crpc" class="flex items-center gap-2"><span class="text-ellipsis text-balance font-semibold capitalize text-primary group-hover:text-primary">Read more</span><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-5 w-5 text-primary transition-transform group-hover:translate-x-1" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg></a></div></article></div></div></div><div class="flex w-full justify-end gap-0 pr-2"><button class="inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 border border-input bg-background hover:text-accent-foreground w-8 rounded-full h-5 !w-5 border-none p-1 text-primary hover:bg-gray-100" disabled=""><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-4 w-4" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M5 12l6 6"></path><path d="M5 12l6 -6"></path></svg><span class="sr-only">Previous slide</span></button><button class="inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 border border-input bg-background hover:text-accent-foreground w-8 rounded-full h-5 !w-5 border-none pl-0 text-primary hover:bg-gray-100" disabled=""><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" class="h-4 w-4" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M5 12l14 0"></path><path d="M13 18l6 -6"></path><path d="M13 6l6 6"></path></svg><span class="sr-only">Next slide</span></button></div></div></div></section><!--astro:end--></astro-island> </div></div> <div class="hidden w-14 lg:block"><div class="flex flex-col items-center justify-center col-span-12  h-full"> <astro-island uid="Z1kFxM7" component-url="/_astro/index.CkwFUVJq.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[1,[[0,{&quot;url&quot;:[0],&quot;title&quot;:[0,&quot;LinkedIn&quot;]}],[0,{&quot;url&quot;:[0],&quot;title&quot;:[0,&quot;Facebook&quot;]}],[0,{&quot;url&quot;:[0],&quot;title&quot;:[0,&quot;X&quot;]}]]],&quot;isShowPrinter&quot;:[0],&quot;direction&quot;:[0],&quot;position&quot;:[0],&quot;mailTo&quot;:[0],&quot;isShare&quot;:[0,true]}" ssr client="only" opts="{&quot;name&quot;:&quot;SocialShare&quot;,&quot;value&quot;:true}"></astro-island> </div></div> <div class="hidden !w-[300px] flex-col gap-8 lg:flex"> <div class="flex flex-col items-center justify-center col-span-12  "> <astro-island uid="Z1gEs5N" prefix="r88" component-url="/_astro/AD300x250.DpBj1VD8.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[0,null],&quot;networkID&quot;:[0,&quot;4688&quot;],&quot;adUnit&quot;:[0,&quot;cmpm.cancernetwork&quot;],&quot;pos&quot;:[0,&quot;rec1&quot;],&quot;targeting&quot;:[0,{&quot;content_placement&quot;:[1,[[0,&quot;news&quot;],[0,&quot;journals/oncology&quot;]]],&quot;document_url&quot;:[1,[[0,&quot;gerson-regimen&quot;]]],&quot;document_group&quot;:[1,[]],&quot;content_group&quot;:[1,[]],&quot;rootDocumentGroup&quot;:[1,[]],&quot;issue_url&quot;:[1,[[0,&quot;oncology-vol-24-no-2&quot;]]],&quot;publication_url&quot;:[1,[[0,&quot;oncology&quot;]]],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;barrie-r-cassileth-ms-phd&quot;]]],&quot;hostname&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;adLayer&quot;:[0,{&quot;adSlotSelection&quot;:[1,[]]}]}],&quot;hidden&quot;:[0,false]}" ssr client="load" opts="{&quot;name&quot;:&quot;AD300x250&quot;,&quot;value&quot;:true}" await-children><div class="z-50"><div class="hidden text-center text-[8px] text-gray-500">Advertisement</div><div id="div-gpt-ad-rec1" class="" style="width:300px;min-height:250px"></div></div><!--astro:end--></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  "> <astro-island uid="Z1u89OL" prefix="r89" component-url="/_astro/AD300x250.DpBj1VD8.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[0,null],&quot;networkID&quot;:[0,&quot;4688&quot;],&quot;adUnit&quot;:[0,&quot;cmpm.cancernetwork&quot;],&quot;pos&quot;:[0,&quot;rec2&quot;],&quot;hidden&quot;:[0,false],&quot;targeting&quot;:[0,{&quot;content_placement&quot;:[1,[[0,&quot;news&quot;],[0,&quot;journals/oncology&quot;]]],&quot;document_url&quot;:[1,[[0,&quot;gerson-regimen&quot;]]],&quot;document_group&quot;:[1,[]],&quot;content_group&quot;:[1,[]],&quot;rootDocumentGroup&quot;:[1,[]],&quot;issue_url&quot;:[1,[[0,&quot;oncology-vol-24-no-2&quot;]]],&quot;publication_url&quot;:[1,[[0,&quot;oncology&quot;]]],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;barrie-r-cassileth-ms-phd&quot;]]],&quot;hostname&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;adLayer&quot;:[0,{&quot;adSlotSelection&quot;:[1,[]]}]}]}" ssr client="load" opts="{&quot;name&quot;:&quot;AD300x250&quot;,&quot;value&quot;:true}" await-children><div class="z-50"><div class="hidden text-center text-[8px] text-gray-500">Advertisement</div><div id="div-gpt-ad-rec2" class="" style="width:300px;min-height:250px"></div></div><!--astro:end--></astro-island> </div><div class="flex flex-col items-center justify-center col-span-12  sticky top-32"> <div class="w-full my-4"><h2 class="py-2 pr-4 text-lg font-bold tracking-tight text-gray-900">Trending on CancerNetwork</h2><div class="divide-y divide-gray-100"><a href="https://www.cancernetwork.com/view/how-emory-became-the-first-adopter-of-the-liberty-endovascular-robotic-system" class="group flex items-start gap-3 py-3 transition-colors duration-150 hover:bg-gray-50 focus:bg-gray-50 focus:outline-none" aria-label="Read trending article: How Emory Became the First Adopter of the Liberty Endovascular Robotic System"><div class="mt-0.5 flex-shrink-0"><div class="flex h-5 w-5 items-center justify-center rounded-full bg-primary text-xs font-bold text-white transition-transform duration-150 group-hover:scale-105">1</div></div><div class="min-w-0 flex-1"><h3 class="text-sm font-medium leading-relaxed text-gray-900 transition-colors duration-150 group-hover:text-gray-700">How Emory Became the First Adopter of the Liberty Endovascular Robotic System</h3></div></a><a href="https://www.cancernetwork.com/view/building-out-a-radiopharmaceuticals-program-in-oncology-care" class="group flex items-start gap-3 py-3 transition-colors duration-150 hover:bg-gray-50 focus:bg-gray-50 focus:outline-none" aria-label="Read trending article: Building out a Radiopharmaceuticals Program in Oncology Care"><div class="mt-0.5 flex-shrink-0"><div class="flex h-5 w-5 items-center justify-center rounded-full bg-primary text-xs font-bold text-white transition-transform duration-150 group-hover:scale-105">2</div></div><div class="min-w-0 flex-1"><h3 class="text-sm font-medium leading-relaxed text-gray-900 transition-colors duration-150 group-hover:text-gray-700">Building out a Radiopharmaceuticals Program in Oncology Care</h3></div></a><a href="https://www.cancernetwork.com/view/fda-approves-atezolizumab-chemo-for-stage-iii-dmmr-msi-h-colon-cancer" class="group flex items-start gap-3 py-3 transition-colors duration-150 hover:bg-gray-50 focus:bg-gray-50 focus:outline-none" aria-label="Read trending article: FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer"><div class="mt-0.5 flex-shrink-0"><div class="flex h-5 w-5 items-center justify-center rounded-full bg-primary text-xs font-bold text-white transition-transform duration-150 group-hover:scale-105">3</div></div><div class="min-w-0 flex-1"><h3 class="text-sm font-medium leading-relaxed text-gray-900 transition-colors duration-150 group-hover:text-gray-700">FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer</h3></div></a><a href="https://www.cancernetwork.com/view/rinatabart-sesutecan-elicits-responses-in-proc-regardless-of-fr-expression" class="group flex items-start gap-3 py-3 transition-colors duration-150 hover:bg-gray-50 focus:bg-gray-50 focus:outline-none" aria-label="Read trending article: Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression"><div class="mt-0.5 flex-shrink-0"><div class="flex h-5 w-5 items-center justify-center rounded-full bg-primary text-xs font-bold text-white transition-transform duration-150 group-hover:scale-105">4</div></div><div class="min-w-0 flex-1"><h3 class="text-sm font-medium leading-relaxed text-gray-900 transition-colors duration-150 group-hover:text-gray-700">Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression</h3></div></a><a href="https://www.cancernetwork.com/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization" class="group flex items-start gap-3 py-3 transition-colors duration-150 hover:bg-gray-50 focus:bg-gray-50 focus:outline-none" aria-label="Read trending article: Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization "><div class="mt-0.5 flex-shrink-0"><div class="flex h-5 w-5 items-center justify-center rounded-full bg-primary text-xs font-bold text-white transition-transform duration-150 group-hover:scale-105">5</div></div><div class="min-w-0 flex-1"><h3 class="text-sm font-medium leading-relaxed text-gray-900 transition-colors duration-150 group-hover:text-gray-700">Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization </h3></div></a></div></div> </div> </div> </div> </div> </main> </div> </div> <astro-island uid="Z14pCB1" prefix="r70" component-url="/_astro/ui.3g1jLusn.js" component-export="Footer1" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;data&quot;:[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-21T05:32:50Z&quot;],&quot;_id&quot;:[0,&quot;siteSettings&quot;],&quot;_rev&quot;:[0,&quot;4hScsMJksV8DfWCIi5xR9D&quot;],&quot;_system&quot;:[0,{&quot;base&quot;:[0,{&quot;id&quot;:[0,&quot;siteSettings&quot;],&quot;rev&quot;:[0,&quot;MwLKLXcGME1e2SHZC28FAQ&quot;]}]}],&quot;_type&quot;:[0,&quot;siteSettings&quot;],&quot;_updatedAt&quot;:[0,&quot;2026-09-01T16:39:56Z&quot;],&quot;address&quot;:[0,{&quot;addressCountry&quot;:[0,&quot;United States of America&quot;],&quot;addressLocality&quot;:[0,&quot;Monroe&quot;],&quot;addressRegion&quot;:[0,&quot;New Jersey&quot;],&quot;postalCode&quot;:[0,&quot;08831&quot;],&quot;streetAddress&quot;:[0,&quot;259 Prospect Plains Rd, Bldg H&quot;]}],&quot;alternateName&quot;:[0,&quot;Cancer Network&quot;],&quot;contactPoint&quot;:[0,{&quot;email&quot;:[0,&quot;MJHINFO@mjhlifesciences.com&quot;],&quot;telephone&quot;:[0,&quot;609-716-7777&quot;]}],&quot;creativeLayout&quot;:[0,null],&quot;creativeLayoutLatestNews&quot;:[0,null],&quot;description&quot;:[0,&quot;CancerNetwork is home to the journal Oncology &amp; provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.&quot;],&quot;employees&quot;:[1,[[0,&quot;Silas Inman&quot;],[0,&quot;Kristie Kahl&quot;],[0,&quot;Gina Mauro&quot;]]],&quot;footerLinks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;8bd16c9bde67&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;About&quot;],&quot;url&quot;:[0,&quot;/about&quot;]}],[0,{&quot;_key&quot;:[0,&quot;ea0dfb860a3f&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Advertise&quot;],&quot;url&quot;:[0,&quot;/advertise&quot;]}],[0,{&quot;_key&quot;:[0,&quot;469bf68ad414&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;CureToday.com&quot;],&quot;url&quot;:[0,&quot;https://www.curetoday.com&quot;]}],[0,{&quot;_key&quot;:[0,&quot;84af95169a2e&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;OncLive.com&quot;],&quot;url&quot;:[0,&quot;https://www.onclive.com&quot;]}],[0,{&quot;_key&quot;:[0,&quot;6020c55d604e&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;OncNursingNews.com&quot;],&quot;url&quot;:[0,&quot;https://www.oncnursingnews.com/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;875b21c82b0f&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;TargetedOnc.com&quot;],&quot;url&quot;:[0,&quot;https://www.targetedonc.com/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;f96b785e0728&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Editorial&quot;],&quot;url&quot;:[0,&quot;/oncology-journal/about-editors/editorial-board&quot;]}],[0,{&quot;_key&quot;:[0,&quot;3231ba8a0915&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Contact&quot;],&quot;url&quot;:[0,&quot;https://www.cancernetwork.com/contact-us&quot;]}],[0,{&quot;_key&quot;:[0,&quot;ea912af38c6b&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Terms and Conditions&quot;],&quot;url&quot;:[0,&quot;/terms&quot;]}],[0,{&quot;_key&quot;:[0,&quot;fb5ad6bdf90e&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Privacy&quot;],&quot;url&quot;:[0,&quot;/privacy&quot;]}],[0,{&quot;_key&quot;:[0,&quot;b18a84a0197e&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;title&quot;:[0,&quot;Do Not Sell My Personal Information&quot;],&quot;url&quot;:[0,&quot;https://www.mjhlifesciences.com/ccpa?domain=www.cancernetwork.com&quot;]}]]],&quot;founder&quot;:[0,&quot;MJH Life Sciences&quot;],&quot;foundingDate&quot;:[0,&quot;1998-12-06&quot;],&quot;gaID&quot;:[0,&quot;UA-630614-16,UA-155582410-3&quot;],&quot;iconUrl&quot;:[0,&quot;https://www.cancernetwork.com/pubmedOncologyText.png&quot;],&quot;idLayerSchema&quot;:[0,{&quot;active&quot;:[0,true],&quot;fields&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;p1&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;32a5b498-2d9d-414c-96f0-fbfaca8620f8&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p2&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;18a93476-c49b-42f9-9b04-0f1ff76521c8&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p3&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;2c2aeff6-2e51-402c-8669-592c1ced14f7&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p4&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;0e0f9cfc-d576-481c-bf80-edf53e8adf79&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p5&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;d70cd5df-6b30-4509-a16a-b7401bd5d6e6&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p6&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;40853432-71f1-4558-82ca-2d8753add7b7&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p7&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;e9467504-2b98-42ad-9872-a4674f4014da&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p8&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;91d6accd-dad2-4b70-bf40-548278d9eca0&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;]}],[0,{&quot;_key&quot;:[0,&quot;p9&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;de1eb7be-22f0-417e-8b0b-5c5b40de0d6d&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;]}]]]}],&quot;name&quot;:[0],&quot;orangizationName&quot;:[0,&quot;CancerNetwork&quot;],&quot;printMagazineConfig&quot;:[0,{&quot;enabled&quot;:[0,true],&quot;publications&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;86c7e68f767d&quot;],&quot;name&quot;:[0,&quot;Oncology® Magazine&quot;],&quot;publicationId&quot;:[0,&quot;55&quot;]}]]]}],&quot;profilePageConfig&quot;:[0,{&quot;active&quot;:[0,true],&quot;profileTab&quot;:[0,{&quot;content&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;f1&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;32a5b498-2d9d-414c-96f0-fbfaca8620f8&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f2&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;18a93476-c49b-42f9-9b04-0f1ff76521c8&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f3&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;2c2aeff6-2e51-402c-8669-592c1ced14f7&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f4&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;0e0f9cfc-d576-481c-bf80-edf53e8adf79&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f5&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;d70cd5df-6b30-4509-a16a-b7401bd5d6e6&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f6&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;40853432-71f1-4558-82ca-2d8753add7b7&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f7&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;e9467504-2b98-42ad-9872-a4674f4014da&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f8&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceBrandSpecific&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;91d6accd-dad2-4b70-bf40-548278d9eca0&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}],[0,{&quot;_key&quot;:[0,&quot;f9&quot;],&quot;_type&quot;:[0,&quot;profileField&quot;],&quot;fieldReferenceCommon&quot;:[0,{&quot;_dataset&quot;:[0,&quot;id-layer&quot;],&quot;_projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;_ref&quot;:[0,&quot;de1eb7be-22f0-417e-8b0b-5c5b40de0d6d&quot;],&quot;_type&quot;:[0,&quot;crossDatasetReference&quot;]}],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;fullWidth&quot;:[0,false],&quot;required&quot;:[0,false]}]]]}]}],&quot;salesforceDMPId&quot;:[0,&quot;upniwmm0d&quot;],&quot;siteURL&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;socialLinks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;cf1a4e4539f3&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;Facebook&quot;],&quot;url&quot;:[0,&quot;https://www.facebook.com/Cancer-Network-124530046330/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;322cbf854512&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;LinkedIn&quot;],&quot;url&quot;:[0,&quot;https://www.linkedin.com/company/cancer-network/&quot;]}],[0,{&quot;_key&quot;:[0,&quot;95a8c955ea12&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;X&quot;],&quot;url&quot;:[0,&quot;https://twitter.com/CancerNetwrk&quot;]}],[0,{&quot;_key&quot;:[0,&quot;3616df2f3815&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;RSS&quot;],&quot;url&quot;:[0,&quot;/rss.xml&quot;]}],[0,{&quot;_key&quot;:[0,&quot;1c8fcd4705db&quot;],&quot;_type&quot;:[0,&quot;urlArray&quot;],&quot;blank&quot;:[0,true],&quot;title&quot;:[0,&quot;Youtube&quot;],&quot;url&quot;:[0,&quot;https://www.youtube.com/@CancerNetwork&quot;]}]]],&quot;brandLogo&quot;:[0,&quot;/an_mjhls_brand_ko.webp&quot;],&quot;secondaryBrandLogo&quot;:[0],&quot;imageLinks&quot;:[1,[[0,{&quot;altText&quot;:[0,&quot;Alt Text&quot;],&quot;imageSrc&quot;:[0],&quot;url&quot;:[0,&quot;/&quot;]}],[0,{&quot;altText&quot;:[0,&quot;Alt Text&quot;],&quot;imageSrc&quot;:[0],&quot;url&quot;:[0,&quot;www.google.com&quot;],&quot;targetBlank&quot;:[0,true],&quot;absolutePath&quot;:[0,true]}]]]}],&quot;subFooterLinks&quot;:[1,[[0,{&quot;url&quot;:[0,&quot;/&quot;],&quot;title&quot;:[0,&quot;Home&quot;]}],[0,{&quot;url&quot;:[0,&quot;/about&quot;],&quot;title&quot;:[0,&quot;About Us&quot;]}],[0,{&quot;url&quot;:[0,&quot;/news&quot;],&quot;title&quot;:[0,&quot;News&quot;]}],[0,{&quot;url&quot;:[0,&quot;/contact-us&quot;],&quot;title&quot;:[0,&quot;Contact Us&quot;]}]]],&quot;partnerLogos&quot;:[1,[]],&quot;settings&quot;:[0,{&quot;siteConfig&quot;:[0,{&quot;sanityClientConfig&quot;:[0,{&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;useCdn&quot;:[0,true]}],&quot;gtmID&quot;:[0,&quot;5KJPVFH&quot;],&quot;title&quot;:[0,&quot;CancerNetwork&quot;],&quot;attentiveLanguageBrandName&quot;:[0,&quot;Cancer Network&quot;],&quot;liveDomain&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;logo&quot;:[0,&quot;/logo.webp&quot;],&quot;white_logo&quot;:[0,&quot;/logo.webp&quot;],&quot;megaMenuTaxName&quot;:[0,&quot;clinical&quot;],&quot;twitter&quot;:[0,&quot;@onclive&quot;],&quot;sharingImageUrl&quot;:[0,&quot;https://cancernetwork.s3.amazonaws.com/cancernetwork-primary-10-15.png&quot;],&quot;fixSecondaryNavigationLinksIdentifier&quot;:[0,true],&quot;oneTrustId&quot;:[0,&quot;0196a059-28cb-71f3-a7fc-4659bcc6ca6d&quot;],&quot;subFooterLinks&quot;:[1,[[0,{&quot;url&quot;:[0,&quot;/&quot;],&quot;title&quot;:[0,&quot;Home&quot;]}],[0,{&quot;url&quot;:[0,&quot;/about&quot;],&quot;title&quot;:[0,&quot;About Us&quot;]}],[0,{&quot;url&quot;:[0,&quot;/news&quot;],&quot;title&quot;:[0,&quot;News&quot;]}],[0,{&quot;url&quot;:[0,&quot;/contact-us&quot;],&quot;title&quot;:[0,&quot;Contact Us&quot;]}]]],&quot;subscribe&quot;:[0,{&quot;href&quot;:[0,&quot;/subscribe&quot;],&quot;text&quot;:[0,&quot;Stay up to date on recent advances in the multidisciplinary approach to cancer.&quot;]}],&quot;customSpecialtyText&quot;:[0,&quot;Cancer Focus&quot;]}],&quot;styleConfig&quot;:[0,{&quot;logoSize&quot;:[0,&quot;medium&quot;],&quot;navigation&quot;:[0,5],&quot;footer&quot;:[0,1],&quot;featureDeck&quot;:[0,5],&quot;featureSlider&quot;:[0,1]}],&quot;adConfig&quot;:[0,{&quot;networkID&quot;:[0,&quot;4688&quot;],&quot;adUnit&quot;:[0,&quot;cmpm.cancernetwork&quot;]}],&quot;pageConfig&quot;:[0,{&quot;publicationName&quot;:[0,&quot;CancerNetwork&quot;],&quot;publicationUrl&quot;:[0,&quot;journals&quot;],&quot;authorUrl&quot;:[0,&quot;authors&quot;]}],&quot;sanityConfig&quot;:[0,{&quot;taxonomy&quot;:[0,{&quot;news&quot;:[0,&quot;cn_taxonomy_5565_news&quot;],&quot;conference&quot;:[0,&quot;f37ff7cb-bf12-45d7-aa1d-508e79d3b99f&quot;],&quot;clinical&quot;:[0,&quot;d4c0d7f9-f28d-423f-8bdc-0b7e0d1333d9&quot;]}],&quot;docGroup&quot;:[0,{&quot;conference&quot;:[0,&quot;cn_documentGroup_53204_conference&quot;]}],&quot;contentCategory&quot;:[0,{&quot;articles&quot;:[0,&quot;8bdaa7fc-960a-4b57-b076-75fdce3741bb&quot;],&quot;sponsored&quot;:[0,&quot;f62337b2-e8ae-4a6a-beb6-c93553984c92&quot;],&quot;videos&quot;:[0,&quot;42000fd0-0d05-4832-9f2c-62c21079b76c&quot;],&quot;podcasts&quot;:[0,&quot;93d57b69-2d72-45fe-8b8a-d18e7e7e5f20&quot;],&quot;poll&quot;:[0,&quot;9e4880fc-85b8-4ffb-a066-79af8dfaa4e1&quot;],&quot;hero&quot;:[0,&quot;2504da4c-b21a-465e-88ba-3841a00c0395&quot;],&quot;slideshows&quot;:[0,&quot;61085300-0cae-4cd1-b0e8-26323ac5c2e6&quot;]}]}],&quot;customPageTypes&quot;:[1,[]],&quot;gateEnabled&quot;:[0,&quot;modal&quot;],&quot;sMaxAge&quot;:[0,300],&quot;staleWhileRevalidate&quot;:[0,329],&quot;allowedDomains&quot;:[1,[[0,&quot;ce.dvm360.com&quot;],[0,&quot;www.pharmacytimes.org&quot;],[0,&quot;www.gotoper.com&quot;]]]}]}" ssr client="load" opts="{&quot;name&quot;:&quot;Footer1&quot;,&quot;value&quot;:true}" await-children><footer id="footer"><div id="" class="w-full bg-footer-primary"><div class=" mx-auto w-full max-w-[1480px] px-4 md:px-6"><div class="flex flex-col py-8 xl:flex-row xl:items-center"><ul class="mx-auto text-center xl:m-0 xl:w-[55%] xl:columns-3 xl:text-left"><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="/about">About</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="/advertise">Advertise</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="https://www.curetoday.com">CureToday.com</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="https://www.onclive.com">OncLive.com</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="https://www.oncnursingnews.com/">OncNursingNews.com</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="https://www.targetedonc.com/">TargetedOnc.com</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="/oncology-journal/about-editors/editorial-board">Editorial</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="https://www.cancernetwork.com/contact-us">Contact</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="/terms">Terms and Conditions</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="/privacy">Privacy</a></li><li class="text-md text-footer-primary-foreground hover:text-footer-primary-foreground/80 hover:underline"><a href="https://www.mjhlifesciences.com/ccpa?domain=www.cancernetwork.com">Do Not Sell My Personal Information</a></li><li><button id="ot-sdk-btn" class="ot-sdk-show-settings !hover:text-footer-primary-foreground/80 !hover:underline !bg-transparent !p-0 !text-base !text-footer-primary-foreground">Your Privacy Choices</button></li></ul><div class="my-4 flex w-full flex-col items-center border-b-1 border-t-1 border-accent py-3 pl-0 xl:w-[25%] xl:items-start xl:border-b-0 xl:border-l-1 xl:border-r-1 xl:border-t-0 xl:pl-8"><div class="pb-2 pl-11 text-xl text-footer-primary-foreground">Contact Info</div><div class="my-3 py-2 xl:my-0 xl:py-0"><div class="mb-5 flex flex-row gap-4"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" class="fill-accent" height="28" width="28" xmlns="http://www.w3.org/2000/svg"><path d="M18.364 4.636a9 9 0 0 1 .203 12.519l-.203 .21l-4.243 4.242a3 3 0 0 1 -4.097 .135l-.144 -.135l-4.244 -4.243a9 9 0 0 1 12.728 -12.728zm-6.364 3.364a3 3 0 1 0 0 6a3 3 0 0 0 0 -6z"></path></svg><p class="text-left text-sm text-footer-primary-foreground">259 Prospect Plains Rd, Bldg H<br/> <!-- -->Cranbury, NJ 08512</p></div></div><div class=""></div></div><div class="mx-auto flex flex-col"><div class="mx-2 flex flex-col space-y-6"><img class="mb-0 ml-2 block h-8" src="/an_mjhls_brand_ko.webp" alt="Brand Logo"/></div><div class="mx-auto mt-4 flex flex-row gap-2"><a target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/Cancer-Network-124530046330/"><svg role="img" aria-label="facebook social icon" viewBox="0 0 64 64" class="relative rounded-full w-8 h-8"><g class="fill-primary"><path d="M0,0H64V64H0ZM0 0v64h64V0zm39.6 22h-2.8c-2.2 0-2.6 1.1-2.6 2.6V28h5.3l-.7 5.3h-4.6V47h-5.5V33.3H24V28h4.6v-4c0-4.6 2.8-7 6.9-7 2 0 3.6.1 4.1.2z"></path></g><g class="fill-white"><path d="M0 0v64h64V0zm39.6 22h-2.8c-2.2 0-2.6 1.1-2.6 2.6V28h5.3l-.7 5.3h-4.6V47h-5.5V33.3H24V28h4.6v-4c0-4.6 2.8-7 6.9-7 2 0 3.6.1 4.1.2z"></path></g></svg></a><a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/company/cancer-network/"><svg role="img" aria-label="linkedin social icon" viewBox="0 0 64 64" class="relative rounded-full w-8 h-8"><g class="fill-primary"><path d="M0,0H64V64H0ZM0 0v64h64V0zm25.8 44h-5.4V26.6h5.4zm-2.7-19.7c-1.7 0-3.1-1.4-3.1-3.1s1.4-3.1 3.1-3.1 3.1 1.4 3.1 3.1-1.4 3.1-3.1 3.1M46 44h-5.4v-8.4c0-2 0-4.6-2.8-4.6s-3.2 2.2-3.2 4.5V44h-5.4V26.6h5.2V29h.1c.7-1.4 2.5-2.8 5.1-2.8 5.5 0 6.5 3.6 6.5 8.3V44z"></path></g><g class="fill-white"><path d="M0 0v64h64V0zm25.8 44h-5.4V26.6h5.4zm-2.7-19.7c-1.7 0-3.1-1.4-3.1-3.1s1.4-3.1 3.1-3.1 3.1 1.4 3.1 3.1-1.4 3.1-3.1 3.1M46 44h-5.4v-8.4c0-2 0-4.6-2.8-4.6s-3.2 2.2-3.2 4.5V44h-5.4V26.6h5.2V29h.1c.7-1.4 2.5-2.8 5.1-2.8 5.5 0 6.5 3.6 6.5 8.3V44z"></path></g></svg></a><a target="_blank" rel="noopener noreferrer" href="https://twitter.com/CancerNetwrk"><svg role="img" aria-label="x social icon" viewBox="0 0 64 64" class="relative rounded-full w-8 h-8"><g class="fill-primary"><path d="M0,0H64V64H0ZM0 0v64h64V0zm16 17.537h10.125l6.992 9.242 8.084-9.242h4.908L35.39 29.79 48 46.463h-9.875l-7.734-10.111-8.85 10.11h-4.908l11.465-13.105zm5.73 2.783 17.75 23.205h2.72L24.647 20.32z"></path></g><g class="fill-white"><path d="M0 0v64h64V0zm16 17.537h10.125l6.992 9.242 8.084-9.242h4.908L35.39 29.79 48 46.463h-9.875l-7.734-10.111-8.85 10.11h-4.908l11.465-13.105zm5.73 2.783 17.75 23.205h2.72L24.647 20.32z"></path></g></svg></a><a target="_blank" rel="noopener noreferrer" href="/rss.xml"><svg role="img" aria-label="rss social icon" viewBox="0 0 64 64" class="relative rounded-full w-8 h-8"><g class="fill-primary"><path d="M0,0H64V64H0ZM0 0v64h64V0zm24 44c-2.2 0-4-1.8-4-4s1.8-4 4-4 4 1.8 4 4-1.8 4-4 4m11-1c-1.1 0-2-.9-2-2 0-5.5-4.5-10-10-10-1.1 0-2-.9-2-2s.9-2 2-2c7.7 0 14 6.3 14 14 0 1.1-.9 2-2 2m9 0c-1.1 0-2-.9-2-2 0-10.5-8.5-19-19-19-1.1 0-2-.9-2-2s.9-2 2-2c12.7 0 23 10.3 23 23 0 1.1-.9 2-2 2"></path></g><g class="fill-white"><path d="M0 0v64h64V0zm24 44c-2.2 0-4-1.8-4-4s1.8-4 4-4 4 1.8 4 4-1.8 4-4 4m11-1c-1.1 0-2-.9-2-2 0-5.5-4.5-10-10-10-1.1 0-2-.9-2-2s.9-2 2-2c7.7 0 14 6.3 14 14 0 1.1-.9 2-2 2m9 0c-1.1 0-2-.9-2-2 0-10.5-8.5-19-19-19-1.1 0-2-.9-2-2s.9-2 2-2c12.7 0 23 10.3 23 23 0 1.1-.9 2-2 2"></path></g></svg></a><a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@CancerNetwork"><svg role="img" aria-label="youtube social icon" viewBox="0 0 64 64" class="relative rounded-full w-8 h-8"><g class="fill-primary"><path d="M0,0H64V64H0ZM0 0v64h64V0zm47 33.1c0 2.4-.3 4.9-.3 4.9s-.3 2.1-1.2 3c-1.1 1.2-2.4 1.2-3 1.3-4.2.2-10.5.3-10.5.3s-7.8-.1-10.2-.3c-.7-.1-2.2-.1-3.3-1.3-.9-.9-1.2-3-1.2-3s-.3-2.4-.3-4.9v-2.3c0-2.4.3-4.9.3-4.9s.3-2.1 1.2-3c1.1-1.2 2.4-1.2 3-1.3 4.2-.3 10.5-.3 10.5-.3s6.3 0 10.5.3c.6.1 1.9.1 3 1.3.9.9 1.2 3 1.2 3s.3 2.4.3 4.9zm-18.1 2.8 8.1-4.2-8.1-4.2z"></path></g><g class="fill-white"><path d="M0 0v64h64V0zm47 33.1c0 2.4-.3 4.9-.3 4.9s-.3 2.1-1.2 3c-1.1 1.2-2.4 1.2-3 1.3-4.2.2-10.5.3-10.5.3s-7.8-.1-10.2-.3c-.7-.1-2.2-.1-3.3-1.3-.9-.9-1.2-3-1.2-3s-.3-2.4-.3-4.9v-2.3c0-2.4.3-4.9.3-4.9s.3-2.1 1.2-3c1.1-1.2 2.4-1.2 3-1.3 4.2-.3 10.5-.3 10.5-.3s6.3 0 10.5.3c.6.1 1.9.1 3 1.3.9.9 1.2 3 1.2 3s.3 2.4.3 4.9zm-18.1 2.8 8.1-4.2-8.1-4.2z"></path></g></svg></a></div></div></div></div></div><div id="" class="w-full bg-footer-secondary py-7 text-sm font-bold"><div class=" mx-auto w-full max-w-[1480px] px-4 md:px-6"><div class="flex flex-col xl:flex-row xl:items-center"><div class="text-footer-secondary-foreground xl:mb-0"><p class="mb-2">© 2026 MJH Life Sciences<sup>®</sup><span class="xl:hidden"></span></p><p>All rights reserved.</p></div><div class="flex-column mx-auto flex gap-6 xl:mx-0 xl:ml-auto"><div class="text-footer-secondary-foreground w-max cursor-pointer p-1 pt-0 hover:text-primary/80 hover:underline"><a class="text-sm" href="/">Home</a></div><div class="text-footer-secondary-foreground w-max cursor-pointer p-1 pt-0 hover:text-primary/80 hover:underline"><a class="text-sm" href="/about">About Us</a></div><div class="text-footer-secondary-foreground w-max cursor-pointer p-1 pt-0 hover:text-primary/80 hover:underline"><a class="text-sm" href="/news">News</a></div><div class="text-footer-secondary-foreground w-max cursor-pointer p-1 pt-0 hover:text-primary/80 hover:underline"><a class="text-sm" href="/contact-us">Contact Us</a></div></div></div></div></div></footer><!--astro:end--></astro-island>   </div><astro-island uid="UD1x" prefix="r2" component-url="/_astro/islands.QStbZxvE.js" component-export="ScrollDepthTracker" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;slot&quot;:[0,&quot;article-recs&quot;],&quot;surface&quot;:[0,&quot;article&quot;],&quot;contentId&quot;:[0,&quot;cn_article_374309&quot;],&quot;rootSelector&quot;:[0,&quot;[data-scroll-depth-region=&#39;article-body&#39;]&quot;],&quot;clientConfig&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;],&quot;storageNamespace&quot;:[0,&quot;cancernetwork&quot;],&quot;cookies&quot;:[0,{&quot;prefs&quot;:[0,&quot;cancernetwork_prefs&quot;],&quot;cognitoId&quot;:[0,&quot;cancernetwork_cognito_id&quot;]}],&quot;prefsEventName&quot;:[0,&quot;cancernetwork:personalization-prefs&quot;],&quot;endpoint&quot;:[0],&quot;idlayer&quot;:[0,{&quot;brand&quot;:[0,&quot;cancernetwork.com&quot;]}],&quot;engagement&quot;:[0,{&quot;segmentDualWrite&quot;:[0,true]}],&quot;taxonomyQuery&quot;:[0,{&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;parentGroup&quot;:[0,&quot;clinical&quot;]}],&quot;experiment&quot;:[0,{&quot;enabled&quot;:[0,true],&quot;salt&quot;:[0,&quot;dv6834-cancernetwork-homepage-v1&quot;]}]}]}" ssr client="idle" opts="{&quot;name&quot;:&quot;ScrollDepthTracker&quot;,&quot;value&quot;:true}"></astro-island><astro-island uid="Z1u4rii" prefix="r3" component-url="/_astro/islands.QStbZxvE.js" component-export="ResumeReading" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;slot&quot;:[0,&quot;article-recs&quot;],&quot;rootSelector&quot;:[0,&quot;[data-scroll-depth-region=&#39;article-body&#39;]&quot;]}" ssr client="idle" opts="{&quot;name&quot;:&quot;ResumeReading&quot;,&quot;value&quot;:true}"></astro-island> <astro-island uid="2ohYHs" prefix="r9" component-url="/_astro/InitLoadSignals.CfSEZBip.js" component-export="default" renderer-url="/_astro/client.BR7zMcor.js" props="{}" ssr client="load" opts="{&quot;name&quot;:&quot;InitLoadSignals&quot;,&quot;value&quot;:true}"></astro-island> <astro-island uid="9HG5N" prefix="r10" component-url="/_astro/ui.3g1jLusn.js" component-export="Analytics" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;targeting&quot;:[0,{&quot;content_placement&quot;:[1,[[0,&quot;news&quot;],[0,&quot;journals/oncology&quot;]]],&quot;document_url&quot;:[1,[[0,&quot;gerson-regimen&quot;]]],&quot;document_group&quot;:[1,[]],&quot;content_group&quot;:[1,[]],&quot;rootDocumentGroup&quot;:[1,[]],&quot;issue_url&quot;:[1,[[0,&quot;oncology-vol-24-no-2&quot;]]],&quot;publication_url&quot;:[1,[[0,&quot;oncology&quot;]]],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;barrie-r-cassileth-ms-phd&quot;]]],&quot;hostname&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;adLayer&quot;:[0,{&quot;adSlotSelection&quot;:[1,[]]}]}],&quot;settings&quot;:[0,{&quot;siteConfig&quot;:[0,{&quot;sanityClientConfig&quot;:[0,{&quot;dataset&quot;:[0,&quot;cancernetwork&quot;],&quot;projectId&quot;:[0,&quot;0vv8moc6&quot;],&quot;useCdn&quot;:[0,true]}],&quot;gtmID&quot;:[0,&quot;5KJPVFH&quot;],&quot;title&quot;:[0,&quot;CancerNetwork&quot;],&quot;attentiveLanguageBrandName&quot;:[0,&quot;Cancer Network&quot;],&quot;liveDomain&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;logo&quot;:[0,&quot;/logo.webp&quot;],&quot;white_logo&quot;:[0,&quot;/logo.webp&quot;],&quot;megaMenuTaxName&quot;:[0,&quot;clinical&quot;],&quot;twitter&quot;:[0,&quot;@onclive&quot;],&quot;sharingImageUrl&quot;:[0,&quot;https://cancernetwork.s3.amazonaws.com/cancernetwork-primary-10-15.png&quot;],&quot;fixSecondaryNavigationLinksIdentifier&quot;:[0,true],&quot;oneTrustId&quot;:[0,&quot;0196a059-28cb-71f3-a7fc-4659bcc6ca6d&quot;],&quot;subFooterLinks&quot;:[1,[[0,{&quot;url&quot;:[0,&quot;/&quot;],&quot;title&quot;:[0,&quot;Home&quot;]}],[0,{&quot;url&quot;:[0,&quot;/about&quot;],&quot;title&quot;:[0,&quot;About Us&quot;]}],[0,{&quot;url&quot;:[0,&quot;/news&quot;],&quot;title&quot;:[0,&quot;News&quot;]}],[0,{&quot;url&quot;:[0,&quot;/contact-us&quot;],&quot;title&quot;:[0,&quot;Contact Us&quot;]}]]],&quot;subscribe&quot;:[0,{&quot;href&quot;:[0,&quot;/subscribe&quot;],&quot;text&quot;:[0,&quot;Stay up to date on recent advances in the multidisciplinary approach to cancer.&quot;]}],&quot;customSpecialtyText&quot;:[0,&quot;Cancer Focus&quot;]}],&quot;styleConfig&quot;:[0,{&quot;logoSize&quot;:[0,&quot;medium&quot;],&quot;navigation&quot;:[0,5],&quot;footer&quot;:[0,1],&quot;featureDeck&quot;:[0,5],&quot;featureSlider&quot;:[0,1]}],&quot;adConfig&quot;:[0,{&quot;networkID&quot;:[0,&quot;4688&quot;],&quot;adUnit&quot;:[0,&quot;cmpm.cancernetwork&quot;]}],&quot;pageConfig&quot;:[0,{&quot;publicationName&quot;:[0,&quot;CancerNetwork&quot;],&quot;publicationUrl&quot;:[0,&quot;journals&quot;],&quot;authorUrl&quot;:[0,&quot;authors&quot;]}],&quot;sanityConfig&quot;:[0,{&quot;taxonomy&quot;:[0,{&quot;news&quot;:[0,&quot;cn_taxonomy_5565_news&quot;],&quot;conference&quot;:[0,&quot;f37ff7cb-bf12-45d7-aa1d-508e79d3b99f&quot;],&quot;clinical&quot;:[0,&quot;d4c0d7f9-f28d-423f-8bdc-0b7e0d1333d9&quot;]}],&quot;docGroup&quot;:[0,{&quot;conference&quot;:[0,&quot;cn_documentGroup_53204_conference&quot;]}],&quot;contentCategory&quot;:[0,{&quot;articles&quot;:[0,&quot;8bdaa7fc-960a-4b57-b076-75fdce3741bb&quot;],&quot;sponsored&quot;:[0,&quot;f62337b2-e8ae-4a6a-beb6-c93553984c92&quot;],&quot;videos&quot;:[0,&quot;42000fd0-0d05-4832-9f2c-62c21079b76c&quot;],&quot;podcasts&quot;:[0,&quot;93d57b69-2d72-45fe-8b8a-d18e7e7e5f20&quot;],&quot;poll&quot;:[0,&quot;9e4880fc-85b8-4ffb-a066-79af8dfaa4e1&quot;],&quot;hero&quot;:[0,&quot;2504da4c-b21a-465e-88ba-3841a00c0395&quot;],&quot;slideshows&quot;:[0,&quot;61085300-0cae-4cd1-b0e8-26323ac5c2e6&quot;]}]}],&quot;customPageTypes&quot;:[1,[]],&quot;gateEnabled&quot;:[0,&quot;modal&quot;],&quot;sMaxAge&quot;:[0,300],&quot;staleWhileRevalidate&quot;:[0,329],&quot;allowedDomains&quot;:[1,[[0,&quot;ce.dvm360.com&quot;],[0,&quot;www.pharmacytimes.org&quot;],[0,&quot;www.gotoper.com&quot;]]]}],&quot;seoData&quot;:[0,{&quot;title&quot;:[0,&quot;Gerson Regimen | CancerNetwork&quot;],&quot;description&quot;:[0,&quot;Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.&quot;],&quot;noindex&quot;:[0,false],&quot;nofollow&quot;:[0,false],&quot;image&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png&quot;],&quot;twitter&quot;:[0,&quot;@onclive&quot;],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;Barrie R. Cassileth, MS, PhD&quot;]]],&quot;publishedTime&quot;:[0,&quot;2010-02-09T05:00:00.000Z&quot;],&quot;modifiedTime&quot;:[0,&quot;2020-11-11T15:58:47.000Z&quot;],&quot;canonicalUrl&quot;:[0,&quot;&quot;],&quot;videoData&quot;:[0,null],&quot;breadcrumbSchema&quot;:[0,{&quot;@context&quot;:[0,&quot;https://schema.org&quot;],&quot;@type&quot;:[0,&quot;BreadcrumbList&quot;],&quot;itemListElement&quot;:[1,[[0,{&quot;@type&quot;:[0,&quot;ListItem&quot;],&quot;position&quot;:[0,1],&quot;name&quot;:[0,&quot;Home&quot;],&quot;item&quot;:[0,&quot;https://www.cancernetwork.com/&quot;]}],[0,{&quot;@type&quot;:[0,&quot;ListItem&quot;],&quot;position&quot;:[0,2],&quot;name&quot;:[0,&quot;Publications&quot;],&quot;item&quot;:[0,&quot;https://www.cancernetwork.com/journals&quot;]}],[0,{&quot;@type&quot;:[0,&quot;ListItem&quot;],&quot;position&quot;:[0,3],&quot;name&quot;:[0,&quot;Oncology Journal&quot;],&quot;item&quot;:[0,&quot;https://www.cancernetwork.com/journals/journals/oncology&quot;]}],[0,{&quot;@type&quot;:[0,&quot;ListItem&quot;],&quot;position&quot;:[0,4],&quot;name&quot;:[0,&quot;Gerson Regimen&quot;]}]]]}],&quot;articleSchema&quot;:[0,{&quot;@context&quot;:[0,&quot;https://schema.org&quot;],&quot;@type&quot;:[0,&quot;NewsArticle&quot;],&quot;headline&quot;:[0,&quot;Gerson Regimen&quot;],&quot;datePublished&quot;:[0,&quot;2010-02-09T05:00:00.000Z&quot;],&quot;dateModified&quot;:[0,&quot;2020-11-11T15:58:47.000Z&quot;],&quot;inLanguage&quot;:[0,&quot;en-US&quot;],&quot;image&quot;:[0,{&quot;@type&quot;:[0,&quot;ImageObject&quot;],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png&quot;],&quot;caption&quot;:[0,&quot;Gerson Regimen&quot;],&quot;alternateName&quot;:[0,&quot;Gerson Regimen&quot;]}],&quot;thumbnail&quot;:[0,{&quot;@type&quot;:[0,&quot;ImageObject&quot;],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png&quot;],&quot;caption&quot;:[0,&quot;Gerson Regimen&quot;],&quot;alternateName&quot;:[0,&quot;Gerson Regimen&quot;]}],&quot;publisher&quot;:[0,{&quot;@type&quot;:[0,&quot;Organization&quot;],&quot;name&quot;:[0,&quot;CancerNetwork&quot;],&quot;logo&quot;:[0,{&quot;@type&quot;:[0,&quot;ImageObject&quot;],&quot;url&quot;:[0,&quot;https://www.cancernetwork.com/logo.webp&quot;]}]}],&quot;keywords&quot;:[0,&quot;Integrative Oncology, Oncology Journal&quot;],&quot;articleBody&quot;:[0,&quot;Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.\nThe strict dietary recommendations can cause severe nutritional deficiencies, and excessive use of coffee enemas can cause sepsis, dangerous electrolyte deficiencies, and death.\nA recent trial of the closely related Gonzalez therapy found that pancreatic cancer patients on standard chemotherapy survived three times longer and had better quality of life than those who chose the Gonzalez regimen (pancreatic enzymes, nutritional supplements, detoxification, and organic diet).\n-Barrie Cassileth, PhD\nALSO KNOWN AS: Gerson diet, Gerson therapy, Gerson method, Gerson program, Gerson treatment\nSUMMARY: The Gerson regimen, developed by Max Gerson in the 1930s, is promoted as an alternative cancer treatment. It involves consuming fresh, raw fruit and vegetable juices, eliminating salt from the diet, taking supplements such as potassium, vitamin B12, thyroid hormone, pancreatic enzymes, and detoxifying liver with coffee enemas to stimulate metabolism.\nGerson therapy is based on the theory that cancer is caused by alteration of cell metabolism by toxic environmental substances and processed food, which changes its sodium and potassium content. It emphasizes increasing potassium intake and minimizing sodium consumption in an effort to correct the electrolyte imbalance, repair tissue, and detoxify the liver. The coffee enemas are believed to cause dilation of bile ducts and excretion of toxic breakdown products by the liver and through the colon wall. None of these theories has been substantiated by scientific research.[1,2]\nDespite proponents’ claims of recovery rates as high as 70% to 90%, case reviews by the National Cancer Institute (NCI) and the New York County Medical Society found no evidence of usefulness for the Gerson diet.[3]\nAn NCI-sponsored study of Gonzalez therapy, which is similar to the Gerson diet, showed that patients with inoperable pancreatic adenocarcinoma who underwent standard chemotherapy with gemcitabine (Gemzar) survived three times longer and had better quality of life than those who chose enzyme treatment, which included pancreatic enzymes, nutritional supplements, detoxification, and an organic diet.[4]\nADVERSE REACTIONS: Adverse reactions to the Gerson regimen include flu-like symptoms, loss of appetite, perspiration with foul odor, weakness, dizziness, cold sores, fever blisters, high fever, tumor pain, intestinal cramping, diarrhea, and vomiting. (The Gerson Therapy Handbook claims that these adverse reactions are indicative of response.)[5] Campylobacter fetus sepsis caused by the liver injections was reported in 13 patients on Gerson therapy between1980 and 1986. Coma from low serum sodium occurred in 5 of these patients.[6]\nCoffee enemas cause electrolyte imbalance, which has resulted in serious infections, dehydration, colitis, constipation, and death.[7]\n \nReferences:\nREFERENCES\n\t\t\t\t\n1. Cope FW: A medical application of the Ling association-induction hypothesis: The high potassium, low sodium diet of the Gerson cancer therapy. Physiol Chem Phys 10:465-468, 1978. \n\t\t\t\t\n2. Jansson B: Geographic cancer risk and intracellular potassium/sodium ratios. Cancer Detect Prevent 9:171-194, 1986. \n\t\t\t\t\n3. American Cancer Society: Making treatment decisions: Gerson therapy. Available at http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Gerson_Therapy.asp?sitearea=ETO. Accessed Dec 30, 2009.\n\t\t\t\t\n4. Chabot JA, Tsai WY, Fine RL, et al: Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol Aug 17, 2009 (epub ahead of print).\n\t\t\t\t\n5. Gerson M: Gerson Therapy Handbook, 5th ed. San Diego, Calif; Gerson Institute; 1999.\n\t\t\t\t\n6. American Cancer Society: Questionable methods of cancer management: ‘Nutritional’ therapies. CA Cancer J Clin 43:309-319, 1993. \n\t\t\t\t\n7. Eisele JW, Reay DT: Deaths related to coffee enemas. JAMA 244:1608-1609, 1980.&quot;],&quot;description&quot;:[0,&quot;Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.&quot;],&quot;author&quot;:[1,[[0,{&quot;@type&quot;:[0,&quot;Person&quot;],&quot;name&quot;:[0,&quot;Barrie R. Cassileth, MS, PhD&quot;],&quot;url&quot;:[0,&quot;https://www.cancernetwork.com/authors/barrie-r-cassileth-ms-phd&quot;]}]]]}]}],&quot;articleData&quot;:[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-11T09:51:23Z&quot;],&quot;_id&quot;:[0,&quot;cn_article_374309&quot;],&quot;_rev&quot;:[0,&quot;1EEz1a7Vx2lRO9S7MkNDDL&quot;],&quot;_type&quot;:[0,&quot;article&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-11-11T15:58:47Z&quot;],&quot;articleType&quot;:[0,null],&quot;authorMapping&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-12T09:11:08Z&quot;],&quot;_id&quot;:[0,&quot;cn_author_317672&quot;],&quot;_rev&quot;:[0,&quot;89xezVoxyX62cPX9Rki8La&quot;],&quot;_type&quot;:[0,&quot;author&quot;],&quot;_updatedAt&quot;:[0,&quot;2025-06-26T19:38:10Z&quot;],&quot;authorType&quot;:[0,&quot;author&quot;],&quot;displayName&quot;:[0,&quot;Barrie R. Cassileth, MS, PhD&quot;],&quot;url&quot;:[0,{&quot;_type&quot;:[0,&quot;slug&quot;],&quot;current&quot;:[0,&quot;barrie-r-cassileth-ms-phd&quot;]}]}]]],&quot;authors&quot;:[1,[[0,{&quot;displayName&quot;:[0,&quot;Barrie R. Cassileth, MS, PhD&quot;],&quot;profileImage&quot;:[0,null],&quot;url&quot;:[0,&quot;/authors/barrie-r-cassileth-ms-phd&quot;]}]]],&quot;body&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;xqo1YuSj&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;FclbU7R7&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;z4D4pMfF&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;DQKwm0xq&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;The strict dietary recommendations can cause severe nutritional deficiencies, and excessive use of coffee enemas can cause sepsis, dangerous electrolyte deficiencies, and death.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;aiv1C9Rn&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;mX3SVVsh&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;A recent trial of the closely related Gonzalez therapy found that pancreatic cancer patients on standard chemotherapy survived three times longer and had better quality of life than those who chose the Gonzalez regimen (pancreatic enzymes, nutritional supplements, detoxification, and organic diet).&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;ozEC9srL&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;avqS18B2&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;-&quot;]}],[0,{&quot;_key&quot;:[0,&quot;NylC2rFQ&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;em&quot;]]],&quot;text&quot;:[0,&quot;Barrie Cassileth, PhD&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;ypm9UgDY&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;JCfAfhlU&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;strong&quot;]]],&quot;text&quot;:[0,&quot;ALSO KNOWN AS:&quot;]}],[0,{&quot;_key&quot;:[0,&quot;fAjCad5w&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; Gerson diet, Gerson therapy, Gerson method, Gerson program, Gerson treatment&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;kbtzOTSW&quot;],&quot;_type&quot;:[0,&quot;figure&quot;],&quot;asset&quot;:[0,{&quot;_createdAt&quot;:[0,&quot;2020-06-09T06:36:21Z&quot;],&quot;_id&quot;:[0,&quot;image-2e03f572093fb586d628535cb0d8ba25992bb2a2-200x192-png&quot;],&quot;_ref&quot;:[0,&quot;image-2e03f572093fb586d628535cb0d8ba25992bb2a2-200x192-png&quot;],&quot;_rev&quot;:[0,&quot;2cZRobJdCnKNZSLmCQSCuL&quot;],&quot;_type&quot;:[0,&quot;sanity.imageAsset&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-06-09T06:36:21Z&quot;],&quot;assetId&quot;:[0,&quot;2e03f572093fb586d628535cb0d8ba25992bb2a2&quot;],&quot;extension&quot;:[0,&quot;png&quot;],&quot;metadata&quot;:[0,{&quot;dimensions&quot;:[0,{&quot;_type&quot;:[0,&quot;sanity.imageDimensions&quot;],&quot;aspectRatio&quot;:[0,1.0416666666666667],&quot;height&quot;:[0,192],&quot;width&quot;:[0,200]}]}],&quot;mimeType&quot;:[0,&quot;image/png&quot;],&quot;originalFilename&quot;:[0,&quot;1843226.png&quot;],&quot;path&quot;:[0,&quot;images/0vv8moc6/cancernetwork/2e03f572093fb586d628535cb0d8ba25992bb2a2-200x192.png&quot;],&quot;sha1hash&quot;:[0,&quot;2e03f572093fb586d628535cb0d8ba25992bb2a2&quot;],&quot;size&quot;:[0,61382],&quot;uploadId&quot;:[0,&quot;uJTMNQDUX1SnHkgUrPjNIQgcozrfjfO0&quot;],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2e03f572093fb586d628535cb0d8ba25992bb2a2-200x192.png&quot;]}],&quot;blank&quot;:[0,false],&quot;caption&quot;:[0,&quot;&quot;],&quot;link&quot;:[0,&quot;1522193.png&quot;],&quot;medias&quot;:[0,null],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;vSDSlPJH&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;y1xggxlc&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;strong&quot;]]],&quot;text&quot;:[0,&quot;SUMMARY:&quot;]}],[0,{&quot;_key&quot;:[0,&quot;SHf31Ahy&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; The Gerson regimen, developed by Max Gerson in the 1930s, is promoted as an alternative cancer treatment. It involves consuming fresh, raw fruit and vegetable juices, eliminating salt from the diet, taking supplements such as potassium, vitamin B12, thyroid hormone, pancreatic enzymes, and detoxifying liver with coffee enemas to stimulate metabolism.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;B46W5pv2&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;QZ2fXcPm&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Gerson therapy is based on the theory that cancer is caused by alteration of cell metabolism by toxic environmental substances and processed food, which changes its sodium and potassium content. It emphasizes increasing potassium intake and minimizing sodium consumption in an effort to correct the electrolyte imbalance, repair tissue, and detoxify the liver. The coffee enemas are believed to cause dilation of bile ducts and excretion of toxic breakdown products by the liver and through the colon wall. None of these theories has been substantiated by scientific research.[1,2]&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;FUqxeuaI&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;hfu8uzpa&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Despite proponents’ claims of recovery rates as high as 70% to 90%, case reviews by the National Cancer Institute (NCI) and the New York County Medical Society found no evidence of usefulness for the Gerson diet.[3]&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;542mZR0G&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;s0Rrr8cb&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;An NCI-sponsored study of Gonzalez therapy, which is similar to the Gerson diet, showed that patients with inoperable pancreatic adenocarcinoma who underwent standard chemotherapy with gemcitabine (Gemzar) survived three times longer and had better quality of life than those who chose enzyme treatment, which included pancreatic enzymes, nutritional supplements, detoxification, and an organic diet.[4]&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;u3tvQRrg&quot;],&quot;_type&quot;:[0,&quot;figure&quot;],&quot;asset&quot;:[0,{&quot;_createdAt&quot;:[0,&quot;2020-06-09T06:36:21Z&quot;],&quot;_id&quot;:[0,&quot;image-6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846-380x486-jpg&quot;],&quot;_ref&quot;:[0,&quot;image-6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846-380x486-jpg&quot;],&quot;_rev&quot;:[0,&quot;gHtozpBUvKAPYE37IWAR54&quot;],&quot;_type&quot;:[0,&quot;sanity.imageAsset&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-06-09T06:36:21Z&quot;],&quot;assetId&quot;:[0,&quot;6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846&quot;],&quot;extension&quot;:[0,&quot;jpg&quot;],&quot;metadata&quot;:[0,{&quot;dimensions&quot;:[0,{&quot;_type&quot;:[0,&quot;sanity.imageDimensions&quot;],&quot;aspectRatio&quot;:[0,0.7818930041152263],&quot;height&quot;:[0,486],&quot;width&quot;:[0,380]}]}],&quot;mimeType&quot;:[0,&quot;image/jpeg&quot;],&quot;originalFilename&quot;:[0,&quot;1522197.png&quot;],&quot;path&quot;:[0,&quot;images/0vv8moc6/cancernetwork/6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846-380x486.jpg&quot;],&quot;sha1hash&quot;:[0,&quot;6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846&quot;],&quot;size&quot;:[0,54371],&quot;uploadId&quot;:[0,&quot;UzARJ1AKTb4LtAysVOFSgcvzUsqcUaCX&quot;],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6492ca7f7f1c7a3eda5eb2b46e86b40cb3a7b846-380x486.jpg&quot;]}],&quot;blank&quot;:[0,false],&quot;caption&quot;:[0,&quot;&quot;],&quot;link&quot;:[0,&quot;1522197.png&quot;],&quot;medias&quot;:[0,null],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;1m9ai56k&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;p8V2BD2O&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;strong&quot;]]],&quot;text&quot;:[0,&quot;ADVERSE REACTIONS:&quot;]}],[0,{&quot;_key&quot;:[0,&quot;yFtKRxnS&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; Adverse reactions to the Gerson regimen include flu-like symptoms, loss of appetite, perspiration with foul odor, weakness, dizziness, cold sores, fever blisters, high fever, tumor pain, intestinal cramping, diarrhea, and vomiting. (&quot;]}],[0,{&quot;_key&quot;:[0,&quot;pcivgH0O&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;em&quot;]]],&quot;text&quot;:[0,&quot;The Gerson Therapy Handbook&quot;]}],[0,{&quot;_key&quot;:[0,&quot;mDd6YPhU&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; claims that these adverse reactions are indicative of response.)[5] &quot;]}],[0,{&quot;_key&quot;:[0,&quot;7FgVHuIk&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;em&quot;]]],&quot;text&quot;:[0,&quot;Campylobacter fetus&quot;]}],[0,{&quot;_key&quot;:[0,&quot;tTUxN1TC&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; sepsis caused by the liver injections was reported in 13 patients on Gerson therapy between1980 and 1986. Coma from low serum sodium occurred in 5 of these patients.[6]&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;l2Lf1usW&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;AoPbMSHt&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Coffee enemas cause electrolyte imbalance, which has resulted in serious infections, dehydration, colitis, constipation, and death.[7]&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;aNpTuEyY&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;Z36kPePv&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; &quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;kjXCbjXF&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;RoOXDYYn&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;References:&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;h3&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;0rf54yYk&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;WVFLyM1o&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;strong&quot;]]],&quot;text&quot;:[0,&quot;REFERENCES&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;Lo2tGbXe&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;W6IcWJeA&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;\t\t\t\t&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;B9r7i8xX&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;NtN3f3fD&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;1. Cope FW: A medical application of the Ling association-induction hypothesis: The high potassium, low sodium diet of the Gerson cancer therapy. &quot;]}],[0,{&quot;_key&quot;:[0,&quot;4Pvs2tC6&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;em&quot;]]],&quot;text&quot;:[0,&quot;Physiol Chem Phys&quot;]}],[0,{&quot;_key&quot;:[0,&quot;LIQYxlDb&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; 10:465-468, 1978. &quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;Itzwafg7&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;rcotiFcc&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;\t\t\t\t&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;6zWRKnL5&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;YU6j4An5&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;2. Jansson B: Geographic cancer risk and intracellular potassium/sodium ratios. C&quot;]}],[0,{&quot;_key&quot;:[0,&quot;8UvyvBf6&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;em&quot;]]],&quot;text&quot;:[0,&quot;ancer Detect Prevent&quot;]}],[0,{&quot;_key&quot;:[0,&quot;PqqH4rS9&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; 9:171-194, 1986. &quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;hB2Eu9OP&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;cjxP7mtj&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;\t\t\t\t&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;9KDPC9rW&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;wwLD4y5Q&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;3. American Cancer Society: Making treatment decisions: Gerson therapy. Available at http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Gerson_Therapy.asp?sitearea=ETO. Accessed Dec 30, 2009.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;LlQBjNTe&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;pcnIU79I&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;\t\t\t\t&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;9P1cPRky&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;jwVnKnOc&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;4. Chabot JA, Tsai WY, Fine RL, et al: Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. &quot;]}],[0,{&quot;_key&quot;:[0,&quot;zj3TkPcM&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;em&quot;]]],&quot;text&quot;:[0,&quot;J Clin Oncol&quot;]}],[0,{&quot;_key&quot;:[0,&quot;uD7ojCuT&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; Aug 17, 2009 (epub ahead of print).&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;3ayD2IYZ&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;5YXAYmeE&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;\t\t\t\t&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;fyAUL4Mb&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;W7oSzVj4&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;5. Gerson M: &quot;]}],[0,{&quot;_key&quot;:[0,&quot;71IO00vF&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;em&quot;]]],&quot;text&quot;:[0,&quot;Gerson Therapy Handbook&quot;]}],[0,{&quot;_key&quot;:[0,&quot;eNblXHmU&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;, 5th ed. San Diego, Calif; Gerson Institute; 1999.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;DhnKSTQq&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;SWHhiUBs&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;\t\t\t\t&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;z6am5raV&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;7ocoOXUE&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;6. American Cancer Society: Questionable methods of cancer management: ‘Nutritional’ therapies. &quot;]}],[0,{&quot;_key&quot;:[0,&quot;2xFNQU8O&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;em&quot;]]],&quot;text&quot;:[0,&quot;CA Cancer J Clin&quot;]}],[0,{&quot;_key&quot;:[0,&quot;u01LqoyR&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; 43:309-319, 1993. &quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;yYWk3wDR&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;GNtAnes8&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;\t\t\t\t&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;M2Gxe96t&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;zkmD63yt&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;7. Eisele JW, Reay DT: Deaths related to coffee enemas. &quot;]}],[0,{&quot;_key&quot;:[0,&quot;H7iq9WOT&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;em&quot;]]],&quot;text&quot;:[0,&quot;JAMA&quot;]}],[0,{&quot;_key&quot;:[0,&quot;Do7M0YTo&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot; 244:1608-1609, 1980.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;uploadAudio&quot;:[0,null],&quot;upload_doc&quot;:[0,null]}]]],&quot;contentCategory&quot;:[0,{&quot;_id&quot;:[0,&quot;8bdaa7fc-960a-4b57-b076-75fdce3741bb&quot;],&quot;name&quot;:[0,&quot;Articles&quot;]}],&quot;contentGroup&quot;:[0,null],&quot;disableKeyTakeaways&quot;:[0,null],&quot;disableRelatedContent&quot;:[0,null],&quot;display_summary&quot;:[0,null],&quot;documentGroup&quot;:[0,null],&quot;documentGroupMapping&quot;:[0,null],&quot;estimatedReadingTime&quot;:[0,5],&quot;factCheckAuthorMapping&quot;:[0,null],&quot;filter&quot;:[0,null],&quot;gptTakeaways&quot;:[0,null],&quot;internalTag&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;isGated&quot;:[0,null],&quot;is_visible&quot;:[0,true],&quot;issueGroup&quot;:[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-11T18:38:28Z&quot;],&quot;_id&quot;:[0,&quot;cn_publication_457871&quot;],&quot;_rev&quot;:[0,&quot;7qmad4L2LigKUtCCyTI5ge&quot;],&quot;_type&quot;:[0,&quot;publication&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-10-19T12:58:14Z&quot;],&quot;identifier&quot;:[0,{&quot;_type&quot;:[0,&quot;slug&quot;],&quot;current&quot;:[0,&quot;oncology-vol-24-no-2&quot;]}],&quot;is_visible&quot;:[0,true],&quot;month&quot;:[0,&quot;02&quot;],&quot;name&quot;:[0,&quot;ONCOLOGY Vol 24 No 2&quot;],&quot;number&quot;:[0,&quot;2&quot;],&quot;parent&quot;:[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-11T18:17:41Z&quot;],&quot;_id&quot;:[0,&quot;2e58d1ee-d811-4a4e-a7e4-7607a0cd1c53&quot;],&quot;_rev&quot;:[0,&quot;cR6hzbgTLChPy9YHFT66vD&quot;],&quot;_type&quot;:[0,&quot;publication&quot;],&quot;_updatedAt&quot;:[0,&quot;2023-11-07T14:14:15Z&quot;],&quot;description&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;4593b94aae93&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;bdaaa6d87312&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;The journal ONCOLOGY® provides oncology professionals with practical and timely clinical information necessary to deliver the highest level of patient care. Expert authors and peer review ensure the quality of the journal’s articles and features. Focused discussions capture key clinical take-aways for application in today’s time-constrained practice environment.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;style&quot;:[0,&quot;normal&quot;]}],[0,{&quot;_key&quot;:[0,&quot;21f8f8f8537e&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;c110bf802a9b&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;e295c8000ed2&quot;]]],&quot;text&quot;:[0,&quot;Click Here to Subscribe&quot;]}]]],&quot;markDefs&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;e295c8000ed2&quot;],&quot;_type&quot;:[0,&quot;link&quot;],&quot;blank&quot;:[0,true],&quot;href&quot;:[0,&quot;https://www.cancernetwork.com/subscribe?utm_source=web&amp;utm_medium=button&amp;utm_campaign=pub_page_listing&quot;],&quot;nofollow&quot;:[0,true]}]]],&quot;style&quot;:[0,&quot;normal&quot;]}]]],&quot;identifier&quot;:[0,{&quot;_type&quot;:[0,&quot;slug&quot;],&quot;current&quot;:[0,&quot;oncology&quot;]}],&quot;is_visible&quot;:[0,true],&quot;name&quot;:[0,&quot;Oncology&quot;],&quot;parent&quot;:[0,null],&quot;pubmedXmlFile&quot;:[0,{&quot;providerId&quot;:[0,&quot;7896&quot;],&quot;pubMedIssueIdentifier&quot;:[0,&quot;10.46883&quot;],&quot;publisherName&quot;:[0,&quot;MJH Life Sciences&quot;]}],&quot;risMapping&quot;:[0,{&quot;abbreviatedJournal&quot;:[0,&quot;Oncology&quot;],&quot;isbn_issn&quot;:[0,&quot;0890-9091&quot;]}],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-6aad8ed21220fb03d2b384092f6b923649718dcc-2377x3253-jpg&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}]}]}],&quot;pdf&quot;:[0,null],&quot;volume&quot;:[0,&quot;24&quot;],&quot;year&quot;:[0,&quot;2010&quot;]}],&quot;issueSection&quot;:[0,null],&quot;nodeId&quot;:[0,&quot;374309&quot;],&quot;pageNumber&quot;:[0,null],&quot;password&quot;:[0,null],&quot;passwordLock&quot;:[0,null],&quot;pdfUrl&quot;:[0,null],&quot;published&quot;:[0,&quot;2010-02-09T05:00:00Z&quot;],&quot;pubmedID&quot;:[0,&quot;20361473&quot;],&quot;seoTag&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;source&quot;:[0,null],&quot;summary&quot;:[0,&quot;Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy.&quot;],&quot;taxonomyMapping&quot;:[1,[[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-24T10:20:37Z&quot;],&quot;_id&quot;:[0,&quot;cn_taxonomy_5565_news&quot;],&quot;_rev&quot;:[0,&quot;FdGECH42hQ5Ikva2G8iwch&quot;],&quot;_type&quot;:[0,&quot;taxonomy&quot;],&quot;_updatedAt&quot;:[0,&quot;2022-04-04T10:00:21Z&quot;],&quot;identifier&quot;:[0,&quot;news&quot;],&quot;name&quot;:[0,&quot;News&quot;],&quot;parent&quot;:[0,null],&quot;pixelTrackingCode&quot;:[0,null]}],[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-24T10:20:37Z&quot;],&quot;_id&quot;:[0,&quot;cn_taxonomy_285_oncologyjournal&quot;],&quot;_rev&quot;:[0,&quot;iZl9SWjRZ14S1eLFkdNFTs&quot;],&quot;_type&quot;:[0,&quot;taxonomy&quot;],&quot;_updatedAt&quot;:[0,&quot;2021-08-11T10:57:49Z&quot;],&quot;identifier&quot;:[0,&quot;journals/oncology&quot;],&quot;name&quot;:[0,&quot;Oncology Journal&quot;],&quot;parent&quot;:[0,{&quot;_createdAt&quot;:[0,&quot;2020-02-24T10:20:37Z&quot;],&quot;_id&quot;:[0,&quot;cn_taxonomy_53206_publications&quot;],&quot;_rev&quot;:[0,&quot;89yplCgIzX7Yw7YHdVFact&quot;],&quot;_type&quot;:[0,&quot;taxonomy&quot;],&quot;_updatedAt&quot;:[0,&quot;2020-06-10T16:35:50Z&quot;],&quot;identifier&quot;:[0,&quot;journals&quot;],&quot;name&quot;:[0,&quot;Publications&quot;],&quot;parent&quot;:[0,null]}],&quot;pixelTrackingCode&quot;:[0,null]}]]],&quot;thumbnail&quot;:[0,{&quot;_type&quot;:[0,&quot;mainImage&quot;],&quot;aspectRatio&quot;:[0,1],&quot;asset&quot;:[0,{&quot;_ref&quot;:[0,&quot;image-ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50-png&quot;],&quot;_type&quot;:[0,&quot;reference&quot;]}],&quot;url&quot;:[0,&quot;https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ecdcabca30274a065c68ccd7d7c000bb2f1976d7-50x50.png&quot;]}],&quot;title&quot;:[0,&quot;Gerson Regimen&quot;],&quot;trailStates&quot;:[0,null],&quot;type&quot;:[0,null],&quot;updatedOn&quot;:[0,null],&quot;url&quot;:[0,&quot;/view/gerson-regimen&quot;]}]}" ssr client="load" opts="{&quot;name&quot;:&quot;Analytics&quot;,&quot;value&quot;:true}" await-children><div class="fixed -left-20 -top-20 z-[-1] h-[1px] w-[1px] overflow-hidden opacity-0"></div><!--astro:end--></astro-island> <astro-island uid="Z1fdD8r" prefix="r11" component-url="/_astro/ui.3g1jLusn.js" component-export="Identity" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;authEnabled&quot;:[0,true],&quot;idlayerUrl&quot;:[0,&quot;https://id.mjhlifesciences.com&quot;],&quot;identifyOnly&quot;:[0,false],&quot;enableMagicToken&quot;:[0,true],&quot;brandName&quot;:[0,&quot;cancernetwork&quot;]}" ssr client="load" opts="{&quot;name&quot;:&quot;Identity&quot;,&quot;value&quot;:true}"></astro-island> <astro-island uid="isqA4" prefix="r12" component-url="/_astro/id-layer.C2C6IZJY.js" component-export="ProgressiveForm" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;formSchema&quot;:[0,{&quot;id&quot;:[0,&quot;id-layer-form&quot;],&quot;fields&quot;:[1,[[0,{&quot;label&quot;:[0,&quot;Phone&quot;],&quot;placeholder&quot;:[0,null],&quot;id&quot;:[0,&quot;phone&quot;],&quot;type&quot;:[0,&quot;number&quot;],&quot;options&quot;:[1,[]],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;profileBucket&quot;:[0,&quot;common&quot;],&quot;idLayerProfileKey&quot;:[0,&quot;phoneCell&quot;]}],[0,{&quot;label&quot;:[0,&quot;First Name&quot;],&quot;placeholder&quot;:[0,null],&quot;id&quot;:[0,&quot;firstName&quot;],&quot;type&quot;:[0,&quot;text&quot;],&quot;options&quot;:[1,[]],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;profileBucket&quot;:[0,&quot;common&quot;],&quot;idLayerProfileKey&quot;:[0,null]}],[0,{&quot;label&quot;:[0,&quot;Last Name&quot;],&quot;placeholder&quot;:[0,null],&quot;id&quot;:[0,&quot;lastName&quot;],&quot;type&quot;:[0,&quot;text&quot;],&quot;options&quot;:[1,[]],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;profileBucket&quot;:[0,&quot;common&quot;],&quot;idLayerProfileKey&quot;:[0,null]}],[0,{&quot;label&quot;:[0,&quot;Zipcode&quot;],&quot;placeholder&quot;:[0,null],&quot;id&quot;:[0,&quot;zipcode&quot;],&quot;type&quot;:[0,&quot;text&quot;],&quot;options&quot;:[1,[]],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;profileBucket&quot;:[0,&quot;common&quot;],&quot;idLayerProfileKey&quot;:[0,null]}],[0,{&quot;label&quot;:[0,&quot;Occupation&quot;],&quot;placeholder&quot;:[0,null],&quot;id&quot;:[0,&quot;occupation&quot;],&quot;type&quot;:[0,&quot;dropdown&quot;],&quot;options&quot;:[1,[[0,{&quot;value&quot;:[0,&quot;Dental/Oral Health Provider/DSO&quot;],&quot;label&quot;:[0,&quot;Dental/Oral Health Provider/DSO&quot;]}],[0,{&quot;value&quot;:[0,&quot;Health/Business Administration&quot;],&quot;label&quot;:[0,&quot;Health/Business Administration&quot;]}],[0,{&quot;value&quot;:[0,&quot;Infection Control&quot;],&quot;label&quot;:[0,&quot;Infection Control&quot;]}],[0,{&quot;value&quot;:[0,&quot;Media/Press&quot;],&quot;label&quot;:[0,&quot;Media/Press&quot;]}],[0,{&quot;value&quot;:[0,&quot;Medical Science Liaison&quot;],&quot;label&quot;:[0,&quot;Medical Science Liaison&quot;]}],[0,{&quot;value&quot;:[0,&quot;Medical Student&quot;],&quot;label&quot;:[0,&quot;Medical Student&quot;]}],[0,{&quot;value&quot;:[0,&quot;Nurse/Advanced Practice Nurse&quot;],&quot;label&quot;:[0,&quot;Nurse/Advanced Practice Nurse&quot;]}],[0,{&quot;value&quot;:[0,&quot;Optometrist/Optician/Ophthalmic Technician&quot;],&quot;label&quot;:[0,&quot;Optometrist/Optician/Ophthalmic Technician&quot;]}],[0,{&quot;value&quot;:[0,&quot;Other Health Care Provider&quot;],&quot;label&quot;:[0,&quot;Other Health Care Provider&quot;]}],[0,{&quot;value&quot;:[0,&quot;Patient&quot;],&quot;label&quot;:[0,&quot;Patient&quot;]}],[0,{&quot;value&quot;:[0,&quot;Physician&quot;],&quot;label&quot;:[0,&quot;Physician&quot;]}],[0,{&quot;value&quot;:[0,&quot;Physician Assistant&quot;],&quot;label&quot;:[0,&quot;Physician Assistant&quot;]}],[0,{&quot;value&quot;:[0,&quot;Psychiatry/Psychology Professional&quot;],&quot;label&quot;:[0,&quot;Psychiatry/Psychology Professional&quot;]}],[0,{&quot;value&quot;:[0,&quot;Resident/Fellow&quot;],&quot;label&quot;:[0,&quot;Resident/Fellow&quot;]}],[0,{&quot;value&quot;:[0,&quot;Pharmacy Professional&quot;],&quot;label&quot;:[0,&quot;Pharmacy Professional&quot;]}]]],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;profileBucket&quot;:[0,&quot;common&quot;],&quot;idLayerProfileKey&quot;:[0,&quot;occupation&quot;]}],[0,{&quot;label&quot;:[0,&quot;Workplace&quot;],&quot;placeholder&quot;:[0,null],&quot;id&quot;:[0,&quot;workplace&quot;],&quot;type&quot;:[0,&quot;dropdown&quot;],&quot;options&quot;:[1,[[0,{&quot;value&quot;:[0,&quot;Medical Practice&quot;],&quot;label&quot;:[0,&quot;Medical Practice&quot;]}],[0,{&quot;value&quot;:[0,&quot;Hospital/Health System&quot;],&quot;label&quot;:[0,&quot;Hospital/Health System&quot;]}],[0,{&quot;value&quot;:[0,&quot;Pharmacy&quot;],&quot;label&quot;:[0,&quot;Pharmacy&quot;]}],[0,{&quot;value&quot;:[0,&quot;Payor&quot;],&quot;label&quot;:[0,&quot;Payor&quot;]}],[0,{&quot;value&quot;:[0,&quot;Other&quot;],&quot;label&quot;:[0,&quot;Other&quot;]}]]],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;profileBucket&quot;:[0,&quot;common&quot;],&quot;idLayerProfileKey&quot;:[0,&quot;workplace&quot;]}],[0,{&quot;label&quot;:[0,&quot;Specialty&quot;],&quot;placeholder&quot;:[0,null],&quot;id&quot;:[0,&quot;specialty&quot;],&quot;type&quot;:[0,&quot;dropdown&quot;],&quot;options&quot;:[1,[[0,{&quot;value&quot;:[0,&quot;Oncology&quot;],&quot;label&quot;:[0,&quot;Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Advanced Surgical Oncology&quot;],&quot;label&quot;:[0,&quot;Advanced Surgical Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Gynecological Oncology&quot;],&quot;label&quot;:[0,&quot;Gynecological Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Hematology/Oncology&quot;],&quot;label&quot;:[0,&quot;Hematology/Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Orthopedic Musculo Oncology&quot;],&quot;label&quot;:[0,&quot;Orthopedic Musculo Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Pathology&quot;],&quot;label&quot;:[0,&quot;Pathology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Pediatric Hematology/Oncology&quot;],&quot;label&quot;:[0,&quot;Pediatric Hematology/Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Radiation Oncology&quot;],&quot;label&quot;:[0,&quot;Radiation Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Surgical Oncology&quot;],&quot;label&quot;:[0,&quot;Surgical Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Other Healthcare Specialty&quot;],&quot;label&quot;:[0,&quot;Other Healthcare Specialty&quot;]}]]],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;profileBucket&quot;:[0,&quot;common&quot;],&quot;idLayerProfileKey&quot;:[0,&quot;specialty&quot;]}],[0,{&quot;label&quot;:[0,&quot;Cancer Focus&quot;],&quot;placeholder&quot;:[0,null],&quot;id&quot;:[0,&quot;cancer focus&quot;],&quot;type&quot;:[0,&quot;dropdown&quot;],&quot;options&quot;:[1,[[0,{&quot;value&quot;:[0,&quot;Bone Marrow/Stem Cell Transplant&quot;],&quot;label&quot;:[0,&quot;Bone Marrow/Stem Cell Transplant&quot;]}],[0,{&quot;value&quot;:[0,&quot;Bone Marrow / Stem Cell Transplant ; Transfusion Medicine&quot;],&quot;label&quot;:[0,&quot;Bone Marrow / Stem Cell Transplant ; Transfusion Medicine&quot;]}],[0,{&quot;value&quot;:[0,&quot;Breast Cancer&quot;],&quot;label&quot;:[0,&quot;Breast Cancer&quot;]}],[0,{&quot;value&quot;:[0,&quot;Dermatology Oncology&quot;],&quot;label&quot;:[0,&quot;Dermatology Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Gastrointestinal Oncology&quot;],&quot;label&quot;:[0,&quot;Gastrointestinal Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Genitourinary Oncology&quot;],&quot;label&quot;:[0,&quot;Genitourinary Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Head &amp; Neck Cancer&quot;],&quot;label&quot;:[0,&quot;Head &amp; Neck Cancer&quot;]}],[0,{&quot;value&quot;:[0,&quot;Hematology Oncology&quot;],&quot;label&quot;:[0,&quot;Hematology Oncology&quot;]}],[0,{&quot;value&quot;:[0,&quot;Lung Cancer&quot;],&quot;label&quot;:[0,&quot;Lung Cancer&quot;]}],[0,{&quot;value&quot;:[0,&quot;Melanoma and Skin Cancer&quot;],&quot;label&quot;:[0,&quot;Melanoma and Skin Cancer&quot;]}],[0,{&quot;value&quot;:[0,&quot;Sarcoma&quot;],&quot;label&quot;:[0,&quot;Sarcoma&quot;]}],[0,{&quot;value&quot;:[0,&quot;Transfusion Medicine&quot;],&quot;label&quot;:[0,&quot;Transfusion Medicine&quot;]}],[0,{&quot;value&quot;:[0,&quot;Eye, Brain &amp; CNS&quot;],&quot;label&quot;:[0,&quot;Eye, Brain &amp; CNS&quot;]}],[0,{&quot;value&quot;:[0,&quot;Ill-Defined &amp; Unspecified Sites&quot;],&quot;label&quot;:[0,&quot;Ill-Defined &amp; Unspecified Sites&quot;]}],[0,{&quot;value&quot;:[0,&quot;In Situ Neoplasms&quot;],&quot;label&quot;:[0,&quot;In Situ Neoplasms&quot;]}],[0,{&quot;value&quot;:[0,&quot;Malignant Neuroendocrine Tumors&quot;],&quot;label&quot;:[0,&quot;Malignant Neuroendocrine Tumors&quot;]}],[0,{&quot;value&quot;:[0,&quot;Secondary Neuroendocine Tumors&quot;],&quot;label&quot;:[0,&quot;Secondary Neuroendocine Tumors&quot;]}],[0,{&quot;value&quot;:[0,&quot;Thyroid &amp; Endocrine Glands&quot;],&quot;label&quot;:[0,&quot;Thyroid &amp; Endocrine Glands&quot;]}],[0,{&quot;value&quot;:[0,&quot;Unspecified Neoplasms&quot;],&quot;label&quot;:[0,&quot;Unspecified Neoplasms&quot;]}]]],&quot;fieldType&quot;:[0,&quot;brand-specific&quot;],&quot;profileBucket&quot;:[0,&quot;brand-specific&quot;],&quot;idLayerProfileKey&quot;:[0,null]}],[0,{&quot;label&quot;:[0,&quot;NPI Number&quot;],&quot;placeholder&quot;:[0,null],&quot;id&quot;:[0,&quot;npi&quot;],&quot;type&quot;:[0,&quot;number&quot;],&quot;options&quot;:[1,[]],&quot;fieldType&quot;:[0,&quot;common&quot;],&quot;profileBucket&quot;:[0,&quot;common&quot;],&quot;idLayerProfileKey&quot;:[0,&quot;npiNumber&quot;]}]]]}],&quot;conditions&quot;:[1,[[0,{&quot;conditionType&quot;:[0,&quot;scrollPercentage&quot;],&quot;value&quot;:[0,25]}],[0,{&quot;conditionType&quot;:[0,&quot;loggedIn&quot;],&quot;value&quot;:[0,true]}],[0,{&quot;conditionType&quot;:[0,&quot;cookieCheck&quot;],&quot;name&quot;:[0,&quot;id-layer-shown&quot;],&quot;mode&quot;:[0,&quot;notExists&quot;],&quot;setOnPass&quot;:[0,true],&quot;days&quot;:[0,3]}],[0,{&quot;conditionType&quot;:[0,&quot;isIdLayerComplete&quot;],&quot;value&quot;:[0,false]}]]]}" ssr client="load" opts="{&quot;name&quot;:&quot;ProgressiveForm&quot;,&quot;value&quot;:true}"></astro-island><astro-island uid="Z1e8XI5" prefix="r13" component-url="/_astro/marketing-layer.CoOUkyW5.js" component-export="MarketingLayerRuntime" renderer-url="/_astro/client.BR7zMcor.js" props="{&quot;campaigns&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;d2e1b0cf-4f4a-4a5c-baa2-02ac67ea1886&quot;],&quot;_type&quot;:[0,&quot;marketingCampaign&quot;],&quot;active&quot;:[0,true],&quot;conditionGroups&quot;:[1,[[0,{&quot;enableAuthorCondition&quot;:[0,null],&quot;enableBehavioralCondition&quot;:[0,false],&quot;enableBrandCondition&quot;:[0,null],&quot;enableContentPlacementCondition&quot;:[0,true],&quot;enableDeviceCondition&quot;:[0,false],&quot;enableDocumentGroupCondition&quot;:[0,false],&quot;enableDomainCondition&quot;:[0,null],&quot;enableGeoCondition&quot;:[0,false],&quot;enableReferralSourceCondition&quot;:[0,null],&quot;enableScoutCondition&quot;:[0,null],&quot;enableUrlCondition&quot;:[0,true],&quot;enableUrlParameterCondition&quot;:[0,null],&quot;enableUserCondition&quot;:[0,false],&quot;excludeAuthors&quot;:[0,null],&quot;excludeContentPlacements&quot;:[0,null],&quot;excludeDocumentGroups&quot;:[0,null],&quot;excludeReferralSources&quot;:[0,null],&quot;excludeUrls&quot;:[0,null],&quot;geoRules&quot;:[0,null],&quot;groupName&quot;:[0,null],&quot;pageViewsRequired&quot;:[0,null],&quot;profileFieldConditions&quot;:[0,null],&quot;scoutTopics&quot;:[0,null],&quot;scoutWindow&quot;:[0,null],&quot;scrollPercentage&quot;:[0,null],&quot;targetAuthors&quot;:[0,null],&quot;targetBrands&quot;:[0,null],&quot;targetContentPlacements&quot;:[1,[[0,{&quot;_id&quot;:[0,&quot;1595d8bf-6647-4f4a-bb4a-44ce69ce32ba&quot;],&quot;grandParentIdentifier&quot;:[0,null],&quot;identifier&quot;:[0,&quot;access-billing&quot;],&quot;parentIdentifier&quot;:[0,&quot;the-bispecific-network&quot;]}],[0,{&quot;_id&quot;:[0,&quot;4061e942-2a4b-42af-bbd3-9636222ed630&quot;],&quot;grandParentIdentifier&quot;:[0,null],&quot;identifier&quot;:[0,&quot;the-bispecific-network&quot;],&quot;parentIdentifier&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;10cd63fd-622f-4dad-86fd-37001462b4cd&quot;],&quot;grandParentIdentifier&quot;:[0,null],&quot;identifier&quot;:[0,&quot;safety-toxicity&quot;],&quot;parentIdentifier&quot;:[0,&quot;the-bispecific-network&quot;]}],[0,{&quot;_id&quot;:[0,&quot;12bcbf5b-ebd8-41c4-a559-48635676b34c&quot;],&quot;grandParentIdentifier&quot;:[0,null],&quot;identifier&quot;:[0,&quot;practice-models&quot;],&quot;parentIdentifier&quot;:[0,&quot;the-bispecific-network&quot;]}],[0,{&quot;_id&quot;:[0,&quot;4fb085f8-d8bb-43e3-99b4-dc3b40c18c83&quot;],&quot;grandParentIdentifier&quot;:[0,null],&quot;identifier&quot;:[0,&quot;other&quot;],&quot;parentIdentifier&quot;:[0,&quot;the-bispecific-network&quot;]}],[0,{&quot;_id&quot;:[0,&quot;54f797d0-0c13-45ad-81f9-7572df0fdd2d&quot;],&quot;grandParentIdentifier&quot;:[0,null],&quot;identifier&quot;:[0,&quot;scaling-forward&quot;],&quot;parentIdentifier&quot;:[0,&quot;the-bispecific-network&quot;]}],[0,{&quot;_id&quot;:[0,&quot;61513b69-fff4-4d17-8116-c1ffed030cce&quot;],&quot;grandParentIdentifier&quot;:[0,null],&quot;identifier&quot;:[0,&quot;program-readiness&quot;],&quot;parentIdentifier&quot;:[0,&quot;the-bispecific-network&quot;]}]]],&quot;targetDevices&quot;:[0,null],&quot;targetDocumentGroups&quot;:[0,null],&quot;targetDomains&quot;:[0,null],&quot;targetReferralSources&quot;:[0,null],&quot;targetUrls&quot;:[1,[[0,&quot;/view/&quot;]]],&quot;timeOnPageSeconds&quot;:[0,null],&quot;triggerType&quot;:[0,&quot;immediate&quot;],&quot;urlMatchType&quot;:[0,&quot;startsWith&quot;],&quot;urlParameterRules&quot;:[0,null],&quot;userLoginState&quot;:[0,&quot;any&quot;],&quot;videoProgressMode&quot;:[0,null],&quot;videoProgressPercent&quot;:[0,null],&quot;videoProgressTimestamp&quot;:[0,null],&quot;videoWatchTimeSeconds&quot;:[0,null]}]]],&quot;conditionLogic&quot;:[0,&quot;and&quot;],&quot;conversionCooldownDays&quot;:[0,null],&quot;description&quot;:[0,&quot;Submit a question based on the content you&#39;re exploring.&quot;],&quot;enableABTest&quot;:[0,false],&quot;enableScheduling&quot;:[0,false],&quot;endDate&quot;:[0,&quot;2026-06-30T16:38:00.000Z&quot;],&quot;exclusive&quot;:[0,null],&quot;frequencyHours&quot;:[0,null],&quot;frequencyType&quot;:[0,&quot;always&quot;],&quot;maxImpressions&quot;:[0,null],&quot;name&quot;:[0,&quot;Bispecifics Form - Have a Question?&quot;],&quot;popupRef&quot;:[0,{&quot;_id&quot;:[0,&quot;dbda4169-8373-4738-ac5f-8f000471643d&quot;],&quot;_type&quot;:[0,&quot;popup-form&quot;],&quot;active&quot;:[0,true],&quot;autoClose&quot;:[0,false],&quot;autoCloseSeconds&quot;:[0,null],&quot;blockPageScroll&quot;:[0,true],&quot;closeButtonStyling&quot;:[0,{&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0],&quot;hex&quot;:[0,&quot;#24a3e3&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,200.00000000000006],&quot;l&quot;:[0,0.5155],&quot;s&quot;:[0,0.7731000000000001]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,200.00000000000006],&quot;s&quot;:[0,0.8416601694962386],&quot;v&quot;:[0,0.89006695]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0],&quot;b&quot;:[0,227],&quot;g&quot;:[0,163],&quot;r&quot;:[0,36]}]}],&quot;color&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0],&quot;hex&quot;:[0,&quot;#24a3e3&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,200.00000000000006],&quot;l&quot;:[0,0.5155],&quot;s&quot;:[0,0.7731000000000001]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,200.00000000000006],&quot;s&quot;:[0,0.8416601694962386],&quot;v&quot;:[0,0.89006695]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0],&quot;b&quot;:[0,227],&quot;g&quot;:[0,163],&quot;r&quot;:[0,36]}]}],&quot;position&quot;:[0,&quot;topRight&quot;],&quot;size&quot;:[0,&quot;medium&quot;]}],&quot;closeOnBackdropClick&quot;:[0,false],&quot;closeOnEscape&quot;:[0,false],&quot;contentBlockGap&quot;:[0,24],&quot;contentBlocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;d3efb6d73136&quot;],&quot;_type&quot;:[0,&quot;popupColumnGroup&quot;],&quot;columns&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;92640b8abbb5&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,&quot;solid&quot;],&quot;backgroundGradient&quot;:[0,{&quot;angle&quot;:[0,135],&quot;colorEnd&quot;:[0,null],&quot;colorStart&quot;:[0,null],&quot;gradientType&quot;:[0,&quot;linear&quot;]}],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;6ce0a4f6526d&quot;],&quot;_type&quot;:[0,&quot;popupContentBlock&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,&quot;solid&quot;],&quot;backgroundGradient&quot;:[0,{&quot;angle&quot;:[0,135],&quot;colorEnd&quot;:[0,null],&quot;colorStart&quot;:[0,null],&quot;gradientType&quot;:[0,&quot;linear&quot;]}],&quot;body&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;39b68a0b150f&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;27e389bb0b1a&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Have a Question?&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;h2&quot;],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;e70420562779&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;734b1686cc3c&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;764872613f96&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;b080258acb8e&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[[0,&quot;4baed6dcaedd&quot;]]],&quot;text&quot;:[0,&quot;Submit a question based on the content you&#39;re exploring.&quot;]}]]],&quot;markDefs&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;4baed6dcaedd&quot;],&quot;_type&quot;:[0,&quot;coloredText&quot;],&quot;color&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#718096&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,215.67567567567568],&quot;l&quot;:[0,0.5156862745098039],&quot;s&quot;:[0,0.14979757085020248]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,215.67567567567568],&quot;s&quot;:[0,0.24666666666666673],&quot;v&quot;:[0,0.5882352941176471]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,150],&quot;g&quot;:[0,128],&quot;r&quot;:[0,113]}]}]}]]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;upload_doc&quot;:[0,null]}]]],&quot;bodyFontWeight&quot;:[0,&quot;400&quot;],&quot;bodySize&quot;:[0,16],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,0],&quot;bottomRight&quot;:[0,0],&quot;topLeft&quot;:[0,0],&quot;topRight&quot;:[0,0]}],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,null],&quot;buttonLayout&quot;:[0,null],&quot;buttons&quot;:[0,null],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,null],&quot;fontWeight&quot;:[0,&quot;631&quot;],&quot;formManagerHeight&quot;:[0,null],&quot;formManagerRef&quot;:[0,null],&quot;headingSize&quot;:[0,30],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,1.6],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,0],&quot;left&quot;:[0,0],&quot;right&quot;:[0,0],&quot;top&quot;:[0,0]}],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,&quot;left&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#003768&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,208.2692307692308],&quot;l&quot;:[0,0.20392156862745098],&quot;s&quot;:[0,1]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,208.2692307692308],&quot;s&quot;:[0,1],&quot;v&quot;:[0,0.40784313725490196]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,104],&quot;g&quot;:[0,55],&quot;r&quot;:[0,0]}]}],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,0],&quot;bottomRight&quot;:[0,0],&quot;topLeft&quot;:[0,0],&quot;topRight&quot;:[0,0]}],&quot;gap&quot;:[0,12],&quot;horizontalAlign&quot;:[0,&quot;start&quot;],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,0],&quot;left&quot;:[0,0],&quot;right&quot;:[0,0],&quot;top&quot;:[0,0]}],&quot;verticalAlign&quot;:[0,&quot;start&quot;],&quot;width&quot;:[0,null]}]]],&quot;gap&quot;:[0,24],&quot;hideOn&quot;:[1,[]],&quot;reverseOnMobile&quot;:[0,false],&quot;stackOnMobile&quot;:[0,true]}],[0,{&quot;_key&quot;:[0,&quot;660f54335113&quot;],&quot;_type&quot;:[0,&quot;popupColumnGroup&quot;],&quot;columns&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;39a722b01547&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,&quot;solid&quot;],&quot;backgroundGradient&quot;:[0,{&quot;angle&quot;:[0,135],&quot;colorEnd&quot;:[0,null],&quot;colorStart&quot;:[0,null],&quot;gradientType&quot;:[0,&quot;linear&quot;]}],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;7d1e36878133&quot;],&quot;_type&quot;:[0,&quot;popupFormBlock&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[0,null],&quot;bodyFontWeight&quot;:[0,null],&quot;bodySize&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,null],&quot;buttonLayout&quot;:[0,null],&quot;buttons&quot;:[0,null],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,null],&quot;fontWeight&quot;:[0,null],&quot;formManagerHeight&quot;:[0,600],&quot;formManagerRef&quot;:[0,{&quot;_id&quot;:[0,&quot;4123f29f-06d7-4538-a9eb-dd24379b46d7&quot;],&quot;active&quot;:[0,true],&quot;name&quot;:[0,&quot;Have a Question?(Bispecifics)&quot;]}],&quot;headingSize&quot;:[0,null],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,null],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,null],&quot;textColor&quot;:[0,null],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,0],&quot;bottomRight&quot;:[0,0],&quot;topLeft&quot;:[0,0],&quot;topRight&quot;:[0,0]}],&quot;gap&quot;:[0,12],&quot;horizontalAlign&quot;:[0,&quot;start&quot;],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,0],&quot;left&quot;:[0,16],&quot;right&quot;:[0,16],&quot;top&quot;:[0,0]}],&quot;verticalAlign&quot;:[0,&quot;start&quot;],&quot;width&quot;:[0,null]}]]],&quot;gap&quot;:[0,24],&quot;hideOn&quot;:[1,[[0,&quot;mobile&quot;]]],&quot;reverseOnMobile&quot;:[0,false],&quot;stackOnMobile&quot;:[0,true]}],[0,{&quot;_key&quot;:[0,&quot;69c8c8931454&quot;],&quot;_type&quot;:[0,&quot;popupColumnGroup&quot;],&quot;columns&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;26cfd759b9fc&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,&quot;solid&quot;],&quot;backgroundGradient&quot;:[0,{&quot;angle&quot;:[0,135],&quot;colorEnd&quot;:[0,null],&quot;colorStart&quot;:[0,null],&quot;gradientType&quot;:[0,&quot;linear&quot;]}],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;f94fb27aecc8&quot;],&quot;_type&quot;:[0,&quot;popupFormBlock&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[0,null],&quot;bodyFontWeight&quot;:[0,null],&quot;bodySize&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,null],&quot;buttonLayout&quot;:[0,null],&quot;buttons&quot;:[0,null],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,null],&quot;fontWeight&quot;:[0,null],&quot;formManagerHeight&quot;:[0,750],&quot;formManagerRef&quot;:[0,{&quot;_id&quot;:[0,&quot;4123f29f-06d7-4538-a9eb-dd24379b46d7&quot;],&quot;active&quot;:[0,true],&quot;name&quot;:[0,&quot;Have a Question?(Bispecifics)&quot;]}],&quot;headingSize&quot;:[0,null],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,null],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,null],&quot;textColor&quot;:[0,null],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,0],&quot;bottomRight&quot;:[0,0],&quot;topLeft&quot;:[0,0],&quot;topRight&quot;:[0,0]}],&quot;gap&quot;:[0,12],&quot;horizontalAlign&quot;:[0,&quot;start&quot;],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,0],&quot;left&quot;:[0,16],&quot;right&quot;:[0,16],&quot;top&quot;:[0,0]}],&quot;verticalAlign&quot;:[0,&quot;start&quot;],&quot;width&quot;:[0,100]}]]],&quot;gap&quot;:[0,24],&quot;hideOn&quot;:[1,[[0,&quot;desktop&quot;]]],&quot;reverseOnMobile&quot;:[0,false],&quot;stackOnMobile&quot;:[0,true]}]]],&quot;dismissable&quot;:[0,true],&quot;displayMode&quot;:[0,&quot;inline&quot;],&quot;inlineConfig&quot;:[0,{&quot;contentPercentage&quot;:[0,50],&quot;hideParagraphsBelow&quot;:[0,false],&quot;paragraphIndex&quot;:[0,3],&quot;placementType&quot;:[0,&quot;contentPercentage&quot;]}],&quot;margin&quot;:[0,null],&quot;mobileMargin&quot;:[0,null],&quot;name&quot;:[0,&quot;Bispecifics Form - Have a Question?(CancerNetwork)&quot;],&quot;overlayConfig&quot;:[0,{&quot;backdropOpacity&quot;:[0,50],&quot;position&quot;:[0,&quot;center&quot;],&quot;showBackdrop&quot;:[0,true]}],&quot;parallaxConfig&quot;:[0,{&quot;blendColor&quot;:[0,null],&quot;blendHeight&quot;:[0,96],&quot;customHeight&quot;:[0,null],&quot;edgeBlend&quot;:[0,false],&quot;height&quot;:[0,&quot;75vh&quot;],&quot;overlayStyle&quot;:[0,&quot;none&quot;],&quot;scrollSpeed&quot;:[0,0]}],&quot;showCloseButton&quot;:[0,true],&quot;showSponsoredLabel&quot;:[0,null],&quot;slideInConfig&quot;:[0,{&quot;position&quot;:[0,&quot;bottomRight&quot;]}],&quot;sponsoredLabelText&quot;:[0,null],&quot;stickyConfig&quot;:[0,{&quot;position&quot;:[0,&quot;bottom&quot;]}],&quot;styling&quot;:[0,{&quot;animation&quot;:[0,&quot;fade&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,&quot;gradient&quot;],&quot;backgroundGradient&quot;:[0,{&quot;angle&quot;:[0,180],&quot;colorEnd&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,200.00000000000088],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,200.00000000000088],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;colorStart&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#e3f4fc&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,199.20000000000002],&quot;l&quot;:[0,0.9392156862745098],&quot;s&quot;:[0,0.8064516129032265]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,199.20000000000002],&quot;s&quot;:[0,0.0992063492063493],&quot;v&quot;:[0,0.9882352941176471]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,252],&quot;g&quot;:[0,244],&quot;r&quot;:[0,227]}]}],&quot;gradientType&quot;:[0,&quot;linear&quot;]}],&quot;backgroundImage&quot;:[0,null],&quot;border&quot;:[0,{&quot;bottom&quot;:[0,0],&quot;left&quot;:[0,0],&quot;right&quot;:[0,0],&quot;top&quot;:[0,0]}],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,12],&quot;bottomRight&quot;:[0,12],&quot;topLeft&quot;:[0,12],&quot;topRight&quot;:[0,12]}],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,&quot;px&quot;],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,&quot;px&quot;],&quot;mobileBorder&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobilePadding&quot;:[0,{&quot;bottom&quot;:[0,24],&quot;left&quot;:[0,12],&quot;right&quot;:[0,12],&quot;top&quot;:[0,24]}],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,32],&quot;left&quot;:[0,32],&quot;right&quot;:[0,32],&quot;top&quot;:[0,32]}],&quot;shadow&quot;:[0,&quot;none&quot;],&quot;size&quot;:[0,&quot;fullscreen&quot;]}]}],&quot;priority&quot;:[0,100],&quot;startDate&quot;:[0,&quot;2026-06-09T16:38:00.000Z&quot;],&quot;suppressAfterConversion&quot;:[0,true],&quot;variants&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;12b8dd80-9c7b-4eae-a265-2e9e9b48e321&quot;],&quot;_type&quot;:[0,&quot;marketingCampaign&quot;],&quot;active&quot;:[0,true],&quot;conditionGroups&quot;:[1,[[0,{&quot;enableAuthorCondition&quot;:[0,false],&quot;enableBehavioralCondition&quot;:[0,false],&quot;enableBrandCondition&quot;:[0,null],&quot;enableContentPlacementCondition&quot;:[0,false],&quot;enableDeviceCondition&quot;:[0,false],&quot;enableDocumentGroupCondition&quot;:[0,false],&quot;enableDomainCondition&quot;:[0,null],&quot;enableGeoCondition&quot;:[0,false],&quot;enableReferralSourceCondition&quot;:[0,false],&quot;enableScoutCondition&quot;:[0,null],&quot;enableUrlCondition&quot;:[0,true],&quot;enableUrlParameterCondition&quot;:[0,null],&quot;enableUserCondition&quot;:[0,false],&quot;excludeAuthors&quot;:[0,null],&quot;excludeContentPlacements&quot;:[0,null],&quot;excludeDocumentGroups&quot;:[0,null],&quot;excludeReferralSources&quot;:[0,null],&quot;excludeUrls&quot;:[0,null],&quot;geoRules&quot;:[0,null],&quot;groupName&quot;:[0,null],&quot;pageViewsRequired&quot;:[0,null],&quot;profileFieldConditions&quot;:[0,null],&quot;scoutTopics&quot;:[0,null],&quot;scoutWindow&quot;:[0,null],&quot;scrollPercentage&quot;:[0,null],&quot;targetAuthors&quot;:[0,null],&quot;targetBrands&quot;:[0,null],&quot;targetContentPlacements&quot;:[0,null],&quot;targetDevices&quot;:[0,null],&quot;targetDocumentGroups&quot;:[0,null],&quot;targetDomains&quot;:[0,null],&quot;targetReferralSources&quot;:[0,null],&quot;targetUrls&quot;:[1,[[0,&quot;/view/how-to-treat-depression-in-patients-with-cancer-a-practical-framework&quot;],[0,&quot;/view/how-oncologists-can-navigate-patient-requests-for-medical-aid-in-dying&quot;]]],&quot;timeOnPageSeconds&quot;:[0,null],&quot;triggerType&quot;:[0,&quot;immediate&quot;],&quot;urlMatchType&quot;:[0,&quot;startsWith&quot;],&quot;urlParameterRules&quot;:[0,null],&quot;userLoginState&quot;:[0,&quot;any&quot;],&quot;videoProgressMode&quot;:[0,&quot;percent&quot;],&quot;videoProgressPercent&quot;:[0,null],&quot;videoProgressTimestamp&quot;:[0,{&quot;hours&quot;:[0,0],&quot;minutes&quot;:[0,0],&quot;seconds&quot;:[0,0]}],&quot;videoWatchTimeSeconds&quot;:[0,null]}]]],&quot;conditionLogic&quot;:[0,&quot;or&quot;],&quot;conversionCooldownDays&quot;:[0,null],&quot;description&quot;:[0,null],&quot;enableABTest&quot;:[0,false],&quot;enableScheduling&quot;:[0,true],&quot;endDate&quot;:[0,&quot;2026-10-18T23:59:00.000Z&quot;],&quot;exclusive&quot;:[0,null],&quot;frequencyHours&quot;:[0,null],&quot;frequencyType&quot;:[0,&quot;session&quot;],&quot;maxImpressions&quot;:[0,null],&quot;name&quot;:[0,&quot;Psycho-Oncology Podcast Sticky Banner&quot;],&quot;popupRef&quot;:[0,{&quot;_id&quot;:[0,&quot;33b1a077-0947-4cd1-803d-6e46dbd3d5d5&quot;],&quot;_type&quot;:[0,&quot;popup-form&quot;],&quot;active&quot;:[0,true],&quot;autoClose&quot;:[0,null],&quot;autoCloseSeconds&quot;:[0,null],&quot;blockPageScroll&quot;:[0,null],&quot;closeButtonStyling&quot;:[0,{&quot;backgroundColor&quot;:[0,null],&quot;color&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.7],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.7],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.7],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.7],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;position&quot;:[0,&quot;topRight&quot;],&quot;size&quot;:[0,&quot;small&quot;]}],&quot;closeOnBackdropClick&quot;:[0,null],&quot;closeOnEscape&quot;:[0,false],&quot;contentBlockGap&quot;:[0,0],&quot;contentBlocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;g1&quot;],&quot;_type&quot;:[0,&quot;popupColumnGroup&quot;],&quot;columns&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;col1&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;txt1&quot;],&quot;_type&quot;:[0,&quot;popupContentBlock&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;ca81cd46777c&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;h1s&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Cancer Network is here for the Psycho-Oncology Community&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;h2&quot;],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;p1&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;p1s&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Make an account to personalize your experience and never miss content relevant to your practice.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;upload_doc&quot;:[0,null]}]]],&quot;bodyFontWeight&quot;:[0,&quot;594&quot;],&quot;bodySize&quot;:[0,16],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,null],&quot;buttonLayout&quot;:[0,null],&quot;buttons&quot;:[0,null],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;743&quot;],&quot;formManagerHeight&quot;:[0,null],&quot;formManagerRef&quot;:[0,null],&quot;headingSize&quot;:[0,20],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,1.4],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,&quot;left&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,null],&quot;gap&quot;:[0,null],&quot;horizontalAlign&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;verticalAlign&quot;:[0,&quot;center&quot;],&quot;width&quot;:[0,65]}],[0,{&quot;_key&quot;:[0,&quot;col2&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;btn1&quot;],&quot;_type&quot;:[0,&quot;popupButtonGroup&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[0,null],&quot;bodyFontWeight&quot;:[0,null],&quot;bodySize&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,12],&quot;buttonLayout&quot;:[0,&quot;sideBySide&quot;],&quot;buttons&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;b1&quot;],&quot;action&quot;:[0,&quot;navigate&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,6],&quot;bottomRight&quot;:[0,6],&quot;topLeft&quot;:[0,6],&quot;topRight&quot;:[0,6]}],&quot;buttonCustomWidth&quot;:[0,null],&quot;buttonWidth&quot;:[0,&quot;auto&quot;],&quot;countsAs&quot;:[0,&quot;conversion&quot;],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;600&quot;],&quot;hoverColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#e2e8f0&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,214.28571428571428],&quot;l&quot;:[0,0.9137254901960784],&quot;s&quot;:[0,0.31818181818181823]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,214.28571428571428],&quot;s&quot;:[0,0.05833333333333336],&quot;v&quot;:[0,0.9411764705882353]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,240],&quot;g&quot;:[0,232],&quot;r&quot;:[0,226]}]}],&quot;hoverColorType&quot;:[0,null],&quot;hoverGradient&quot;:[0,null],&quot;hoverTextColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;keepOpenOnClick&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;mobileTextSize&quot;:[0,null],&quot;openInNewTab&quot;:[0,true],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,10],&quot;left&quot;:[0,24],&quot;right&quot;:[0,24],&quot;top&quot;:[0,10]}],&quot;shadow&quot;:[0,null],&quot;subtitle&quot;:[0,null],&quot;subtitleColor&quot;:[0,null],&quot;subtitleFontWeight&quot;:[0,null],&quot;subtitleSize&quot;:[0,null],&quot;text&quot;:[0,&quot;Create An Account&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;textSize&quot;:[0,14],&quot;url&quot;:[0,&quot;https://id.mjhlifesciences.com/login?client_id=72sqb1hdl874l7itgfjdcgd93r&amp;redirect_uri=https%3a%2f%2fwww.cancernetwork.com%2fauth%2fcallback&amp;response_type=code&amp;scope=openid+email+profile&amp;state=ofjdedakcrtarobcubjfzsdsp62h5g6a&amp;code_challenge=lgq_3udtrpawmis-v9vwnzpjmc5pf44px3x_4fvunsy&amp;code_challenge_method=s256&amp;oauth_flow=true&amp;utm_medium=banner&amp;utm_source=mkt_layer&amp;utm_campaign=psych_onc_signup&quot;]}],[0,{&quot;_key&quot;:[0,&quot;b2&quot;],&quot;action&quot;:[0,&quot;auth&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;border&quot;:[0,{&quot;bottom&quot;:[0,1],&quot;left&quot;:[0,1],&quot;right&quot;:[0,1],&quot;top&quot;:[0,1]}],&quot;borderColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.25],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.25],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.25],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.25],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,6],&quot;bottomRight&quot;:[0,6],&quot;topLeft&quot;:[0,6],&quot;topRight&quot;:[0,6]}],&quot;buttonCustomWidth&quot;:[0,null],&quot;buttonWidth&quot;:[0,&quot;auto&quot;],&quot;countsAs&quot;:[0,null],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;400&quot;],&quot;hoverColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;hoverColorType&quot;:[0,null],&quot;hoverGradient&quot;:[0,null],&quot;hoverTextColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;keepOpenOnClick&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;mobileTextSize&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,10],&quot;left&quot;:[0,16],&quot;right&quot;:[0,16],&quot;top&quot;:[0,10]}],&quot;shadow&quot;:[0,null],&quot;subtitle&quot;:[0,null],&quot;subtitleColor&quot;:[0,null],&quot;subtitleFontWeight&quot;:[0,null],&quot;subtitleSize&quot;:[0,null],&quot;text&quot;:[0,&quot;Sign In&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.6],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.6],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.6],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.6],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;textSize&quot;:[0,13],&quot;url&quot;:[0,null]}]]],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,null],&quot;fontWeight&quot;:[0,null],&quot;formManagerHeight&quot;:[0,null],&quot;formManagerRef&quot;:[0,null],&quot;headingSize&quot;:[0,null],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,null],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,null],&quot;textColor&quot;:[0,null],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,null],&quot;gap&quot;:[0,null],&quot;horizontalAlign&quot;:[0,&quot;end&quot;],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;verticalAlign&quot;:[0,&quot;center&quot;],&quot;width&quot;:[0,35]}]]],&quot;gap&quot;:[0,24],&quot;hideOn&quot;:[0,null],&quot;reverseOnMobile&quot;:[0,null],&quot;stackOnMobile&quot;:[0,true]}]]],&quot;dismissable&quot;:[0,true],&quot;displayMode&quot;:[0,&quot;sticky&quot;],&quot;inlineConfig&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileMargin&quot;:[0,null],&quot;name&quot;:[0,&quot;Podcast Psycho-Oncologist Sticky&quot;],&quot;overlayConfig&quot;:[0,null],&quot;parallaxConfig&quot;:[0,null],&quot;showCloseButton&quot;:[0,true],&quot;showSponsoredLabel&quot;:[0,null],&quot;slideInConfig&quot;:[0,null],&quot;sponsoredLabelText&quot;:[0,null],&quot;stickyConfig&quot;:[0,{&quot;position&quot;:[0,&quot;bottom&quot;]}],&quot;styling&quot;:[0,{&quot;animation&quot;:[0,&quot;rise&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;backgroundImage&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,0],&quot;bottomRight&quot;:[0,0],&quot;topLeft&quot;:[0,0],&quot;topRight&quot;:[0,0]}],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;mobileBorder&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,16],&quot;left&quot;:[0,55],&quot;right&quot;:[0,55],&quot;top&quot;:[0,16]}],&quot;shadow&quot;:[0,&quot;medium&quot;],&quot;size&quot;:[0,&quot;large&quot;]}]}],&quot;priority&quot;:[0,37],&quot;startDate&quot;:[0,&quot;2026-09-20T23:59:00.000Z&quot;],&quot;suppressAfterConversion&quot;:[0,true],&quot;variants&quot;:[0,null]}],[0,{&quot;_id&quot;:[0,&quot;b5cfddf0-9b2e-4ad4-a3fe-8f0eb648893a&quot;],&quot;_type&quot;:[0,&quot;marketingCampaign&quot;],&quot;active&quot;:[0,true],&quot;conditionGroups&quot;:[1,[[0,{&quot;enableAuthorCondition&quot;:[0,false],&quot;enableBehavioralCondition&quot;:[0,false],&quot;enableBrandCondition&quot;:[0,null],&quot;enableContentPlacementCondition&quot;:[0,false],&quot;enableDeviceCondition&quot;:[0,false],&quot;enableDocumentGroupCondition&quot;:[0,false],&quot;enableDomainCondition&quot;:[0,null],&quot;enableGeoCondition&quot;:[0,false],&quot;enableReferralSourceCondition&quot;:[0,false],&quot;enableScoutCondition&quot;:[0,null],&quot;enableUrlCondition&quot;:[0,true],&quot;enableUrlParameterCondition&quot;:[0,null],&quot;enableUserCondition&quot;:[0,false],&quot;excludeAuthors&quot;:[0,null],&quot;excludeContentPlacements&quot;:[0,null],&quot;excludeDocumentGroups&quot;:[0,null],&quot;excludeReferralSources&quot;:[0,null],&quot;excludeUrls&quot;:[0,null],&quot;geoRules&quot;:[0,null],&quot;groupName&quot;:[0,null],&quot;pageViewsRequired&quot;:[0,null],&quot;profileFieldConditions&quot;:[0,null],&quot;scoutTopics&quot;:[0,null],&quot;scoutWindow&quot;:[0,null],&quot;scrollPercentage&quot;:[0,null],&quot;targetAuthors&quot;:[0,null],&quot;targetBrands&quot;:[0,null],&quot;targetContentPlacements&quot;:[0,null],&quot;targetDevices&quot;:[0,null],&quot;targetDocumentGroups&quot;:[0,null],&quot;targetDomains&quot;:[0,null],&quot;targetReferralSources&quot;:[0,null],&quot;targetUrls&quot;:[1,[[0,&quot;/view/elinzanetant-enhances-qol-despite-prior-endocrine-therapy-in-breast-cancer&quot;],[0,&quot;/view/perceived-social-support-anxiety-and-depression-among-women-with-breast-cancer&quot;],[0,&quot;/view/scaling-integrative-oncology-implementation-and-patient-reported-outcomes&quot;],[0,&quot;/view/cbt-framework-shows-feasibility-in-pediatric-oncology-caregivers&quot;],[0,&quot;/view/the-intersection-of-technology-and-psycho-oncology-care&quot;],[0,&quot;/view/strategies-for-managing-cancer-related-fatigue-impact-on-cognitive-function&quot;],[0,&quot;/view/considering-venlafaxine-as-distress-treatment-in-breast-cancer&quot;],[0,&quot;/view/why-cognitive-behavioral-therapy-for-insomnia-remains-the-gold-standard-in-oncology&quot;],[0,&quot;/view/spotlighting-a-program-aimed-at-improving-sleep-and-well-being-in-oncology&quot;],[0,&quot;/view/the-evolution-of-distress-screening-in-cancer-care&quot;],[0,&quot;/view/auditory-attention-decay-noted-post-treatment-in-pediatric-cerebellar-tumors&quot;],[0,&quot;/view/psychosocial-support-for-treatment-related-challenges-in-relapsed-refractory-multiple-myeloma&quot;],[0,&quot;/view/delirium-palliative-care&quot;],[0,&quot;/view/the-emotional-impact-of-relapsed-refractory-multiple-myeloma&quot;],[0,&quot;/view/suicide-patients-cancer-identifying-risk-factors&quot;],[0,&quot;/view/antidepressants-patients-advanced-cancer-when-theyre-warranted-and-how-choose-therapy&quot;],[0,&quot;/view/onco-anxiology-framework-targets-anxiety-across-the-cancer-care-continuum&quot;],[0,&quot;/view/rising-psa-level-anxious-postprostatectomy-patient&quot;],[0,&quot;/view/diagnosing-and-managing-delirium-cancer-patients&quot;],[0,&quot;/view/managing-insomnia-in-cancer-care-sleep-hygiene-cbt-i-and-medications&quot;],[0,&quot;/view/how-mentorship-and-peer-support-help-oncologists-avoid-burnout&quot;],[0,&quot;/view/journal-psycho-oncology-and-the-relevance-of-a-biopsychosocial-screening-program&quot;],[0,&quot;/view/giving-honest-information-patients-advanced-cancer-maintains-hope&quot;],[0,&quot;/view/distress-screening-making-the-fifth-vital-sign-integral-to-oncology-care&quot;],[0,&quot;/view/what-does-an-end-of-life-doula-do-for-patients-with-cancer&quot;],[0,&quot;/view/it-drug-related-akathisia-or-anxiety-diagnostic-dilemma&quot;],[0,&quot;/view/burnout-oncology&quot;],[0,&quot;/view/patients-had-inaccurate-expectations-well-being-after-mastectomy&quot;],[0,&quot;/view/what-patterns-are-seen-physician-assisted-suicides&quot;],[0,&quot;/view/understanding-the-training-credentialing-landscapes-for-end-of-life-doulas&quot;],[0,&quot;/view/stress-and-burnout-oncology&quot;],[0,&quot;/view/addressing-psychological-challenges-after-cancer-guide-clinical-practice&quot;],[0,&quot;/view/parents-childhood-cancer-survivors-may-show-symptoms-post-traumatic-stress&quot;],[0,&quot;/view/human-side-cancer-offers-insights-coping-disease&quot;],[0,&quot;/view/how-end-of-life-doulas-help-patients-exercise-autonomy-in-their-care&quot;],[0,&quot;/view/updated-sio-asco-guidelines-recommend-integrative-therapies-to-reduce-anxiety-depression-in-patients-with-cancer&quot;],[0,&quot;/view/sexuality-and-body-image-concerns-after-treatment-breast-cancer&quot;],[0,&quot;/view/psychological-and-social-aspects-breast-cancer&quot;],[0,&quot;/view/monitors-and-blunters-different-patient-coping-styles&quot;],[0,&quot;/view/mindfulness-meditation&quot;],[0,&quot;/view/anxiety-depression-women-high-risk-breast-cancer&quot;],[0,&quot;/view/workplace-burnout-among-oncologists-has-risen-what-can-be-done-&quot;],[0,&quot;/view/psycho-oncology-is-a-core-component-of-comprehensive-cancer-care&quot;],[0,&quot;/view/exercise-psychological-interventions-best-reducing-cancer-related-fatigue&quot;],[0,&quot;/view/discussing-mental-health-disorders-and-cancer-treatment-outcomes&quot;],[0,&quot;/view/childhood-cancer-survivors-may-be-at-high-risks-for-loneliness&quot;],[0,&quot;/view/calm-approach-relieving-and-preventing-depression-advanced-cancer&quot;],[0,&quot;/view/delirium-often-misdiagnosed-advanced-cancer&quot;],[0,&quot;/view/beyond-the-tumor-addressing-body-image-in-oncology&quot;],[0,&quot;/view/screening-emotional-distress-older-patients-lung-cancer&quot;],[0,&quot;/view/how-do-mental-health-disorders-impact-all-cause-cancer-mortality-&quot;],[0,&quot;/view/emotional-distress-may-confer-worse-immunotherapy-outcomes-in-nsclc&quot;],[0,&quot;/view/depression-many-cancer-patients-may-go-undiagnosed&quot;],[0,&quot;/view/coping-chemobrain&quot;],[0,&quot;/view/supportive-care-patient-pancreatic-cancer-role-psycho-oncologist&quot;],[0,&quot;/view/psychosocial-cancer-care-has-direct-ties-to-qol-emotional-well-being&quot;],[0,&quot;/view/psychiatric-care-lung-cancer-patients&quot;],[0,&quot;/view/integrating-mental-health-screenings-into-early-routine-cancer-care&quot;],[0,&quot;/view/hormone-therapy-prostate-cancer-linked-depression&quot;],[0,&quot;/view/depression-cancer-patients&quot;],[0,&quot;/view/advocating-for-psycho-social-oncology-care&quot;]]],&quot;timeOnPageSeconds&quot;:[0,null],&quot;triggerType&quot;:[0,&quot;immediate&quot;],&quot;urlMatchType&quot;:[0,&quot;startsWith&quot;],&quot;urlParameterRules&quot;:[0,null],&quot;userLoginState&quot;:[0,&quot;any&quot;],&quot;videoProgressMode&quot;:[0,&quot;percent&quot;],&quot;videoProgressPercent&quot;:[0,null],&quot;videoProgressTimestamp&quot;:[0,{&quot;hours&quot;:[0,0],&quot;minutes&quot;:[0,0],&quot;seconds&quot;:[0,0]}],&quot;videoWatchTimeSeconds&quot;:[0,null]}]]],&quot;conditionLogic&quot;:[0,&quot;or&quot;],&quot;conversionCooldownDays&quot;:[0,null],&quot;description&quot;:[0,null],&quot;enableABTest&quot;:[0,true],&quot;enableScheduling&quot;:[0,true],&quot;endDate&quot;:[0,&quot;2026-10-18T23:59:00.000Z&quot;],&quot;exclusive&quot;:[0,null],&quot;frequencyHours&quot;:[0,null],&quot;frequencyType&quot;:[0,&quot;session&quot;],&quot;maxImpressions&quot;:[0,null],&quot;name&quot;:[0,&quot;Psycho-Oncology Mapping&quot;],&quot;popupRef&quot;:[0,{&quot;_id&quot;:[0,&quot;GQVU06hOSTmzD9h8lsswwN&quot;],&quot;_type&quot;:[0,&quot;popup-form&quot;],&quot;active&quot;:[0,true],&quot;autoClose&quot;:[0,null],&quot;autoCloseSeconds&quot;:[0,null],&quot;blockPageScroll&quot;:[0,null],&quot;closeButtonStyling&quot;:[0,{&quot;backgroundColor&quot;:[0,null],&quot;color&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.7],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.7],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.7],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.7],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;position&quot;:[0,&quot;topRight&quot;],&quot;size&quot;:[0,&quot;small&quot;]}],&quot;closeOnBackdropClick&quot;:[0,null],&quot;closeOnEscape&quot;:[0,false],&quot;contentBlockGap&quot;:[0,0],&quot;contentBlocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;g1&quot;],&quot;_type&quot;:[0,&quot;popupColumnGroup&quot;],&quot;columns&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;col1&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;txt1&quot;],&quot;_type&quot;:[0,&quot;popupContentBlock&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;h1&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;h1s&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Cancer Network is here for the Psycho-Oncology Community&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;h2&quot;],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;p1&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;p1s&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Make an account to personalize your experience and never miss content relevant to your practice.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;upload_doc&quot;:[0,null]}]]],&quot;bodyFontWeight&quot;:[0,&quot;594&quot;],&quot;bodySize&quot;:[0,16],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,null],&quot;buttonLayout&quot;:[0,null],&quot;buttons&quot;:[0,null],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;743&quot;],&quot;formManagerHeight&quot;:[0,null],&quot;formManagerRef&quot;:[0,null],&quot;headingSize&quot;:[0,28],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,1.4],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,&quot;left&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,null],&quot;gap&quot;:[0,null],&quot;horizontalAlign&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;verticalAlign&quot;:[0,&quot;center&quot;],&quot;width&quot;:[0,65]}],[0,{&quot;_key&quot;:[0,&quot;col2&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;btn1&quot;],&quot;_type&quot;:[0,&quot;popupButtonGroup&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[0,null],&quot;bodyFontWeight&quot;:[0,null],&quot;bodySize&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,12],&quot;buttonLayout&quot;:[0,&quot;sideBySide&quot;],&quot;buttons&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;b1&quot;],&quot;action&quot;:[0,&quot;navigate&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,6],&quot;bottomRight&quot;:[0,6],&quot;topLeft&quot;:[0,6],&quot;topRight&quot;:[0,6]}],&quot;buttonCustomWidth&quot;:[0,null],&quot;buttonWidth&quot;:[0,&quot;auto&quot;],&quot;countsAs&quot;:[0,&quot;conversion&quot;],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;600&quot;],&quot;hoverColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#e2e8f0&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,214.28571428571428],&quot;l&quot;:[0,0.9137254901960784],&quot;s&quot;:[0,0.31818181818181823]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,214.28571428571428],&quot;s&quot;:[0,0.05833333333333336],&quot;v&quot;:[0,0.9411764705882353]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,240],&quot;g&quot;:[0,232],&quot;r&quot;:[0,226]}]}],&quot;hoverColorType&quot;:[0,null],&quot;hoverGradient&quot;:[0,null],&quot;hoverTextColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;keepOpenOnClick&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;mobileTextSize&quot;:[0,null],&quot;openInNewTab&quot;:[0,true],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,10],&quot;left&quot;:[0,24],&quot;right&quot;:[0,24],&quot;top&quot;:[0,10]}],&quot;shadow&quot;:[0,null],&quot;subtitle&quot;:[0,null],&quot;subtitleColor&quot;:[0,null],&quot;subtitleFontWeight&quot;:[0,null],&quot;subtitleSize&quot;:[0,null],&quot;text&quot;:[0,&quot;Create An Account&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;textSize&quot;:[0,14],&quot;url&quot;:[0,&quot;https://id.mjhlifesciences.com/login?client_id=72sqb1hdl874l7itgfjdcgd93r&amp;redirect_uri=https%3a%2f%2fwww.cancernetwork.com%2fauth%2fcallback&amp;response_type=code&amp;scope=openid+email+profile&amp;state=ofjdedakcrtarobcubjfzsdsp62h5g6a&amp;code_challenge=lgq_3udtrpawmis-v9vwnzpjmc5pf44px3x_4fvunsy&amp;code_challenge_method=s256&amp;oauth_flow=true&amp;utm_medium=banner&amp;utm_source=mkt_layer&amp;utm_campaign=psych_onc_a&quot;]}],[0,{&quot;_key&quot;:[0,&quot;b2&quot;],&quot;action&quot;:[0,&quot;auth&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;border&quot;:[0,{&quot;bottom&quot;:[0,1],&quot;left&quot;:[0,1],&quot;right&quot;:[0,1],&quot;top&quot;:[0,1]}],&quot;borderColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.25],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.25],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.25],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.25],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,6],&quot;bottomRight&quot;:[0,6],&quot;topLeft&quot;:[0,6],&quot;topRight&quot;:[0,6]}],&quot;buttonCustomWidth&quot;:[0,null],&quot;buttonWidth&quot;:[0,&quot;auto&quot;],&quot;countsAs&quot;:[0,null],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;400&quot;],&quot;hoverColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;hoverColorType&quot;:[0,null],&quot;hoverGradient&quot;:[0,null],&quot;hoverTextColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;keepOpenOnClick&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;mobileTextSize&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,10],&quot;left&quot;:[0,16],&quot;right&quot;:[0,16],&quot;top&quot;:[0,10]}],&quot;shadow&quot;:[0,null],&quot;subtitle&quot;:[0,null],&quot;subtitleColor&quot;:[0,null],&quot;subtitleFontWeight&quot;:[0,null],&quot;subtitleSize&quot;:[0,null],&quot;text&quot;:[0,&quot;Sign In&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.6],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.6],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.6],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.6],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;textSize&quot;:[0,13],&quot;url&quot;:[0,null]}]]],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,null],&quot;fontWeight&quot;:[0,null],&quot;formManagerHeight&quot;:[0,null],&quot;formManagerRef&quot;:[0,null],&quot;headingSize&quot;:[0,null],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,null],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,null],&quot;textColor&quot;:[0,null],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,null],&quot;gap&quot;:[0,null],&quot;horizontalAlign&quot;:[0,&quot;end&quot;],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;verticalAlign&quot;:[0,&quot;center&quot;],&quot;width&quot;:[0,35]}]]],&quot;gap&quot;:[0,24],&quot;hideOn&quot;:[0,null],&quot;reverseOnMobile&quot;:[0,null],&quot;stackOnMobile&quot;:[0,true]}]]],&quot;dismissable&quot;:[0,true],&quot;displayMode&quot;:[0,&quot;sticky&quot;],&quot;inlineConfig&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileMargin&quot;:[0,null],&quot;name&quot;:[0,&quot;Psycho-Oncologist Sticky A (Sign In)&quot;],&quot;overlayConfig&quot;:[0,null],&quot;parallaxConfig&quot;:[0,null],&quot;showCloseButton&quot;:[0,true],&quot;showSponsoredLabel&quot;:[0,null],&quot;slideInConfig&quot;:[0,null],&quot;sponsoredLabelText&quot;:[0,null],&quot;stickyConfig&quot;:[0,{&quot;position&quot;:[0,&quot;bottom&quot;]}],&quot;styling&quot;:[0,{&quot;animation&quot;:[0,&quot;rise&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;backgroundImage&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,0],&quot;bottomRight&quot;:[0,0],&quot;topLeft&quot;:[0,0],&quot;topRight&quot;:[0,0]}],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;mobileBorder&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,16],&quot;left&quot;:[0,55],&quot;right&quot;:[0,55],&quot;top&quot;:[0,16]}],&quot;shadow&quot;:[0,&quot;medium&quot;],&quot;size&quot;:[0,&quot;large&quot;]}]}],&quot;priority&quot;:[0,37],&quot;startDate&quot;:[0,&quot;2026-09-20T23:59:00.000Z&quot;],&quot;suppressAfterConversion&quot;:[0,true],&quot;variants&quot;:[1,[[0,{&quot;popup&quot;:[0,{&quot;_id&quot;:[0,&quot;GQVU06hOSTmzD9h8lsswwN&quot;],&quot;_type&quot;:[0,&quot;popup-form&quot;],&quot;active&quot;:[0,true],&quot;autoClose&quot;:[0,null],&quot;autoCloseSeconds&quot;:[0,null],&quot;blockPageScroll&quot;:[0,null],&quot;closeButtonStyling&quot;:[0,{&quot;backgroundColor&quot;:[0,null],&quot;color&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.7],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.7],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.7],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.7],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;position&quot;:[0,&quot;topRight&quot;],&quot;size&quot;:[0,&quot;small&quot;]}],&quot;closeOnBackdropClick&quot;:[0,null],&quot;closeOnEscape&quot;:[0,false],&quot;contentBlockGap&quot;:[0,0],&quot;contentBlocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;g1&quot;],&quot;_type&quot;:[0,&quot;popupColumnGroup&quot;],&quot;columns&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;col1&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;txt1&quot;],&quot;_type&quot;:[0,&quot;popupContentBlock&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;h1&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;h1s&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Cancer Network is here for the Psycho-Oncology Community&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;h2&quot;],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;p1&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;p1s&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Make an account to personalize your experience and never miss content relevant to your practice.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;upload_doc&quot;:[0,null]}]]],&quot;bodyFontWeight&quot;:[0,&quot;594&quot;],&quot;bodySize&quot;:[0,16],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,null],&quot;buttonLayout&quot;:[0,null],&quot;buttons&quot;:[0,null],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;743&quot;],&quot;formManagerHeight&quot;:[0,null],&quot;formManagerRef&quot;:[0,null],&quot;headingSize&quot;:[0,28],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,1.4],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,&quot;left&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,null],&quot;gap&quot;:[0,null],&quot;horizontalAlign&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;verticalAlign&quot;:[0,&quot;center&quot;],&quot;width&quot;:[0,65]}],[0,{&quot;_key&quot;:[0,&quot;col2&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;btn1&quot;],&quot;_type&quot;:[0,&quot;popupButtonGroup&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[0,null],&quot;bodyFontWeight&quot;:[0,null],&quot;bodySize&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,12],&quot;buttonLayout&quot;:[0,&quot;sideBySide&quot;],&quot;buttons&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;b1&quot;],&quot;action&quot;:[0,&quot;navigate&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,6],&quot;bottomRight&quot;:[0,6],&quot;topLeft&quot;:[0,6],&quot;topRight&quot;:[0,6]}],&quot;buttonCustomWidth&quot;:[0,null],&quot;buttonWidth&quot;:[0,&quot;auto&quot;],&quot;countsAs&quot;:[0,&quot;conversion&quot;],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;600&quot;],&quot;hoverColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#e2e8f0&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,214.28571428571428],&quot;l&quot;:[0,0.9137254901960784],&quot;s&quot;:[0,0.31818181818181823]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,214.28571428571428],&quot;s&quot;:[0,0.05833333333333336],&quot;v&quot;:[0,0.9411764705882353]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,240],&quot;g&quot;:[0,232],&quot;r&quot;:[0,226]}]}],&quot;hoverColorType&quot;:[0,null],&quot;hoverGradient&quot;:[0,null],&quot;hoverTextColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;keepOpenOnClick&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;mobileTextSize&quot;:[0,null],&quot;openInNewTab&quot;:[0,true],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,10],&quot;left&quot;:[0,24],&quot;right&quot;:[0,24],&quot;top&quot;:[0,10]}],&quot;shadow&quot;:[0,null],&quot;subtitle&quot;:[0,null],&quot;subtitleColor&quot;:[0,null],&quot;subtitleFontWeight&quot;:[0,null],&quot;subtitleSize&quot;:[0,null],&quot;text&quot;:[0,&quot;Create An Account&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;textSize&quot;:[0,14],&quot;url&quot;:[0,&quot;https://id.mjhlifesciences.com/login?client_id=72sqb1hdl874l7itgfjdcgd93r&amp;redirect_uri=https%3a%2f%2fwww.cancernetwork.com%2fauth%2fcallback&amp;response_type=code&amp;scope=openid+email+profile&amp;state=ofjdedakcrtarobcubjfzsdsp62h5g6a&amp;code_challenge=lgq_3udtrpawmis-v9vwnzpjmc5pf44px3x_4fvunsy&amp;code_challenge_method=s256&amp;oauth_flow=true&amp;utm_medium=banner&amp;utm_source=mkt_layer&amp;utm_campaign=psych_onc_a&quot;]}],[0,{&quot;_key&quot;:[0,&quot;b2&quot;],&quot;action&quot;:[0,&quot;auth&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;border&quot;:[0,{&quot;bottom&quot;:[0,1],&quot;left&quot;:[0,1],&quot;right&quot;:[0,1],&quot;top&quot;:[0,1]}],&quot;borderColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.25],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.25],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.25],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.25],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,6],&quot;bottomRight&quot;:[0,6],&quot;topLeft&quot;:[0,6],&quot;topRight&quot;:[0,6]}],&quot;buttonCustomWidth&quot;:[0,null],&quot;buttonWidth&quot;:[0,&quot;auto&quot;],&quot;countsAs&quot;:[0,null],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;400&quot;],&quot;hoverColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;hoverColorType&quot;:[0,null],&quot;hoverGradient&quot;:[0,null],&quot;hoverTextColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;keepOpenOnClick&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;mobileTextSize&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,10],&quot;left&quot;:[0,16],&quot;right&quot;:[0,16],&quot;top&quot;:[0,10]}],&quot;shadow&quot;:[0,null],&quot;subtitle&quot;:[0,null],&quot;subtitleColor&quot;:[0,null],&quot;subtitleFontWeight&quot;:[0,null],&quot;subtitleSize&quot;:[0,null],&quot;text&quot;:[0,&quot;Sign In&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.6],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.6],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.6],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.6],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;textSize&quot;:[0,13],&quot;url&quot;:[0,null]}]]],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,null],&quot;fontWeight&quot;:[0,null],&quot;formManagerHeight&quot;:[0,null],&quot;formManagerRef&quot;:[0,null],&quot;headingSize&quot;:[0,null],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,null],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,null],&quot;textColor&quot;:[0,null],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,null],&quot;gap&quot;:[0,null],&quot;horizontalAlign&quot;:[0,&quot;end&quot;],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;verticalAlign&quot;:[0,&quot;center&quot;],&quot;width&quot;:[0,35]}]]],&quot;gap&quot;:[0,24],&quot;hideOn&quot;:[0,null],&quot;reverseOnMobile&quot;:[0,null],&quot;stackOnMobile&quot;:[0,true]}]]],&quot;dismissable&quot;:[0,true],&quot;displayMode&quot;:[0,&quot;sticky&quot;],&quot;inlineConfig&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileMargin&quot;:[0,null],&quot;name&quot;:[0,&quot;Psycho-Oncologist Sticky A (Sign In)&quot;],&quot;overlayConfig&quot;:[0,null],&quot;parallaxConfig&quot;:[0,null],&quot;showCloseButton&quot;:[0,true],&quot;showSponsoredLabel&quot;:[0,null],&quot;slideInConfig&quot;:[0,null],&quot;sponsoredLabelText&quot;:[0,null],&quot;stickyConfig&quot;:[0,{&quot;position&quot;:[0,&quot;bottom&quot;]}],&quot;styling&quot;:[0,{&quot;animation&quot;:[0,&quot;rise&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;backgroundImage&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,0],&quot;bottomRight&quot;:[0,0],&quot;topLeft&quot;:[0,0],&quot;topRight&quot;:[0,0]}],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;mobileBorder&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,16],&quot;left&quot;:[0,55],&quot;right&quot;:[0,55],&quot;top&quot;:[0,16]}],&quot;shadow&quot;:[0,&quot;medium&quot;],&quot;size&quot;:[0,&quot;large&quot;]}]}],&quot;variantWeight&quot;:[0,50]}],[0,{&quot;popup&quot;:[0,{&quot;_id&quot;:[0,&quot;JGH2pUIgN0Zz8oOYjYnhow&quot;],&quot;_type&quot;:[0,&quot;popup-form&quot;],&quot;active&quot;:[0,true],&quot;autoClose&quot;:[0,null],&quot;autoCloseSeconds&quot;:[0,null],&quot;blockPageScroll&quot;:[0,null],&quot;closeButtonStyling&quot;:[0,{&quot;backgroundColor&quot;:[0,null],&quot;color&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,0.7],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,0.7],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,0.7],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,0.7],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;position&quot;:[0,&quot;topRight&quot;],&quot;size&quot;:[0,&quot;small&quot;]}],&quot;closeOnBackdropClick&quot;:[0,null],&quot;closeOnEscape&quot;:[0,false],&quot;contentBlockGap&quot;:[0,0],&quot;contentBlocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;g1&quot;],&quot;_type&quot;:[0,&quot;popupColumnGroup&quot;],&quot;columns&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;col1&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;txt1&quot;],&quot;_type&quot;:[0,&quot;popupContentBlock&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;h1&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;h1s&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Go Deeper With The Oncology On The Go Podcast&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;h2&quot;],&quot;upload_doc&quot;:[0,null]}],[0,{&quot;_key&quot;:[0,&quot;p1&quot;],&quot;_type&quot;:[0,&quot;block&quot;],&quot;asset&quot;:[0,null],&quot;children&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;p1s&quot;],&quot;_type&quot;:[0,&quot;span&quot;],&quot;marks&quot;:[1,[]],&quot;text&quot;:[0,&quot;Dr. Daniel C. McFarland, DO, discusses treating depression in patients with cancer.&quot;]}]]],&quot;markDefs&quot;:[1,[]],&quot;medias&quot;:[0,null],&quot;style&quot;:[0,&quot;normal&quot;],&quot;upload_doc&quot;:[0,null]}]]],&quot;bodyFontWeight&quot;:[0,&quot;586&quot;],&quot;bodySize&quot;:[0,16],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,null],&quot;buttonLayout&quot;:[0,null],&quot;buttons&quot;:[0,null],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;737&quot;],&quot;formManagerHeight&quot;:[0,null],&quot;formManagerRef&quot;:[0,null],&quot;headingSize&quot;:[0,20],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,1.4],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,&quot;left&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,null],&quot;gap&quot;:[0,null],&quot;horizontalAlign&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;verticalAlign&quot;:[0,&quot;center&quot;],&quot;width&quot;:[0,65]}],[0,{&quot;_key&quot;:[0,&quot;col2&quot;],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;blocks&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;btn1&quot;],&quot;_type&quot;:[0,&quot;popupButtonGroup&quot;],&quot;action&quot;:[0,null],&quot;alt&quot;:[0,null],&quot;aspectRatio&quot;:[0,null],&quot;autoplay&quot;:[0,null],&quot;backgroundColor&quot;:[0,null],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;body&quot;:[0,null],&quot;bodyFontWeight&quot;:[0,null],&quot;bodySize&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,null],&quot;brightcoveVideoId&quot;:[0,null],&quot;buttonAlign&quot;:[0,null],&quot;buttonDistribution&quot;:[0,null],&quot;buttonGap&quot;:[0,12],&quot;buttonLayout&quot;:[0,&quot;sideBySide&quot;],&quot;buttons&quot;:[1,[[0,{&quot;_key&quot;:[0,&quot;b1&quot;],&quot;action&quot;:[0,&quot;navigate&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#ffffff&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;l&quot;:[0,1],&quot;s&quot;:[0,0]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,0],&quot;s&quot;:[0,0],&quot;v&quot;:[0,1]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,255],&quot;g&quot;:[0,255],&quot;r&quot;:[0,255]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,6],&quot;bottomRight&quot;:[0,6],&quot;topLeft&quot;:[0,6],&quot;topRight&quot;:[0,6]}],&quot;buttonCustomWidth&quot;:[0,null],&quot;buttonWidth&quot;:[0,&quot;auto&quot;],&quot;countsAs&quot;:[0,&quot;conversion&quot;],&quot;fontFamily&quot;:[0,&quot;Inter, sans-serif&quot;],&quot;fontWeight&quot;:[0,&quot;600&quot;],&quot;hoverColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#e2e8f0&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,214.28571428571428],&quot;l&quot;:[0,0.9137254901960784],&quot;s&quot;:[0,0.31818181818181823]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,214.28571428571428],&quot;s&quot;:[0,0.05833333333333336],&quot;v&quot;:[0,0.9411764705882353]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,240],&quot;g&quot;:[0,232],&quot;r&quot;:[0,226]}]}],&quot;hoverColorType&quot;:[0,null],&quot;hoverGradient&quot;:[0,null],&quot;hoverTextColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;keepOpenOnClick&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;mobileTextSize&quot;:[0,null],&quot;openInNewTab&quot;:[0,true],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,10],&quot;left&quot;:[0,24],&quot;right&quot;:[0,24],&quot;top&quot;:[0,10]}],&quot;shadow&quot;:[0,null],&quot;subtitle&quot;:[0,null],&quot;subtitleColor&quot;:[0,null],&quot;subtitleFontWeight&quot;:[0,null],&quot;subtitleSize&quot;:[0,null],&quot;text&quot;:[0,&quot;Listen To The Episode&quot;],&quot;textColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;textSize&quot;:[0,14],&quot;url&quot;:[0,&quot;https://www.cancernetwork.com/view/how-to-treat-depression-in-patients-with-cancer-a-practical-framework?utm_medium=banner&amp;utm_source=mkt_layer&amp;utm_campaign=psych_onc_b&quot;]}]]],&quot;controls&quot;:[0,null],&quot;countsAs&quot;:[0,null],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;dayLabel&quot;:[0,null],&quot;evergreenDuration&quot;:[0,null],&quot;expirationAction&quot;:[0,null],&quot;expirationMessage&quot;:[0,null],&quot;expirationRedirectUrl&quot;:[0,null],&quot;fontFamily&quot;:[0,null],&quot;fontWeight&quot;:[0,null],&quot;formManagerHeight&quot;:[0,null],&quot;formManagerRef&quot;:[0,null],&quot;headingSize&quot;:[0,null],&quot;height&quot;:[0,null],&quot;hourLabel&quot;:[0,null],&quot;iframeHeight&quot;:[0,null],&quot;iframeUrl&quot;:[0,null],&quot;image&quot;:[0,null],&quot;keepOpenOnClick&quot;:[0,null],&quot;leadingZero&quot;:[0,null],&quot;lineHeight&quot;:[0,null],&quot;loop&quot;:[0,null],&quot;maxHeight&quot;:[0,null],&quot;minLabel&quot;:[0,null],&quot;mobileBodySize&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobileFormManagerHeight&quot;:[0,null],&quot;mobileHeadingSize&quot;:[0,null],&quot;mobileIframeHeight&quot;:[0,null],&quot;mobileMaxHeight&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;muted&quot;:[0,null],&quot;objectFit&quot;:[0,null],&quot;objectPosition&quot;:[0,null],&quot;openInNewTab&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;restartOnExpire&quot;:[0,null],&quot;secLabel&quot;:[0,null],&quot;separatorCharacter&quot;:[0,null],&quot;separatorColor&quot;:[0,null],&quot;showDays&quot;:[0,null],&quot;showHours&quot;:[0,null],&quot;showMinutes&quot;:[0,null],&quot;showSeconds&quot;:[0,null],&quot;showSeparator&quot;:[0,null],&quot;targetDate&quot;:[0,null],&quot;textAlign&quot;:[0,null],&quot;textColor&quot;:[0,null],&quot;timerMode&quot;:[0,null],&quot;unitStyle&quot;:[0,null],&quot;url&quot;:[0,null],&quot;width&quot;:[0,null]}]]],&quot;borderRadius&quot;:[0,null],&quot;gap&quot;:[0,null],&quot;horizontalAlign&quot;:[0,&quot;end&quot;],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,null],&quot;verticalAlign&quot;:[0,&quot;center&quot;],&quot;width&quot;:[0,35]}]]],&quot;gap&quot;:[0,24],&quot;hideOn&quot;:[0,null],&quot;reverseOnMobile&quot;:[0,null],&quot;stackOnMobile&quot;:[0,true]}]]],&quot;dismissable&quot;:[0,true],&quot;displayMode&quot;:[0,&quot;sticky&quot;],&quot;inlineConfig&quot;:[0,null],&quot;margin&quot;:[0,null],&quot;mobileMargin&quot;:[0,null],&quot;name&quot;:[0,&quot;Pysch-Oncologist Sticky B (Podcast Direct)&quot;],&quot;overlayConfig&quot;:[0,null],&quot;parallaxConfig&quot;:[0,null],&quot;showCloseButton&quot;:[0,true],&quot;showSponsoredLabel&quot;:[0,null],&quot;slideInConfig&quot;:[0,null],&quot;sponsoredLabelText&quot;:[0,null],&quot;stickyConfig&quot;:[0,{&quot;position&quot;:[0,&quot;bottom&quot;]}],&quot;styling&quot;:[0,{&quot;animation&quot;:[0,&quot;rise&quot;],&quot;backgroundColor&quot;:[0,{&quot;_type&quot;:[0,&quot;color&quot;],&quot;alpha&quot;:[0,1],&quot;hex&quot;:[0,&quot;#0f2b46&quot;],&quot;hsl&quot;:[0,{&quot;_type&quot;:[0,&quot;hslaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;l&quot;:[0,0.16666666666666669],&quot;s&quot;:[0,0.6470588235294117]}],&quot;hsv&quot;:[0,{&quot;_type&quot;:[0,&quot;hsvaColor&quot;],&quot;a&quot;:[0,1],&quot;h&quot;:[0,209.45454545454544],&quot;s&quot;:[0,0.7857142857142857],&quot;v&quot;:[0,0.27450980392156865]}],&quot;rgb&quot;:[0,{&quot;_type&quot;:[0,&quot;rgbaColor&quot;],&quot;a&quot;:[0,1],&quot;b&quot;:[0,70],&quot;g&quot;:[0,43],&quot;r&quot;:[0,15]}]}],&quot;backgroundColorType&quot;:[0,null],&quot;backgroundGradient&quot;:[0,null],&quot;backgroundImage&quot;:[0,null],&quot;border&quot;:[0,null],&quot;borderColor&quot;:[0,null],&quot;borderRadius&quot;:[0,{&quot;bottomLeft&quot;:[0,0],&quot;bottomRight&quot;:[0,0],&quot;topLeft&quot;:[0,0],&quot;topRight&quot;:[0,0]}],&quot;customHeight&quot;:[0,null],&quot;customHeightUnit&quot;:[0,null],&quot;customWidth&quot;:[0,null],&quot;customWidthUnit&quot;:[0,null],&quot;mobileBorder&quot;:[0,null],&quot;mobileBorderRadius&quot;:[0,null],&quot;mobileCustomHeight&quot;:[0,null],&quot;mobileCustomWidth&quot;:[0,null],&quot;mobilePadding&quot;:[0,null],&quot;padding&quot;:[0,{&quot;bottom&quot;:[0,16],&quot;left&quot;:[0,55],&quot;right&quot;:[0,55],&quot;top&quot;:[0,16]}],&quot;shadow&quot;:[0,&quot;medium&quot;],&quot;size&quot;:[0,&quot;large&quot;]}]}],&quot;variantWeight&quot;:[0,50]}]]]}]]],&quot;targeting&quot;:[0,{&quot;content_placement&quot;:[1,[[0,&quot;news&quot;],[0,&quot;journals/oncology&quot;],[0,&quot;journals&quot;]]],&quot;document_url&quot;:[1,[[0,&quot;gerson-regimen&quot;]]],&quot;document_group&quot;:[1,[]],&quot;content_group&quot;:[1,[]],&quot;rootDocumentGroup&quot;:[1,[]],&quot;issue_url&quot;:[1,[[0,&quot;oncology-vol-24-no-2&quot;]]],&quot;publication_url&quot;:[1,[[0,&quot;oncology&quot;]]],&quot;tags&quot;:[1,[[0,&quot;Integrative Oncology&quot;],[0,&quot;Oncology Journal&quot;]]],&quot;authors&quot;:[1,[[0,&quot;barrie-r-cassileth-ms-phd&quot;]]],&quot;hostname&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;adLayer&quot;:[0,{&quot;adSlotSelection&quot;:[1,[]]}]}],&quot;siteDomain&quot;:[0,&quot;www.cancernetwork.com&quot;],&quot;brightcoveAccountId&quot;:[0,&quot;10203567001&quot;],&quot;brightcovePlayerId&quot;:[0,&quot;dDZp7kuoR&quot;],&quot;multiPopupSettings&quot;:[0,{&quot;allowMultipleOverlays&quot;:[0,false],&quot;multiOverlayMinPriority&quot;:[0,75],&quot;overlayCooldownSeconds&quot;:[0,30],&quot;excludedPaths&quot;:[1,[]]}]}" ssr client="load" opts="{&quot;name&quot;:&quot;MarketingLayerRuntime&quot;,&quot;value&quot;:true}"></astro-island> </body></html>